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Abstract
The use of fibrin sealant during non-emergency surgery:
a systematic review of evidence of benefits and harms
Steven J Edwards,* Fay Crawford, Michelle Helena van Velthoven,
Andrea Berardi, George Osei-Assibey, Mariana Bacelar, Fatima Salih
and Victoria Wakefield
BMJ Technology Assessment Group, London, UK
*Corresponding author sedwards@bmj.com
Background: Fibrin sealants are used in different types of surgery to prevent the accumulation of
post-operative fluid (seroma) or blood (haematoma) or to arrest haemorrhage (bleeding). However, there is
uncertainty around the benefits and harms of fibrin sealant use.
Objectives: To systematically review the evidence on the benefits and harms of fibrin sealants in
non-emergency surgery in adults.
Data sources: Electronic databases [MEDLINE, EMBASE and The Cochrane Library (including the Cochrane
Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Health Technology
Assessment database and the Cochrane Central Register of Controlled Trials)] were searched from
inception to May 2015. The websites of regulatory bodies (the Medicines and Healthcare products
Regulatory Agency, the European Medicines Agency and the Food and Drug Administration) were also
searched to identify evidence of harms.
Review methods: This review included randomised controlled trials (RCTs) and observational studies
using any type of fibrin sealant compared with standard care in non-emergency surgery in adults.
The primary outcome was risk of developing seroma and haematoma. Only RCTs were used to inform
clinical effectiveness and both RCTs and observational studies were used for the assessment of harms
related to the use of fibrin sealant. Two reviewers independently screened all titles and abstracts to identify
potentially relevant studies. Data extraction was undertaken by one reviewer and validated by a second.
The quality of included studies was assessed independently by two reviewers using the Cochrane
Collaboration risk-of-bias tool for RCTs and the Centre for Reviews and Dissemination guidance for
adverse events for observational studies. A fixed-effects model was used for meta-analysis.
Results: We included 186 RCTs and eight observational studies across 14 surgical specialties and five
reports from the regulatory bodies. Most RCTs were judged to be at an unclear risk of bias. Adverse events
were inappropriately reported in observational studies. Meta-analysis across non-emergency surgical
specialties did not show a statistically significant difference in the risk of seroma for fibrin sealants versus
standard care in 32 RCTs analysed [n = 3472, odds ratio (OR) 0.84, 95% confidence interval (CI) 0.68 to
1.04; p = 0.13; I2 = 12.7%], but a statistically significant benefit was found on haematoma development in
24 RCTs (n = 2403, OR 0.62, 95% CI 0.44 to 0.86; p = 0.01; I2 = 0%). Adverse events related to fibrin
sealant use were reported in 10 RCTs and eight observational studies across surgical specialties, and 22
RCTs explicitly stated that there were no adverse events. One RCT reported a single death but no other
study reported mortality or any serious adverse events. Five regulatory body reports noted death from air
emboli associated with fibrin sprays.
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Limitations: It was not possible to provide a detailed evaluation of individual RCTs in their specific
contexts because of the limited resources that were available for this research. In addition, the number of
RCTs that were identified made it impractical to conduct independent data extraction by two reviewers in
the time available.
Conclusions: The effectiveness of fibrin sealants does not appear to vary according to surgical procedures
with regard to reducing the risk of seroma or haematoma. Surgeons should note the potential risk of gas
embolism if spray application of fibrin sealants is used and not to exceed the recommended pressure and
spraying distance. Future research should be carried out in surgery specialties for which only limited data
were found, including neurological, gynaecological, oral and maxillofacial, urology, colorectal and
orthopaedics surgery (for any outcome); breast surgery and upper gastrointestinal (development of
haematoma); and cardiothoracic heart or lung surgery (reoperation rates). In addition, studies need to use
adequate sample sizes, to blind participants and outcome assessors, and to follow reporting guidelines.
Study registration: This study is registered as PROSPERO CRD42015020710.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Surgeons use fibrin sealants during operations in place of stitches. The sealants act like a biological glue,joining tissues together and stopping tissues leaking fluids. Using a fibrin sealant might lower the risk of
having a seroma (a collection of fluids) or a haematoma (a collection of blood outside a blood vessel). It is
not clear if fibrin sealants are more effective in operations at some body sites than at others, or in different
types of operation. In addition, there have been reports of fibrin sealants causing serious harm to people.
This study brings together the evidence on the benefits and harms related to the use of fibrin sealants in
different types of surgery. A total of 186 randomised controlled trials and eight observational studies were
found that looked at the use of fibrin sealants during surgery at various body sites, including the liver,
stomach, pancreas, heart and lungs. The evidence suggests a benefit for fibrin sealants in reducing the
likelihood of haematomas, particularly in hernia surgery, but there is uncertainty regarding whether or not
there is a benefit in surgery at all sites. Harms related to fibrin sealant use were reported in 10 randomised
controlled trials and eight observational studies across surgical specialties, whereas 22 randomised
controlled trials stated no harmful events. One randomised controlled trial reported a death caused by a
large bleed that was possibly related to fibrin sealant use, but other studies did not report deaths or
serious harms. However, holding the spray too close to a wound during application of the sealant has
been found to introduce air into the body, which could increase the risk of dying, but this is rare.
We found a large number of studies that showed a reduction in the risk of developing haematoma during
non-emergency surgery when fibrin sealant is used. Overall, the quality of the evidence found was unclear,
mostly because the methods used in studies were not reported clearly. Future research is needed to
improve the confidence of decision-making.
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Scientific summary
Background
Fibrin sealants are used in different surgery procedures to arrest haemorrhage (bleeding) or prevent the
accumulation of post-operative fluid (seroma) or blood (haematoma). It is unclear whether or not all
surgical procedures benefit from fibrin sealants and there is concern that use of fibrin sealants could be
associated with substantial harm.
Objectives
To systematically review the evidence on the clinical effectiveness and harms of fibrin sealants in
non-emergency surgery in adults.
Data sources
Electronic databases [MEDLINE, EMBASE and The Cochrane Library (including the Cochrane Database of
Systematic Reviews, the Database of Abstracts of Review of Effects, the Health Technology Assessment
database and the Cochrane Central Register of Controlled Trials)] were searched from inception to May 2015.
Ongoing and unpublished randomised controlled trials (RCTs) were identified from clinicaltrials.gov,
controlledtrials.com and clinicaltrialsregister.eu. The Medicines and Healthcare products Regulatory Agency
(MHRA), the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) websites were
also searched to identify evidence of harms.
Methods
This review included RCTs and observational studies using any type of fibrin sealant compared with
standard care in non-emergency surgery in adults that assessed at least one of the specified outcomes.
The primary outcome was risk of seroma and/or haematoma, and secondary outcomes were haemorrhage
(bleeding), infection, pain levels, complications arising from the use of drains, resource use (reoperation,
length of hospital stay, duration of drainage and use of analgesics), health-related quality of life and
adverse events related to the use of fibrin sealants. Only RCTs were used to review clinical effectiveness
and both RCTs and observational studies were used for the assessment of harms related to the use of
fibrin sealant.
Randomised controlled trials and observational studies were included based on pre-specified inclusion
criteria. Two reviewers independently screened all titles and abstracts to identify potentially relevant studies
for inclusion in the review. Full-text publications were evaluated independently by two reviewers. Data from
included studies were extracted into a standardised data extraction form by one reviewer and validated
by a second reviewer. The quality of included studies was assessed independently by two reviewers using
the Cochrane Collaboration risk-of-bias tool for RCTs and Centre for Reviews and Dissemination guidance
on adverse events for observational studies. Extracted data and quality assessment for each study were
presented in structured tables. A fixed-effects model was used for the primary meta-analysis and a
random-effects model was used for the sensitivity analysis. Subgroup analyses for different surgical
specialties were conducted. Treatment effects were analysed as odds ratios (ORs) for dichotomous data
and as mean difference (MD) for continuous outcomes. Data that could not be appropriately combined by
meta-analysis were summarised in a narrative overview and presented in tables.
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Changes between the protocol and this review include the addition of risk of haematoma as a co-primary
outcome because haematoma was frequently reported and the mechanism of haematoma and seroma
formation was found to be similar based on clinical advice.
Results
The search for benefits and harms of fibrin sealants in RCTs resulted in 1428 full papers and abstracts
being screened for inclusion in the review. Full publications for 443 studies were evaluated, of which 186
RCTs were included. The search for harms identified 4714 studies and 93 reports that were screened for
inclusion, of which eight observational studies and five reports of death in patients treated with fibrin
sealants during surgical procedures from the MHRA, EMA and FDA were included.
Thirty-seven trials across different surgical areas (breast and axillary/inguinal lymph nodes, hernia, plastic,
hepatic and otolaryngology surgery) reported the incidence of seroma as a study outcome. A meta-analysis
of data from 32 RCTs (n = 3472) did result in a non-significant reduction in risk of seroma with fibrin
sealant over standard procedures [OR 0.84, 95% confidence interval (CI) 0.68 to 1.04; p = 0.13;
I2 = 12.7%). The co-primary outcome, risk of haematoma, was reported in 26 RCTs in breast and axillary/
inguinal lymph nodes, hernia, plastic, orthopaedic, upper gastrointestinal (GI), oral and otolaryngology
surgery. A meta-analysis of 24 RCTs (n = 2665) demonstrated a statistically significant reduction in risk for
fibrin sealant versus standard care (OR 0.62, 95% CI 0.44 to 0.86; p = 0.01; I2 = 0%) that was driven by the
results for hernia surgery in four RCTs (n = 794, pooled OR 0.22, 95% CI 0.06 to 0.74; p = 0.01; I2 = 0%).
Furthermore, there was a trend towards a reduction in the risk of haematoma in the remaining surgical
specialties, but this was not statistically significant (p = 0.87 for breast, p = 0.20 for orthopaedic and
p = 0.88 for upper GI tract). The random-effects models for the primary outcomes showed similar results.
Secondary dichotomous outcomes of this review were risk of haemorrhage, reoperation and infections,
use of analgesics and complications arising from the use of drains. There was no statistically significant
difference between patients receiving fibrin sealants and those receiving standard care in the risk of
haemorrhage in a meta-analysis of 2125 patients in 17 RCTs (OR 0.64, 95% CI 0.40 to 1.02; p = 0.08;
I2 = 0%) or in the rate of infections in a meta-analysis of 3902 patients in 25 RCTs (pooled OR 0.76, 95%
CI 0.54 to 1.06; p = 0.12; I2 = 0%). However, a meta-analysis of six RCTs of upper GI surgery (n = 995)
found a statistically significant reduction in risk of haemorrhage when using fibrin sealants (OR 0.39, 95%
CI 0.19 to 0.80; p = 0.01; I2 = 0%). In a meta-analysis of 15 RCTs (n = 3789), the risk of reoperation was
statistically significantly lower in patients receiving fibrin sealants than in control subjects (OR 0.65, 95% CI
0.48 to 0.87; p < 0.01; I2 = 0%). Use of analgesics was reported by only three RCTs that could not be
meta-analysed; there appeared to be no difference between fibrin sealant and standard care in two RCTs,
but patients with trans-sphincteric anal fistulas treated with fibrin sealant did not require analgesics,
whereas all those who received standard treatment did. No RCTs reported on complications arising from
the use of drains.
Secondary continuous outcomes included duration of operation, length of hospital stay, use of drains,
pain levels and health-related quality of life. A statistically significant benefit of fibrin sealants compared
with standard care was identified in the mean duration of operations for eyes in eight RCTs (n = 519, MD
–12.13 minutes, 95% CI –12.59 to –11.67 minutes; p < 0.01; I2 = 99.1%) and hernia surgery in two RCTs
(n = 784, MD –2.56 minutes, 95% CI –3.57 to –1.56 minutes; p < 0.01). However, in surgery with liver
mobilisation, two RCTs showed a statistically significant longer duration of surgery when fibrin sealants
were used (n = 364, MD 19.07 minutes, 95% CI 2.75 to 35.38 minutes; p = 0.02). Fibrin sealants were
shown to reduce the length of hospital stay for people undergoing upper GI surgery involving the pancreas
in two RCTs (n = 181, MD –1.40 days, 95% CI –1.72 to –1.09 days; p < 0.01), cardiothoracic lung surgery
in three RCTs (n = 269, MD –1.37 days, 95% CI –1.93 to –0.81 days; p < 0.01; I2 = 91.9%) and breast
surgery in eight RCTs (n = 440, MD –0.73 days, 95% CI –0.95 to –0.50 days; p < 0.01; I2 = 88.7%).
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Fibrin sealants slightly reduce the duration of post-operative drainage for breast and axillary lymph nodes
in 12 RCTs (n = 953, MD –0.50 days, 95% CI –0.68 to –0.33 days; p < 0.01; I2 = 90.6%) and the duration
of lung surgery in five RCTs (n = 399, MD –0.46 days, 95% CI –0.53 to –0.39 days; p < 0.01; I2 = 91.0%)
than standard care. These results were not consistent across surgical procedures, with fibrin sealants
showing no beneficial effect when compared with standard care in the following specialties: duration of
operation in surgery without liver mobilisation in four RCTs (p = 0.46); gastric surgery in two RCTs
(p = 0.07); length of hospital stay in gastric and bowel surgery in two RCTs (p = 0.82); joint surgery in four
RCTs (p = 0.87); and duration of drainage in hepatic surgery in four RCTs (p = 0.33). The high level of
heterogeneity warrants caution when interpreting the results of the secondary continuous outcomes. Pain
levels were reported in 20 RCTs but the large differences in the different scales used, time points at which
assessments took place and the lack of data on variability did not permit a meta-analysis. Health-related
quality of life was not reported in any of the RCTs.
Adverse events were reported in 10 RCTs in various surgical procedures (liver, kidney, mixed, oral and
maxillofacial, hernia, plastic and reconstructive, vascular and orthopaedic) that were reported as related to
the use of fibrin sealants by the investigators, and 22 RCTs explicitly reported that there were no adverse
events related to fibrin sealant use. Only one RCT reported a death as possibly related to fibrin sealant
application in upper-GI surgery caused by a large bleed, but bleeding did not occur at the target site and
no further information was provided. Other RCTs reported on various non-severe adverse events including
mild cellulitis and mild seroma, anaemia, extravasation of urine, incision site complication and mild
generalised skin rash. Severity was unclear for excessive pain, scar pain, testicular pain hydrocele,
post-procedural haemorrhage and antibodies to hepatitis B. The eight observational studies reported
adverse events that appeared to be fibrin related in the view of primary study investigators and reviewers,
but there were no reports of death or serious adverse events.
Most full-text publications presented limited details on trial methodology and, as a consequence, were
judged to be at an unclear risk of bias. Overall, 154 RCTs were assessed as having an ‘unclear risk of bias’,
eight RCTs as having a ‘high risk of bias’ and 24 RCTs as having a ‘low risk of bias’. Therefore, study
quality was not used in the meta-analyses as a sensitivity analysis. The validity of the eight observational
studies was compromised by a general failure to report whether or not adverse events were assessed
independently and if blinding to the assigned treatment was performed.
Limitations
It was not possible to provide a detailed evaluation of individual RCTs in their respective contexts because
of the limited resources that were available for this research. In addition, the number of RCTs that were
identified made it impractical to conduct independent data extraction by two reviewers in the time available.
Conclusions
The effectiveness of fibrin sealants does not appear to vary according to surgical procedures, as there was
virtually no heterogeneity in the meta-analyses of primary and secondary dichotomous outcomes. Fibrin
sealants appear to reduce the risk of haematoma development when used in non-emergency surgical
procedures compared with standard care, but the reduction in risk of post-operative seroma development
remains unproven.
Randomised controlled trials and observational studies mostly reported on no or minor adverse events
that appeared to be related to the use of fibrin sealants in the view of primary study investigators and
reviewers, but poor reporting of adverse events in primary studies warrants caution when interpreting
these results. Surgeons should note the potential risk of gas embolism if spray application is not performed
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in accordance with manufacturers’ recommendations and take the necessary precautions detailed in the
updated prescribing advice for these medicines.
It is necessary for those who undertake future RCTs to capture all important outcomes in the same
population of patients. Researchers should plan RCTs that collect data for biological outcomes
(e.g. seroma, haematoma, duration of drainage) as well as more service-related outcomes (e.g. length
of hospital stays and rates of reoperations) in order to reach a balanced view of the benefits or harms
arising from these products. Future research should be carried out in surgery specialties where only limited
data were found, including neurological, gynaecological, oral and maxillofacial, urology, colorectal and
orthopaedics knee or hip surgery (for any outcome); breast and upper-GI surgery (for development of
haematoma); and cardiothoracic heart or lung surgery (for reoperation rates). Furthermore, reporting of
methodological aspects of studies, particularly for adverse events, should improve while following existing
reporting guidelines.
Study registration
This study is registered as PROSPERO CRD42015020710.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Fibrin sealants are commercial products used during surgical procedures in many sites of the body
(including the liver, breast, pancreas, thorax and nervous system) and are widely regarded as useful
adjuncts to make blood clot, seal tissues and help the body repair mechanisms that can aid haemostasis
and reduce seroma formation. However, the benefits and harms of fibrin sealants remain controversial and
seem to be dependent on the surgical procedure.
Seroma and repair
Seroma is formed by acute inflammatory exudates in response to surgical trauma and in the acute phase
of wound healing.1 After surgery, the body’s natural response to the removal of organs or tissues is to fill
the space with fluid and blood cells. During this process, a collection of fluid and cells can result in the
formation of a seroma (collection of a clear, yellow fluid). Some parts of the body are especially prone to
seroma, for example the breasts and parts of the digestive tract.
Avoidance of post-operative drains
Post-operative drains are intended to prevent the build-up of fluid or seroma after some types of surgery by
filling ‘dead space’. The main concerns with seroma are that they can become infected or leak fluid and,
if they remain, over time become swollen, hard and uncomfortable. Both additional surgery to remove the
seroma and fine-needle aspiration are associated with increased resource use, such as nursing time, hospital
stay and analgesic or antibiotic use. There is contradictory evidence from two small randomised controlled
trials (RCTs)2,3 (n = 100 and n = 75) about the use of fibrin sealants as an alternative to post-operative
drains during thyroid surgery. In one trial, patient outcomes were best in the fibrin sealant group; pain
was significantly reduced, as was the length of time spent in hospital.2 However, no statistically different
effects on any outcome was observed in a second trial.3 The findings from individual RCTs also suggest that
post-operative pain can be reduced when fibrin sealants are used in skin graft surgery.
Fibrin sealants are not recommended for surgical use in some sites; they were reported to be ineffective in
reducing post-operative leakage from oesophago-gastric anastomoses.4
Tissue adhesion or sealing
A systematic review summarised the evidence for fibrin glue in the repair of pilonidal disease (the invasion
of hair into the skin of the natal cleft).5 The review included five RCTs in which fibrin glue was used to fill
dead space and sinus tracks during surgery. The reviewers reported equivalent or better healing times at
an average of 2–6 weeks and low recurrence rates between 0% and 17% at follow-up periods between
4 and 28 months for all patients treated with fibrin glue than for those treated with conventional
therapies. However, no statistically significant differences between those who received fibrin glue and
those who did not were observed. Furthermore, fibrin sealants are commonly used to prevent fistula
during pancreatic surgery.6–8
Hernia repair
A systematic review of randomised and non-randomised studies evaluating fibrin sealants used in the
surgical management of hernia repair concluded that fibrin sealants are an effective alternative to
mechanical approaches.9
Dural repair in neurosurgery
Fibrin sealants can be used as an adjunct to dura (the outer-most layer of the brain and spinal cord) repair to
achieve intraoperative watertight closure of the dura and to reduce post-operative cerebrospinal fluid leak.
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A RCT (n = 139) showed the fibrin sealant EVICEL® (Ethicon, Livingston, UK) to be effective as an adjunct to
dural sutures. Intra-operative watertight closure was achieved in 82 out of 89 participants (92.1%) in the
EVICEL group, compared with 19 out of 50 participants (38.0%) in the control group (p < 0.001).10
Haemorrhage (bleeding)
Perioperative or post-operative haemorrhage is a common complication of surgery. Unexpected, excessive
perioperative bleeding can be due to a pre-existing undetected bleeding disorder, or to coagulation
abnormalities arising from massive blood loss and/or various coexisting pathologies.11 It can be related to
the nature of the operation itself. Red blood cell transfusion is often required as a result of perioperative
bleeding, but this resource can be scarce and there has been worldwide concern regarding its safety.
Assisting the arrest of haemorrhage (haemostasis) perioperatively is an important function of fibrin sealant
preparations. In a previous systematic review12 researchers demonstrated that fibrin use during the removal
of uterine fibroids in premenopausal women reduced blood loss and, consequently, the rate of blood
transfusions. However, the quality of evidence was assessed as low. This effect was also reported in a
systematic review of surgical interventions for liver, orthopaedic, vascular, prostate, thoracic, renal,
pancreatic and cardiac conditions.13 A RCT evaluating the use of fibrin sealants in total knee arthroplasty
procedures also demonstrated statistically significant reductions in blood loss.14
Aetiology, pathology and prognosis
Incidence and/or prevalence and impact of the health problem
Seroma and repair
The development of seroma formation depends on the site of surgery. Approximately 50% of inpatients with
a closed suction drain develop post-operative seroma,15 and the incidence after breast cancer surgery and
axillary node dissections ranges from 15% to 60%.16 The most common complication of abdominoplasty is
seroma formation, and the incidence in abdominal procedures, including abdominoplasty, panniculectomy
and transverse rectus abdominis myocutaneous flap abdominal donor sites, ranges from 1% to 38%.17
In a study of incisional hernia repair involving a combined fascial and prosthetic mesh repair in 35 patients
(16 males and 19 females), the incidence of post-operative seroma formation was 17%.18 One of the most
common and serious complications of pancreatic surgery is post-operative pancreatic fistula, defined as a
drain output of any measurable volume or fluid on or after post-operative day 3, with an amylase content
greater than three times the serum amylase activity.19–21 The estimated incidence of post-operative pancreatic
fistula ranges between 2% and 24% based on different studies.19,22
Haemorrhage (bleeding)
The incidence of perioperative or post-operative bleeding also depends on the site or type of surgery.
Severe bleeding occurs in about 7% of patients undergoing cardiac surgery.23 Excess perioperative
bleeding following surgery results in the increased use of red blood cell transfusions: between 60% and
70% of all red blood cell transfusions are used in surgical settings.24,25 Moreover, bleeding perioperatively
or post-operatively increases the risk of morbidity and mortality.11 The mortality rate among patients
undergoing elective vascular surgery who experience severe bleeding has been reported to be
approximately 20%.26 Uncontrolled bleeding has been reported to be the cause of 30–40% of all
trauma-related deaths.27
Significance for patients in terms of ill health (burden of disease)
A seroma may cause problems because it can become infected or leak fluid and, over time, may also
become swollen, hard and uncomfortable. After thoracic surgery the placement of a post-surgical drain
can increase the length of hospital stay and cause discomfort. Problems arise when the drains do not work
properly and, as a result, become blocked and infected.
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Current service provision
Management of condition
Seroma and repair
To try to stop seroma formation, surgeons sometimes leave a drain (tube) in the wound to make sure fluid
can escape and does not build up after the operation. Occasionally, the only way to cure the problem is
further surgery to remove the seroma or drainage with a fine needle, which might increase the time spent
in hospital.
To prevent post-operative pancreatic fistulas, a number of methods have been proposed, including
application of duct stents, modification of anastomotic techniques and administration of somatostatin
(a hormone that inhibits the secretion of pancreatic juice).20,21,28,29
Haemorrhage (haemostasis)
To look for ways to minimise the need for perioperative blood transfusion, a number of systematic reviews
assessed the efficacy and safety of different interventions for the International Study of Perioperative
Transfusion.30–34 These reviews showed that techniques for reinfusing patients’ own blood provided only
relatively small reductions in the need for blood transfusion. However, interventions to reduce surgical
blood loss resulted in significant improvements in reducing the need for blood transfusion.35
Variation in services and/or uncertainty about best practice
Relevant national guidelines
In 2012, a European review of the safety of sprayable fibrin sealants was started after reports of
life-threatening events and deaths following administration of fibrin sealants using a pressure regulator.36
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)
stated that the benefits of fibrin sealants outweigh their risks, but that appropriate procedures have to be
undertaken to optimise the safe use of fibrin sealant sprays during surgery.36
In 2013, four sprayable fibrin sealants were authorised in the UK: EVICEL, Tisseel Lyo® (Baxter Healthcare,
Norfolk, UK), Tisseel Ready® to Use (Baxter Healthcare, Norfolk, UK) and Artiss® [Solutions for Sealant],
deep frozen (Baxter Healthcare, Norfolk, UK). In all cases, the surface area of the wound should be dried
with standard procedures before applying the fibrin sealants spray with a pressure regulator device.37
Description of technology under assessment
Summary of intervention
Fibrin sealants are commercial products that usually comprise two substances that occur naturally in
mammals: (1) fibrinogen, a protein; and (2) thrombin, an enzyme that acts on fibrinogen to produce a
fibrin clot, exactly as in normal blood clotting. The components used in these products are derived from
either human or animal blood. There are different preparations of fibrin sealants: patches, sponges and
bandage formulations, which can all be impregnated with fibrinogen and thrombin. Alternatively, fibrin
glue is a mixture of the two substances in liquid form, which is dispensed via a ‘gun’ and there is also a
liquid ‘droplet’ formulation that is delivered in an aerosol spray.38
Fibrin sealants are used during surgical procedures in many sites of the body (including the liver, breast,
pancreas, thorax and nervous system) and are widely regarded as useful adjuncts to aid haemostasis and
reduce seroma formation. They are used to seal tissues and prevent the accumulation of post-operative
fluid and blood loss. Aerosol sprays, sponges, bandages and pad preparations are available, and all contain
elements that make blood clot and help the body repair.
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Concerns about safety
Fibrin sealants have been found to stop fluid collecting in the body after operations, but it is unclear if this
‘good effect’ works for all types of operations. There is concern that some types of fibrin sealants can have
harmful effects, such as leaving pockets of air in the body, which can be dangerous.
The Food and Drug Administration (FDA) in the USA has issued warnings about life-threatening air or
gas emboli developing after the use of fibrin sealant aerosol sprays during surgery. Users of the products
have been advised about the dangers of using sprays too close to exposed tissue surfaces and at higher
pressures than those recommended by the manufacturers.39 However, despite concerns about safety, data
from RCTs about harms are scarce.40 A multicentre RCT41 conducted in three Italian hospitals compared the
rate of adverse events in a group of patients receiving fibrin sealants as an adjuvant for air leak control
in patients undergoing lung resection. Air leakage and broncopleural fistulas in the lungs are both common
complications after these procedures. With a follow-up period of 30–40 days the investigators found that
the rate of adverse events was not statistically significantly different between patients who received fibrin
sealant and those who did not.41
A review conducted in 201042 on the risks and complications of spinal fibrin sealants, included the two
fibrin glues EVICEL and Tisseel. It concluded that Tisseel had been used in clinical studies without adverse
events. However, the review found a lack of large clinical studies on the safety of EVICEL for neurosurgery.
A more recent RCT evaluating the safety of EVICEL found that the incidence of adverse events and
cerebrospinal leakage up to 30 days post surgery was similar in the EVICEL and control groups. No deaths
or suspected unexpected serious adverse drug reactions occurred during the trial.10
The authors of a systematic review of RCTs have suggested that the beneficial patient outcomes that have
been observed when using fibrin sealants are dependent on surgeon training in their use.40
Identification of important subgroups
Surgical specialties
The efficacy of fibrin sealants in different surgical specialties has been reported to differ. Therefore, where
possible, after carrying out a meta-analysis combining all surgical specialties, additional subgroup analysis
was carried out according to identified surgical specialties.
Type of intervention
For assessing the efficacy of fibrin sealant in reducing operative time, subgroup analysis according to
interventions and comparators was carried out, as application times of different interventions was expected
to vary.
Current usage in the NHS
Fibrin sealants are believed to be widely used by surgeons from many different disciplines working in the
UK. There are no data collected at a national level about the cost of fibrin products to the NHS; costs data
are likely to be available only at the level of NHS trust (NHS England, 2015, personal communication). It is
anticipated that variations in the use of fibrin sealants are likely.
BACKGROUND
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Chapter 2 Definition of the decision problem
Decision problem
The eligibility criteria pertaining to population, intervention, comparators and outcomes are summarised in
Table 1.
Overall aims and objectives of assessment
Objectives
l To map the evidence of benefits (clinical effectiveness) of use of fibrin sealants from RCTs.
l To map the evidence of harms (adverse events) related to the use of fibrin sealants from RCTs,
observational studies and regulatory body reports.
TABLE 1 Eligibility criteria
PICOS Criteria
Population People aged ≥ 18 years undergoing non-emergency surgery at any site in secondary care (hospital)
Intervention Any fibrin sealant product including
l fibrin glue
l fibrin spray
l fibrin sponges, bandages
l fibrin aerosol
l fibrin tissue adhesive
Comparators Standard care
Outcomes Primary outcomes
l seroma development
l haematoma development
Secondary outcomes
l haemorrhage (blood loss)
l infections
l pain levels
l complications arising from the use of drains
Resource use
l use of analgesics
l nurse or doctor time
l length of hospital stay
l use of drains
Health-related quality of life
Adverse events related to the use of fibrin sealant (attributed by the primary study authors and/or reviewers)
In addition, an important output of the review will include an overview of gaps in knowledge to inform
recommendations for future primary research, including specific outcomes for different conditions
Study design RCTs and observational studies
PICOS, population, intervention, comparators, outcomes and study design.
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing clinical effectiveness
Evidence on the clinical effectiveness of fibrin sealants was identified by conducting a systematic review of
the published research literature. The review was undertaken following the general principles published
by the Centre for Reviews and Dissemination (CRD) and the Cochrane Collaboration.43,44 The protocol for
the systematic review is registered on PROSPERO (registration number CRD42015020710).45 The protocol
and review were developed with clinical experts who had experience with using fibrin sealants (Professor
John MacFie, University of Hull, Hull, and Mr Alexander Green, John Radcliffe Hospital, Oxford). Guidance
for systematic review reporting on benefits46 and harms47 was followed where possible.
Eligibility criteria
Eligibility criteria for the review of clinical effectiveness were as specified in the decision problem
(see Table 1 for a summary). The review included RCTs to assess both the benefits and harms, and
observational studies and regulatory body reports to assess adverse events related to fibrin sealants in the
view of primary study investigators and/or reviewers. Systematic reviews and other types of studies were
excluded. The interventions of interest were any type of fibrin sealant. RCTs and observational studies were
included if the treatments were evaluated in an adult population undergoing non-emergency surgery in a
secondary care setting and compared with standard care. Regulatory body reports were included if they
reported on deaths or serious adverse events related to fibrin sealants. RCTs were excluded if none of the
outcomes of interest was reported. Observational studies were excluded if they did not report on adverse
events that were thought to be related to the use of fibrin sealants.
Identification of studies
Search strategy
Two search strategies, one for RCTs and one for observational studies, were developed (see Appendix 1).
Information on benefits and harms were extracted from RCTs. The searches for RCTs combined terms
for the technology being assessed and the study design using the Cochrane Collaboration RCT filter.44
Evidence of harms was obtained from observational studies with a search strategy focused on adverse
events. For observational studies, the searches combine both controlled vocabulary terms (medical subject
heading and EMTREE) and free-text terms for general adverse events from the CRD43 and Cochrane
guidance,43,44 including the following: safe, safety, side effect, undesirable effect, treatment emergent,
adverse effects, contraindications and complications.48–51 Both search strategies for RCTs and observational
studies included terms for the technology, which used both controlled vocabulary terms (medical subject
heading and EMTREE) and free-text terms including the following: fibrin sealant, fibrin adhesive, fibrin
glue, fibrin sponges, fibrin bandages or aerosol and commercial names. The search strategies were refined
by scanning key papers identified during the review, through discussion with the review team, clinical
experts and information specialists (see Appendix 1). No limits relating to inception date or language were
applied to the searches.
The following searches were conducted in May 2015. The following electronic sources were searched:
MEDLINE, EMBASE and The Cochrane Library (including the Cochrane Database of Systematic Reviews,
the Database of Abstracts of Reviews of Effects, the Health Technology Assessment database and the
Cochrane Central Register of Controlled Trials). Ongoing and unpublished RCTs were searched for in the
following websites: clinicaltrials.gov, controlled-trials.com and clinicaltrialsregister.eu. For observational
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studies websites from the following organisations were searched: Medicines and Healthcare products
Regulatory Agency (MHRA) (www.gov.uk/search?q=fibrin+sealants), the EMA (www.ema.europa.eu/ema/
index.jsp?curl=search.jsp&q=FIBRIN+SEALANT&spell=1&site=pfoi_collection&client=pfoi_frontend&
ie=UTF-8&output=xml_no_dtd&proxystylesheet=pfoi_frontend&access=p) and the FDA (www.accessdata.
fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=4277068). Relevant reviews and guidelines
were identified through searching additional resources, including Clinical Evidence, National Institute
for Health and Care Excellence, National Institute for Health Research Health Technology Assessment
programme and the University of York Database of Abstracts for Reviews of Effectiveness. Additionally,
reference lists of included papers were assessed and the abstracts from key conference proceedings were
screened. Furthermore, clinical experts in the relevant therapy area were contacted to request details of
RCTs and observational studies (published and unpublished) of which they may be aware.
Abstract appraisal
Titles and abstracts of studies identified by the search process were assessed for inclusion independently by
two reviewers (GOA and MvV). In cases where the reviewers were unable to reach a consensus regarding
whether or not the full text should be obtained for further appraisal, the full text was obtained. When
potentially relevant data were identified, corresponding authors were contacted to obtain the full
publications. A deadline for response to the initial contact of 1 calendar month was imposed. Studies were
not screened on the basis of the presence or absence of harms-related terms in title or abstract as harms
were expected to be reported in other sections of the primary study publications.47
Study inclusion assessment
Two teams of two reviewers (GOA and MvV, FSa and MB) independently assessed the full text of the RCTs
and observational studies identified during the abstract assessment stage for inclusion, and differences in
opinion were arbitrated by a third reviewer (FC). Studies rejected at this or subsequent stages were
recorded in a ‘characteristics of excluded studies table’ and reasons for exclusion recorded.46 Only RCTs
reporting on one of the outcomes specified in Table 1 and only observational studies or regulatory body
reports of adverse events related to the use of fibrin sealants were included.
Data extraction and management
Data were extracted by one reviewer using a standardised data extraction form (items for which data
were reported are presented in Appendix 2) and independently checked by another reviewer. Information
extracted included details of the study’s design and methodology; the intervention and comparators; baseline
characteristics of participants and outcome measures, including clinical efficacy outcomes (variables for which
data were sought are reported in Table 20 in Assessment of benefits) and any type of adverse event related
to the use of fibrin sealants as attributed by the primary study authors of studies or regulatory organisations.
No data were sought for patient-underlying risk factors or for practitioner training or qualifications. When
there was incomplete information, attempts were made to contact authors to request for further details.
Discrepancies in the data extraction were resolved by discussion with involvement of a third reviewer.
Data from intention-to-treat (ITT) analyses were extracted. When a trial did not report ITT data for
dichotomous outcomes, missing data were treated as treatment failures to allow analysis to conform to an
ITT analysis.50 For the purpose of this review, ITT analysis was defined as the analysis of patients according
to the treatment group to which they were allocated at randomisation, irrespective of whether they
received the allocated intervention, withdrew or were lost to follow-up.
Quality assessment strategy
The quality of included studies was assessed by one reviewer and independently checked by another.
Any disagreements were resolved by consensus and the opinion of a third reviewer was sought.43,46
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Randomised controlled trials were assessed according to the guidance published by the CRD43 and the
Cochrane Handbook for Systematic Reviews of Interventions,44 and recorded using the Cochrane
risk-of-bias tool. Seven domains were assessed for each included study:
1. random sequence generation
2. allocation concealment
3. blinding of participants and personnel
4. blinding of outcomes assessment
5. incomplete outcome data (study level)
6. selective reporting
7. ‘other bias’.
Three bias assessment categories were used: low, high and unclear risk. Unclear risk was assigned because
of poor reporting of how the trial was conducted rather than a poorly conducted trial. RCTs that were
deemed to be at low or unclear risk of bias were included in the main analysis.
Within a study, a summary assessment of low risk of bias was given when there was a low risk of bias for
all key domains, unclear risk of bias when there was an unclear risk of bias for one or more key domains
and high risk of bias when there was a high risk of bias for one or more key domains. Across studies,
a summary assessment of the risk of bias for the primary outcome (across domains) was undertaken.
For observational studies, guidance from the CRD43 was used to inform the quality assessment of adverse
event reporting in observational studies. Although criteria for quality assessment of adverse event data
from observational studies are currently being developed, most tools have not been validated and there is
currently no agreement on how these quality assessments should be used in systematic reviews.49,51 Tools
that have been validated for different types of observational studies seemed inadequate for the purpose
of this systematic review.51,52 Therefore, the relevant questions for quality assessment from the CRD43
guidance were used:
1. Is there an adequate explanation of how adverse effects were identified?
2. Were the adverse effects assessed independently by someone other than the surgeon performing
the procedure?
3. Are the measurement instruments described?
4. Is the timing and duration of follow-up reported?
5. Was a standardised or validated measurement instrument used?
6. How was the adverse effect(s) attributed to the intervention?
7. Was the process was blinded to assigned treatment?
8. Are the terms clearly explained?
The following question that was deemed relevant was also added: Are all adverse events from the
population reported?
Publication bias
For each of the primary pairwise meta-analyses, a funnel plot was assessed for publication bias when at
least 10 studies were included. A regression of normalised effect versus precision was calculated as a test
for small study effects (using p < 0.10 as an indicator of a significant result), and Egger bias values are
presented in Quantity and quality of research available.53
Methods of analysis/synthesis
For all study designs (RCTs and observational studies) data were tabulated and discussed in a narrative
analysis. In this narrative the evidence is grouped according to shared characteristics relevant to the review
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question. A meta-analysis was performed to estimate a summary measure of effect on relevant outcomes
based on ITT analyses. For dichotomous outcomes, odds ratios (ORs) were used as the summary statistic.
For continuous outcomes, mean difference (MD) was the summary statistic. Meta-analyses were conducted
when clinically homogeneous studies of similar comparisons reporting the same outcome measures were
identified. Standard pairwise meta-analysis was conducted when more than one RCT was identified.
Meta-analysis of continuous outcomes was carried out with the inverse variance method.44 For dichotomous
outcomes meta-analysis was carried out using a fixed-effects model with the Mantel–Haenszel method.54
Sensitivity analysis was conducted using a random-effects model with the DerSimonian and Laird method.55
Subgroup analyses were performed for specific surgical indications, when possible. Studies with zero events
in both the intervention and control group were reported in a narrative.
In RCTs with more than one control group, the control that was reported as standard care was
included. However, in RCTs where standard care was unclear or variable, all control groups were included.
In cases for which standard care was unclear or variable, the different control groups were compared with
a respective proportion of patients of the intervention group; for example if there were three control
groups, the fibrin population was divided by three and compared in a pairwise meta-analysis with each
control. The same approach was undertaken in RCTs with more than one fibrin group (i.e. different
concentrations) and one control group; all the fibrin sealant groups were included and the number of
patients in the control group was divided appropriately. This procedure was followed to avoid double
counting of events.
Heterogeneity
For pairwise meta-analysis, heterogeneity was explored through consideration of the study populations,
methods and interventions, by visual inspection of results and, in statistical terms, by the chi-squared test
for homogeneity and the I2 statistic. Statistically significant heterogeneity was defined as p < 0.10. Levels of
inconsistency were assessed using I2 and were defined as follows: I2 of 0–25% = low level of inconsistency;
26–50% =moderate level of inconsistency; and > 50% = high level of inconsistency.56 In instances when
statistically significant heterogeneity was detected in the analyses, a hypothesis-generating subgroup
analysis was conducted.57
Sensitivity analysis
The sensitivity analysis was conducted using a random-effects model with the DerSimonian and
Laird method.55
Changes between protocol and systematic review
Systematic reviews were not included and, therefore, the quality of systematic reviews was not assessed
as was mentioned in the protocol. Haematoma is an additional post hoc primary outcome that was not
reported in protocol. As the mechanism of haematoma and seroma formation is similar and is reported in
some studies interchangeably, it was deemed important to include haematoma as a primary outcome.
In addition, a post hoc analysis of combined seroma and haematoma development was undertaken.
Haemorrhage, pain levels and infections were described in the protocol as adverse events, but have been
moved to secondary outcomes as these were found to be adverse events of surgery, but not adverse
events related to fibrin sealant (and fibrin sealants are used to reduce these adverse events related to
surgery). Duration of the operation was used to reflect the outcome ‘nurse or doctor time’ instead of the
previously mentioned ‘dressing or fine-needle aspirations’. Sensitivity analyses were planned for aspects
of the review that might have an impact on the results; for example, including studies where there is a
high risk of bias.53 However, most studies were assessed as having an unclear risk of bias and, therefore,
these analyses were not deemed to be appropriate. Sensitivity analysis using a random-effects model
was conducted, but because of the large number of RCTs identified in the review, it was not possible
to perform additional analyses in the time available.
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Results
Quantity and quality of research available
Quantity of randomised controlled trials
A total of 2509 records were identified by searching MEDLINE, EMBASE and The Cochrane Library (Figure 1).
After deduplication and screening records, 443 full-text papers were assessed for inclusion. After reviewing the
full text, 257 studies were excluded for various reasons, as outlined in Figure 1 (for details of excluded studies
see Appendix 3). We included 186 RCTs, which are summarised in Table 2. These RCTs were undertaken
in 14 different surgical specialties (classification based on the Royal College of Surgeons of England58) or
included a mix of different surgical specialties (four papers combined different surgical specialties), and are
presented in Table 2.
Records identified through 
database searching
(n = 2509)
Records identified through
 other sources
(n = 2)
Records after duplicates removed
(n = 1428)
Records screened
(n = 1428)
Records excluded
(n = 985)
Full-text articles 
assessed for eligibility
(n = 443)
Studies included in 
narrative synthesis
(n = 186)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 37)
Full-text articles excluded, 
with reasons 
(n = 257)
• Not fibrin glue, n = 14
• Abstracts, n = 58
• Not a RCT, n = 33
• Included children, n = 25
• Control is fibrin sealant, n = 14
• Both trial arms received 
   fibrin sealant, n = 9
• Control not standard
   care, n = 9
• Discussion papers, n = 2
• Duplicate, n = 23
• Letters without data, n = 11
• Review article, n = 10
• Not surgery, n = 9
• Commentary, n = 6
• Outcomes not of interest, n = 6
• No translator found, n = 5
• Not in humans, n = 3
• Unobtainable, n = 3
• Interim results, n = 2
• Emergency procedures/wrong
   indication, n = 4
• Protocol, n = 1
• Erratum, n = 1
• Other, n = 9
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram for RCTs.
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TABLE 2 Overview of surgical specialties and number of RCTs
Surgical area Number of RCTs
Upper GI tract (digestive system) 33
Stomach 11
Liver 13
Gallbladder 3
Pancreas 6
Breast and lymph nodes 30
Breast and/or axillary lymph nodes 19
Inguinal and/or axillary lymph nodes 9
Pelvic and/or para-aortic lymph nodes 1
Thorax/oesophagus lymph nodes 1
Cardiothoracic 20
Lung 16
Heart 4
Orthopaedic (joints) 17
Shoulder 1
Hip 5
Knee 11
Eye 15
Hernia 14
Otolaryngology (ENT) 7
Nose 6
Tonsils 1
Vascular 13
Plastic or reconstructive 10
Skin (graft and ulcer) 5
Buttock (pilonidal disease) 2
Abdomen (lipoabdominoplasty) 2
Ischial region 1
Colorectal (anus) 5
Urology (urinary tract) 5
Kidney 3
Prostate 1
Urethra 1
Oral (mouth) and maxillofacial 7
Mixed 4
Gynaecological 4
Neurological 2
Total 186
ENT, ear, nose and throat; GI, gastrointestinal.
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Sample sizes ranged from seven participants in Nativ et al.59 to 1436 participants in Tavilla et al.,60 with a
median sample size of 62 participants and most values at the lower end. RCTs were published over the
past 30 years, since 1985. The main fibrin sealants used were Tisseel (n = 37)/Tissucol® (ImmunoAG,
Vienna, Austria) (n = 16), Quixil® (Johnson & Johnson Wound Management, Somerville, NJ, USA) (n = 23),
TachoSil® (Takeda Austria GmbH, Linz, Austria) (n = 18), Beriplast® (Behringwerke, Marburg, Germany;
FSBP, Aventis Behring, Strasbourg, France) (n = 12), Vivostat® (Vivolution A/S, Birkerød, Denmark) (n = 8)
and EVICEL (n = 6).
In addition, 87 RCTs from clinicaltrials.gov were identified, of which 11 relevant trials started since
January 2013 (see Appendix 4). Seven trials from controlled-trials.com were found, of which none was
recent (since January 2013). A total of 26 trials from clinicaltrialsregister.eu were found, of which 4 were
relevant, recent RCTs (see Appendix 4).
In the following subsections the quantity of RCTs and their characteristics for each of the 14 surgical
specialties are described.
Upper gastrointestinal (digestive system) surgery
A total of 33 upper gastrointestinal (GI) tract surgery RCTs were identified:61–93 13 liver surgeries,65–75,77,250
three cholecystectomies,78–80 seven pancreatic surgeries,81–86,93 five gastric surgeries63,64,89,90,92 and five
surgeries in other areas of the digestive tract61,62,87,88,91 (Table 3). Fibrin sealants had a range of indications
in the RCTs reporting GI tract surgeries: improving haemostasis, reducing leakage and wound drainage,
and preventing post-operative complications. A variety of different fibrin sealants were used. The sample
size ranged from 1361 to 32062 participants, with a mean size of 116 participants. The follow-up duration
varied from approximately 7 days in Fernandez et al.63 to 53 months in Huang et al.,64 but was
infrequently reported.
TABLE 3 Summary of included RCTs in upper GI tract (digestive system) surgery
Study (author, year)
Sample
size Surgery Intervention Control
Bektas et al., 201465 31 Liver resection Tisseel spray Compression
de Boer et al., 201266 45 Liver resection Quixil/Crosseal (Johnson &
Johnson Wound Management,
Somerville, NJ, USA)
Standard care
Chapman et al.,
200067
60 Hemihepatectomy or
segmental liver resection
CoStasis Surgical Hemostat
(Cohesion Technologies Inc.,
Palp Alto, CA, USA)
Standard care
Uetsuji et al., 199468 96 Hepatectomy IMMUNOAG spray (IMMUNO
AG, Vienna, Austria)
Liver mobilisation
Liu and Lui, 199369 118 Liver resection Fibrin sponge/bandage Standard care
Noun et al., 199670 137 Liver resection Biocol glue (Bio-transfusion,
Lille, France)
Standard care
Figueras et al., 200771 143 Liver and contralateral
resection
Tissucol Standard care
Fischer et al., 201172 146 Liver resection TachoSil patch Argon beam coagulation
Frilling et al., 200573 148 Liver resection TachoSil Argon beam coagulation
Kakaei et al., 201374 166 Liver resection TachoSil patch Surgicel (Ethicon,
Somerville, NJ, USA)
Kohno et al., 199275 174 Liver resection Beriplast Bovine microcrystalline
collagen powder
continued
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TABLE 3 Summary of included RCTs in upper GI tract (digestive system) surgery (continued )
Study (author, year)
Sample
size Surgery Intervention Control
Moench et al., 201476 187 Liver resection TachoSil patch Collagen hemostat
sangustop fleeces
(B. Braun Surgical S.A.,
Barcelona, Spain)
Schwartz et al.,
200477
207 Liver resection Crosseal/Quixil spray Haemostatic agents
Fu et al., 200978 60 Laparoscopic
cholecystectomy
Fibrin sealant Fibrin sealant and
ropivacaine hydrochloride
Danielsen et al.,
201079
51 Laparoscopic
cholecystectomy
Vivostat Human albumin
Dimo et al., 198980 80 Cholecystectomy Beriplast spray Standard care
Carter et al., 201381 101 Pancreatectomies Vitagel injection (Stryker,
Kalamazoo, MI, USA)
Staples or sutures
Suzuki et al., 199582 56 Distal pancreatectomy Tisseel glue Standard care
Lillemoe et al., 200483 124 Pancreaticoduodenectomy Hemaseel glue (Baxter
Healthcare Corp, Deerfield,
MA, USA)
Standard care
Montorsi et al.,
201284
275 Pancreatectomy TachoSil patch Standard suturing or
stapling
Suc et al., 200385 182 Pancreaticoduodenectomy Tissucol spray Standard care
Martin and Au,
201386
57 Pancreaticoduodenectomy Tisseel adhesive Standard care
Hwang and Chen,
199661
13 Closure of low-output
enterocutaneous fistula
Fibrin tissue glue, infused Conservative treatment
Huang et al., 201564 42 Locally advanced gastric
cancer without peritoneal
metastases
Fibrin sealant spray Cisplatin hyperthermic
intraoperative
chemotherapy
Fernandez Fernandez
et al., 199663
86 Total gastrectomy for
gastric adenocarcinoma
Tissucol fibrin glue Standard care
Oliver et al., 201287 104 Anastomosis of the
digestive tract
Tissucol Duo (1 ml) Standard care
Musella et al., 201488 100 Laparoscopic sleeve
gastrectomy
Tiseel spray Standard care
Silecchia et al.,
200862
320 Laparoscopic Roux-en-Y
antecolic antegastric
gastric bypass
Tissucol/Tisseel Sutures
Pilone et al., 201289 30 Laparoscopic sleeve
gastrectomy for bariatric
surgery
TachoSil spray Standard care
Sroka et al., 201590 165 Laparoscopic sleeve
gastrectomy
EVICEL spray Sutures
Fékété et al., 199291 100 Surgery requiring
oesophageal anastomosis
Quick-setting fibrin glue Standard care
Bulbuller et al.,
201392
65 Gastrectomy Tisseel Without suture
Huang and Qian,
201493
95 Radical gastrectomy Fibrin spray Standard care
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Breast and lymph node surgery
A total of 30 breast and lymph nodes surgery RCTs94–123 were identified: 19 in breast and/or axillary lymph
nodes,95–112,123 nine in inguinal and/or axillary lymph nodes,94,113–120 one in pelvic and/or para-aortic lymph
nodes121 and one in thorax/oesophagus lymph nodes122 (Table 4). Fibrin sealants were used as a wound
sealant in all RCTs apart from Zhibo and Miaobo,95 when a local anaesthetic was incorporated into
the fibrin sealant. A variety of different fibrin sealants were used in different forms, such as patches
[TachoComb (Takeda Pharma, Apotekerstien, Denmark) and TachoSil] and sprays (Vivostat, Tisseel and
Beriplast). Control-group interventions included standard closure, lidocaine only, no fibrin and no drain.
The sample size ranged from 26114 to 159110 participants, with a mean size of 66 participants. Individual
randomisation took place in all the RCTs. The follow-up duration varied from approximately 3 days in
Moore et al.106 to 46 months in Swan et al.,113 but was infrequently reported.
TABLE 4 Summary of included RCTs in breast and lymph nodes surgery
Study (author, year)
Sample
size Surgery Intervention Control
Zhibo and Miaobo,
200995
30 Breast: surgical augmentation Fibrin glue and lidocaine Lidocaine only
Ulusoy et al., 200396 54 Breast: mastectomy Fibrin sealant, spray Standard closure
Dinsmore et al.,
200097
27 Breast: mastectomy Autologous fibrin glue,
spray
Standard closure
Nielsen et al., 1985123 38 Breast: mastectomy Tisseel, spray Standard care
Udén et al., 199398 68 Breast and axillary lymph nodes Tisseel, adhesive Standard closure
Jain et al., 200499 116 Breast and axillary lymph nodes Tisseel spray; no drains No fibrin, no drain
Johnson et al., 2005100 82 Breast and axillary lymph nodes Hemaseel APR, spray Standard closure
Llewellyn-Bennett
et al., 2012101
101 Breast and axillary lymph nodes Tisseel, spray Standard closure
Ko et al., 2009102 95 Breast and axillary lymph nodes Greenplast kit (Green Cross
Corp., Seoul, Korea), spray
Standard closure
Miri Bonjar et al.,
2012103
60 Breast and axillary lymph nodes Hemaseel, spray Standard closure
Mustonen et al.,
2004104
40 Breast and axillary lymph nodes Tisseel, spray Standard closure
Segura-Castillo et al.,
2005105
45 Breast and axillary lymph nodes Quixil, spray Standard closure
Moore et al., 1997106 63 Breast and axillary lymph nodes Autologous fibrin sealant,
spray
Standard closure
Berger et al., 2001107 60 Axillary lymph nodes TachoComb H, patch Standard closure
GiIlly et al., 1998108 108 Axillary lymph nodes Tissucol, unclear
application
Standard closure
Benevento et al.,
2014109
60 Axillary lymph nodes Fibrin sealant Standard closure
Cipolla et al., 2010110 159 Axillary lymph nodes Fibrin sealant, spray Standard closure
Moore et al., 2001111 80 Axillary lymph nodes Fibrin sealant VI Guard
spray (V.I. Technologies,
Inc. Vitex, Watertown, MA,
USA) 4/8/16 ml
Standard closure
continued
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Cardiothoracic surgery
A total of 18 cardiothoracic surgery RCTs60,124–140 were identified, of which 14 were in lung surgery124–137
and four were in heart surgery60,138–140 (Table 5). In lung surgery, fibrin sealants were used to prevent
or reduce air leakage, whereas in heart surgery the indication for fibrin sealants was to stop bleeding.
A variety of different fibrin sealants were used, such as patches (TachoComb and TachoSil) and sprays
(Vivostat, Tisseel or Beriplast). Control-group interventions included sutures, stapling, clips, standard
patches, fleece material, electrocautery or no additional procedures. The sample size ranged from 23138
to 346129 participants, with a mean size of 115 participants.
TABLE 4 Summary of included RCTs in breast and lymph nodes surgery (continued )
Study (author, year)
Sample
size Surgery Intervention Control
Vaxman et al., 1995112 40 Axillary lymph nodes Tisseel, spray Standard closure
Swan et al., 2011113 74 Axillary or inguinal lymph nodes Tisseel, spray Standard closure
Siim et al., 1994114 26 Axillary or inguinal lymph nodes Tisseel, unclear application Standard closure
Gilly et al., 1994115 40 Axillary or inguinal lymph nodes Tissucol, spray Standard closure
Furrer et al., 1993116 30 Axillary or inguinal lymph nodes Tissucol, spray Standard closure
Di Monta et al.,
2012117
70 Axillary or ilioinguinal lymph
nodes
TachoSil, patch Standard closure
Neuss et al., 2009118 58 Inguinal lymph nodes Tissucol, spray Standard closure
Simonato et al.,
2009119
60 Inguinal lymph nodes TachoSil, patch Standard closure
Carlson et al., 200894 137 Inguinal lymph nodes Tisseel, spray Standard closure
Mortenson et al.,
2008120
30 Inguinofemoral lymph nodes Tisseel, unclear application Standard closure
Scholz et al., 2002121 93 Pelvic or pelvic and para-aortic
lymph nodes
Tissucol, spray Standard closure
Tachibana et al.,
2003122
43 Thorax/oesophagus lymph nodes Bohleal (Kaketsuken
Pharmaceutical,
Kumamoto, Japan), spray
Standard closure
TABLE 5 Summary of included RCTs in cardiothoracic surgery
Study (author, year)
Sample
size Surgery Intervention Control
Lung
Fabian et al., 2003128 100 Pulmonary resection Fibrin glue spray Stapling
Droghetti et al.,
2008124
40 Pulmonary resection Fibrin patch Stapling
Lopez et al., 2013129 346 Pulmonary resection TachoSil patch Suturing
Rena et al., 2009127 60 Pulmonary resection TachoSil patch Standard treatment
Gonfiotti et al.,
2011130
186 Pulmonary resection Fibrin sealant No additional
interventions
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Orthopaedic (joint) surgery
A total of 17 RCTs14,141–156 in orthopaedic surgery were identified (Table 6). Eleven reported fibrin usage
for knee arthroplasty,14,142–151 whereas five reported on hip arthroplasty141,152–154,156 and one on shoulder
surgery.155 In knee and hip arthroplasty, fibrin was used as a haemostatic agent. The most commonly
reported sealant used was Quixil spray, which was used in eight RCTs.14,144–148,154,156 The remaining RCTs
reported using EVICEL,149–151 Vivostat141 and Omrixil® spray (Omrix Biopharmaceuticals, Tel Hashomer,
Israel),153 whereas two RCTs did not specify the product that was used.152,155 Control groups mostly
constituted patients receiving standard care. The sample size ranged from 24145 to 198142 participants, with
a mean size of 81 participants. Within-patient randomisation took place in Kjaergard and Trumbull139 and
individual randomisation was undertaken in the remaining RCTs. Duration of follow-up ranged from 7 days
in Randelli et al.149 to 3 years in Mawatari et al.152
TABLE 5 Summary of included RCTs in cardiothoracic surgery (continued )
Study (author, year)
Sample
size Surgery Intervention Control
Moser et al., 2008126 25 Pulmonary resection Vivostat system No additional
interventions
Belcher et al., 2010131 102 Pulmonary resection Vivostat system, spray BioGlue (CryoLife,
Kennesaw, GA,
USA)
Mouritzen et al.,
1993132
114 Pulmonary resection
(pneumonectomies, lobectomies,
bilobectomies, segmental
resections, subsegmental
resections or decortications)
Beriplast P spray Not specified
Belboul et al., 2004133 40 Pulmonary resection (lobectomy) Vivostat system No additional
interventions
Lang et al., 2004134 186 Pulmonary resection (lobectomy) TachoComb,
fleece-bound sealant
Sutures
Anegg et al., 2007125 152 Pulmonary resection (lobectomy,
segmentectomy)
TachoSil, fleece-bound
sealant patch
Sutures with
absorbable patches
or staples
Marta et al., 2010135 299 Pulmonary resection (lobectomy) TachoSil, surgical patch Resuturing, stapling
or no treatment
Filosso et al., 2013136 24 Pulmonary resection
(thoracotomy, lobectomy)
TachoSil, patch Stapling/suturing
Czerny et al., 2004137 80 Lobectomy and mediastinal
lymph node dissection
TachoComb, bandage/
patch
Conventional
surgical
haemostasis
Heart
Kjaergard and
Trumbull, 1998138
23 Primary coronary artery bypass
surgery/grafting
Vivostat system Sutures, clips and
electrocautery
Kjaergard and
Trumbull, 2000139
60 Median sternotomy Vivostat system No additional
interventions
Maisano et al., 2009140 119 Elective surgery on the heart,
ascending aorta or arch
requiring a cardiopulmonary
bypass procedure
TachoSil, patch Standard
haemostatic fleece
material
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Eye surgery
A total of 15 eye surgery RCTs157–171 were identified, of which 13 were on pterygium surgeries,157–163,165–169,171
one was a cataract surgery170 and one a corneal perforation surgery164 (Table 7). In pterygium surgery, fibrin
adhesives were used to attach conjunctival autografts. For cataracts and perforation, fibrin sealants were
used for wound closure and perforation closure, respectively. The most commonly reported sealant used
within the RCTs was Tisseel (used in seven RCTs157,160–163,167,171). Quixil159,166,169 and Beriplast158,168 were also
used, whereas the product was not specified in three RCTs.164,165,170 Control group interventions were
sutures in all the RCTs except for one in which cyanoacrylate tissue adhesive was used (Sharma et al.164).
The sample size ranged from 22168 to 116165 participants, with a mean size of 63 participants.
TABLE 6 Summary of included RCTs in orthopaedic (joint) surgery
Study (author, year)
Sample
size Surgery Intervention Control
Knee
Aguilera et al., 2013143 166 Total knee arthroplasty Fibrin glue, Tissucol None
Levy et al., 199914 58 Total knee arthroplasty Quixil, spray Standard care
Wang et al., 2001144 46 Knee arthroplasty Quixil, spray Standard care
Kluba et al., 2012145 24 Total knee arthroplasty Quixil, spray Anaesthesia and fluid
regimen
McConnell et al., 2012146 65 Knee arthroplasty Quixil, spray Tranexamic acid
Molloy et al., 2007147 150 Total knee arthroplasty Quixil, spray Tranexamic acid
Sabatini et al., 2012148 70 Total knee, cement-less
arthroplasty
Quixil Dideco blood recovery device
(Liva Nova, London, UK)
Randelli et al., 2014149 62 Total knee arthroplasty EVICEL, spray Electrocautery
Skovgaard et al., 2013150 48 Total knee arthroplasty EVICEL, spray Saline
Choufani et al., 2015151 60 Total knee arthroplasty EVICEL, spray Standard care
Heyse et al., 2014142 198 Total knee arthroplasty Fibrin, spray Standard care
Hip
Mawatari et al., 2006152 100 Total hip arthroplasty Autologous fibrin
tissue adhesive, spray
Standard care
Wang et al., 2003153 81 Total hip arthroplasty Omrixil, spray Standard care
Lassen et al., 2006141 58 Hip arthroplasty Vivostat, spray Standard care
Falez et al., 2013154 95 Hip arthroplasty Quixil, spray Bipolar sealer (Medtronic,
Minneapolis, MN, USA)
McConnell et al., 2011156 66 Hip arthroplasty Quixil, spray Tranexamic acid
Shoulder
Antuña et al., 2013155 28 Arthroscopic massive
rotator cuff tears repair
Platelet-rich fibrin Standard care
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Hernia surgery
A total of 14 hernia surgery RCTs172–185 were identified (Table 8). Fibrin sealants were used mostly for
prosthetic mesh fixation (12 RCTs172–176,178,181–186). The most commonly reported sealant used was Tisseel/
Tissucol (10 RCTs172,176–178,180–185). Quixil (two RCTs174,179) and Vivostat (one RCT173) were also used, whereas
one RCT did not report which fibrin product was used.175 Three papers reported using fibrin sealant in spray
form176,177,179 and three reported using laparoscopic applicators.172,178,180 One paper reported using a needle
applicator,174 another reported using a manual application catheter183 and the remaining six papers did not
specify how it was applied.173,175,181,182,184,185 Fibrin was compared with a range of interventions across the
RCTs including sutures, staples, tacks and self-gripping mesh. The sample size ranged from 22173 to 600185
participants, with a mean size of 172 participants. Within-patient randomisation took place in Boldo173 and
individual randomisation was undertaken in the remaining RCTs. The follow-up duration varied from
approximately 3 months in Cambal et al.175 to 26 months in Olmi et al.185
Ear, nose and throat surgery
Seven RCTs186–192 were identified in ear, nose and throat (ENT) surgery: six nasal surgeries186–191 and one
tonsillectomy192 (Table 9). Fibrin adhesives were mostly used to aid haemostasis (five RCTs188–192) and to
improve healing. The most commonly reported sealant used was Quixil (spray/glue) and was used in four
TABLE 7 Summary of included RCTs in eye surgery
Study (author, year)
Sample
size Surgery Intervention Control
Ocular surface
Kucukerdonmez et al.,
2010157
70 Pterygium surgery with autograft Tisseel VH, glue Sutures
Eye
Yüksel et al., 2010158 58 Pterygium surgery with autograft Beriplast P/Combi-set
(Aventis Hehring GmbH,
Marburg, Germany)
Sutures
Bahar et al., 2006159 65 Pterygium surgery Quixil Sutures
Rubin et al., 2011166 42 Pterygium surgery with autograft Quixil, glue Sutures
Conjunctiva
Hall et al., 2009160 50 Pterygium surgery with autograft Tisseel, glue Sutures
Karalezli et al., 2008161 50 Pterygium surgery with autograft Tisseel, glue Sutures
Koranyi et al., 2005162 43 Pterygium surgery with autograft Tisseel, glue Sutures
Sati et al., 2014163 90 Pterygium surgery with autograft Tisseel, spray Sutures
Ratnalingam et al., 2010165 137 Pterygium surgery with autograft Fibrin, glue Sutures
Srinivasan et al., 2009167 40 Pterygium surgery with autograft Tisseel Sutures
Uy et al., 2005168 22 Pterygium surgery with autograft Beriplast P, glue Sutures
Mellin and Kondler, 1989170 100 Cataract surgery Fibrin, glue Sutures
Malik and Kumar, 2010171 50 Pterygium surgery with autograft Tisseel Duo Quick Sutures
Cornea
Sharma et al., 2003164 40 Corneal perforation Fibrin, glue Cyanoacrylate
tissue adhesive
Bahar et al., 2007169 81 Pterygium surgery with autograft Quixil Sutures
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TABLE 9 Summary of included RCTs in ENT surgery
Study (author, year)
Sample
size Surgery Intervention Control
Nose
Prado et al., 2006187 22 Rhinoplasty Beriplast Standard care
Pryor et al., 2008186 10 Rhinoplasty EVICEL Compression
Vaiman et al., 2005189 64 Endoscopic sinus surgery Quixil/Crosseal (Johnson
& Johnson Wound
Management, Somerville,
NJ, USA) spray
Nasal packing
Yu et al., 2014190 41 Rhinosinusitis refractory Fibrin spray Sponge packing
Vaiman et al., 2005191 513 Endonasal surgery Quixil glue Nasal packing
Nose and septum
Vaiman et al., 2002188 204 Septoplasty and conchotomy Quixil aerosol glue Quixil aerosol glue and
trans-septal suturing
Tonsils
Vaiman et al., 2006192 80 Tonsillectomy Quixil spray Electrocautery
TABLE 8 Summary of included RCTs in hernia surgery
Study (author, year)
Sample
size Surgery Intervention Control
Inguinal canal
Lau, 2005172 93 Endoscopic totally
extraperitoneal inguinal
hernioplasty
Tisseel VH Staples
Boldo, 2008173 22 Laparoscopic hernioplasty Vivostat Staples
Bracale et al., 2014174 102 Hernioplasty Quixil Sutures
Cambal et al., 2012175 100 Laparoscopic hernioplasty Fibrin glue Self-gripping
(or self-anchoring) mesh
Campanelli et al.,
2012176
316 Hernioplasty Tissucol/Tisseel Sutures
Canonico et al., 1999177 50 Hernioplasty Tissucol Standard care
Chan et al., 2014178 129 Total extraperitoneal
hernioplasty
Tisseel spray Staples
Lionetti et al., 2012179 148 Hernioplasty Quixil spray Sutures
Wong et al., 2011182 56 Hernioplasty Tisseel glue Sutures
Damiano et al., 2014184 468 Herniorrhaphy Tissucol Sutures
Olmi et al., 2007185 600 Laparoscopic transabdominal
pre-peritoneal hernia repair
Tissucol/Tisseel Staples
Inguinal and femoral canals
Lovisetto et al., 2007180 197 Hernioplasty Tissucol/Tisseel Staples
Tolver et al., 2013181 100 Laparoscopic groin hernia Tisseel spray Tacks
Umbilicus
Eriksen et al., 2013183 34 Laparoscopic ventral hernia
repair
Tisseel Duo Quick Tacks
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RCTs,188,189,191,192 whereas Beriplast187 and EVICEL186 were also used. Control-group interventions included
packing, compression, sutures and standard care. The sample size ranged from 10186 to 513191 participants,
with a mean size of 133 participants. Within-patient randomisation took place in two RCTs,186,190 whereas
individual randomisation was undertaken in the remaining RCTs. The follow-up duration varied from
approximately 21 days in Pryor et al.186 to 1 year in Prado et al.187
Vascular surgery
A total of 13 vascular surgery RCTs193–205 were identified (Table 10). Fibrin sealant was used in all cases to
control suture hole bleeding from placing the graft for vascular access or vascular reconstruction surgery.
In Bajardi et al.194 Poly(ethyl benzene-1,4-dicarboxylate) [Dacron® (Ethicon Inc., Somerville, NJ, USA)] grafts
were used, whereas in all other RCTs193,195–204 polytetrafluoroethylene grafts were used. These materials are
frequently used for vascular replacement or bypass when no autologous venae are available. All RCTs used
different fibrin sealants apart from the Joseph et al.200 and Czerny et al.205 RCTs that used TachoComb
patches. Control group interventions were manual compression194,196–198,200,204,205 or use of thrombin,196
thrombin-soaked materials,196,199 Surgicel195,196 or Kalkostat.202 The sample size ranged from 24200 to 199199
participants, with a mean size of 66 participants. Individual randomisation was undertaken in all RCTs.
Follow-up duration varied from approximately 30 days in Sintler et al.202 to 6 months in Schenk et al.,195
but was infrequently reported.
TABLE 10 Summary of included RCTs in vascular surgery
Study
(author, year)
Sample
size Surgical area Surgery Intervention Control
Schenk et al.,
2003195
48 Upper extremity; artery
and vein in the upper
arm or forearm
Vascular access
surgery using PTFE
graft placement
(dialysis required for
end-stage renal
failure)
Bioplasma (ZLB,
Bioplasma AG,
Bern, Switzerland)
glue
Surgicel (Johnson &
Johnson, Somerville,
NJ, USA)
Schenk et al.,
2002196
28 Upper extremity; artery
and vein in the upper
arm or forearm
Vascular access
surgery using PTFE
graft placement
Hemaseel spray
(Haemacure Corp.,
Sarasota, FL, USA)
Thrombin (n= 8);
pressure (n= 6);
thrombin-soaked
Gelfoam (Pfizer Inc.,
New York City, NY,
USA) (n= 2); Surgicel
(n= 2)
Saha et al.,
2012197
140 Upper and lower
extremity:
axillofemoral,
iliofemoral,
femorofemoral,
iliopopliteal, proximal
femoropopliteal, distal
femoropopliteal and
femorotibial vessel
bypass
Arterio-arterial
bypasses and
arteriovenous
shunting for dialysis
access with expanded
PTFE graft placement
Fibrin sealant Compression
Chalmers
et al., 2010198
147 Femoral or upper
extremity arteries
PTFE grafts EVICEL Compression
Taylor et al.,
2003199
199 Femoral artery PTFE grafts Beriplast P gel Thrombin-soaked
gelatin sponge
Joseph et al.,
2004200
24 Femoral or carotid
artery
Femoral anastomosis
and femoral or
carotid patch
angioplasty with PTFE
grafts
TachoComb patch Compression
continued
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Plastic or reconstructive surgery
Ten RCTs206–215 in plastic/reconstructive surgery in various body sites were found (Table 11). Fibrin sealant
had different indications within plastic/reconstructive surgery: haemostasis (four RCTs207,208,211,212), reduction
of seroma formation (two RCTs213,214), reduction of drainage (two RCTs210,215) and wound healing (two
RCTs206,209). Various types of fibrin sealants were used across the RCTs: sprays (Tisseel,210,211 Cryoseal,206,212
Quixil213 and autologous sealant using a spraypen207) and a Bioseed fibrin net.208 Control-group interventions
included standard care,206,210,212,214,215 pressure,208,209 thrombogen kit,207 fabric dressing211 and suction drains.213
The sample size ranged from 10210 to 225208 participants, with a mean size of 58 participants. Individual
randomisation was undertaken in all RCTs except Drake and Wong,207 which reported within-patient
randomisation. The follow-up duration varied from 1 week207 to 12 months210 and was not reported in
Oliver et al.215
Colorectal surgery
Five RCTs were found in colorectal surgery216–220 (Table 12). Fibrin sealant was used mainly to minimise
recurrence and prevent incontinence after anal fistula surgery. Three RCTs216,217,219 reported the use of
Tisseel/Tissucol in the fibrin group, whereas Beriplast was used in one RCT218 and the remaining RCT220
did not specify the product used. The sample size ranged from 28219 to 62217 participants and the mean
TABLE 10 Summary of included RCTs in vascular surgery (continued )
Study
(author, year)
Sample
size Surgical area Surgery Intervention Control
Jackson et al.,
1999193
47 Carotid artery Elective carotid
endarterectomy with
expanded PTFE patch
angioplasty
(atherosclerotic
occlusive diseases)
Investigational new
drug number 4353,
human fibrin
sealant
Gelfoam
Milne et al.,
1995201
17 Carotid artery Endarterectomy with
a PTFE patch
Fibrin spray No treatment
Sintler et al.,
2005202
20 Carotid artery Endarterectomy with
an expanded PTFE
patch
Quixil Kaltostat (ConvaTec,
Flintshire, UK)
Milne et al.,
1996203
39 Artery or aorta Arterial bypass
surgery with a PTFE
bypass graft and
aortic aneurysm
repair with a woven
Dacron graft
Fibrin injection No treatment
Saha et al.,
2011204
73 Anastomoses (junction)
of arterio-arterial
bypasses and
arteriovenous shunts
Bypass vessel PTFE
grafts
Tisseel Compression
Czerny et al.,
2000205
60 Aortofemoral,
femoropopliteal and
crossover bypasses,
femoral artery, arteria
carotis interna
Vascular
reconstruction;
anastomoses or patch
angioplasties with
PTFE prostheses
TachoComb H
patch
Compression
Bajardi et al.,
2009194
20 Infrarenal abdominal
aorta
Elective infrarenal
abdominal aortic
aneurysm
replacement with a
Dacron graft
TachoSil patch Compression
PTFE, poly(1,1,2,2-tetrafluoroethylene).
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TABLE 12 Summary of included RCTs in colorectal surgery (anal fistula)
Study (author, year)
Sample
size Surgery Intervention Control
Ellis and Clark, 2006216 57 Mucosal or anodermal advancement
flap for surgical management of anal
fistulas
Tisseel injection Flap repair
Altomare et al., 2011217 62 Treatment of trans-sphincteric anal
fistulas
Tissucol Seton treatment
Lindsey et al., 2002218 42 Treatment of anal fistulas Beriplast glue Fistulotomy or loose
seton insertion
Hammond et al., 2011219 28 Treatment of idiopathic anal fistula Tisseel glue Permacol (Covidien,
Dublin, Ireland)
van der Hagen et al.,
2011220
30 Treatment of complex perianal fistulas Fibrin sealant glue Seton drainage
TABLE 11 Summary of included RCTs in plastic or reconstructive surgery
Study
(author, year)
Sample
size Surgical area Surgery Intervention Control
Drake and
Wong, 2003207
34 Skin Skin graft Vivolution spraypen
(Vivolution A/S,
Birkerød, Denmark)
Thrombogen Kit (Johnson
& Johnson Wound
Management, Somerville,
NJ, USA)
Vanscheidt
et al., 2007208
225 Lower legs Treatment of recalcitrant
venous leg ulcers
BioSeed fibrin net
(BioTissue
Technologies
GmbH, Freiburg,
Germany)
Pressure dressing pad
Danielsen et al.,
2008209
39/40 Legs Treatment of leg ulcers Vivolution Gauze and pressure
Erba et al.,
2010210
10 Ischial region Seal fasciocutaneous
flaps to cover ischial
pressure sore
Tisseel spray Standard care
Healy et al.,
2013211
40 Thigh Treat split skin graft
donor sites
Tisseel spray Mefix self-adhesive fabric
dressing (MoInlycke
Healthcare, Lancashire,
UK)
Altinli et al.,
2007206
32 Buttock Limberg flap procedure
in pilonidal disease
CryoSeal spray
(Thermogenesis,
Rancho Cordova,
CA, USA)
Standard care
Sözen et al.,
2011212
50 Buttock Karydakis flap operation
for pilonidal sinus
CryoSeal spray Standard care
Bercial et al.,
2012213
43 Abdomen Abdominoplasty Quixil spray Suction drains
Mabrouk et al.,
2013214
60 Abdomen Lipoabdominoplasty Fibrin glue Standard care
Oliver et al.,
2002215
44 Axilla, groin, back
and abdomen
Axillary dissection, groin
dissection, latissimus
dorsi flaps and
abdominoplasty
Beriplast spray Standard care
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number of patients was 44. Individual randomisation was undertaken in all RCTs. The follow-up duration
varied from approximately 1 year217 to 60 months.220
Urology (urinary tract)
Five RCTs59,221–224 were found in urological surgery (Table 13). Fibrin sealant was used for haemostasis in all the
RCTs except for Schultz and Christiansen224 in which it was used to reduce the post-operative drainage period.
Various fibrin sealants were used across the RCTs: Siemer et al.221 and Cormio et al.222 used a TachoSil patch,
Nativ et al.59 used an Ethicon pad, Luke et al.223 used Beriplast and Schultz and Christiansen224 used Tisseel.
Control groups received standard care in all the RCTs. The sample size ranged from 759 to 185221 participants,
and the mean number of patients was 67. Individual randomisation was undertaken in all RCTs. The follow-up
duration varied from 159,221 to 3 months223 but was not reported for Cormio et al.222 and Schultz and
Christiansen.224 Randomisation was carried out at an individual level in all RCTs.
Oral and maxillofacial surgery
Seven RCTs225–231 were found in oral and maxillofacial surgery (Table 14). Fibrin sealant was used mostly to
reduce post-operative wound drainage in different types of procedures. A variety of fibrin sealants were
used across RCTs: Tisseel,225,226,230 Crosseal,227 Beriplast spray,228 autologous fibrin glue229 and Artiss.231
Control-group interventions included ‘no sealant’,225,228,231 tranexamic acid229 and sutures.230 The sample
size ranged from 9227 to 75231 participants, with a mean size of 41 participants. Within-patient
randomisation was carried out in four RCTs,226–228,231 whereas the remaining three reported individual-level
randomisation.225,229,230 The follow-up duration varied from 24 hours in Oliver et al.228 to 3 weeks in
Maharaj et al.230
Gynaecological surgery
Four RCTs232–235 were found in gynaecological surgery (Table 15). Fibrin sealant was indicated for the
following: the prevention of post-operative adhesions,232,234 haemostasis around myomectomy suture
sites233 and prevention of a vesicovaginal fistula.235 A variety of fibrin sealants were used across RCTs
and control group patients received ‘no sealant’ procedures. The sample size ranged from 16232 to
91 participants,234 with a mean size of 54 participants. Follow-up duration was 3 months235 to 1 year,233
but not reported in Diamond et al.232 and Takeuchi et al.234
TABLE 13 Summary of included RCTs in urology (urinary tract) surgery
Study (author, year)
Sample
size Surgery Intervention Control
Kidney
Nativ et al., 201259 7 Open partial nephrectomy Ethicon pad (Johnson &
Johnson Wound
Management, Somerville,
NJ, USA)
Standard care
Siemer et al., 2007221 185 Resection of small, superficial
kidney tumours not extending
into the collecting duct system;
nephron-sparing surgery
TachoSil patch Standard suturing
Cormio et al., 2012222 96 Percutaneous nephrolithotomy TachoSil patch Nephrostomy tube
Prostate
Luke et al., 1986223 30 Transurethral resection of the
prostate
Beriplast glue Standard care
Urethra
Schultz and
Christiansen, 1985224
16 Closure of the ureterotomy after
ureteral stone surgery
Tisseel adhesive Dexon sutures
(Syneture,
Mansfield, MA,
USA)
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Neurosurgery
Two RCTs236,237 reporting on fibrin sealant for prevention of cerebrospinal fluid leakage were found in
neurosurgery (Table 16). Beriplast adhesive was compared with autologous fibrin sealant in Nakamura
et al.,236 whereas collagen sponge was compared with standard care in Hutter et al.237 Nakamura et al.236
reported a sample size of 30 participants, whereas the sample size in Hutter et al.237 was 229 participants,
giving a mean sample size of 134 participants. Individual randomisation was undertaken in both RCTs.
The follow-up duration was 32 days in Hutter et al.237 and 8 weeks in Nakamura et al.236
TABLE 15 Summary of included RCTs in gynaecological surgery
Study
(author, year)
Sample
size Surgical area Surgery Intervention Control
Diamond et al.,
2011232
16 Ovaries Bilateral ovarian
surgery
Adhexil spray/drip
(Johnson &
Johnson Wound
Management,
Somerville, NJ,
USA)
Standard care
Maggiore et al.,
2011233
70 Uterus/endometrium Laparoscopic removal
of myomas (neoplasm)
TachoSil sponge Standard care
Takeuchi et al.,
2005234
91 Uterus/abdomen Laparoscopic
myomectomy
Beriplast spray TachoComb sheet
Safan et al.,
2009235
38 Vesicovaginal region Treatment of
vesicovaginal fistula
Fibrin adhesive Standard care
TABLE 14 Summary of included RCTs in oral and maxillofacial surgery
Study
(author, year)
Sample
size Surgery Intervention Control
Face
Marchac and
Greensmith,
2005226
29 Rhytidectomy Tisseel spray Rhytidectomy using the vertical U
incision technique without glue
Oliver et al.,
2001228
20 Rhytidectomy Beriplast spray No sealant
Face and neck
Lee et al., 2009227 9 Rhytidectomy Crosseal No Crosseal treatment
Hester et al.,
2013231
75 Rhytidectomy Artiss No application of fibrin sealant
Thyroid gland
Uwiera et al.,
2005225
56 Hemithyroidectomy and
total thyroidectomy
Tisseel No sealant
Tooth socket
Carter et al.,
2003229
49 Dental extraction Autologous fibrin glue Active 4.8% tranexamic acid solution
Parotid glands
Maharaj et al.,
2006230
50 Superficial and total
parotidectomy
Tisseel fibrin glue Vicryl and Monocryl sutures (Johnson
& Johnson Wound Management,
Somerville, NJ, USA)
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Mixed surgery
Four RCTs238–241 across more than one surgical area were found (Table 17): Bochicchio et al.239 and Verhoef
et al.240 were in spinal and vascular surgery, hepatic resection and soft tissue dissection; Hanks et al.238
was cardiothoracic, general, obstetric and gynaecological and vascular surgery; and Fischer et al.241
was in abdominal, retroperitoneal, pelvic and non-cardiac thoracic surgeries. Fibrin sealant was used for
haemostasis in all the RCTs and different products were used across them. Raplixa fibrocaps powder was
used in Bochiccio et al.239 and Verhoef et al.240 In Hanks et al.238 autologous fibrin sealant derived from
patients’ blood was used, whereas in Fischer et al.241 fibrin pads were used. The sample size ranged from
69238 to 719239 participants, with a mean size of 263 participants. Individual randomisation was undertaken
in all RCTs. The follow-up duration was around 1 month in Bochicchio et al.239 and Fischer et al.,241 but
was not reported in the other two RCTs.
Quality of randomised controlled trials
A risk-of-bias table for RCTs can be found in Appendix 5. Overall, 154 studies were assessed as having an
‘unclear risk of bias’, eight RCTs as having a ‘high risk of bias’ and 24 RCTs as having a ‘low risk of bias’
(see Table 37). The risk-of-bias table (see Table 37) shows a high level of uncertainty about the validity of data
collected across all parameters, especially regarding the blind collection of patient outcomes. Owing to the
nature of the intervention, surgeons could not be blinded to the intervention, as they had to apply the fibrin
sealant; however, patients and outcome assessors who could be blinded to the intervention were frequently
not blinded either.
TABLE 17 Summary of included RCTs in mixed surgery
Study
(author, year)
Sample
size Surgical specialties Surgery Interventions Control
Bochicchio
et al., 2015239
719 Spine, liver, arteries,
soft tissues
Spinal procedures;
vascular procedures with
suture hole bleeding;
hepatic resection; soft
tissue dissection
Raplixa fibrocaps
powder (ProFibrix
BV – The Medicines
Company, Leiden,
The Netherlands)
Gelatin sponge
Verhoef et al.,
2015240
122 Spine, liver, arteries,
soft tissues
Hepatic resections (46%),
spinal procedures (30%),
vascular procedures
(24%) and soft tissue
dissection (1%)
Raplixa fibrocaps
powder
Pressure
dressing pad
Hanks et al.,
2003238
69 Cardiothoracic,
general, obstetric
and gynaecological,
and vascular
Not reported Vivostat system Dry surgical
sponge
Fischer et al.,
2013241
90/141 Abdomen,
retroperitoneum,
pelvis and
non-cardiothoracic
surgery
Surgical operations
in the abdomen,
retroperitoneum, pelvis
and non-cardiothoracics
Fibrin pad Surgicel
TABLE 16 Summary of included RCTs in neurosurgery
Study
(author, year)
Sample
size Surgical area Surgery Intervention Control
Nakamura et al.,
2005236
39 Dura layer of spinal
cord
Spinal cord tumours and
related illnesses
Beriplast adhesive Autologous
fibrin sealant
Hutter et al.,
2014237
229 Dura mater of the
brain
Elective cranial surgery
involving a dural incision
Collagen sponge Standard care
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Most of the funnel plots did not show publication bias (see Appendix 6); however, the funnel plot for
development of haematoma meta-analysis [Egger bias –0.63, 95% confidence interval (CI) –1.20 to –0.06;
p = 0.03] (see Figure 43) and duration of drainage for breast surgery meta-analysis (Egger bias –3.34,
95% CI –6.75 to –0.05; p = 0.05) (see Figure 47) showed a skewed figure of publications, which indicated
the presence of small study effects.
Quantity of observational studies and regulatory body reports
The search of electronic databases identified 4714 potentially relevant articles about harms related to the
use of fibrin sealants, of which 3709 references were excluded and 1005 full-text papers assessed (Figure 2
and Appendix 7). There were an additional 93 reports, reviews or notifications about harms from the use
of these products from the MHRA, EMA and FDA websites.
Records identified through 
FDA and MHRA websites
(n = 93)
Records identified 
through database searching
(n = 6511)
Duplicates removed
(n = 1797)
Records after duplicates removed
Databases 
(n = 4714)
MHRA/EMA/FDA 
(n = 93)
Records screened
Databases
(n = 4714)
MHRA/EMA/FDA
(n = 93)
Records excluded
(n = 3709)
Full-text articles/reports
 assessed for eligibility
Databases 
(n = 1005)
MHRA/EMA/FDA 
(n = 93)
Studies/reports included 
in narrative synthesis
Databases 
(n = 8)
MHRA/EMA/FDA 
(n = 5)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 0)
Database full-text articles 
excluded, with reasons 
(n = 995)
• No comparison group, n = 471
• RCT, n = 248
• No adverse events related 
   to fibrin, n = 76
• Letters/commentary without 
   data, n = 52
• Not a relevant/valid 
   comparison, n = 33
• Not a comparative 
   observational study, n = 24
• Not fibrin glue, n = 21
• Included children, n = 19
• Abstracts, n = 12
• Duplicate, n = 10
• Control is fibrin sealant, n = 8
• Emergency procedures, n = 8
• Unobtainable, n = 5
• Review article, n = 2
• Technical note, n = 1
• Not surgery, n = 3
• Not in humans, n = 1
• Fibrin data not shown 
   separately from control, n = 1
FIGURE 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of observational
studies and regulatory body reports.
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After screening and applying the eligibility criteria, eight observational studies were included242–249 (Table 18).
Three observational studies were in eye surgery,242–244 three in upper GI tract surgery,245–247 one in plastic/
reconstructive surgery248 and one in vascular surgery.249 There were three cohort studies,243,245,249 three
comparative studies242,244,247 and two reviews of patient records.246,248 The following fibrin sealants were
used: unspecified fibrin glue in eye surgery,242–244 Tiseel,245 Beriplast,247 aerosolised fibrin glue248 and
platelet-enriched fibrin glue sealant.249 Comparator interventions were standard care245–249 or sutures in eye
surgery.242–244 Sample sizes ranged from 40243 to 529246 participants.
Five reports from the regulatory body websites that reported on harms related to the use of fibrin sealants
were included (see Table 43).
Quality of observational studies
The validity of the eight observational studies was compromised owing to a general failure to report
whether or not adverse events were assessed independently and whether or not blinding to the assigned
was performed (Table 19). Cagatay et al.242 reported that harms were assessed independently. Five studies
described measurement instruments,243,245,246,248,249 but only three studies reported timing and duration of
follow-up.243,246,249 Only Sakic et al.249 appeared to have used objective measures. All eight studies, except
that by Jiang et al.,243 attributed the harms to the use of fibrin sealants and seven studies explained terms
used to identify harms.242–246,248,249 No studies reported to have blinded the collection of outcomes to the
treatment assignment.
TABLE 18 Overview of observational studies
Study (author,
year)
Sample
size
Type of comparative
study Surgery Intervention Control
Eye surgery
Cagatay et al.,
2014242
103 Comparative study
(consecutive sample)
Conjunctival autografting
for pterygium surgery
Fibrin glue Sutures
Jiang et al.,
2008243
40 Cohort study Conjunctival autografting
for pterygium surgery
Fibrin glue Sutures
Choi et al.,
2010244
126 Comparative study Pars plana vitrectomy (eye) Fibrin glue Sutures
Upper GI tract surgery
Efthimiou et al.,
2010245
474 Cohort (consecutive sample
supplemented with clinical
observations and chart
reviews)
Laparoscopic Roux-en-Y
gastric bypass
Tisseel Standard care
Ibele et al.,
2014246
529 Review of patient records
(consecutive sample)
Laparoscopic Roux-en-Y
gastric bypass
Autologous
fibrin sealant
Standard care
Nanashima
et al., 2012247
341 Comparative study
(consecutive sample)
Hepatobiliary pancreas
surgery; hepatectomy and
pancreatectomy
Beriplast fibrin
glue spray
Standard care
Plastic/reconstructive surgery
Marchac and
Sándor, 1994248
200 Review of patient records
(consecutive sample)
Rhytidectomy Aerosolised
fibrin glue
Standard care
Vascular surgery
Sakic et al.,
2013249
418 Cohort study (consecutive
sample)
Bilateral internal thoracic
artery grafting
Platelet-enriched
fibrin glue
sealant
Standard care
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Assessment of benefits
The following sections present the analyses of benefits for the primary and secondary outcomes (Table 20).
Fixed-effects model results are presented in the text and random-effects model results in Appendix 8. Data
on primary and secondary outcomes used in the meta-analysis for all RCTs are presented in Appendix 9.
Primary outcomes
Seroma development
Development of seroma was reported in 37 RCTs, of which 33 (n = 3472) were included in the meta-
analysis (Figure 3). The remaining four RCTs were excluded for the following reasons: Cipolla et al.110 as all
participants in the fibrin and control groups developed seroma; Erba et al.210 and Uwiera et al.225 because
no patients developed seroma; and Siim et al.114 because seroma development was not reported separately
but combined with other complications reported as ‘post-operative complications’. The included RCTs were
across different surgical specialties: breast and axillary/inguinal (19 RCTs94,96–105,107–109,111,113,115,118,120), hernia
(8 RCTs172–174,178,181,182,184,185), plastic, hepatic and otolayrngology.202,204,227
Patients receiving fibrin sealants rather than the control had a statistically non-significant reduced risk
of developing seroma (OR 0.84, 95% CI 0.68 to 1.04; p = 0.13; I2 = 12.7%, fixed-effects model). The
random-effects model showed a similar result (see Appendix 8). Two of the 32 RCTs with an unclear risk
of bias showed a statistically significant difference in seroma development: Mabrouk et al.214 reported a
significant benefit of fibrin sealant, whereas Lau172 reported more seroma development in patients
receiving fibrin sealants.
TABLE 20 Overview of outcomes and analysis
Outcomes Variables
Primary outcomes (dichotomous)
Seroma development Number of patients who developed seroma
Haematoma development Number of patients who developed haematoma and a post hoc analysis in which the
development of seroma and haematoma are combined
Secondary outcomes (dichotomous)
Haemorrhage (blood loss) Number of patients with bleeding
Reoperation Number of patients with reoperation
Infections Number of patients with wound infection
Use of analgesics Number of patients (no meta-analysis as the data from RCTs were too heterogeneous)
Complications arising from the
use of drains
Number of patients with complications (no data in RCTs reported)
Secondary outcomes (continuous)
Duration of operation Mean duration in minutes
Length of hospital stay Mean duration in days
Use of drains Mean duration of drainage in days
Pain levels Mean level of pain (no meta-analysis as the data from RCTs were too heterogeneous)
Health-related quality of life Mean health-related quality-of-life value (no data in RCTs reported)
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OR meta-analysis plot (fixed effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Wong 2011182 0.862 (0.011 to 70.345)
Ulusoy 200396 1.818 (0.308 to 12.953)
Udén 199398 1.561 (0.530 to 4.614)
Tolver 2013181 0.574 (0.085 to 3.169)
Swan 2011113 0.895 (0.326 to 2.453)
Sözen 2011212 3.632 (0.550 to 39.842)
Segura-Castillo 2005105 0.188 (0.018 to 1.172)
Olmi 2007185 0.371 (0.048 to 2.119)
Olmi 2007185 0.317 (0.041 to 1.758)
Olmi 2007185 0.405 (0.052 to 2.354)
Neuss 2009118 1.341 (0.407 to 4.452)
Mustonen 2004104 0.642 (0.150 to 2.697)
Mortenson 2008120 0.846 (0.094 to 7.709)
Moore 2001111 1.000 (0.116 to 13.262)
Moore 2001111 0.667 (0.068 to 9.653)
Moore 2001111 0.469 (0.041 to 7.341)
Moench 2010250 1.268 (0.204 to 9.012)
Miri Bonjar 2012103 0.604 (0.132 to 2.598)
Chan 2014178 1.356 (0.415 to 4.594)
Carlson 200894 0.751 (0.255 to 2.168)
Bracale 2014174 7.442 (0.418 to infinity)
Boldo 2008173 1.212 (0.305 to 4.852)
Berger 2001107 0.846 (0.265 to 2.689)
Benevento 2014109 0.138 (0.003 to 1.294)
Altinli 2007206 0.313 (0.000 to 39.000)
Combined (fixed) 0.838 (0.680 to 1.032)
OR (95% CI)
Mabrouk 2013214 0.060 (0.001 to 0.489)
Maharaj 2006230 0.126 (0.003 to 1.314)
Llewellyn-Bennett 2012101 3.379 (0.028 to infinity)
Lau 2005172 4.480 (1.354 to 17.119)
Ko 2009102 0.811 (0.276 to 2.346)
Johnson 2005100 0.700 (0.262 to 1.856)
Jain 200499 0.746 (0.225 to 2.455)
Hester 2013231 1.000 (0.179 to 5.591)
Gilly 1998108 1.163 (0.015 to 92.893)
Gilly 1994115 2.353 (0.111 to 145.635)
Dinsmore 200097 2.500 (0.368 to 19.869)
Damiano 2014184 0.573 (0.151 to 1.879)
FIGURE 3 Seroma development in all surgical specialties: fibrin sealant vs. standard care.
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There were some differences in how seroma was defined and at which time point it was reported;
the data used in the meta-analysis were the first point at which seroma was reported for the hernia
RCTs.144,172–174,178,181,184,185 Jain et al.99 had two control groups: (1) no drain and no fibrin, and (2) drain
and no fibrin. The first was deemed to be most appropriate for analysis as the only difference from the
intervention group was the addition of fibrin. In Moore et al.111 three intervention groups were reported
in which different amounts of fibrin were used; therefore, the control group was divided into three and
compared accordingly. Olmi et al.185 reported one intervention group and three control groups which were
different types of fixation, and so the fibrin group was divided into three and compared with each control
group. In cases where seroma development was reported at different time points, only the development at
the first time point was included in the analysis.
Subgroup analysis was conducted for two surgical specialties that were deemed comparable: breast
surgery RCTs (Figure 4) and hernia RCTs (Figure 5). In breast RCTs, patients (n = 1277) receiving fibrin
sealants had a statistically non-significantly reduced risk of developing seroma than control group patients
(OR 0.84, 95% CI 0.64 to 1.11; p = 0.26; I2 = 0.0%, fixed-effects model). In hernia RCTs, patients
OR meta-analysis plot (fixed effects)
0.001 0.01 0.10.2 0.5 1 2 5 10 100 1000
Ulusoy 200396 1.818 (0.308 to 12.953)
Udén 199398 1.561 (0.530 to 4.614)
Swan 2011113 0.895 (0.326 to 2.453)
Segura-Castillo 2005105 0.188 (0.018 to 1.172)
Neuss 2009118 1.341 (0.407 to 4.452)
Mustonen 2004104 0.642 (0.150 to 2.697)
Mortenson 2008120 0.846 (0.094 to 7.709)
Moore 2001111 1.000 (0.116 to 13.262)
Moore 2001111 0.667 (0.068 to 9.653)
Moore 2001111 0.469 (0.041 to 7.341)
Miri Bonjar 2012103 0.604 (0.132 to 2.598)
Llewellyn-Bennett 2012101 3.379 (0.028 to infinity)
Ko 2009102 0.811 (0.276 to 2.346)
Johnson 2005100 0.700 (0.262 to 1.856)
Jain 200499 0.746 (0.225 to 2.455)
Gilly 1998108 1.163 (0.015 to 92.893)
Gilly 1994115 2.353 (0.111 to 145.635)
Dinsmore 200097 2.500 (0.368 to 19.869)
Carlson 200894 0.751 (0.255 to 2.168)
Berger 2001107 0.846 (0.265 to 2.689)
Benevento 2014109 0.138 (0.003 to 1.294)
Combined (fixed) 0.844 (0.641 to 1.113)
OR (95% CI)
FIGURE 4 Seroma development in breast surgery: fibrin sealant vs. standard care.
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(n = 1592) receiving fibrin sealants had no difference in risk of developing seroma than control group
patients (OR 0.98, 95% CI 0.66 to 1.46; p = 1.00; I2 = 0.0%, fixed-effects model). The random-effects
models showed similar results for these subgroups (see Appendix 8). These results are broadly consistent
with the primary analysis that showed an apparent trend of a decrease in the risk of seroma development
in patients receiving fibrin sealants.
Haematoma development
Development of haematoma was reported in 26 RCTs, of which 24 were included in the meta-analysis
(Figure 6). Two RCTs were excluded from the primary analysis for following reasons: Prado et al.187
reported only median, quartiles and ranges across a 12-month period and Lovisetto et al.180 reported
haematoma and seroma combined and not separately. The 24 included RCTs65,70,90,100,101,103,110,111,113,118,141,143,
144,148,173,177,181,185,188,221,222,227,228,231 (n = 2665) were within the following surgical specialties: breast and
axillary/inguinal lymph nodes, hernia, plastic, orthopaedic, upper GI tract, oral and otolaryngology. Patients
receiving fibrin sealant had a statistically significant lower risk of developing haematomas than control
patients (n = 2403, OR 0.62, 95% CI 0.44 to 0.86; p = 0.01; I2 = 0%, fixed-effects model). The
random-effects model showed a similar result (see Appendix 8).
Overall haematoma development was calculated by combining groin and axillary haematomas in Swan
et al.,113 and by combining hepatic and post procedural haematomas in Bektas et al.65 Reviewers checked
that different haematomas did not occur in the same person and, therefore, that data were not
double-counted. Data from multiple intervention and control groups in Olmi et al.185 and Moore et al.111
were dealt with in the same manner as in the seroma analysis. As two different fibrin groups and two
controls were reported in Aguilera et al.143 it was decided for analysis purposes to compare fibrin glue to
control and Tissucol to tranexamic acid.
OR meta-analysis plot (fixed effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Wong 2011182 0.86 (0.01 to 70.35)
Tolver 2013181 0.57 (0.08 to 3.17)
Olmi 2007185 0.40 (0.05 to 2.36)
Olmi 2007185 0.36 (0.05 to 2.13)
Olmi 2007185 0.31 (0.04 to 1.76)
Lau 2005172 4.48 (1.35 to 17.12)
Damiano 2014184 0.57 (0.15 to 1.88)
Chan 2014178 1.36 (0.42 to 4.59)
Bracale 2014174 7.74 (0.44 to infinity)
Boldo 2008173 1.21 (0.30 to 4.85)
Combined (fixed) 0.98 (0.66 to 1.46)
OR (95% CI)
FIGURE 5 Seroma development in hernia surgery: fibrin sealant vs. standard care.
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OR meta-analysis plot (fixed effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Wang 2001144 0.250 (0.005 to 2.837)
Vaiman 2002188 0.248 (0.000 to 0.000)
Vaiman 2002188 0.248 (0.000 to 0.000)
Tolver 2013181 0.082 (0.000 to 1.048)
Swan 2011113 1.057 (0.013 to 85.197)
Sroka 201590 0.469 (0.008 to 9.365)
Siemer 2007221 0.896 (0.424 to 1.891)
Sabatini 2012148 0.293 (0.027 to 1.834)
Olmi 2007185 0.322 (0.000 to 4.563)
Olmi 2007185 0.417 (0.000 to 7.301)
Olmi 2007185 0.417 (0.000 to 7.301)
Oliver 2001228 3.154 (0.026 to infinity)
Noun 199670 0.759 (0.197 to 2.738)
Neuss 2009118 0.482 (0.008 to 9.887)
Moore 2001111 2.838 (0.132 to infinity)
Moore 2001111 1.216 (0.009 to infinity)
Miri Bonjar 2012103 0.931 (0.063 to 13.699)
Llewellyn-Bennett 2012101 0.654 (0.156 to 2.488)
Lee 2009227 0.158 (0.000 to 5.221)
Lassen 2006141 0.800 (0.067 to 6.213)
Johnson 2005100 1.167 (0.081 to 16.819)
Hester 2013231 0.240 (0.005 to 2.521)
Cormio 2012222 0.128 (0.000 to 2.290)
Cipolla 2010110 0.987 (0.012 to 78.484)
Canonico 1999177 0.184 (0.000 to 5.290)
Boldo 2008173 0.182 (0.000 to 5.285)
Bektas 201465 1.292 (0.250 to 7.144)
Aguilera 2013143 3.158 (0.238 to 169.846)
Aguilera 2013143 0.191 (0.000 to 5.304)
Combined (fixed) 0.617 (0.441 to 0.863)
OR (95% CI)
FIGURE 6 Haematoma development in all surgical specialties: fibrin sealant vs. standard care.
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Subgroup analyses were conducted for the following areas: breast (Figure 7), hernia (Figure 8), orthopaedics
(Figure 9) and upper GI tract (Figure 10). A statistically significant reduction in the risk of haematoma
formation due to fibrin use occurred only in a meta-analysis of four hernia surgery RCTs173,177,181,185 (n = 794,
OR 0.22, 95% CI 0.06 to 0.74; p = 0.01; I2 = 0%, fixed-effects model). There was a trend of a decreased
risk of haematoma when using fibrin sealants within the remaining surgical specialties, but these reductions
were not statistically significant: p = 0.87 (seven breast RCTs,100,101,103,110,111,113,118 n = 588), p = 0.20
(four orthopaedic RCTs,141,143,144,148 n = 347) and p = 0.88 (three upper GI tract RCTs,65,70,90 n = 243). The
random-effects models showed similar results (see Appendix 8).
A post hoc analysis including 48 RCTs65,70,90,94,96–105,107–111,113,115,118,120,141,143,144,148,172–174,177,178,180–182,184,185,188,206,212,
214,221,222,227,228,230,231,250 (n = 4876) was carried out to explore impact of combining seroma and haematoma
OR meta-analysis plot (fixed effects)
1 2 5 10
Tolver 2013181 0.08 (0.00 to 1.05)
Olmi 2007185 0.32 (0.00 to 4.56)
Olmi 2007185 0.42 (0.00 to 7.30)
Olmi 2007185 0.42 (0.00 to 7.30)
Canonico 1999177 0.18 (0.00 to 5.29)
Boldo 2008173 0.18 (0.00 to 5.28)
Combined (fixed) 0.22 (0.06 to 0.74)
OR (95% CI)
FIGURE 7 Haematoma development in hernia surgery: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100
Swan 2011113 1.057 (0.013 to 85.197)
Neuss 2009118 0.482 (0.008 to 9.887)
Moore 2001111 2.838 (0.132 to infinity)
Moore 2001111 1.216 (0.009 to infinity)
Miri Bonjar 2012103 0.931 (0.063 to 13.699)
Llewellyn-Bennett 2012101 0.654 (0.156 to 2.488)
Johnson 2005100 1.167 (0.081 to 16.819)
Cipolla 2010110 0.987 (0.012 to 78.484)
Combined (fixed) 0.880 (0.427 to 1.814)
OR (95% CI)
FIGURE 8 Haematoma development in breast surgery: fibrin sealant vs. standard care.
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as an outcome (Figure 11). The study by Lovisetto et al.,180 who reported only combined haematoma and
seroma rates (and, therefore, was excluded from the haematoma analysis), was included in the combined
analysis. This meta-analysis demonstrated a statistically significant reduction in the risk of developing
seroma or haematoma with fibrin sealant compared with control (OR 0.77, 95% CI 0.64 to 0.92; p = 0.01;
I2 = 6.7%, fixed-effects model). The random-effects model showed a similar result (see Appendix 8).
OR meta-analysis plot (fixed effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Lassen 2006141 0.800 (0.067 to 6.213)
Sabatini 2012148 0.293 (0.027 to 1.834)
Wang 2001144 0.250 (0.005 to 2.837)
Aguilera 2013143 3.158 (0.238 to 169.846)
Aguilera 2013143 0.191 (0.000 to 5.304)
Combined (fixed) 0.529 (0.227 to 1.236)
OR (95% CI)
FIGURE 9 Haematoma development in orthopaedic surgery: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10
Sroka 201590 0.469 (0.008 to 9.365)
Noun 199670 0.759 (0.197 to 2.738)
Bektas 201465 1.292 (0.250 to 7.144)
Combined (fixed) 0.861 (0.377 to 1.965)
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FIGURE 10 Haematoma development in upper GI tract surgery: fibrin sealant vs. standard care.
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OR meta-analysis plot (fixed effects)
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Combined (fixed) 0.767 (0.639 to 0.920)
OR (95% CI)
FIGURE 11 Seroma and haematoma development combined in all surgical specialties: fibrin sealant vs.
standard care.
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Secondary dichotomous outcomes
The following sections present the five dichotomous outcomes: haemorrhage (bleeding), reoperation,
infections, use of analgesics and complications arising from the use of drains.
Haemorrhage (bleeding)
Haemorrhage was reported in 19 RCTs, of which 1759,62,74,75,84,85,99,102,134,135,158,168,177,197,199,205,250 (n = 2125)
were included in the meta-analysis (Figure 12). Two RCTs (Neuss et al.118 and Jackson et al.193) were
excluded because they reported that none of the participants experienced post-operative bleeding. The
included RCTs were within several surgical specialties: cardiothoracic,134,135,205 breast and axillary/inguinal
lymph nodes,99,102 hernia,177 vascular,197,199 eye,158,168 upper GI tract62,74,75,84,85,250 and urology.59 There was
statistically non-significant reduction in risk of post-operative bleeding between patients receiving fibrin
sealants versus standard care (OR 0.64, 95% CI 0.40 to 1.02; p = 0.08; I2 = 0%, fixed-effects model).
The random-effects model showed a similar result (see Appendix 8).
Randomised controlled trials that did not report the number of patients and only reported bleeding as total
number of blood units were also excluded. In Jain et al.99 two control groups (no drain and no fibrin; drain
and no fibrin) were reported and the first group was deemed to be most appropriate for analysis as the
only difference between the intervention and control group was the addition of fibrin.
Subgroup analyses were conducted for the following surgical specialties: upper GI tract (Figure 13),
cardiothoracic lung (Figure 14), breast (Figure 15), vascular (Figure 16) and eye (Figure 17). There was a
OR meta-analysis plot (fixed effects)
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Suc 200385 0.462 (0.145 to 1.389)
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Saha 2012197 1.000 (0.013 to 79.620)
Nativ 201259 3.000 (0.019 to infinity)
Montorsi 201284 0.294 (0.006 to 3.729)
Moench 2010250 0.938 (0.012 to 74.802)
Marta 2010135 0.503 (0.045 to 3.582)
Lang 2004134 2.905 (0.025 to infinity)
Kohno 199275 1.000 (0.068 to 14.664)
Ko 2009102 1.568 (0.170 to 19.520)
Kakaei 201374 0.062 (0.000 to 0.933)
Jain 200499 3.105 (0.026 to infinity)
Czerny 2000205 1.714 (0.069 to 117.746)
Canonico 1999177 0.132 (0.003 to 1.276)
Combined (fixed) 0.643 (0.404 to 1.023)
OR (95% CI)
FIGURE 12 Haemorrhage (bleeding) in all surgical specialties: fibrin sealant vs. standard.
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statistically significant reduction in risk of haemorrhage when using fibrin sealants compared with standard
care within upper GI tract surgery (six RCTs,62,74,75,84,85,250 n = 995, OR 0.39, 95% CI 0.19 to 0.80; p = 0.01;
I2 = 0%, fixed-effects model) and no significant difference in the remaining surgical specialties: p = 0.84
(three cardiothoracic lung RCTs,134,135,205 n = 501), p = 0.69 (two breast RCTs,99,102 n = 153), p = 0.76
(two vascular RCTs,197,199 n = 339) and p = 0.61 (two eye RCTs,158,168 n = 80). The random-effects models
showed similar results (see Appendix 8).
OR meta-analysis plot (fixed effects)
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OR (95% CI)
FIGURE 14 Haemorrhage (bleeding) in cardiothoracic lung surgery: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
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OR (95% CI)
FIGURE 13 Haemorrhage (bleeding) in upper GI tract surgery: fibrin sealant vs. standard.
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Reoperation
A total of 20 RCTs reported reoperation as an outcome, of which 1560,77,85,86,93,101,107,116,125,135,138,140,143,237,239
were included in the meta-analysis (Figure 18). Five RCTs were excluded for the following reasons:
Droghetti et al.,124 Milne et al.201 and Dimo et al.80 reported that none of the trial patients had a
reoperation; Bulbuller et al.92 reported that the only patients who had a reoperation were in an additional
intervention arm and not in the fibrin or standard care arms; and Moser et al.126 did not report any data
for the fibrin group.
OR meta-analysis plot (fixed effects)
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FIGURE 16 Haemorrhage (bleeding) in vascular surgery: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
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FIGURE 15 Haemorrhage (bleeding) in breast surgery: fibrin sealant vs. standard care.
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OR meta-analysis plot (fixed effects)
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Suc 200385 0.75 (0.32 to 1.77)
Schwartz 200477 0.36 (0.14 to 0.91)
Martin 201386 0.75 (0.17 to 3.12)
Marta 2010135 1.23 (0.31 to 5.23)
Maisano 2009140 0.35 (0.06 to 1.56)
Llewellyn-Bennett 2012101 1.48 (0.47 to 4.77)
Kjaergard 1998138 0.33 (0.00 to 42.55)
Hutter 2014237 0.59 (0.17 to 1.88)
Huang 201493 0.03 (0.00 to 0.29)
Furrer 1993116 1.00 (0.06 to 15.77)
Bochicchio 2015239 0.17 (0.00 to 19.42)
Berger 2001107 0.34 (0.00 to 41.69)
Anegg 2007125 2.08 (0.11 to 124.43)
Aguilera 2013143 1.00 (0.01 to 80.43)
Aguilera 2013143 1.00 (0.01 to 80.39)
Combined (fixed) 0.65 (0.48 to 0.87)
OR (95% CI)
FIGURE 18 Reoperation in all surgical specialties: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
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FIGURE 17 Haemorrhage (bleeding) in eye surgery: fibrin sealant vs. standard care.
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The RCTs included in the meta-analysis reported fibrin use within four surgical specialties: cardiothoracic
lung and heart, breast and axillary/inguinal lymph nodes, orthopaedics and neurosurgery. Patients receiving
fibrin sealants had a statistically significant lower risk of reoperation than those in the control group
(15 RCTs,60,77,85,86,93,101,107,116,125,135,138,140,143,237,239 n = 3789, OR 0.65, 95% CI 0.48 to 0.87; p ≤ 0.01; I2 = 0%,
fixed-effects model). The random-effects model showed a similar result (see Appendix 8).
A subgroup analysis was conducted for the following surgical specialties: upper GI tract (Figure 19),
cardiothoracic lung (Figure 20), cardiothoracic heart (Figure 21) and breast (Figure 22). The decrease
in reoperations associated with using fibrin sealants was only statistically significant in upper GI tract
(four RCTs,77,85,86,93 n = 455, OR 0.43, 95% CI 0.27 to 0.70; p = 0.0009; I2 = 51.4%, fixed-effects model).
There was a statistically non-significant decrease in the risk of reoperation in cardiothoracic heart surgery
OR meta-analysis plot (fixed effects)
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FIGURE 19 Reoperation in upper GI tract surgery: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
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FIGURE 20 Reoperation in cardiothoracic lung surgery: fibrin sealant vs. standard care.
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(three RCTs,60,138,140 n = 1578; OR 0.71, 95% CI 0.43 to 1.19; p = 0.24; I2 = 0%, fixed-effects model),
whereas in cardiothoracic lung surgery (two RCTs,125,135 n = 451; OR 1.38, 95% CI 0.47 to 4.04; p = 0.76;
no I2, fixed-effects model) and breast surgery (three RCTs,101,107,116 n = 191; OR 1.21, 95% CI 0.51 to 2.90;
p = 0.83; I2 = 0%, fixed-effects model) there was a non-significant increase in risk of reoperation for fibrin
sealant compared with standard care.
Infection
Wound infections were reported by 30 RCTs, of which 2514,59,60,64,72,73,75,83,84,86,96,99,102,111,118,120,122,130,135,143,170,178,
198,230,250 were included in meta-analysis (Figure 23). The RCTs included in the meta-analysis reported fibrin
OR meta-analysis plot (fixed effects)
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FIGURE 21 Reoperation in cardiothoracic heart surgery: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
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FIGURE 22 Reoperation in breast surgery: fibrin sealant vs. standard care.
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use within four surgical specialties: upper GI tract (eight RCTs),64,72,73,75,83,84,86,250 breast (seven RCTs),96,99,102,
111,118,120,122 cardiothoracic lung (two RCTs)130,135 and heart (one RCT),60 orthopaedic knee (two RCTs),14,143
vascular (one RCT),198 eye (one RCT),170 urology (one RCT),59 oral (one RCT)230 and hernia (one RCT).178 The
following five RCTs were excluded because they reported no wound infections in the fibrin sealant and
standard care group: Udén et al.,98 Sabatini et al.,148 Danielsen et al.,79 Lovisetto et al.180 and Lau.172
Patients receiving fibrin sealants did not have a statistically significant lower risk of wound infection than
control patients (25 RCTs, n = 3902, OR 0.76, 95% CI 0.54 to 1.06; p = 0.12; I2 = 0%, fixed-effects
model). The random-effects model showed a similar result (see Appendix 8).
OR meta-analysis plot (fixed effects)
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Moench 2010250 2.903 (0.224 to 154.905)
Kohno 199275 0.483 (0.008 to 9.868)
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Fischer 201172 0.483 (0.008 to 9.574)
Nativ 201259 0.185 (0.000 to 29.250)
Mellin 1989170 0.122 (0.027 to 0.447)
Chalmers 2010198 0.755 (0.144 to 3.679)
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Aguilera 2013143 1.000 (0.012 to 80.435)
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Mortenson 2008120 0.778 (0.147 to 4.103)
Moore 2001111 1.098 (0.009 to infinity)
Moore 2001111 2.143 (0.067 to infinity)
Moore 2001111 1.216 (0.009 to infinity)
Ko 2009102 1.568 (0.170 to 19.520)
Neuss 2009118 0.861 (0.257 to 2.869)
Jain 200499 1.000 (0.012 to 81.266)
Combined (fixed) 0.756 (0.538 to 1.061)
OR (95% CI)
FIGURE 23 Infections in all surgeries: fibrin sealant vs. standard care.
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A subgroup analysis was conducted for the following surgical specialties: upper GI tract (Figure 24), breast
(Figure 25), cardiothoracic lung (Figure 26) and orthopaedic knee (Figure 27). The risk of wound infection
appeared not to be statistically significantly different in upper GI tract surgery (n = 917, OR 1.15, 95% CI
0.59 to 2.27; p = 0.81; I2 = 0%, fixed-effects model), cardiothoracic lung surgery (n = 484, OR 0.34,
95% CI 0.05 to 2.16; p = 0.43; I2 = 0%, fixed-effects model), breast surgery (n = 418, OR 0.95, 95% CI
OR meta-analysis plot (fixed effects)
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Moench 2010250 2.903 (0.224 to 154.905)
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Fischer 201172 0.483 (0.008 to 9.574)
Combined (fixed) 1.153 (0.585 to 2.273)
OR (95% CI)
FIGURE 24 Infections in upper GI tract surgery: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
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Combined (fixed) 0.953 (0.501 to 1.813)
OR (95% CI)
FIGURE 25 Infections in breast surgery: fibrin sealant vs. standard care.
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0.50 to 1.81; p = 0.99; I2 = 0%, fixed-effects model) or orthopaedic surgery (n = 224, OR 1.00, 95% CI
0.22 to 4.51; p = 0.70; I2 = 0%, fixed-effects model).
Use of analgesics
Three RCTs133,217,222 reported on use of analgesics, but the data were too heterogeneously reported for
meta-analysis. Belboul et al.133 (cardiothoracic lung) reported on the number of days of post-operative
thoracic epidural analgesia, which was 2 days in the fibrin group and 3 days in the standard care group.
Altomare et al.217 (colorectal) reported that no patients were on analgesics in the fibrin group and almost
all patients in the standard care group received analgesics. Cormio et al.222 (kidney) reported on the
number of doses of analgesic required during the first 24 hours post operation, which was 1.2 [standard
deviation (SD) 1.69] in the fibrin group and 1.17 (SD 1.56) in the control group.
OR meta-analysis plot (fixed effects)
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FIGURE 26 Infections in cardiothoracic lung surgery: fibrin sealant vs. standard care.
OR meta-analysis plot (fixed effects)
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FIGURE 27 Infections in orthopaedic knee surgery: fibrin sealant vs. standard care.
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Complications arising from the use of drains
No RCTs reported on complications arising from the use of drains.
Continuous secondary outcomes
Continuous outcomes were analysed separately for each surgical area for RCTs with similar interventions
and comparators as the type of intervention (e.g. staples vs. stitches). The following continuous outcomes
are reported below: duration of operation, length of hospital stay, duration of drainage, pain levels and
health-related quality of life.
Duration of operation (minutes)
Duration of operation was reported in the following surgical specialties: upper GI tract (gastric and liver),
eye and hernia.
Upper gastrointestinal surgery
Gastric surgery Mean duration of operation was reported in five gastric surgery RCTs,62,88–90,92 of which
two were included in the meta-analysis88,90 (Figure 28). As operation time was expected to be dictated by
the type of surgery and interventions, only Sroka et al.90 and Musella et al.,88 who reported on use of fibrin
in laparoscopic sleeve gastrectomies, were comparable. Sroka et al.90 compared sealant application with
both sutures and not applying sealant and Musella et al.88 compared fibrin sealant with no sealant. A
non-significantly shorter mean time of –2.03 minutes (95% CI –4.12 to 0.14 minutes; p = 0.07) was found
for fibrin sealant versus no sealant (n = 198).
Three RCTs were excluded from the meta-analysis: Pilone et al.89 compared fibrin sealant with no sealant,
Silecchia et al.62 compared sealant application with sutures and Bulbuller et al.92 compared sealant application
with both sutures and not applying sealant. SDs were reported only by Silecchia et al.,62 who investigated
the use of fibrin in laparoscopic gastric bypass and reported no statistically significant difference in operative
time. Challenges faced in interpreting these data are that duration of operation was not explicitly defined in
the papers and the type of sealant applied may have an effect on the time taken.
Liver surgery Mean duration of surgery was reported by four RCTs68–71 using fibrin in hepatic resection
surgery: Liu and Liu69 and Noun et al.70 seemed comparable as hepatic resection was carried out without
Effect size meta-analysis plot (fixed effects)
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MD –2.027426 (95% CI –4.199663 to 0.144811)
FIGURE 28 Mean duration of gastric surgery in minutes: fibrin sealant vs. no sealant.
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liver mobilisation (Figure 29). Without liver mobilisation, the MD of the duration of surgery for fibrin
sealant compared with standard care is a decrease of 14 minutes (two RCTs,69,70 n = 117, 95% CI –54.2
to 24.3 minutes; p = 0.46), but this is not statistically significant.
In Figueras et al.,71 liver mobilisation was carried out in both intervention and comparator groups.
Uetsuji et al.68 had three groups: (1) liver mobilisation and no sealant, (2) liver mobilisation with sealant
and (3) no liver mobilisation or sealant. Figueras et al.71 and the ‘liver mobilisation’ groups were combined
in a separate meta-analysis. In liver with mobilisation, the MD increased by 19.07 minutes (two RCTs,68,71
n = 364, 95% CI 2.75 to 35.38 minutes; p= 0.02) for fibrin sealant compared with standard care (Figure 30).
Effect size meta-analysis plot (fixed effects)
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Pooled weighted MD –14.959524 (95% CI –54.247356 to 24.328308)
FIGURE 29 Mean duration of hepatic resection without liver mobilisation in minutes: fibrin sealant vs. standard care.
Effect size meta-analysis plot (fixed effects)
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FIGURE 30 Mean duration of hepatic resection with liver mobilisation in minutes: fibrin sealant vs. standard care.
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This result indicates a statistically significant increase in surgery time associated with the use of fibrin sealants
compared with standard care in hepatic resection with liver mobilisation.
Eye surgery Duration of surgery was reported in 12 RCTs157–163,165,166,168,169,171 that all compared fibrin
sealant with sutures and eight RCTs were included in the meta-analysis (Figure 31). Three RCTs159,160,169 did
not report variability around the means and, thus, were excluded from the analysis.
The mean duration was statistically significant shorter in the fibrin group than the sutures group, with a
MD of –12.13 minutes (95% CI –12.59 to –11.67 minutes; p < 0.01; I2 = 99.1%, fixed-effects model, eight
RCTs,157,158,161,163,165,166,168,171 n = 519). The high level of heterogeneity was explored by sequentially excluding
individual RCTs to identify if the potential cause of the heterogeneity was caused by any individual RCT. This
was found not to be the case as I2 always remained > 90%. The random-effects model showed a MD of
–17.19 minutes (95% CI –23.35 to –12.50 minutes; p < 0.0001; I2 = 99.1%, see Appendix 8). Furthermore,
the RCTs excluded from the meta-analysis also reported a shorter mean duration of surgery in the fibrin
group than the sutures group: Hall et al.160 (12.04 vs. 26.04 minutes, respectively), Bahar et al.159 (16 vs.
20 minutes, respectively) and Bahar et al.169 (16 vs. 28 minutes, respectively).
Hernia surgery Five RCTs175,176,178,180,184 reported mean duration of surgery, of which four176,178,180,184
reported means and SDs and were included in two separate meta-analyses. Campanelli et al.176 and Damiano
et al.184 compared fibrin sealant with sutures (Figure 32). Surgery time was statistically significantly shorter for
fibrin sealant than sutures in the meta-analysis (n = 784), with a MD of –2.56 minutes (95% CI –3.57 to
–1.56 minutes; p < 0.01). Lovisetto et al.180 and Chan et al.178 compared fibrin with staples (Figure 33).
Surgery time was statistically significantly longer with fibrin than with staples (n = 326), with a MD in surgery
time of 13.22 minutes (95% CI 11.59 to 15.26 minutes; p < 0.01). The excluded RCT175 reported on a using
self-gripping mesh instead of fibrin and, therefore, could not be compared with either intervention.
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MD –12.132799 (95% CI –12.593928 to –11.671669)
Effect size meta-analysis plot (fixed effects)
FIGURE 31 Duration of eye surgery in minutes: fibrin sealant vs. sutures.
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Length of hospital stay (days)
Length of hospital stay was reported in the following surgical specialties: upper GI tract (pancreas, gastric
and bowel), cardiothoracic (lung and heart), breast and joint (knee).
Upper gastrointestinal surgery
Pancreatic surgery Three RCTs81,83,86 reported mean length of hospital stay for pancreatic surgery when
using fibrin sealant and two83,86 were included in the meta-analysis (Figure 34). The study by Carter et al.81
was excluded because the authors did not report variability around the mean. Fibrin sealants statistically
significantly decreased hospital stay for fibrin sealant compared with standard care in a meta-analysis
(n = 181), with a MD of –1.40 days (95% CI –1.72 to –1.09 days; p < 0.01). Carter et al.81 reported that
mean hospital stay was shorter in the fibrin sealant group (6.4 days) than in the control group (7.3 days),
which is consistent with the results of the meta-analysis.
Damiano 2014184
Campanelli 2012176
Effect size meta-analysis plot (fixed effects)
MD –2.564442 (95% CI –3.56903 to –1.559854)
–5 –4 –3 –2 –1 0 1
FIGURE 32 Duration of hernia surgery in minutes: fibrin sealant vs. sutures.
Effect size meta-analysis plot (fixed effects)
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Pooled weighted MD 13.224962 (95% CI 11.192096 to 15.257828)
FIGURE 33 Duration of hernia surgery in minutes: fibrin sealant vs. staples.
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Gastric and bowel surgery Three RCTs62,88,89 reported mean length of hospital stay: two for surgery
around the gastric region88,89 and one for stay after bowel surgery,62 utilising fibrin sealant. The three RCTs
were considered sufficiently similar to be analysed together; however, Pilone et al.89 did not report
variability around the mean and was therefore excluded. Silecchia et al.62 and Musella et al.88 were
combined in meta-analysis (Figure 35). There was not a statistically significant increase in hospital stay for
fibrin sealant compared with standard care in the meta-analysis (n = 420), which had a MD of 0.04 days
(95% CI –0.34 to 0.42 days; p = 0.82). Pilone et al.89 reported a mean hospital stay of 6.5 days and 7 days
for the fibrin sealant and control groups, respectively.
Cardiothoracic surgery
Lung surgery Six RCTs124,125,127,128,130,136 reported mean hospital stay for lung surgery and were considered
similar enough to be included in a meta-analysis. However, only three RCTs127,130,136 reported variability
around the mean and were analysed (Figure 36). Mean length of hospital stay was statistically significantly
Silecchia 200862
Musella 201488
Effect size meta-analysis plot (fixed effects)
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Pooled weighted MD 0.044414 (95% CI –0.336102 to 0.42493)
FIGURE 35 Length of hospital stay in days in pancreatic surgery: fibrin sealant vs. standard care.
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Effect size meta-analysis plot (fixed effects)
FIGURE 34 Length of hospital stay in days in pancreatic surgery: fibrin sealant vs. standard care.
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reduced for fibrin sealant compared with standard care in the meta-analysis (n = 269), with a MD of
–1.37 days (95% CI –1.93 to –0.81 days; p< 0.01; I2= 91.9%). However, there is a high level of heterogeneity
between the RCTs, and the significant result becomes non-significant in a random-effects meta-analysis
(MD –1.20 days, 95% CI –3.22 to 0.81 days; p= 0.24). The studies excluded from the meta-analysis reported
a lower mean hospital stay for the fibrin group than the control group: Fabian et al.128 reported 4.6 versus
4.9 days, respectively; Droghetti et al.124 reported 11 versus 14.3 days, respectively; and Anegg et al.125
reported 6.2 versus 7.7 days, respectively.
Heart surgery Tavilla et al.60 (n = 1436) reported a mean length of hospital stay of 5.99 days (SD 3.95 days)
and 6.07 days (SD 4.21 days) between fibrin and control groups, respectively, and p-value of 0.71 indicating
no statistically significant difference.
Breast surgery Ten RCTs reported mean hospital stay following breast surgery using fibrin sealants, of
which eight104,106–109,112,115,116 were included in the meta-analysis (Figure 37). Two RCTs were excluded for
the following reasons: Udén et al.98 did not report variability around the mean and Jain et al.99 did not
report mean duration separately for two of the groups. Mean length of hospital stay was statistically
significantly reduced in the meta-analysis (n = 440), with a MD of –0.73 days (95% CI –0.95 to –0.50
days; p < 0.01; I2 = 88.7%). The high level of heterogeneity was explored by sequentially excluding
individual RCTs to identify if the potential cause of the heterogeneity was caused by any individual RCT.
This was found not to be the case as I2 always remained > 80%. However, the statistically significant
result became non-significant in a random-effects meta-analysis (MD –0.87 days, 95% CI –1.75 to
0.01 days; p = 0.05).
Joint surgery (knee) Four RCTs reported mean hospital stay following knee surgery using fibrin sealants,
of which three143,145,149 were included in the meta-analysis (Figure 38). Molloy et al.147 was excluded from
the meta-analysis because they did not report variability around the mean. There was no significant effect
on the mean duration of hospitalisation for knee surgery for fibrin sealant compared with standard care in
the meta-analysis (n = 251), giving a MD of 0.07 days (95% CI –0.74 to 0.88 days; p = 0.87; I2 = 0%,
fixed-effects model).
Duration of drainage Duration of drainage was reported in the following surgical specialties: breast and
axillary lymph nodes, liver and lung surgery.
Rena 2009127
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MD –1.36681 (95% CI –1.925971 to –0.807649)
Effect size meta-analysis plot (fixed effects)
FIGURE 36 Length of hospital stay in days in cardiothoracic lung surgery: fibrin sealant vs. standard care.
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Breast and axillary lymph nodes A total of 15 RCTs reported mean duration of drainage, of which
1396,102,104–107,109,110,112,115–117,251 were included in the meta-analysis (Figure 39). Two RCTs did not report
variability around the means97,123 and were excluded from the meta-analysis. In the meta-analysis (n = 953),
there was a statistically significantly lower mean number of days of drainage of –0.50 days (95% CI –0.68
to –0.33 days; p < 0.01; I2 = 90.6%, fixed-effects model) when fibrin sealant was used than standard care.
The high level of heterogeneity was explored by sequentially excluding individual RCTs to identify if the
potential cause of the heterogeneity was caused by any individual RCT. This was found not to be the case
as I2 always remained > 90%. However, the random-effects model showed an increased MD of –1.06 days
(95% CI –1.69 to –0.42 days; p = 0.01; see Appendix 8).
Effect size meta-analysis plot (fixed effects)
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FIGURE 37 Length of hospital stay in days in breast surgery: fibrin sealant vs. standard care.
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Effect size meta-analysis plot (fixed effects)
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FIGURE 38 Length of hospital stay in days for knee surgery: fibrin sealant vs. standard care.
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Liver surgery Mean duration of drainage after liver surgery was reported by four RCTs65,69,74,75 and
combined in a meta-analysis (Figure 40). In the meta-analysis (n = 202) there was a not a statistically
significant difference in the number of drainage days for fibrin sealant compared with standard care, with
a MD of –0.27 days (95% CI –0.82 to 0.27 days; p = 0.33; I2 = 0%, fixed-effects model).
Effect size meta-analysis plot (fixed effects)
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FIGURE 40 Duration of drainage in days for liver surgery: fibrin sealant vs. standard care.
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Effect size meta-analysis plot (fixed effects)
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FIGURE 39 Duration of drainage in days in breast and axillary lymph nodes surgery: fibrin sealant vs. standard care.
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Lung surgery Mean duration of drainage after lung surgery was reported by five RCTs126,127,130,136,137 that
were combined in a meta-analysis (Figure 41). In the meta-analysis (n = 399) there was a statistically
significant lower number of drainage days for fibrin sealant than standard care, with a MD of –0.46 days
(95% CI –0.53 to –0.39 days; p < 0.01; I2 = 91%, fixed-effects model). The high level of heterogeneity
was explored by sequentially excluding individual RCTs to identify if the potential cause of the heterogeneity
was caused by any individual RCT. This was found not to be the case as I2 always remained > 80%. The
random-effects model also showed a statistically significant MD of –2.10 days (95% CI –3.65 to –0.56 days;
p = 0.01; see Appendix 8).
Pain levels
Pain was reported by 20 RCTs in six surgical specialties: breast,95,99,101 joint,142,147,150 ENT,187,190,192 plastic
and reconstructive,209,211 eye157,159,161,165,166,168,169,171 and urology.222 The large differences in the different
scales used, time points at which assessments took place and lack of variability data did not permit a
meta-analysis. When RCTs measured pain at different time intervals, pain is reported for the first
mentioned measurement point after surgery (Table 21).
No data on pain assessments could be reported for five RCTs for the following reasons: Antuña et al.155
reported values only for the entire group; Mabrouk et al.214 reported only that ‘all of the patients suffered
from pain, ecchymosis, and oedema postoperatively, but to varying degrees’; Diamond et al.232 reported
only that ‘the most common adverse event reported was abdominal pain’; Hall et al.160 did not report
values; and Pryor et al.186 reported only ‘no significance difference for overall rate of pain or recovery
(p = 0.06)’. Furthermore, eight RCTs78,107,108,151,153,221,239,250 only reported the number of patients with pain.
Health-related quality of life
No RCTs reported on health-related quality of life.
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FIGURE 41 Duration of drainage in days for lung surgery: fibrin sealant vs. standard care.
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TABLE 21 Pain levels in included RCTs
Study
(author, year)
Fibrin sealant
and standard
care group
description
Number of
patients
Pain score and variability
description Pain score
Variability
around score
Breast
Jain et al.,
200499
Fibrin sealant
(Tisseel), no drain
29 Mean post-operative pain at
24 hours (not reported
separately for Tisseel, no
drain and no glue, no drain
groups)
3.2 SD 0.9
No glue, no drain 29 3.2 SD 0.9
No glue, drain 58 4.5 SD 1.5
Llewellyn-
Bennett et al.,
2012101
Fibrin sealant
(Tisseel)
48 Donor-site pain visual
analogue scale score over
15 days
27 Range: 0–89
Standard closure 53 34 Range: 7–79
Zhibo and
Miaobo, 200995
Fibrin sealant and
lidocaine
10 Post-operative pain during
first week post operation
(day 1); self-reported pain
recorded on a scale of 0–3,
where 0= no pain, 1= light
pain, 3 =worst pain
1 NR
Standard care
(lidocaine only)
10 9 NR
Fibrin sealant only 10 10 NR
Joint (knee)
Skovgaard
et al., 2013150
Fibrin sealant
(EVICEL), spray
24 Visual analogue scale score
for rest and flexion at day 1
post surgery
Rest: 22;
flexion: 45
Rest: range
8.5–58; flexion:
range 22–71
Standard care
(saline)
24 Rest: 26;
flexion: 44
Rest: range
12–51; flexion:
range 29–67
Molloy et al.,
2007147
Fibrin sealant
(Quixil)
50 Pain scores at 6 hours using
a 100-mm visual analogue
scale, in which 0
represented no pain and
100 the most severe pain
17.6 15.9
Tranexamic acid 50 19.4 17.9
Standard care 50 20.03 20.4
Heyse et al.,
2014142
Fibrin sealant spray 98 Pain (on visual analogue
scale) at 6 weeks
4.3 NR
Standard care 100 3.9 NR
ENT (nose)
Vaiman et al.,
2006192
Fibrin sealant
(Quixil)
40 Visual analogue scale pain
scores at peak for saliva
swallow, normal swallow,
drinking and dysphagia
severity score
Approximately
6.5–7.0
NR
Standard care
(electrocautery)
40 Approximately
6.8–7.6
NR
Prado et al.,
2006187
Fibrin sealant
(Beriplast)
11 Pain (10-cm visual analogue
scale)
4 25% quartile: 3;
75% quartile: 4
Standard care 11 4 25% quartile: 3;
75% quartile: 5
Yu et al.,
2014190
Fibrin sealant spray 41 Pain during packing; pain on
removal of packing
4.2; 4.5 1.4; 1.0
Standard care
(sponge packing)
Within
patienta
3.1; 8.3 0.9; 1.1
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TABLE 21 Pain levels in included RCTs (continued )
Study
(author, year)
Fibrin sealant
and standard
care group
description
Number of
patients
Pain score and variability
description Pain score
Variability
around score
Plastic and reconstructive
Danielsen et al.,
2008209
Fibrin sealant
(Vivolution)
20/19 Pain score on day 5 post
surgery
3 Range: 2.0–5.0
Standard care
(gauze and
pressure)
20 4 Range: 3.0–5.0
Healy et al.,
2013211
Fibrin sealant
(Tisseel)
20 Mean daily pain score at
14 days post surgery
0.42 95% CI 0.19 to
0.65
Mefix self-adhesive
fabric dressing
20 1.6 95% CI 1.11 to
2.08
Eye
Rubin et al.,
2011166
Fibrin sealant 21 Overall mean post-operative
pain as recorded on visual
analogue scale
5.1 SD 1.26
Standard care
(sutures)
26 4.77 SD 1.21
Uy et al.,
2005168
Fibrin sealant
(Beriplast)
11 Pain on day 1; using a
five-point scale adapted
from Lim-Bon-Siong et al.:252
0 = none, no pain; 1= very
mild, presence of pain but
easily tolerated; 2 =mild,
pain causing some
discomfort; 3=moderate,
pain that partially interferes
with usual activity or sleep;
4 = severe, pain that
completely interferes with
usual activity or sleepb
≈2.2 NR
Standard care
(sutures)
11 ≈3.1 NR
Bahar et al.,
2007169
Fibrin sealant
(Quixil)
42 Mean pain score on day 1
post surgery; grading
symptoms and signs on a
scale of 0–4a
≈37 NR
Standard care
(sutures)
39 ≈66 NR
Malik and
Kumar, 2010171
Fibrin sealant
(Tisseel duo-quick)
25 Pain score, based on Wong
Baker FACES® Pain Rating
Scale253
0.44 SD 0.583
Standard care
(sutures)
25 3.32 SD 0.802
Kucukerdonmez
et al., 2010157
Fibrin sealant 32 Five-point scale assessment
of degree of paina
≈2.4 ≈1
Standard care
(Vicryl sutures)
38 ≈3.6 ≈1
Bahar et al.,
2006159
Fibrin sealant
(Quixil)
39 Mean pain score on day 2
post surgery; grading
symptoms and signs on a
scale of 0–4a
≈48 NR
Standard care
(sutures)
26 ≈22 NR
continued
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Assessment of harms
Randomised controlled trials
Ten RCTs in various surgical specialties (liver, two RCTs;73,77 kidney, two RCTs;59,221 mixed, one RCT;241 oral
and maxillofacial, one RCT;231 hernia, one RCT;176 plastic and reconstructive, one RCT;208 vascular, one
RCT;204 and orthopaedic, one RCT143) reported adverse events that were thought to be related to the use
of fibrin sealants (Table 22). Sample sizes varied from 759 to 316176 participants. Only Fischer et al.241
reported a death as possibly related to fibrin sealant application in upper GI tract surgery caused by a large
bleed, but bleeding did not occur at the target bleeding site and no further information was provided.
Other RCTs reported on various non-severe adverse events: mild cellulitis and mild seroma,231 anaemia,73
extravasation of urine,221 incision site complications204 and mild generalised skin rash.143 Severity was
unclear for the following: excessive pain, scar pain and testicular pain hydrocele in Campanelli et al.,176
post-procedural haemorrhage in Nativ et al.59 and antibodies to hepatitis B in Schwartz et al.77 It was not
reported how adverse events were related to the application of fibrin sealant or how severity was
determined. The time when adverse events occurred after surgery was immediately in Aguilera et al.,143
2 hours later in Nativ et al.,59 1 and 14 days later in Hester et al.231 and 32 days later in Saha et al.,204 but
was not reported in Fischer et al.,241 Campanelli et al.,176 Schwartz et al.,77 Frilling et al.73 and Siemer
et al.221 Furthermore, another 21 RCTs explicitly reported that there were no complications or adverse
events related to fibrin.14,62,65,67,88,94,124–127,141,142,193–195,206,207,225,227,232,238
TABLE 21 Pain levels in included RCTs (continued )
Study
(author, year)
Fibrin sealant
and standard
care group
description
Number of
patients
Pain score and variability
description Pain score
Variability
around score
Karalezli et al.,
2008161
Fibrin sealant
(Tisseel)
25 Pain on day 1 post surgery
using a five-point scale,
adapted from Lim-Bon-Siong
et al.252: 0= none, no pain;
1= very mild, presence of
pain but easily tolerated;
2=mild, pain causing some
discomfort; 3 =moderate,
pain that partially interferes
with usual activity or sleep;
4= severe, pain that
completely interferes with
usual activity or sleepb
≈2.5 NR
Standard care
(sutures)
25 ≈3.1 NR
Ratnalingam
et al., 2010165
Fibrin sealant 68 Median pain score day 1
post surgery
1 NR
Standard care
(sutures)
69 2 NR
Urology
Cormio et al.,
2012222
Fibrin sealant
(TachoSil patch)
49 Visual analogue scale pain
score at day 1 post
operation
4.24 SD 2.32
Standard care
(nephrostomy
tube)
47 4.77 SD 2.28
NR, not reported.
a The patient received the intervention and control on different body areas. Therefore, different body parts were
randomised to receive either the intervention or control.
b Absolute values not reported.
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TABLE 22 Fibrin-related adverse events reported in RCTs
Study
(author, year)
Sample
size Surgery Adverse event
Fischer et al.,
2013241
90/141 Mixed Of the patients who received fibrin pads, 2.7% (3/11) experienced a related
or possibly related AE, compared with 6.7% (2/30) of patients who received
absorbable haemostat. These events include operative haemorrhage, ascites
and suspected pulmonary embolism. There was no confirmation to rule out
relatedness, therefore these AEs were attributed as related to the assigned
treatment
Seven serious AEs resulted in death: six (5.4%) in the fibrin group and one
(3.3%) in the absorbable haemostat group. One of the deaths in the fibrin
pad group was considered possibly related to treatment (massive intraluminal
GI bleed, although bleeding did not occur at the target bleeding site)
Hester et al.,
2013231
75 Oral and
maxillofacial
Two of the non-SAE were considered related to treatment: 1 patient
had mild cellulitis on the side of the face treated with FS VH S/D 4
s-apr (14 days postoperatively), and 1 patient had mild seroma on
postoperative day 1
Campanelli
et al., 2012176
316 Hernia Adverse events were attributed to study product in three patients in the
fibrin sealant group (1.9%: one excessive pain; one scar pain; one
testicular pain hydrocele)
Schwartz et al.,
200477
207 Liver One patient developed antibodies to hepatitis B after being treated with
Crosseal. The patient had also received 16 units of allogeneic blood and, in
view of the recognised effectiveness against hepatitis B virus of the viral
inactivation techniques used in the manufacture of Crosseal, this event
was considered unlikely to be related to the fibrin sealant. No further
information was available regarding blood donors
Frilling et al.,
200573
148 Liver Four adverse events were considered to be possibly related to the test
treatment. Three of them were considered to be serious: postoperative
haemorrhage (TachoSil), abscess and pleural effusion (argon beamer),
while one was considered not to be serious: anaemia (TachoSil)
Siemer et al.,
2007221
185 Kidney Two severe adverse events were related to treatments in the trial. In a
subject who received TachoSil extravasation of urine, a non-serious
event was reported. One patient who received standard treatment
reported subileus, a serious event. The patient was treated successfully
with analgesics, laxatives, and diet. Both patients recovered fully
Nativ et al.,
201259
7 Kidney One case was haemodynamically instable and post-procedural haemorrhage
was observed in the drain 2 hours after surgery. This required the patient to
be reoperated, and the source of bleeding was the resection area beneath
the fibrin pad. The fibrin pad was removed and haemostasis was achieved
using a standard surgical technique. A total of 10 units of blood were
administered in the post-operative period and the patient was discharged
from the hospital without sequelae
Vanscheidt
et al., 2007208
225 Plastic or
reconstructive
One patient was found to have a ‘certain’ adverse event (application site
disorders) related to the study treatment; this was in the Bio Seed-Ss group.
Two AEs (general disorders, n = 1; skin and appendages, n= 1) reported in
the BioSeeds treatment group were ‘probably’ related to treatment. Six AEs
(general disorders, n = 2; skin and appendages, n= 2; secondary terms,
n= 2) were ‘possibly’ related
Saha et al.,
2011204
73 Vascular One non-serious AE that was considered possibly related to FS was incision
site complications. The complication occurred 32 days after application of FS
and raised concerns of possible graft occlusion. An angiogram indicated
venous stenosis in the area of the anastomosis. The investigator stated that a
causal relationship to FS was unlikely but could not be completely ruled out
Aguilera et al.,
2013143
166 Orthopaedic
(joint)
A 67-year-old man who received Tissucol developed a mild generalized
skin rash in the immediate postoperative period. This rash resolved
after the administration of an oral antihistamine and topical
corticosteroid treatment
AE, adverse event; FS, fibrin sealant; SAE, serious adverse event; VH S/D 4 s-apr, ARTISS sealant.
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Observational studies
Eight included observational studies reported adverse events that appear to be fibrin related (Table 23).
There were no reports of death or serious adverse events from the observational studies included in the
systematic review. Cagatay et al.242 and Choi et al.244 thought that the application of too much fibrin
sealant caused discomfort for patients undergoing eye surgery, but this was expected to be solved by
surgeons gaining more expertise with fibrin sealant application. Jiang et al.243 reported a slighter higher
proportion of patients with graft oedema in eyes treated with fibrin sealant. In upper GI tract surgery
statistically significantly more events were seen in patients treated with fibrin sealants (i.e. inflammation,245
TABLE 23 Fibrin-related adverse events reported in observational studies
Study
(author, year)
Sample
size Surgery Adverse event
Cagatay et al.,
2014242
103 Conjunctival
autografting for
pterygium surgery
(eye)
One patient experienced serious discomfort post operatively as a
result of excess glue. The excess was removed from the ocular
surface using scissors to trim it under slit lamp biomicroscopy
The development of Tenon’s cyst was not higher in patients
in the fibrin group (5/53) than in the control group (3/53) in a
statistically significant manner (p = 0.71)
Jiang et al.,
2008243
40 Conjunctival
autografting for
pterygium surgery
(eye)
A yellowish graft edema was observed in some eyes in the first few
days post operatively, which resolved gradually and spontaneously.
There were more cases of edema in the fibrin sealant group than
in the sutures group (8/20 vs. 3/20, respectively). However, the
difference between the two groups in graft edema development
was not statistically significant (p= 0.077)
Choi et al.,
2010244
126 Pars plana
vitrectomy (eye)
Three patients reported discomfort, possibly caused by the
application of too much glue, and two cases showed wound
dehiscence, probably caused by too little solution. However,
such problems can be overcome with further experience
Efthimiou
et al., 2010245
474 Laparoscopic
Roux-en-Y gastric
bypass (upper GI
tract)
Patients had an increased inflammatory response with the
application of fibrin sealant, indicated by statistically significant
higher temperature, white blood count and heart rate in the fibrin
group compared to the two control groups (p= 0.001). There was
an increased rate of fever (six patients in fibrin group vs. none in
the control group) and abdominal collection (two patients in fibrin
group vs. none in the control groups)
Ibele et al.,
2014246
529 Laparoscopic
Roux-en-Y gastric
bypass (upper GI
tract)
The rate of stricture requiring dilation was a significantly increased
in the sealant group (11.3%, compared with 4.8% stricture rate
in patients who did not receive sealant; p= 0.04)
Patients in the fibrin sealant group showed a notable stricture
delay with strictures occurring an average of 4.1 weeks following
surgery without sealant and 9.2 weeks after surgery (p= 0.3),
suggesting that the mechanism of stricture formation may have
differed between the two groups
Nanashima
et al., 2012247
341 Hepatobiliary
pancreas surgery;
hepatectomy and
pancreatectomy
(upper GI tract)
In the hepatectomy group, uncontrolled ascites were more
frequent in the fibrin glue group (145/228) than in the
non-fibrin glue group (6/94) (p < 0.05)
Marchac et al.,
1994248
200 Rhytidectomy
(plastic)
One complication unique to the fibrin glue treated group was
the postoperative finding of trapped pockets of air. These had
the appearance of small haematomas and yielded 3–5 cc of
air on aspiration
Sakic et al.,
2013249
418 Bilateral internal
thoracic artery
grafting (vascular)
The use of platelet-enriched-fibrin glue (PRF) sealant, however,
was associated with more superficial sternal infections (OR: 3.7,
95% CI: 1.3 to 10.5, p= 0.02)
ASSESSMENT OF CLINICAL EFFECTIVENESS
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strictures requiring dilatation246 and uncontrolled ascites247). In Marchac et al.248 trapped pockets of air
were only found in the fibrin group and Sakic et al.249 reported more superficial sternal infections in
patients treated with fibrin sealant.
Regulatory body reports
Five reports from the MHRA (one report), EMA (one report) and FDA (three reports) websites reported on
deaths associated with the use of fibrin sealants, as either case series or single case reports (Table 24).
Medicines and Healthcare products Regulatory Agency
The MHRA notes the findings from the EMA, namely the number of life-threatening or fatal air embolisms.
A total of six reports of such events have been reported worldwide according to the EMA – EVICEL
(five reports), Tisseel (four reports), Quixil (four reports)254 – although Quixil is no longer available in the UK.
In 2013, the MHRA provided updated guidance for the use of sprayable fibrin sealants. Four sprayable
fibrin sealants are authorised for use in the UK:254
1. EVICEL
2. Tisseel Lyo
3. Tisseel Ready to use
4. Artiss solution for sealant, deep frozen.
TABLE 24 Serious adverse events (deaths) reported by the MHRA, EMA and FDA
Regulatory
body
Fibrin
sealant
name Date Subject Findings Source
MHRA254 EVICEL, Tisseel
and Artiss
February
2013
Drug safety
update
The MHRA notes the
findings from the EMA
www.gov.uk/drug-safety-
update/sprayable-fibrin-
sealants-evicel-tisseel-and-artiss-
updated-guidance (accessed
11 November 2015)
EMA255 Artiss,
Beriplast P,
EVICEL, Tisseel,
Tissucol spray
applications
15 March
2013
Questions and
answers
Risk of air or gas
embolism;
recommendations for
surgeons
www.ema.europa.eu/ema/
index.jsp?curl=pages/
medicines/human/referrals/
Fibrinogen-containing_
solutions_for_sealant_
authorised_for_administration_
by_spray_application/human_
referral_000332.jsp&mid=
WC0b01ac05805c516f
(accessed 11 November 2015)
FDA256 Artiss and
Tisseel
5 October
2009
Important drug
warning:
fatality reported
Risk of life-threatening
air or gas embolism
with the use of spray
devices employing
pressure regulator to
administer fibrin
sealants
www.fda.gov/
biologicsbloodvaccines/
safetyavailability/ucm209778.
htm (accessed 11 November
2015)
FDA257 Tisseel 2014 Fatalities
reported
Three deaths thought
to have occurred as a
result of the use of
Tisseel fibrin sealant
www.fda.gov/downloads/
advisorycommittees/
committeesmeetingmaterials/
pediatricadvisorycommittee/
ucm386895.doc (accessed
11 November 2015)
FDA258 Tisseel February
2015
Medical device
report analysis
An analysis of nine
reports of adverse
events involving one
death
www.fda.gov/downloads/
advisorycommittees/
committeesmeetingmaterials/
pediatricadvisorycommittee/
ucm388149.pdf (accessed
11 November 2015)
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European Medicines Agency
In 2012, the EMA completed a review of the safety and effectiveness of four fibrin sealants (Tisseel,
Tissucol, Artiss and Beriplast P) used in spray formation.254 The agency’s CHMP considered the evidence
for the development of gas embolisms and concluded that the benefits outweigh the risks. The CHMP
recommended that the wording on product information be strengthened; the manufacturers of the
products should ensure that they are used with pressure regulators that do not exceed the maximum
pressure necessary for the delivery of the fibrin sealant; and labelling with the recommended pressure and
distance. Furthermore, the EMA report suggests that the product information should include a warning
that the risk of gas embolism appears to be higher when sprayed with air than with carbon dioxide (CO2).
The report also recommends patients to be closely monitored for signs of possible gas embolism (heart
rate, blood pressure, oxygen and CO2 levels in blood) during procedures using sprayable fibrin sealants.
Food and Drug Administration
The FDA website contained reports of five fatalities arising from the use of fibrin sealants.
Artiss and Tisseel, 2009256 The FDA reported:
Air or gas embolism has occurred with the use of spray devices employing pressure regulator to
administer fibrin sealants. This event appears to be related to the use of the spray device at higher
than recommended pressures and in close proximity to the tissue surface. When applying fibrin
sealants using a spray device, be sure to use the pressure within the pressure range recommended by
the spray device manufacturer. In the absence of a specific recommendation avoid using pressure
above 20–25 psi. Do not spray closer than the distance recommended by the spray device
manufacturer. In the absence of a specific recommendation avoid spraying closer than 10–15 cm from
the surface of the tissue. When spraying the fibrin sealant, changes in blood pressure, pulse, oxygen
saturation and end tidal CO2 should be monitored because of the possibility of occurrence of air or
gas embolism.
Recommendations for surgeons are similar those previously mentioned for the EMA:
Specifically, the safety update includes the following instructions for sealant application using a spray
device to help prevent air or gas embolism:
l utilize spray pressure that is within the recommended guidelines by the device manufacturer
l ensure that distance between the spray head and the application bed is within the recommended
guidelines of the device manufacturer;
l monitor patients for air or gas embolism.
EVICEL, 2010257 The FDA reported a fatal air embolism after the use of an EVICEL spray device. EVICEL
was being used to arrest a haemorrhage using a spray device (wall unit) at a higher than recommended
pressure. Additionally, the spray head was held at a distance from the bleeding area that was closer than
the recommended guidelines suggest. The website also advises the use of fibrin sealant spray at pressures
of < 20–25 pounds/inch2.
Tisseel, 2014258 A safety review for Tiseel/Tissucol by the Centre for Biologics Evaluation and Research of
the FDA identified three adult deaths considered likely to be associated with the use of the fibrin sealant.
In one case (reference 9283933) from Columbia, a fatal thrombosis and colon necrosis was observed in
a male aged 60 years. Tissucol was sprayed after a right hepatectomy. After the operation the patient
underwent a repeat laparotomy and a mesenteric thrombosis was found; after a hepatectomy the patient
died. Underlying liver disease is a risk factor for development of mesenteric thrombosis. In a second case
ASSESSMENT OF CLINICAL EFFECTIVENESS
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(reference 9540751), from Germany (in 1990), a male experienced a fatal air embolism after gastropic
sealing for the closure of a fistula. It is reported that:
. . . seconds after the Tissucol immune gas flow, the patient lost consciousness and had a cardiac
arrest. Autopsy showed the right ventricle filled with air and death was assumed to be due to
air embolism.
The third death associated with Tissucol (case 8815161) was of a male aged 37 years from the UK who
suffered a fatal cardiac arrest during revision laminectomy. The device was held closer than the
recommended distance to the tissue, with the tip of the applicator being located within the wound.
Furthermore, the FDA Manufacturer and User Safety Device Experience database reports one death of a
patient who lost consciousness and experienced a cardiac arrest:
Autopsy showed the right ventricle was filled with air, and death was assumed to be due to an
air embolism.
However, the source is reported to be published literature from 1990 and, as the wording is similar to that
of case reference 9540751 from the safety review, the researchers of this report consider it highly likely to
be a duplicate report.
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Chapter 4 Discussion
Statement of principal findings
This review included 186 RCTs to assess the benefits of fibrin sealants during non-emergency surgery in
adults. The RCTs, eight observational studies and five reports from regulatory bodies were used to inform
a review of harms caused by the use of fibrin sealants. Studies were found in the following 15 surgical
specialties: upper GI tract (digestive system), breast and lymph nodes, orthopaedic (joints), eye, hernia,
otolaryngology (ENT), vascular, plastic or reconstructive, colorectal (anus), oral (mouth) and maxillofacial,
mixed, gynaecological, urology, neurology and cardiothoracic.
Evidence of effectiveness
A series of meta-analyses carried out over different populations and different formulations of fibrin sealant
to assess the effectiveness of fibrin sealants on improving various post-operative outcomes shows that the
effectiveness of fibrin sealants does not appear to vary according to surgical procedures, as there was
virtually no heterogeneity in the meta-analyses of primary and secondary dichotomous outcomes. The results
from the fixed-effects analyses are presented below. However, the results of secondary continuous outcomes
should be interpreted with caution because of the uncertain quality of included studies and the large amount
of statistical heterogeneity identified in the meta-analyses. Where high levels of heterogeneity were
identified, the results from the random-effects analyses are reported (i.e. duration of eye surgery, length of
hospital stay for breast surgery and duration of post-operative drainage for breast and lungs surgery).
The primary outcomes of this review were seroma and haematoma development. The most frequently
reported indication for fibrin sealant use was the prevention of post-operative seroma (37 RCTs) in surgical
procedures for breast and axillary/inguinal, hernia, plastic, liver and otolaryngology. A meta-analysis of data
from 3472 patients (32 RCTs) did not identify a significant benefit for fibrin sealant over standard procedures
(OR 0.84, 95% CI 0.68 to 1.04; p = 0.13; I2 = 12.7%). Development of haematoma was reported by
26 RCTs in breast and axillary/inguinal lymph nodes, hernia, plastic, orthopaedic, upper GI tract, oral and
otolaryngology. A meta-analysis of 24 RCTs (n = 2403) demonstrated a statistically significant effect for fibrin
sealant compared with standard care (OR 0.62, 95% CI 0.44 to 0.86; p = 0.01; I2 = 0%) that was driven by
the results for hernia surgery in four RCTs (OR 0.22 95% CI 0.06 to 0.74; p = 0.01; I2 = 0%). Furthermore,
there was a trend of haematoma risk reduction in the remaining surgical specialties that was not statistically
significant (p = 0.87 for breast, p = 0.20 for orthopaedic and p = 0.88 for upper GI tract). A post hoc analysis
was conducted that combined both seroma and haematoma as it was plausible that these events were
broadly similar, and in some studies they were combined in a single outcome. This meta-analysis of 48 RCTs
to explore the impact of combining seroma and haematoma showed a statistically significant benefit for
fibrin sealant use compared with control (OR 0.77, 95% CI 0.64 to 0.92; p = 0.01; I2 = 6.7%).
Secondary dichotomous outcomes included in this review were haemorrhage (bleeding), reoperation,
infections, use of analgesics and complications arising from the use of drains. There was no statistically
significant difference in the risk of post-operative bleeding between patients receiving fibrin sealants and
standard care (18 RCTs, OR 0.64, 95% CI 0.40 to 1.02; p = 0.08; I2 = 0%) and the risk of developing
infections (25 RCTs, OR 0.76, 95% CI 0.54 to 1.06; p = 0.12; I2 = 0%). However, there was a statistically
significant reduction in risk of haemorrhage when using fibrin sealants within upper GI tract surgery
(six RCTs, OR 0.39, 95% CI 0.19 to 0.80; p = 0.01). The risk of reoperation was significantly lower among
patients receiving fibrin sealants than among control patients (17 RCTs, OR 0.65, 95% CI 0.48 to 0.87;
p = 0.00; I2 = 0%). However, a non-statistically significant higher risk of reoperation was found in breast
surgery (three RCTs, OR 1.21, 95% CI 0.51 to 2.90; p = 0.83; I2 = 0%) and lung surgery (two RCTs,
OR 1.38, 95% CI 0.47 to 4.04; p = 0.76). Use of analgesics was reported by only four RCTs. No RCTs
reported on complications arising from the use of drains.
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Secondary continuous outcomes included duration of operation, length of hospital stay, use of drains,
pain levels and health-related quality of life. There was evidence of statistically significant benefit of fibrin
sealants compared with standard care in the mean duration of operation for eye surgery in eight RCTs
(fixed-effects model: MD –12.13 minutes, 95% CI –12.59 to –11.67 minutes; p < 0.01; I2 = 99.1%;
random-effects model: MD –17.19 minutes, 95% CI –23.35 to –12.50 minutes; p < 0.0001; I2 = 99.1%)
and hernia surgery in two RCTs (MD –2.56 minutes, 95% CI –3.57 to –1.56 minutes; p < 0.01; no I2).
However, in surgery with liver mobilisation, a meta-analysis of two RCTs showed a statistically significant
longer duration of operation when fibrin sealants were used (MD 19.07 minutes, 95% CI 2.75 to 35.38
minutes; p = 0.02; no I2). Fibrin sealants were shown to reduce the length of hospital stay for people
undergoing upper GI tract surgery involving the pancreas in two RCTs (MD –1.40 days, 95% CI –1.72 to
–1.09 days; p < 0.01; no I2), cardiothoracic lung surgery in two RCTs (MD –1.37 days, 95% CI –1.93 to
–0.81 days; p < 0.01; no I2) and breast surgery in eight RCTs (fixed-effects model: MD –0.73 days, 95% CI
–0.95 to –0.50 days; p < 0.01; I2 = 88.7%; random-effects model: MD –0.87 days, 95% CI –1.75 to 0.01
days; p = 0.05). The duration of post-operative drainage for breast and axillary lymph nodes was slightly
reduced (12 RCTs, fixed-effects model: MD –0.50 days, 95% CI –0.68 to –0.33 days; p < 0.01; I2 = 90.6%;
random-effects model: MD –1.06 days, 95% CI –1.69 to –0.42 days; p = 0.01), as well as the duration of
drainage for lung surgery (five RCTs, fixed-effects model: MD –0.46 days, 95% CI –0.53 to –0.39 days;
p < 0.01; I2 = 91.0%; random-effects model: MD –2.10 days, 95% CI –3.65 to –0.56 days; p = 0.01), for
fibrin sealants than standard care. These results were not consistent across surgical specialties, with fibrin
sealants showing no beneficial effect when compared to standard care in the following surgical specialties:
duration of operation in surgery without liver mobilisation (four RCTs; p = 0.46), gastric surgery (two RCTs;
p = 0.07); length of hospital stay in gastric and bowel surgery (two RCTs; p = 0.82), joint surgery (four
RCTs; p = 0.871) and duration of drainage in liver surgery (four RCTs; p = 0.33). However, the high level
of heterogeneity warrants caution with interpreting the results of these analyses. This might be expected
when the likely duration of different operations conducted is being considered (e.g. a longer duration of
upper GI tract surgery than eye surgery). Pain levels were reported in 20 RCTs, but the large differences in
the various scales used and time points at which assessments took place, as well as lack of variability data,
did not permit a meta-analysis. No RCT reported on health-related quality of life.
Overall, 154 studies were assessed as having an ‘unclear risk of bias’, eight RCTs as having a ‘high risk of
bias’ and 24 RCTs as having a ‘low risk of bias’. The risk-of-bias table (see Table 37) shows a high level
of uncertainty about the validity of data collected across all parameters, especially regarding the blind
collection of patient outcomes.
Evidence of harms
This review considered the evidence that fibrin sealants cause serious adverse events from data contained
in reports from the RCTs, observational studies and the regulatory bodies (MHRA, EMA and FDA).
Ten RCTs in various surgical specialties (liver, kidney, mixed, oral and maxillofacial, hernia, plastic and
reconstructive, vascular, orthopaedic) reported adverse events that were thought to be related to the use
of fibrin sealants by primary study investigators or reviewers. Only one RCT reported a death as possibly
related to fibrin sealant application in upper GI tract surgery caused by a large bleed, but bleeding did not
occur at the target bleeding site and no further information was provided. Other RCTs reported on various
non-severe adverse events including mild cellulitis and mild seroma, anaemia, extravasation of urine,
incision site complications and mild generalised skin rash. Severity was unclear for excessive pain, scar pain,
testicular pain hydrocele and post-procedural haemorrhage antibodies to hepatitis B. It was not reported
how adverse events were related to the application of fibrin sealant or how severity was determined.
The time at which adverse events occurred after surgery was immediate,143 2 hours,59 1 and 14 days231
or 32 days,204 but not reported in five RCTs.73,91,95,110,187 Another 22 RCTs explicitly reported that there were
no complications or adverse events related to fibrin.
Eight observational studies reported adverse events that appear to be fibrin related by primary study
investigators or reviewers, but there were no reports of death or serious adverse events. In eye surgery,
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the application of too much fibrin sealant was thought to cause discomfort for patients, but this was
expected to be solved by surgeons gaining more expertise with fibrin sealant application. It was reported
that the proportion of eyes that developed graft oedema was higher in the fibrin sealant group (8/20) that
in the. in the standard care group (3/20). In upper GI tract surgery more of the following events were seen
in patients treated with fibrin sealants: inflammation, strictures requiring dilatation and uncontrolled
ascites. In plastic or reconstructive surgery trapped pockets of air were only found in the fibrin group.
Furthermore, in vascular surgery more superficial sternal infections were found in patients treated with
fibrin sealant. The evidence from observational studies did not produce evidence of causality about fibrin
sealants resulting in potentially serious adverse events. The validity of the eight observational studies was
compromised by a general failure to report whether or not adverse events were assessed independently,
whether or not blinding to the assigned allocation was performed and at which time point the adverse
event occurred.
Five MHRA, EMA and FDA reports warned about deaths from air emboli as a result of fibrin sealants,
in aerosol form, being held too close to tissues and used at higher than recommended pressures.
Strengths and limitations of the assessment
This research reviewed the evidence on the benefits and harms from the use of fibrin sealants compared
with standard care for adults undergoing non-emergency surgery. The large number of RCTs allowed
analysis of results for the most common and consistently measured outcomes, and the strength of this
systematic review is that the findings are based on increased statistical power from these meta-analyses.
It was not possible to provide a detailed evaluation of individual RCTs in their respective contexts because
of the limited resources that were available for this research. In addition, the number of RCTs that were
identified made it impractical to conduct independent data extraction by two reviewers in the time
available. Another consequence of the resource constraints imposed by the identification of such a large
number of RCTs was our limited ability to perform a thorough evaluation of the source of heterogeneity
in meta-analyses where this was identified at high levels of inconsistency. However, the high level of
heterogeneity in continuous secondary outcomes was explored by sequentially excluding individual RCTs to
identify if the potential cause of the heterogeneity was caused by any individual RCT. This was often found
not to be the case as I2 remained >80% or >90%. Had additional time been available, analyses to assess
the impact of different fibrin glues and delivery mechanisms would have been evaluated. However, all
RCTs that met the eligibility criteria were included in order to create a repository for future researchers.
A second strength of the review is the inclusion of evidence regarding harms arising from the use of fibrin
sealants, a methodologically challenging approach for those engaged in evidence-based research.
However, poor reporting of adverse events in RCTs and observational studies limited our ability to provide
a comprehensive overview of harms. The review cites only reported outcomes that are likely to be
considered important in clinical practice but were not part of the scope of the review; one example is that
the data for the use of fibrin sealant to prevent cerebrospinal fluid leakage in neurology RCTs could not be
included in meta-analyses. Although individual RCTs are referenced, their findings are not discussed
because of the three RCTs evaluating the effect of fibrin sealants for the prevention of cerebrospinal fluid
leakage after neurosurgery,10,236,237 one measured cerebrospinal fluid in ml,236 one categorised data into
minor, moderate or major cerebrospinal fluid leakage and presented absolute numbers237 and another
RCT presented outcome data as the absolute number of patients with watertight closure of the dura.10
The findings of these RCTs did not converge and the inconsistencies make any interpretation difficult.
Furthermore, cost-effectiveness was not assessed and would be a relevant outcome for policy-makers and
budget-holders.
As mentioned in Chapter 3, Methods of analysis/synthesis, there were changes between the protocol and
this review. Systematic reviews were not included and, therefore, the quality of systematic reviews was
not assessed, as was mentioned in the protocol.45 Haematoma is an additional post hoc primary outcome
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that was not included in the protocol. As the mechanism of haematoma and seroma formation is similar,
and is reported in some studies interchangeably, it was deemed important to include haematoma as a
primary outcome. In addition, a post hoc analysis of combined seroma and haematoma development was
undertaken. Haemorrhage, pain levels and infections were described in the protocol as adverse events –
but have been moved to secondary outcomes as these were found to be adverse events of surgery and not
related to fibrin sealant (and fibrin sealants are used to reduce these adverse events related to surgery).
The duration of operation was used to reflect the outcome ‘nurse or doctor time’ instead of the previously
mentioned ‘dressing or fine-needle aspirations’. Sensitivity analyses were planned to be carried out for
aspects of the review that might have an impact on the results, for example, including studies in which
there is a high risk of bias.53 However, most studies were assessed as having an unclear risk of bias and,
therefore, these analyses were not deemed to be appropriate. Sensitivity analysis using a random-effects
model was conducted, but as a result of the large number of RCTs identified in the review it was not
possible to perform additional analyses in the time available. Furthermore, overall risk of bias in included
RCTs was deemed to be ‘unclear’, which may reflect poor reporting of primary studies in published papers
rather than potentially flawed methods employed.
The overall results for haematoma development show a significant benefit for using fibrin sealants over
standard care, and are supported by the trends in all of the subgroup analyses. However, despite the large
number of RCTs included in this systematic review, there remains uncertainty with regard to reducing the
risk of post-operative seroma for most of the secondary outcomes considered. In some cases the direction
of the non-statistically significant trend suggested that fibrin sealants might be harmful; for example, data
from the meta-analyses of RCTs showed a non-statistically significant effect in breast and lung surgery
suggestive of an increase in the risk of reoperation.
Clinical opinion noted that most patients are now managed within enhanced recovery programmes and
may not stay in hospital with drains, as they did previously. Therefore, data on length-of-stay reduction
may not reflect current practice (Mr Kurinchi Gurusamy, UCL and Royal Free NHS Trust, 2016,
personal communication).
The researchers were unable to obtain information about the use and costs of fibrin sealants to the NHS in
England. NHS England replied to our request indicating that it does not hold this information but that
individual hospital trusts may be able to provide these data. It was beyond the scope of the current
research to perform a survey of NHS trusts to provide results that would be representative for the NHS
in England.
DISCUSSION
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Chapter 5 Conclusions
Implications for service provision
Fibrin sealants statistically significantly reduce the risk of development of haematoma when used in
non-emergency surgical procedures compared with standard care, but the reduction in risk of
post-operative seroma remains unproven.
We found reports254 stating that the spraying of fibrin sealants caused the formation of air emboli which
resulted in perioperative deaths during elective surgical procedures. Surgeons should follow the detailed
safely recommendations when using fibrin sealants and they are advised by regulatory bodies that prior to
applying fibrin sealants by spray application, a pressure regulator device should be used and the surface
area of the wound should be dried. The patient’s blood pressure, heart rate, oxygen saturation and
end-tidal CO2 should be closely monitored when spraying fibrin sealants because of the potential to create
an air embolism. The use of air in the spray device is considered more dangerous than CO2, and warnings
to this effect are issued by the regulatory bodies.
Recommendations about how and for which procedures certain products should be used are available.
EVICEL spray should be used with CO2 gas (not pressurised air) and in laparoscopic procedures should be
used only when the spray distance is at least 4 cm; it is not recommended for use in any other endoscopic
procedures.37 The recommended spray distance for Tisseel is even shorter, at 2 cm from the tissue.37 Artiss
is recommended for use only in open-wound surgery and not during laparoscopic or any other endoscopic
procedures,37 and there is no risk of gas embolism with Beriplast P when used in accordance with the
prescribing advice and with the recommended device, although this product is not used in the UK.
Surgeons are advised to utilise spray pressure that is within the recommended guidelines by the device
manufacturer; to ensure that the distance between the spray head and the application bed is within the
recommended guidelines of the device manufacturer; and to monitor patients for air or gas embolism.
Suggested research priorities
The search carried out for this review (May 2015) identified only a small number of RCTs (< 10) that
showed statistically significant differences between fibrin and comparators. No evidence of a statistically
significant effect of fibrin sealants compared with standard care was found for the outcomes listed for the
following surgical indications:
l all surgical specialties (seroma development)
l neurological, gynaecological, oral and maxillofacial, urology, colorectal and orthopaedics knees or hips
(for any outcome)
l breast surgery (haematoma development)
l upper GI tract (haematoma development)
l cardiothoracic heart or lung surgery (reoperation rates).
The most appropriate study type to assess outcomes would be a RCT in which outcome assessors and,
potentially, patients, but not surgeons, are blind to intervention. In general, RCTs of fibrin sealants in
non-emergency surgery are small and involve fewer than 100 people; an a priori sample size that is
adequate to ensure that a statistically significant effect can be detected should be used.
The findings of this review are based on data that show inconsistent effects as a result of the large number
of small RCTs that evaluated different outcomes, sometimes for the same surgical area. It is necessary that
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those who undertake future RCTs capture all important outcomes in the same population of patients.
Researchers should plan RCTs that collect data for biological outcomes, such as seroma, haematoma,
duration of drainage and more service-related outcomes, such as length of hospital stay and rates of
reoperations, in order to reach a balanced view of the benefits and harms arising from fibrin sealants.
A variety of units of analysis were used within the same surgical specialties and this limited the number
of studies included in each meta-analysis. The work of other researchers should be evaluated using, for
example, this review to inform the design of new RCTs and employ units of analysis that are consistent
with those used in previous RCTs to enable the conduct of meta-analyses.
Furthermore, adverse events of the use of fibrin sealants were poorly and infrequently reported in both
RCTs and observational studies. Only Fischer et al.241 reported a death as possibly related to fibrin sealant
application in upper GI tract surgery caused by a large bleed, but bleeding did not occur at the target
bleeding site and no further information was provided. Researchers need to test a biologically plausible
hypothesis when testing whether or not adverse events are related to the use of fibrin sealants. Both RCTs
and observational studies on the use of fibrin sealants in all surgical specialties need to assess harms
relevant to the specific surgical area.
CONCLUSIONS
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Appendix 1 Literature search strategies
Randomised controlled trial search MEDLINE In-Process & Other
Non-Indexed Citations and Ovid MEDLINE search strategy
Date searched: 19 May 2015.
Date range searched: inception to 2015.
Search strategy
1. exp Fibrin tissue adhesive/ (3992)
2. Fibrin Foam/ (155)
3. (fibrin adj2 glu$).tw. (3415)
4. (fibrin adj2 seal$).tw. (1546)
5. (fibrin adj2 adhesi$).tw. (676)
6. fibrin spong$.tw. (38)
7. fibrin bandag$.tw. (7)
8. fibrin aerosol$.tw. (1)
9. (biological adj2 glu$).tw. (541)
10. (biological adj2 seal$).tw. (76)
11. Beriplast.tw. (87)
12. Bolheal.tw. (10)
13. Collaseal.tw. (1)
14. Tissucol.tw. (302)
15. Tisseel.tw. (281)
16. Quixil.tw. (36)
17. Biocol.tw. (6)
18. Omrixil.tw. (1)
19. Vivostat.tw. (36)
20. Hemaseel.tw. (10)
21. Crosseal.tw. (8)
22. Tachocomb.tw. (112)
23. Tachosil.tw. (137)
24. Tissel.tw. (5)
25. Transglutine.tw. (4)
26. or/1-25 (6775)
27. Randomized Controlled Trials as Topic/ (96,124)
28. randomized controlled trial/ (387,346)
29. Random Allocation/ (82,288)
30. Double Blind Method/ (128,148)
31. Single Blind Method/ (19,993)
32. clinical trial/ (490,948)
33. clinical trial, phase i.pt. (14,761)
34. clinical trial, phase ii.pt. (23,777)
35. clinical trial, phase iii.pt. (9622)
36. clinical trial, phase iv.pt. (994)
37. controlled clinical trial.pt. (88,856)
38. randomized controlled trial.pt. (387,346)
39. multicenter study.pt. (181,269)
40. clinical trial.pt. (490,948)
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41. exp Clinical Trials as topic/ (285,725)
42. or/27-41 (1,059,020)
43. (clinical adj trial$).tw. (229,125)
44. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw. (133,359)
45. PLACEBOS/ (32,653)
46. placebo$.tw. (164,245)
47. randomly allocated.tw. (18,131)
48. (allocated adj2 random$).tw. (20,780)
49. or/43-48 (440,148)
50. 42 or 49 (1,217,384)
51. case report.tw. (215,419)
52. letter/ (867,687)
53. historical article/ (311,107)
54. or/51-53 (1,382,196)
55. 50 not 54 (1,186,930)
56. 26 and 55 (788)
Observational study search MEDLINE In-Process & Other
Non-Indexed Citations and Ovid MEDLINE search strategy
Date searched: 19 May 2015.
Date range searched: inception to 2015.
Search strategy
1. exp Fibrin tissue adhesive/ (3992)
2. Fibrin Foam/ (155)
3. (fibrin adj2 glu$).tw. (3415)
4. (fibrin adj2 seal$).tw. (1546)
5. (fibrin adj2 adhesi$).tw. (676)
6. fibrin spong$.tw. (38)
7. fibrin bandag$.tw. (7)
8. fibrin aerosol$.tw. (1)
9. (biological adj2 glu$).tw. (541)
10. (biological adj2 seal$).tw. (76)
11. Beriplast.tw. (87)
12. Bolheal.tw. (10)
13. Collaseal.tw. (1)
14. Tissucol.tw. (302)
15. Tisseel.tw. (281)
16. Quixil.tw. (36)
17. Biocol.tw. (6)
18. Omrixil.tw. (1)
19. Vivostat.tw. (36)
20. Hemaseel.tw. (10)
21. Crosseal.tw. (8)
22. Tachocomb.tw. (112)
23. Tachosil.tw. (137)
24. Tisseel.tw. (5)
25. Transglutine.tw. (4)
26. or/1-25 (6775)
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27. adverse effects.mp. (88,922)
28. contraindications.mp. (15,525)
29. Intraoperative Complications/ or Postoperative Complications/ (312,034)
30. ae.fs. (1,395,438)
31. co.fs. (1,642,251)
32. safe.ti,ab. (235,639)
33. safety.ti,ab. (304,730)
34. side effect$.ti,ab. (184,400)
35. treatment emergent.ti,ab. (2294)
36. undesirable effect$.ti,ab. (2173)
37. adrs.ti,ab. (2252)
38. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab.
(267,285)
39. or/27-38 (359,9151)
40. 26 and 39 (2592)
Footnote
‘ae’ denotes the subheading ‘adverse effects’.
‘co’ denotes the subheading ‘complications’.
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Appendix 2 Tables of study characteristics and
data tables
TABLE 25 Randomised controlled trial characteristics: liver surgery
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Liver
Bektas et al.,
201465
70 Aged ≥ 18 years
scheduled for elective
resection of at least one
anatomical liver segment
Tisseel Spray
(applied from a
distance of
10–15 cm)
Manual
compression
Proportion of subjects
with intraoperative
haemostasis; failure to
achieve haemostasis
within 4 minutes;
intraoperative
rebleeding after
4 minutes
de Boer et al.,
201266
310 Aged ≥ 18 years
who underwent
resection of at least
one liver segment or a
non-anatomical resection
Quixil (Crosseal
in the USA)
Conventional
technique such as
suture, clip or
coagulation
Occurrence of a
resection surface-related
complication; bleeding
or evidence of a
haematoma in proximity
to the resection surface
Chapman
et al., 200067
67 Male or non-pregnant
female patients
scheduled for
hemihepatectomy or
segmental resection of
the liver by tangential
excision
CoStasis Surgical
Hemostat
(Cohesion
Technologies
Inc., Palo Alto,
CA, USA)
Collagen sponge
applied with
pressure
Primary end point:
haemostatic success;
secondary end point:
time to bleeding
Uetsuji et al.,
199468
87 Not reported ‘Spray’
manufactured by
IMMUNOAG
(Vienna, Austria)
Liver mobilisation
without fibrin
sealant
Presence or absence of
liver cirrhosis; operative
procedure; time
required for operation;
duration of anaesthesia;
amount of bleeding;
amount of blood
transfused
Liu and Liu,
199369
40 Patients with diagnoses
of benign or malignant
disease of the liver
scheduled for liver
resection
Fibrin adhesive No fibrin adhesive Operation time; blood
loss; post-operative
bloody discharge;
removal of drain tube;
blood transfusion
Noun et al.,
199670
82 Patients undergoing
elective hepatic resection.
Patients with associated
biliary reconstruction/GI
procedure were excluded
Glue (Biocol;
Bio-transfusion,
Lille, France)
No fibrin sealant Fluid drainage;
haemoglobin
concentration; bilirubin
concentration;
complications
Figueras et al.,
200771
300 Patients undergoing
hepatic resection and
patients who required
contralateral hepatic
resection, concomitant
bowel resection or
bilioenteric anastomosis
5 ml of Tissucol No fibrin sealant or
collagen
Patients with
intraoperative
transfusion (%); blood
transfusion units;
post-operative
transfusion; hospital
mortality; duration of
operation (minutes)
continued
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TABLE 25 Randomised controlled trial characteristics: liver surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Frilling et al.,
200573
121 Patients undergoing
elective hepatic resection.
All patients gave their
written informed consent
before any trial-specific
procedures
TachoSil Argon beamer
(argon beam
coagulator)
Time to haemostasis
was the primary
outcome measure
Fischer et al.,
201172
119 Aged ≥ 18 years, elective
liver resection, at least
segmental resection of
the liver and only minor
(oozing) or moderate
haemorrhage persisting
after primary procedures
TachoSil Argon beam
coagulation
Primary end point:
haemostasis; secondary
end points: total
drainage volume,
post-operative duration
of drainage, content of
haemoglobin and
bilirubin in the drainage
Kakaei et al.,
201374
45 All patients with
resectable liver lesions of
any size during this
period were included in
this study
TachoSil is an
absorbable
surgical patch
Glubran 2 (GEM
SrI, Viareggio, Italy)
is a synthetic
surgical glue
The primary objective
was to compare time to
haemostasis between
groups. Secondary
outcomes were blood
loss calculated; amount
of blood substitute
administered; sponges
used; and total amount
of blood in the suction
Kohno et al.,
199275
62 Not reported Beriplast solution Microcrystalline
collagen powder
from bovine
Primary end point:
(efficacy of the fibrin
tissue adhesive). The
primary efficacy end
point was haemostatic
efficacy during surgery,
post-operative
rebleeding, bile leakage
and other complications
Moench et al.,
201476
128 Patients aged > 18 years
scheduled for an elective,
open liver resection
(segmental or
non-segmental)
Patch (Tachosil) Collagen hemostat
Sangustop fleeces
(Aesculap AG,
Tuttlingen,
Germany)
Haemostasis within
3 minutes after
application of
haemostat; haemostasis
after 5 and 10 minutes
of application of
haemostat; time to
haemostasis; blood
transfusions
Schwartz
et al., 200477
121 Adult patients (aged
> 18 years) were
candidates for entry if
they required liver
resection for any reason
except trauma and
underwent no major
surgical intervention
beyond the liver
Spray (Crosseal/
Quixil)
Actifoam (Davol Inc.,
Cranston, RI, USA),
Avitene (CR Bard,
Murray Hill, NJ,
USA), Gelfoam
(Pfizer Inc., New
York City, NY, USA),
Oxycel (Parke-Davis,
Detroit, MI, USA),
Surgicel and Surgicel
Nu-Knit (Johnson &
Johnson, Somerville,
NJ, USA), and
Thrombinar (King
Pharmaceuticals,
Bristol, TN, USA)
Time to haemostasis;
percentage achieving
haemostasis within
10 seconds; volume of
blood loss; duration of
post-operative bilious
drainage; occurrence of
abdominal fluid
collection
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TABLE 25 Randomised controlled trial characteristics: liver surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Pancreas
Carter et al.,
201381
109 Not reported Fibrin glue was
injected
The remnant could
be stapled or
mattress sutured
Post-operative
complications;
development of a
pancreatic fistula;
percutaneous drain
placement; drain
amylase values
Suzuki et al.,
199582
56 Patients undergoing
distal pancreatectomy
Tisseel, glue
(applied over
suture)
No application of
fibrin glue
Occurrence of
post-operative
pancreatic fistula
Lillemoe et al.,
200483
124 Patients with pancreatic-
enteric anastomosis
considered to be at high
risk for the development
of pancreatic leak
Hemaseel (glue) No such fibrin
application
Pancreatic fistula;
complications; length
of stay; reoperation;
death; cost savings
Montorsi
et al., 201284
275 Adults aged ≥ 18 years
undergoing elective
distal pancreatectomy,
with or without spleen
preservation, for
pancreatic disease other
than chronic pancreatitis
Absorbable fibrin
sealant patch
(TachoSil)
Standard suturing
or stapling
Primary end point:
occurrence of post-
operative pancreatic
fistula; number of days
until drain removal,
volume of fluid drained;
and length of hospital
stay. Adverse events
and post-operative
complications were also
reported
Suc et al.,
200385
182 Patients undergoing
pancreatic resection
Tissucol Resection without
ductal occlusion
Post-operative abdominal
complications;
post-operative mortality;
reoperation
Martin and
Au, 201386
57 Patients undergoing
pancreaticoduodenectomy
Tisseel No application of
Tisseel
Drain lipase levels;
anastomotic leak; all
complications; length of
hospital stay; death
Gall bladder
Fu et al.,
200978
60 All patients whose
American Society of
Anaesthetists physical
status was I or II
Fibrin sealant Laparoscopic
cholecystectomy
Post-operative pain.
Secondary efficacy
parameters: amount of
pethidine hydrochloride
used per capita
Danielsen
et al., 201079
51 Patients aged ≥ 18 years
subjected to elective
laparoscopic
cholecystectomy
Autologous
platelet-rich
fibrin (Vivostat)
Human albumin Wound infection
Dimo et al.,
198980
80 Patients admitted to the
surgical department
for elective simple
cholecystectomy
Beriplast, spray No application of
Beriplast
Secretion volume and
total at day 1 post
surgery; number of days
until drain removal
continued
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TABLE 25 Randomised controlled trial characteristics: liver surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Mixed GI
Hwang and
Chen, 199661
13 Patients with low output
(< 20ml/day)
enterocutaneous fistulas
that had been present for
2–4 weeks
Fibrin tissue
glue, infused
Conservative
treatment with
total parenteral
nutrition
Fistula closure time;
time to discharge;
recurrence; adverse
reactions
Huang et al.,
201564
42 Aged 16–70 years with
locally advanced gastric
cancer confirmed by
pathological testing
and confined to the
abdominal cavity
Cisplatin loaded
into a syringe
and sprayed
Standard care Disease-specific overall
survival; local and/or
systemic infections;
abdominal leakage;
death as a result of the
procedure; biochemical
differences over time
Oliver et al.,
201287
61 Patients undergoing
high-risk anastomosis of
the digestive tract with
or without GI surgery,
intestinal anastomosis
Tissucol Duo No fibrin adhesive
in the suture line
Incidence of
anastomotic leakage;
incidence of further
surgical intervention
and mortality
Bulbuller et al.,
201392
65 Adult patients aged
18–60 years undergoing
classical laparoscopic
sleeve gastrectomy
4 ml of Tisseel
fibrin sealant
Without suture or
with suture
Post-operative
complications: bleeding;
anastomosis leakage;
wound site infection;
abscess formation;
duration of hospital
stay; reoperation
Fernandez
Fernandez
et al., 199663
86 Patients undergoing total
gastrectomy for gastric
adenocarcinoma
Tissucol Curative resection
without fibrin glue
Number of fistulas;
post-operative
complications; length of
hospital stay; death
Musella et al.,
201488
100 Men and women aged
18–65 years with a BMI
ranging from 40 to
55 kg/m2
Spray (Tisseel) No fibrin sealant Occurrence of
complications; operative
time; length of hospital
stay; time to oral diet
initiation
Silecchia et al.,
200862
320 Aged 21–65 years,
morbidly obese
(BMI 40–59 kg/m2),
undergoing laparoscopic
gastric bypass
Tissucol/Tisseel
fibrin sealant
Closure of the
mesentery defects
and the Petersen
space was carried
out using stitches
Proportion of
complication-free
patients; length of
hospital stay;
occurrence of
anastomotic stenosis;
weight loss; occurrence
of early complications;
adverse effects directly
related to fibrin sealant
Pilone et al.,
201289
30 Candidates for sleeve
gastrectomy
Tachosil Spray (Tachosil) Operation time; length
of hospital stay (time of
discharge); complications;
change in haemoglobin
and red blood cells
Sroka et al.,
201590
165 Aged > 18 years and
had clear indication for
bariatric surgery
EVICEL Suture Operating time; change
in haemoglobin level;
drain amount; patients
receiving packed cells;
late, infected
haematoma
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TABLE 25 Randomised controlled trial characteristics: liver surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Fékété et al.,
199291
100 Patients undergoing
surgery and requiring
oesophageal anastomosis
Quick-setting
fibrin glue
No application of
fibrin glue
Operative mortality
rate; fistulas incidence
rate and severity;
anastomotic stenosis
Huang and
Qian, 201493
95 Patients diagnosed with
gastric carcinoma by
preoperative gastric
endoscopy and
pathological examination
Fibrin glue Standard surgery
procedure
Operative time;
intraoperative blood
loss; post-operative
drainage volume;
complications; wound
healing conditions
BMI, body mass index.
TABLE 26 Randomised controlled trial characteristics: mixed orthopaedic surgery
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Antuña et al.,
2013155
28 Patients with a diagnosis
of a massive rotator cuff
tear of the posterosuperior
rotator cuff (two tendons,
> 5 cm) made by clinical
examination and magnetic
resonance imaging
Platelet-rich
fibrin
No additional
treatment was
applied
Primary end point:
shoulder function;
secondary end points:
self-report scale to
evaluate the upper-
extremity of disability,
pain and degree of
satisfaction
Aguilera et al.,
2013143
172 Adult patients (aged
≥ 18 years) scheduled for
elective primary total
knee arthroplasty
Tissucol Tranexamic acid or
routine haemostasis
Post-operative drain
blood; total blood loss;
rate of perioperative
blood transfusion;
haemoglobin; rate of
surgical infections; length
of hospital stay; rate of
venous thrombosis;
mortality
Wang et al.,
2003153
71 Aged > 18 years with
diagnosis of osteoarthritis
of the hip, scheduled for
primary unilateral total
hip replacement
Omrixil, spray Standard
haemostatic
techniques
Intraoperative blood loss;
blood loss for the post-
operative period; volume
of blood in the drains
Lassen et al.,
2006141
69 Patients (aged
> 18 years) undergoing
elective primary hip
arthroplasty surgery in
one Danish hospital
Vivostat (spray) No topical
haemostatic
treatment
Intraoperative blood
loss; drain volume;
auto-transfusion;
hospitalisation times;
oozing; haematoma
Levy et al.,
199914
46 Patients who had
osteoarthritis of the knee
scheduled to have
unilateral total knee
arthroplasty with cement
(cruciate-sparing
implants)
Octacol F15
(Quixil); spray
No fibrin adhesive Reduction in blood loss;
reduction in haemoglobin
levels; reduction in blood
transfusion; development
of haematoma; functional
recovery; range of motion
Skovgaard
et al., 2013150
24 Adults aged > 18 years
with symptomatic and
radiographic bilateral
knee osteoarthritis
EVICEL, spray Saline as placebo Blood loss; pain; range
of movement; swelling;
readmission within
90 days from the
operation
continued
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TABLE 26 Randomised controlled trial characteristics: mixed orthopaedic surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Falez et al.,
2013154
57 Aged between 45 and
75 years; pre-operative
haemoglobin levels equal
to 11 g/dl and fibrinogen
levels within normal
range
Fibrin spray Standard care:
electrocautery to
seal the vessels
Blood loss (ml) at 6, 24,
48 and 72 hours;
measured using
autologous blood
transfusion device
(BellovacTM, Astra Tech
Ltd, Gloucestershire, UK)
Kluba et al.,
2012145
24 Patients diagnosed with
primary osteoarthritis of
the knee and scheduled
for primary bicondylar
knee arthroplasty with
cement
Quixil (topical
spraying)
Standardised
general anaesthesia
and fluid regiment
control
Post-operative fluid loss;
maximum flexion; length
of stay; complications
McConnell
et al., 2011156
66 Patients were eligible if
they were scheduled to
undergo elective primary
unilateral cemented hip
arthroplasty
Fibrin spray Tranexamic acid Median intraoperative
blood loss
Molloy et al.,
2007147
100 Pre-operative
haemoglobin level
≤ 13.0 g/dl prior to total
knee replacement
Quixil spray Tranexamic acid
intravenously
Post-operative pain
scores; total blood loss;
post-operative
haemoglobin level; length
of hospital stay;
complications
Sabatini et al.,
2012148
70 Patients treated for
osteoarthritis of the
knee with total knee
cement-less arthroplasty
Quixil Blood recovery
device
Blood loss; haemoglobin
decrease; surgical time;
transfusions;
complications
Randelli et al.,
2014149
114 Patients with a diagnosis
of osteoarthritis of the
knee scheduled for
primary total knee
arthroplasty
EVICEL Electrocautery after
the release of the
tourniquet
Total blood loss; time to
drain removal; changes in
haemoglobin levels;
mean haemoglobin level
and haemoglobin loss;
drained blood loss; length
of hospital stay
Wang et al.,
2001144
53 Patients with
osteoarthritis and a
baseline haemoglobin
level of ≤ 110 g/l and
evidence of a bleeding
or metabolic-based
haemolytic disorder were
excluded from the study
Spray No placebo was
used in the control
group
Amount of post-operative
drainage in 12 hours;
haemoglobin level on the
first post-operative day;
transfusion requirements;
adverse events; hematoma;
seroconversion
Choufani
et al., 2015151
60 Patients undergoing
elective total knee
replacement
EVICEL, spray No fibrin sealant Post-operative blood
transfusion, difference in
haemoglobin levels
between pre and post
operation; total
blood loss at third
post-operative day;
adverse events
Heyse et al.,
2014142
198 Patients aged > 18 years
who were able and
willing to give informed
consent
Spray applicator Standard care – no
fibrin sealant
Drain output 24 hours
after surgery;
transfusions;
haemoglobin levels;
haematocrit levels; range
of motion; pain scores
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TABLE 26 Randomised controlled trial characteristics: mixed orthopaedic surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Mawatari
et al., 2006152
100 Total hip arthroplasty
patients
Autologous
fibrin tissue
adhesive, spray
No application of
fibrin sealant
Intra- and post-operative
blood loss; complications
such as infection,
deep-vein thrombosis,
pulmonary embolism
TABLE 27 Randomised controlled trial characteristics: vascular surgery
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Bajardi et al.,
2009194
20 Patients with intact
infrarenal abdominal
aortic aneurysm
TachoSil
haemostatic
surgical patch
Compression Primary outcome: time
to achieve haemostasis;
secondary outcomes:
blood loss, duration of
the operation, drain
volume, requirement for
blood transfusion
Schenk et al.,
2003195
38 Patients who were
undergoing PTFE graft
placement for dialysis
access
Glue (Bioplasma) Cellulose (surgical) Time to haemostasis;
occurrence of
haemostasis; time of
application plus time to
haemostasis; duration of
graft implant procedure
Jackson et al.,
1999193
47 Patients undergoing
elective carotid
endarterectomy with
expanded PTFE patch
closure
Human fibrin
sealant, applied
as a liquid
Thrombin-soaked
gelatine sponge
Haemostasis within
15 minutes; amount of
blood loss; time to
haemostasis
Milne et al.,
1995201
16 Patients undergoing a
carotid endocardectomy
Spray Nothing was
applied to the
suture line
Operative blood loss;
time to achieve
haemostasis; total
operative time; drop in
haemoglobin level;
post-operative
cerebrovascular accident
Milne et al.,
1996203
39 Patients undergoing
either arterial bypass
surgery with a PTFE
bypass graft or aortic
aneurysm repair with a
woven Dacron graft
Injection (applied
using a syringe)
Nothing was
applied to the
suture line
Time to achieve
haemostasis; operation
time; intraoperative
blood loss; proportion
achieving haemostasis;
post-operative virology/
infection
Saha et al.,
2012197
140 Patients scheduled for
arterio-arterial bypasses
with expanded PTFE
grafts. Patients with
moderate or severe
anastomotic suture-hole
bleeding that could not
be controlled with
additional suturing
A soluble
mixture that
transforms to
form a matrix
Continuous manual
compression with
surgical gauze pads
Proportion of patients
who achieved
haemostasis at the
study suture line of the
graft; incidence of
intraoperative
rebleeding; incidence
of post-operative
rebleeding
continued
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TABLE 27 Randomised controlled trial characteristics: vascular surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Joseph et al.,
2004200
24 Patients undergoing
femoral anastomosis and
femoral or carotid patch
angioplasty with PTFE
grafts
TachoComb,
moistened
patches
Compression with
10 × 10 cm2
surgical swabs
Time to haemostasis;
blood loss during the
operation; duration
of operation; drain
volume; requirement
for blood transfusion;
surgeons rating of
efficacy; coagulation
parameters
Sintler et al.,
2005202
20 Primary procedure,
normal clotting profile
and on aspirin (75 mg)
for at least 2 weeks prior
to surgery
Quixil Kaltostat Time to achieve
haemostasis; blood loss;
adverse events
Taylor et al.,
2003199
128 Male or non-pregnant,
non-lactating females,
aged > 18 years,
scheduled for elective
extruded PTFE grafting
Beriplast P gel Thrombin-soaked
gelatin sponge
Haemostasis at
4 minutes post
randomisation; volume
of blood loss at the
anastomosis; incidence
of repeat bleeding;
duration of intensive
care unit stay; length of
hospital stay; mortality
Chalmers
et al., 2010198
70 Aged ≥ 18 years,
scheduled for vascular
procedure using
uncoated or heparin-
coated PTFE prosthetic
graft material with at
least one end-to-side
anastomosis to a femoral
or upper-extremity artery
EVICEL Manual
compression
Primary end point:
absence of bleeding
at the anastomosis
at 4 minutes after
randomisation;
secondary end point:
absence of bleeding at
the anastomosis
Czerny et al.,
2000205
60 Vascular reconstruction
surgery with PTFE
prosthesis, aged
≥ 18 years
TachoComb H
patch
Surgical compresses
only to control
suture hole
bleedings
Time to haemostasis;
intraoperative blood
loss; intraoperative
blood substitutes;
duration of the
operation
Saha et al.,
2011204
73 Patients undergoing PTFE
graft placement surgery,
including arterio-arterial
bypasses and
arteriovenous dialysis
access shunts
Fibrin sealant
(Tisseel)
Manual
compression
Proportion of patients
achieving haemostasis;
incidence of
intraoperative rebleeding
after achievement of
haemostasis; incidence
of post-operative
rebleeding that required
surgical exploration;
transfusion requirements
Schenk et al.,
2002196
28 Aged ≥ 18 years who
required placement of a
PTFE graft with arterial
and venous anastomoses
using non-filament
non-absorbable suture to
obtain an arteriovenous
fistula for renal dialysis
access
Hemaseel Commercial topical
bovine thrombin
(thrombogen),
oxidised cellulose
(Surgicel)
Time to haemostasis
PTFE, poly(1,1,2,2-tetrafluoroethylene).
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TABLE 28 Randomised controlled trial characteristics: breast
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Berger et al.,
2001107
61 Primary breast cancer, no
previous breast surgery
or neo-adjuvant
chemotherapy or prior
locoregional radiotherapy
TachoComb Standard closure
(not described)
Duration of axillary
drainage; length of post-
operative hospital stay;
drainage volume;
presence of local
infection; use of
antibiotics; use of local
wound treatments;
seroma formation at
discharge
Udén et al.,
199398
68 Women undergoing
modified radical
mastectomy with axillary
clearance for breast
cancer
Tisseel Control group had
no glue applied
Seroma formation;
wound infection; necrosis
of skin flaps
Benevento
et al., 2014109
60 Female sex, aged
≥ 25 years, absences of
anticoagulopathy,
and/or liver disease,
BMI ≤ 35 kg/m2,
indication to axillary
lymph node dissection
Artiss All patients
received a
percutaneous
vacuum drain
Volume of serous fluid;
time to remove drain
(days); length of post-
operative hospital stay
(hours); seroma; number
of patients with
lymphoedema
Jain et al.,
200499
116 Patients presenting with
newly diagnosed
carcinoma of the breast
who required primary
excision and axillary
lymphadenectomy
Tisseel spray Suction drain, and
no drain and no
fibrin
Frequency and volume of
seroma; post-operative
length of hospital stay;
post-operative pain and
wound infection; bleeding
complication
Johnson et al.,
2005100
82 Females aged ≥ 18 years
scheduled for elective
breast procedure
Hemaseel Placement of
one or two
Jackson–Pratt
drains in their
wound and/or
axilla
Incidence of seroma
formation and volume;
blood loss; length of
hospital stay; complications;
interval to seroma
resolution; number of
post-operative visits
Llewellyn-
Bennett et al.,
2012101
101 Women with newly
diagnosed invasive or
non-invasive breast
cancer who required
mastectomy and axillary
staging
Tisseel Standard closure
of the back skin
wound
Total seroma volume; total
back seroma volumes
aspirated after drain
removal over 3 months;
volume of donor-site
seromas; number of
seroma aspirations
after drain removal;
post-operative
complications
Nielsen et al.,
1985123
38 NR 2 ml of Tisseel
vs. 4 ml of Tisseel
Standard/control
group not defined
Wound secretion
Ko et al.,
2009102
95 Newly diagnosed breast
cancer, female sex,
scheduled for elective
breast lumpectomy and
axillary dissection
Greenplast kit
(Green Cross
Corp., Seoul,
Korea) (spray)
Control group
(non-fibrin glue)
Duration of drainage;
overall drain output;
incidence of seroma
formation; wound-related
complications
continued
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TABLE 28 Randomised controlled trial characteristics: breast (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Di Monta
et al., 2012117
70 Candidates for surgical
treatment of metastatic
melanoma stage III by
axillary or ilioinguinal
radical lymph node
dissection
Tachosil Standard
treatment alone
Post-operative duration of
drainage; incidence of
drainage removal; daily
drainage volume
Miri Bonjar
et al., 2012103
60 Female aged > 18 years
scheduled for elective
breast procedure, had
platelet counts
≥ 100,000/ml, no
diabetes or advanced
liver disease, not
severely obese, not had
axillary lymph surgery
Hemaseel Conventional drain
placement
(Jackson–Pratt
drain)
Estimated blood loss;
length of hospital stay;
post-operative day drain
removal; complications;
incidence of seroma;
interval to seroma
resolution; seroma
aspirate volume; number
of post-operative visits
Moore et al.,
2001111
80 Patients who were
about to undergo
axillary node dissection
with either a
lumpectomy or a
modified radical
mastectomy procedure
4, 8 or 16 ml of
fibrin
Use of no
therapeutic agent
Time of wound drainage;
volume of drainage after
treatment; adverse
events; serological
presence of hepatitis A, B
or C virus
Mortenson
et al., 2008120
30 Patients scheduled to
undergo a superficial
inguinofemoral lymph
node dissection
Tisseel One or two closed
suction drains are
inserted
Time to drain removal
(days); estimated blood
loss; operative time
(minutes); complications
Mustonen
et al., 2004104
40 Patients undergoing
modified radical
mastectomy (including
axillary evacuation) for
breast cancer
Tisseel Non-fibrin sealant
group
Axillary drain volume and
time; breast drain volume
and time; length of
hospital stay; seroma
incidence; number of
aspirations
Segura-Castillo
et al., 2005105
45 Women diagnosed with
breast cancer who
underwent modified
radical mastectomy
Quixil Standard
mastectomy using
electrocauterisation
and sutures
Time to drain removal;
volume of lymphatic fluid
days 1–6 post surgery;
seroma formation
Vaxman et al.,
1995112
20 Patients with breast
cancer requiring axillary
lymph node dissection
with lumpectomy or a
modified radical
mastectomy
Tisseel Standard
mastectomy
technique
(cutaneous suture)
Total drainage fluid
volume and duration of
axillary drainage fluid;
mastectomy drainage
fluid and duration;
hospital stays;
complications
Zhibo and
Miaobo,
200995
30 Women undergoing
surgical breast
augmentation
procedures
Fibrin glue only Fibrin glue and
lidocaine, or
lidocaine only
Self-reported pain
Swan et al.,
2011113
74 Patients aged ≥ 18 years
or who required elective
lymph node dissection
Tisseel No fibrin sealant Total volume of wound
drainage before drain
removal; duration of
drainage; seroma
formation; total number
of aspirations and
volume; wound cellulitis;
locoregional recurrence;
survival
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TABLE 28 Randomised controlled trial characteristics: breast (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Ulusoy et al.,
200396
54 Patients who underwent
modified radical
mastectomy because of
breast cancer
Fibrin glue Siliconised suction
drain
Drainage volumes; drain
removal times; seroma
formation frequency;
seroma formation volume
Cipolla et al.,
2010110
160 Diagnosis of N1 breast
carcinoma, and aged
≥ 18 years
Fibrin sealant Placement of a
Jackson–Pratt
suction drain only
Post-operative day of
drainage removal; total
volume of drained serum;
total volume of evacuated
seroma; number of
seroma aspirations
needed
Dinsmore
et al., 200097
27 Women diagnosed with
breast cancer who had
selected radical
mastectomy for
treatment
Fibrin glue Standard closure
of wound
Drain output
Gilly et al.,
1994115
40 Patients undergoing
inguinal or axillary
lymphadenectomy
Tissucol Same surgical
procedure without
the application of
fibrin glue
Drainage volume; number
of drainage days; number
of hospitalisation days;
occurrence of parietal
suppuration; occurrence
of post-operative seroma;
post-operative comfort
of the patient; skin state
1 month after the
operation
Gilly et al.,
1998108
108 Patients scheduled for
axillary lymphadenectomy
for breast cancer, with no
previous irradiation or
chemotherapy
Tissucol Same intervention
without application
of fibrin glue
Daily and cumulative
drainage volume over
the first 6 post-operative
days; time to hospital
discharge
Moore et al.,
1997106
21 Women who elected
modified radical
mastectomy for
carcinoma, with level I
and II axillary node
dissections for an
infiltrating ductal or
lobular breast carcinoma
Autologous
fibrin sealant
No fibrin sealant Cumulative drainage;
number of days to the
first drainage reading of
≤ 40ml (length of time
the patient needed to
retain a wound drain)
BMI, body mass index; NR, not reported.
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TABLE 29 Randomised controlled trial characteristics: hernia surgery
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Lau, 2005172 93 People aged ≥ 18 years
with bilateral inguinal
hernia
Tisseel Endoscopic stapler Post-operative pain;
analgesic requirement;
incidence of seroma;
operative time; length of
hospital stay; number of
days required to resume
normal activities;
recurrence rate; pain
Boldo, 2008173 27 Patients with bilateral
hernia
Autologous
fibrin sealant,
Vivostat
Staples Post-operative seroma;
post-operative
haematoma; hernia
recurrence
Bracale et al.,
2014174
102 Adult aged ≥ 18 years
primary uncomplicated
inguinal hernia
Quixil Conventional
Lichtenstein
technique
Operative time; inguinal
pain recurrence;
numbness
Cambal et al.,
2012175
100 Patients with unilateral
inguinal hernia
Fibrin glue Self-gripping mesh Operative time; local
complications; recurrence;
ease of product use
Campanelli
et al., 2012176
315 Men aged 18–60 years Tissucol/Tisseel
drops and spray
Lichtenstein
technique
Prevalence of moderate
to severe pain or
numbness and groin
discomfort
Canonico
et al., 1999177
50 Patients with
coagulation disorders
Tissucol Lichtenstein
technique
Haemorrhagic
complications
Eriksen et al.,
2011260
40 Patients with umbilical
hernia defects aged
18–85 years
Tisseel Tack fixation Acute post-operative pain
Lionetti et al.,
2012179
148 Aged > 18 years, male
and with groin hernia
Quixil Lichtenstein
technique
Post-operative pain score;
recurrences; proportion of
patients with chronic pain
Lovisetto et al.,
2007180
197 Aged > 18 years with a
diagnosis of inguinal or
femoral hernia
Tissucol/Tisseel Endopath
multifeed stapler
Post-operative neuralgia
Chan et al.,
2014178
130 Male patients aged
18–70 years
Tisseel spray Staples Incidence of chronic pain
Tolver et al.,
2013181
112 Mean aged 18–80 years
with unilateral inguinal
or femoral hernia
Tisseel spray Protacks fixation
devices
Pain, discomfort, fatigue,
nausea or vomiting;
seroma formation;
haematoma formation;
hernia recurrence
Wong et al.,
2011182
56 Primary inguinal hernia,
aged > 20 years
Glue (Tissucol,
Tisseel)
Sutures Post-operative pain;
seroma or haematoma
formation; infection;
mortality
Damiano
et al., 2014184
468 Patients with primary
unilateral inguinal hernia
Tisscol fibrin
glue
Sutures Operating time; intra-
and post-operative
complications
Olmi et al.,
2007259
600 Patients undergoing
laparoscopic hernia
repair
Tissucol/Tisseel Endopath
multifeed stapler
Operating time; time to
return to work; rates of
conversion; morbidity;
mortality; recurrence
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TABLE 30 Randomised controlled trial characteristics: lymph node surgery
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Carlson et al.,
200894
137 Female patients with a
vulvar malignancy
undergoing a radical
vulvectomy or
hemivulvectomy
Tisseel, spray No fibrin sealant Incidence of grade 2 and
3; incidence of wound
complications; infections;
number of days of
drainage; discontinuation;
incidence of wound
separation
Furrer et al.,
1993116
30 Patients undergoing
inguinal or axillary
radical lymph node
dissection.
Lymphadenectomy-
relapsed interventions,
however, were excluded
Tissucol spray Radical lymph
node dissection
Drainage volume and
time; lymphocele volume;
hospitalisation; wound
healing (clinical follow-up)
Siim et al.,
1994114
30 Patients with malignant
melanoma lymph node
metastases
Fibrin adhesive
glue
Standard
lymphadenectomy
Daily amount of wound
secretion; total amount of
wound secretion; number
of days with drains;
duration of hospital stay;
post-operative,
complications (i.e.
hematomas, seromas,
infections and flap
necrosis)
Neuss et al.,
2009118
58 Patients with malignant
melanoma with stage III
or IV disease with lymph
node metastases of the
groin
Tissomat spray Low-molecular-
weight heparin
Amount and quality of
the drained fluids were
recorded every 24 hours;
duration of drain
placement
Simonato
et al., 2009119
60 The only exclusion
criterion was any
evidence of coagulation
disorders and such cases
were, in fact, excluded
from study
TachoSil patch Standard
technique only
Development of
symptomatic or
asymptomatic
lymphoceles; drainage
volume and duration; all
complications; need for
further surgical
intervention
Tachibana
et al., 2003122
43 Patients with primary
carcinoma of the
thoracic oesophagus
undergoing one-stage
transthoracic
oesophagectomy
Bohleal
(Kaketsuken
Pharmaceuticals,
Kumamoto,
Japan), spray
Same surgical
procedure without
the application of
the fibrin sealant
Reduction in the interval
until the thoracic drain
can be removed;
incidence of post-
operative complications
and viral infectious
diseases
Scholz et al.,
2002121
93 Patients with
gynaecological
malignancies
undergoing surgery
including pelvic or pelvic
and para-aortic
lymphadenectomy
Tissucol spray Sutures Incidence of lymphocysts;
incidence of lymphoedema;
incidence of deep-vein
thrombosis; time to
diagnosis of lymphocysts;
time to regression of
lymphocysts; time to
diagnosis of lymphoedema;
time to thrombosis
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TABLE 31 Randomised controlled trial characteristics: mixed surgery
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Nose
Prado et al.,
2006187
22 Patients undergoing
primary open rhinoplasty
Fibrin sealant
glue (Beriplast)
No fibrin sealant
glue
Post-operative pain;
oedema; ecchymosis;
skin adherence; average
operating time; patient
satisfaction
Pryor et al.,
2008186
10 Patients undergoing
rhinoplasty involving
lateral osteotomy
EVICEL Gentle manual
compression
Swelling, bruising and
pain
Vaiman et al.,
2002188
204 Patients undergoing
septoplasty
Fibrin aerosol
glue (Quixil)
Merocel foam
packing (Medtronic
Inc., Minneapolis,
MN, USA)
Number of post-
operative bleeds
Vaiman et al.,
2005189
64 Patients with excessive
intraoperative or
immediate bleeding
Aerosol spray
(Quixil/Crosseal)
Nasal packing Bleeding
Yu et al.,
2014190
82 Patients aged > 18 years
undergoing bilateral
functional endoscopic
sinus surgery
Fibrin sealant
aerosol spray
Polyvinyl acetyl
sponge packing
Severity of symptoms
Tonsils
Vaiman et al.,
2005191
513 Patients undergoing
endonasal surgeries
Fibrin glue (Quixil) Merocel nasal
packing
Unclear
Vaiman et al.,
2006192
102 Patients undergoing
tonsillectomy
Spray (Quixil) Electrocautery Pain; dysphagia
Skin
Drake and
Wong, 2003207
46 Patients requiring
harvest of a split
thickness skin graft
Spray pen Thrombin solution
and manual
pressure
Time to haemostasis;
differences of rates;
safety of Vivostat sealant
Vanscheidt
et al., 2007208
215 Patients aged 18–90
years with a history of
leg ulceration of at least
3 months
Bioseed Compression
bandage
Time to complete
healing; number of
patients achieving
healing
Danielson
et al., 2008209
40 Patients aged > 18 years
and scheduled for
surgical debridement of
ulcer
Autologous
platelet-rich fibrin
Epithelial
resurfacing; pain
scores
Venous insufficiency
Erba et al.,
2010210
10 Patients with paraplegia
and decubitus ulcers
stage IV (Daniel’s
classification)
Fibrin glue No fibrin glue Drainage volume; time
of drain removal
Healy et al.,
2013211
50 Patients aged > 18 years
undergoing split skin
grafting from a lateral
thigh donor site
Fibrin sealant
(spray)
Self adhesive fabric
dressing (Mefix)
Pain; incapacity
Colorectal
Ellis and Clark,
2006216
58 Patients with trans-
sphincteric anal fistulas
Tisseel Sutures Fistula recurrence
Altomare
et al., 2011217
101 Patients with trans-
sphincteric anal fistulas
Tissucol No fibrin sealant Healing rate; hospital
stay; healing time; faecal
incontinence
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TABLE 31 Randomised controlled trial characteristics: mixed surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Lindsey et al.,
2002218
42 Patients aged ≥ 18 years
with cryptoglandular or
Crohn’s anal fistulas
Beriplast Current standard
fistula practice
Pain score; time to
return to work;
satisfaction
Hammond
et al., 2011219
29 Patients with anal
fistulas
Tisseel glue Permacol, collagen
sheet
Wound healing time;
return to work; patient
satisfaction; continence
disturbance; recurrence;
proportion of symptoms
van der Hagen
et al., 2011220
30 Patients with perianal
fistulas
Fibrin glue No fibrin Treatment failure;
recurrent fistulas; soiling
after treatment; quality
of life; incontinence
score
Prostate
Luke et al.,
1986223
30 Patients undergoing
transurethral
prostatectomy
Beriplast fibrin
glue
No fibrin glue Blood loss; urine
volume; concentration
of haemoglobin
Schultz and
Christiansen,
1985224
16 Patients with obstruction
caused by a ureteral
stone
Tisseel adhesive Interrupted sutures Median drainage of
urine postoperatively
Facelift
Marchac and
Greensmith,
2005226
29 Patients undergoing
rhytidectomy
Tisseel aerosol
spray
No fibrin glue Post-operative drainage;
haematoma; degree of
ecchymosis; degree of
oedema
Lee et al.,
2009227
9 Patients undergoing
rhytidectomy
Crosseal No Crosseal
treatment
Seroma formation;
ecchymosis score
Oliver et al.,
2001228
40 Rhytidectomy
procedures
Beriplast fibrin
spray
No fibrin glue Median drainage; post-
operative haematoma
Thyroid
Uweria et al.,
2005225
56 Patients with anterior
neck dissection in
conjunction with thyroid
surgery
Tisseel No Tisseel
treatment
Drainage from surgical
site; wound drainage;
drain removal
Carter et al.,
2003229
49 Patients undergoing
dental extractions who
were therapeutically
anticoagulated for
comorbidities
Autologous fibrin
glue
Tranexamic acid
solution
Pain; discomfort
haematoma; oedema
Maharaj et al.,
2006230
60 Patients aged > 18 years
planned to receive
superficial or total
parotidectomy
Tisseel fibrin glue Sutures Wound drainage;
duration of
percutaneous drainage;
length of hospital stay;
frequency of
complications
Hester et al.,
2013231
75 Healthy patients aged
18–75 years undergoing
full rhytidectomy
Artiss sealant No fibrin glue Total drainage volume;
incidence of adverse
events
continued
DOI: 10.3310/hta20940 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 94
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
TABLE 31 Randomised controlled trial characteristics: mixed surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Mixed
Bochicchio
et al., 2015239
721 Patients undergoing
spinal vascular, hepatic
and soft tissue
procedures
Fibrocaps
(Raplixa, The
Medicines
Company,
Leiden, the
Netherlands)
No fibrin glue Gelatin sponge
Fischer et al.,
2013241
90 Patients aged
> 18 years requiring
non-emergency surgical
procedures
Fibrin pad Surgical original
absorbable
hemostat
Haemostasis
Verhoef et al.,
2015240
126 Patients with mild or
moderate bleeding
during a surgical
procedure
Fibrocaps Gelatin sponge Haemostasis
Hanks et al.,
2003238
73 Patients aged
18–75 years undergoing
elective surgery
Spray pen Dry surgical
sponge
Time to haemostasis;
success of treatment
Oliver et al.,
2002215
50 Patients undergoing
mixed surgical
procedures
Beriplast No fibrin sealant Average drainage
Gynaecology (uterus)
Diamond
et al., 2011232
34 Patients with bilaterally
documented ovarian
disease scheduled for
laparoscopy
Adhexil (Johnson
& Johnson,
Somerville, NJ,
USA) sprayed or
dipped
No fibrin sealant Incidence of adhesions;
serious adverse events
Maggiore
et al., 2011233
70 Patients with intraurine
uterine fibroma
Tachosil fibrin-
coated sponge
No haemostatic
agent used
Surgery duration;
intraoperative blood
loss; post-operative
drainage; length of
hospital stay
Takeuchi et al.,
2005234
83 Women with
symptomatic uterine
myomas
Beriplast spray No application of
fibrin sealant
Occurrence of post-
operative adhesions
Safan et al.,
2009235
40 Patients with
vesicovaginal fistulas
Autologous fibrin
preparation
No fibrin
preparation
Fistula size and location;
fibrosis; dryness
Neurosurgery
Nakamura
et al., 2005236
39 Patients with spinal cord
tumours
Beripast-P
autologous fibrin
sealant
No fibrin sealant Volume of drainage;
coagulation; mean post-
operative cerebrospinal
fluid leakage
Hutter et al.,
2014237
229 Patients scheduled for
elective cranial surgery,
aged > 18 years
Collagen sponge
coated with a dry
layer of fibrinogen
and thrombin
Standard care Incidence of
cerebrospinal fluid
leakage; incidence of
meningitis
Green et al.,
201510
139 Patients undergoing
elective craniotomy in
the supraentorial region
or the processes in the
posterior fossa, aged
> 18 years
EVICEL Closure with
sutures
Watertight closure of
the dura
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TABLE 32 Randomised controlled trial characteristics: cardiothoracic surgery
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Heart
Kjaergard and
Trumbull,
1998138
24 Aged 18–80 years with
coronary artery disease
demonstrated by
arteriogram and suitable
candidate for coronary
artery bypass grafting
Vivostat Traditional
methods of
haemostasis alone
(sutures, clips and
electrocautery)
Survival (death); atrial
fibrillation; anaemia; pleural
effusion; pneumothoraxes;
post-operative transfusions;
chest tube drainage;
reoperations
Kjaergard and
Trumbull,
2000139
30 Aged > 18 years
admitted for elective
cardiac operation
requiring median
sternotomy
Vivostat No application of
fibrin sealant
Time to haemostasis
Maisano et al.,
2009140
119 Aged ≥ 18 years with
planned elective heart
surgery, ascending aorta
or arch requiring a
cardiopulmonary bypass
procedure
TachoSil Standard
haemostatic fleece
material
Haemostasis; duration
of surgery; need for
intraoperative transfusions;
duration of drainage;
post-operative drainage
volume; incidence of
reoperation; post-operative
transfusion and other
post-operative
complications
Shiono et al.,
1998261
32 Adult patients
undergoing elective
cardiac surgery
Fibrin glue Cryoprecipitate
from patients’ own
fresh-frozen
plasma
Post-operative haemoglobin
concentration; platelet
levels; cardiac index; rate of
homologous transfusion;
homologous transfusion
volume
Tavilla et al.,
201560
1445 Patients undergoing
elective isolated
coronary artery bypass
graft (either on pump or
off pump)
CryoSeal No CryoSeal
treatment
Number of transfused
blood products; duration
of stay in intensive care
unit; amount of blood loss
within 48 hours post
surgery; reoperations;
30-day mortality; duration
of hospital stay
Lung
Fabian et al.,
2003128
100 Patients undergoing
planned open anatomic
pulmonary resection or
wedge resection
HemaMyst
system
(Haemacure
Corp., Sarasota,
FL, USA)
Stapling
techniques
Mean duration of AAL;
mean time to chest tube
removal; incidence of
prolonged AAL; mean
first 24-hour drainage;
percentage of patients
discharged with valve;
mean post-operative
length of stay
Droghetti
et al., 2008124
40 Early stage non-small-
cell lung cancer patients
scheduled for elective
pulmonary lobectomy
TachoSil Routine surgical
procedure with
staplers
Intraoperative alveolar air
leaks; percentage of
patients free of air leaks
throughout hospitalisation;
last post-operative day
when an air leak was
observed; costs of
procedure and
hospitalisation
continued
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TABLE 32 Randomised controlled trial characteristics: cardiothoracic surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Lang et al.,
2004134
186 Lung cancer patients
undergoing elective
standard lobectomy with
or without mediastinal
lymphadenectomy
TachoComb Single or
continuous
running sutures
Incidence of air leakage
48 hours after lobectomy;
post-operative mortality
and morbidity pattern was
recorded in all patients
Anegg et al.,
2007125
152 Patients undergoing
lobectomy or
segmentectomy for
non-small-cell lung
cancer
TachoSil Standard
treatment
Post-operative mean
air leakage (volume in
ml/min); efficacy outcome;
incidence of post-operative
air leakage; rate of
complications
Belboul et al.,
2004133
40 Adult patients with lung
tumour limited to one
lobe, undergoing
elective lobectomy
Vivostat system Patients assigned
to the control
group underwent
no additional
interventions (after
randomisation)
Time to chest tube removal;
volume at removal of
chest tube; duration of
thoracic epidural analgesia
treatment; post-operative
length of hospital stay;
post-operative haemorrhage;
post-operative leucocyte
counts; adverse events
Belcher et al.,
2010131
113 Patients undergoing
elective open thoracic
procedures likely to
result in a post-operative
air leak
Vivostat Reducing AAL
after pulmonary
resection
Duration of air leak; time
to drain removal; length
of hospital stay; post-
operative complications
Lopez et al.,
2013129
346 Aged ≥ 18 years;
patients undergoing
pulmonary resection
(anatomical segmental
resection for lung
cancer)
TachoSil Manual suturing Intraoperative air leakage;
duration of post-operative
air leakage: time to
removal of last chest drain;
duration of surgery;
volume of drained pleural
effusion; hospital length;
adverse events; post-
operative complications
Filosso et al.,
2013136
24 Aged ≥ 18 years who
had previously
undergone pulmonary
resection for a thoracic
malignancy
TachoSil Stapling/suturing Duration of air leaks;
time to first and second
chest tube removal;
possible post-operative
complications; duration of
hospital stay
Gonfiotti et al.,
2011130
185 Aged 18–75 years; lung
resection; primitive/
secondary neoplastic
pulmonary pathology
Fibrin sealant
used is obtained
from human
plasma
The standard
treatment
Mean duration of AAL
from the wound closure;
mean duration of
drainage; percentage of
patients without AALs for
the entire hospitalisation
time; duration of post-
operative hospitalisation
Moser et al.,
2008126
25 Patients with severe
airflow obstruction
Vivostat No additional
treatment
Incidence and intensity of
air leaks
Mouritzen
et al., 1993132
114 Patients undergoing
pulmonary resections
Spray
(Beriplast P)
Suture alone Airway tolerance pressure;
rate of post-operative air
leakages; duration of
post-operative air leakages;
length of hospital stay
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TABLE 32 Randomised controlled trial characteristics: cardiothoracic surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Rena et al.,
2009127
60 Patients requiring a
lobotomy
Fibrin patch Suture Intraoperative air leak
Czerny et al.,
2004137
40 Patients with clinical
stage I
TachoComb Conventional
surgical
haemostasis
Cumulative chest drain
volume; duration of test
tubes
Marta et al.,
2010135
299 Patients aged ≥ 18 years
with lung cancer
TachoSil Resuturing,
stapling or no
treatment
Number of patches used;
success of lung inflation;
need for rescue treatment;
air leakage; atrial
fibrillation; deaths
AAL, alveolar air leak.
TABLE 33 Randomised controlled trial characteristics: eye surgery
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Kucukerdonmez
et al., 2010157
70 Patients with primary
nasal pterygium who
underwent pterygium
excision
Tisseel (two-
component
fibrin glue)
8–0 Vicryl sutures
(8–10 sutures)
Procedure outcome
(photographic images,
graded); post-operative
symptoms; operative
time; recurrence
Yüksel et al.,
2010158
61 Patients with primary
nasal pterygium
Beriplast
P/Combi-set
Aventis 1 ml
Silk (Surgisilk,
Sutures Ltd,
Wrexham, UK)
Complications;
haemorrhage under graft;
conjunctival cyst;
granuloma; recurrence;
surgery time; mean
surgery cost; objective
signs; hyperaemia
Bahar et al.,
2006159
65 Patients undergoing
primary pterygium
removal
Quixil Interrupted 8–0
Vicryl sutures
Best corrected visual
acuity; intraocular pressure;
pain; photophobia; foreign
body sensation; irritation;
epiphora; local
hyperaemia; conjunctival
chemosis; dry-eye
sensation; operative time;
recurrence
Hall et al.,
2009160
50 Patients with primary
nasal pterygia booked
for surgery with
conjunctival autograft
Tisseel (glue) Standard sutured
interrupted (Vicryl)
Surgical time; patient
discomfort; recurrence;
complications; post-
operative pain
Karalezli et al.,
2008161
50 Patients with primary
nasal pterygium
Tisseel (glue) Vicryl 8–10 sutures Operation time;
recurrence; intensity of
post-operative complaints
(pain, irritation, foreign
body, epiphora)
Koranyi et al.,
2005162
43 Patients with nasal
primary pterygium and if
informed consent was
obtained
Tisseel
(glue/spray)
Absorbable sutures Post-operative pain;
surgical times; recurrences
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TABLE 33 Randomised controlled trial characteristics: eye surgery (continued )
Study
(author, year)
Sample
size (n)
Population
(inclusion criteria) Intervention Comparator Outcomes
Sati et al.,
2014163
60 Eyes with ocular pterygia
of grade 1, 2 and 3, and
at least 2-mm extension
from the limbus
Spray (Tisseel) Vicryl suture
group: I, 8/0 Vicryl
Rate of recurrence;
surgical time; post-
operative discomfort
Sharma et al.,
2003164
40 Patients (eyes) treated
for corneal perforation
Glue Cyanoacrylate
tissue adhesive
Anterior chamber depth;
inflammatory reaction;
glue adherence
Ratnalingam
et al., 2010165
113 Patients with pterygium Adhesive Vicryl 8/0 Duration of surgery;
recurrence rate; pain
scores; complications
(displaced graft,
conjunctival cysts)
Rubin et al.,
2011166
47 Aged 18–70 years,
patients diagnosed with
primary medial located
pterygium
Quixil Mononylon 10–0
(Ethicon) suture
Efficacy of the fibrin
tissue adhesive; mean
surgery time; ocular
discomfort measured with
the visual analogue scale;
ocular hyperaemia was
also measured
Srinivasan
et al., 2009167
40 Patients with primary
pterygium
Tisseel, dripped
on the graft
Polygactin sutures Grading of Adobe
Photoshop-edited eye
pictures (version 7.0,
Adobe Systems Inc.,
San Jose, CA, USA) on
the degree of graft
inflammation,
subconjunctival
haemorrhage and stability
Uy et al.,
2005168
22 Patients with primary
pterygia undergoing
primary pterygium
excision at the Philippine
General Hospital, Manila
Fibrin glue Nylon sutures Graft success; recurrence;
subjective sensations of
pain; foreign body
sensation; tearing;
discomfort
Bahar et al.,
2007169
81 Patients undergoing
primary pterygium
removal
Quixil For excessive
bleeding, one drop
of adrenaline 10%
solution or small
amounts of
sodium
hyaluronate
10 mg/ml
Mean operative time
(minutes); intraocular
pressure; post-operative
signs and symptoms
(mean score); overall
patient satisfaction (mean
score); complications
(incidence); recurrence
(number of eyes)
Mellin and
Kondler,
1989170
100 Aged > 70 years,
without other eye
diseases such as
cataract, or maculopathy
Fibrin glue 2 8/0 silk sutures
from the limbus,
nasally
Foreign body sensation;
wound closure
Malik and
Kumar, 2010171
50 Patients with recurrent
pterygium
Tisseel Duo
Quick
Three interrupted
8–0 Vicryl sutures
Pterygium recurrence;
surgical time; post-
operative discomfort
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Appendix 3 Tables of excluded randomised
controlled trials
TABLE 34 Excluded randomised controlled trials
Study excluded Reason for exclusion
Agresta F, Tordin C. Laparoscopic transabdominal inguinal hernia repair: a randomized
study of fibrin sealant versus absorbable tack to fix the mesh. Surg Endosc 2015;29:S35
Abstract/full text unavailable
Ak G, Alpkılıç Bas¸kırt E, Kürklü E, Koray M, Tanyeri H, Zülfikar B. The evaluation of fibrin
sealants and tissue adhesives in oral surgery among patients with bleeding disorders. Turk J
Haematol 2012;29:40–7
Did not meet population/
intervention criteria
Albala DM, Wood C, Fischer C, Hart J, Batiller J, Shen J. A randomized trial of aprotinin
free fibrin sealant versus absorbable hemostat. J Endourol 2011;25:A95
Abstract/full text unavailable
Albillos A, Calleja JL. Randomised trial of fibrin glue versus polidocanol for bleeding peptic
ulcer. Lancet 1997;350:1397–8
Not a RCT
Al-Fayez M. Fibrin Glue vs. Suture Fixation of Limbal Conjunctival Autograft for Pterygium.
American Academy of Ophthalmology; 2008. URL: http://onlinelibrary.wiley.com/o/
cochrane/clcentral/articles/968/CN-00745968/frame.html (accessed 19 May 2015)
Abstract/full text unavailable
Alió JL, Mulet E, Sakla HF, Gobbi F. Efficacy of synthetic and biological bioadhesives in
scleral tunnel phacoemulsification in eyes with high myopia. J Cataract Refract Surg
1998;24:983–8
Outcomes not of interest
Anghelacopoulos SE, Tagarakis GI, Pilpilidis I, Kartsounis C, Chryssafis G. Albumin-
glutaraldehyde bioadhesive (‘Bioglue’) for prevention of postoperative complications after
stapled hemorrhoidopexy: a randomized controlled trial. Wien Klin Wochenschr
2006;118:469–72
Did not meet population/
intervention criteria
Anon. TISSEEL Fibrin Sealant. 2013. URL: http://onlinelibrary.wiley.com/o/cochrane/clcentral/
articles/847/CN-00862847/frame.html (accessed July 2013)
Not a RCT
Arslani N, Patrlj L, Kopljar M, Rajkovic Z, Altarac S, Papes D, et al. Advantages of new
materials in fascia transversalis reinforcement for inguinal hernia repair. Hernia
2010;14:617–21
Not a RCT
Ayala M. Results of pterygium surgery using a biologic adhesive. Cornea 2008;27:663–7 Not a RCT
Babicki A, Dobosz M. Second-look endoscopy with repeated injection of thrombin with
adrenaline vs fibrin glue in bleeding peptic ulcer. Br J Surg 1988;85(Suppl. 2):113
Abstract/full text unavailable
Babicki A, Dobosz M, Marczewski R, Wajda Z. [Evaluation of using fibrin tissue adhesive
(Beriplast) and preparations of thrombin and adrenalin in injection hemostasis methods for
gastric and duodenal ulcer hemorrhage. Randomized, prospective clinical trial.] Wiad Lek
1997;50(Suppl. 1):383–7
Did not meet population/
intervention criteria
Bailey SH, Oni G, Guevara R, Wong C, Saint-Cyr M. Latissimus dorsi donor-site morbidity:
the combination of quilting and fibrin sealant reduce length of drain placement and
seroma rate. Ann Plast Surg 2012;68:555–8
Not a RCT
Ben-Rafael Z, Ashkenazi J, Shelef M, Farhi J, Voliovitch I, Feldberg D, et al. The use of fibrin
sealant in in vitro fertilization and embryo transfer. Int J Fertil Menopausal Stud 1995;40:303–6
Did not meet population/
intervention criteria
Benyamini OG, Barkana Y, Hartstein M, Attas L, Avni I, Zadok D. Biological glue in
pterygium surgery with a rotational flap or sliding flaps. Cornea 2008;27:911–15
Did not meet population/
intervention criteria
Beppu T, Iwatsuki M, Okabe H, Okabe K, Masuda T, Hayashi H, et al. A new approach
to percutaneous transhepatic portal embolization using ethanolamine oleate iopamidol.
J Gastroenterol 2010;45:211–17
Not a RCT
Berg P, Born P, Barina W, Simon W, Zellmer R, Paul F. [Fibrin glue versus Polidocanol by
upper gastrointestinal bleeding.] Gastroenterol 1990;28:467
Abstract/full text unavailable
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Berg PL, Barina W, Born P. Endoscopic injection of fibrin glue versus polidocanol in peptic
ulcer hemorrhage: a pilot study. Endoscopy 1994;26:528–30
Did not meet population/
intervention criteria
Bernardo L, Bernardo WM, Shu EB, Roz LM, Almeida CC, Monaco BA, et al. Does the use
of DuraSeal in head and spinal surgeries reduce the risk of cerebrospinal fluid leaks and
complications when compared to conventional methods of dura mater closure? Rev Assoc
Med Bras 2012;58:402–3
Review
Bernasek TL, Burris RB, Fujii H, Levering MF, Polikandriotis JA, Patterson JJ. Effect on blood
loss and cost-effectiveness of pain cocktails, platelet-rich plasma, or fibrin sealant after total
knee arthroplasty. J Arthroplasty 2012;27:1448–51
Not a RCT
Biedner B, Rosenthal G. Conjunctival closure in strabismus surgery: Vicryl versus fibrin glue.
Ophthalmic Surg Lasers 1996;27:967
Not a RCT
Blinder D, Manor Y, Martinowitz U, Taicher S, Hashomer T. Dental extractions in patients
maintained on continued oral anticoagulant: comparison of local hemostatic modalities.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:137–40
Not a RCT
Bochicchio G, Singla N, Gupta NY, Porter R, Renkens KL, Pattyn P, et al. An international,
multicenter, randomized, single-blind, controlled trial of a dry-powder, fibrin sealant for mild
to moderate perioperative surgical bleeding. J Am Coll Surg 2014;219(Suppl. 1):e13–14
Abstract/full text unavailable
Boereboom C, Watson NFS, Liptrot SA, Lund JN, Tierney GM. A randomised trial of fibrin
glue versus surgery for pilonidal disease: results and long term follow up. Colorectal Dis
2010;12:20
Abstract/full text unavailable
Buciarelli P, Ginelli G, Misani M, Moia M. Fibrin glue plus tranexamic acid mouthwashing in
patients on oral anticoagulants undergoing dental extractions: a randomised study.
Thrombosis Haemostasis 1997;(Suppl.):37
Abstract/full text unavailable
Calabrò B, Ponsetto M, Greco R, Peradotto F, Personnettaz E, Obialero M. [Treatment of
leg ulcers with fibrin glue.] Minerva Chir 1995;50:569–74
Not a RCT
Caldas Neto S, Oliveira RL, Caldas N. Use of in fibrin glue in the prevention of
postoperative bleeding and hematomas after septoplasty. Revista Brasileira de
Otorrinolaringologia 2002;68:635–8
Did not meet population/
intervention criteria
Calvet X, Vergara M, Brullet E, Gisbert JP, Campo R. Addition of a second endoscopic
treatment following epinephrine injection improves outcome in high-risk bleeding ulcers.
Gastroenterology 2004;126:441–50
Review
Campanelli G, Champault G, Pascual MH, Hoeferlin A, Kingsnorth A, Rosenberg J, et al.
Randomized, controlled, blinded trial of Tissucol/Tisseel for mesh fixation in patients
undergoing Lichtenstein technique for primary inguinal hernia repair: rationale and study
design of the TIMELI trial. Hernia 2008;12:159–65
Not a RCT
Canonico S. The use of human fibrin glue in the surgical operations. Acta Bio-Medica
2003;74(Suppl. 2):21–5
Not a RCT
Cardillo G, Lococo A, De Massimi AR, D’Agostino A, Carleo F, Larocca V, et al. Adverse
effects of fibrin sealants in thoracic surgery. The safety of a new fibrin sealant: multicentre,
controlled, prospective, parallel group randomised clinical trial. Interact Cardiovasc Thorac
Surg 2011;13:S56
Did not meet population/
intervention criteria
Carter TI, Fong ZV, Hyslop T, Lavu H, Tan WP, Hardacre J, et al. A dual-institution
randomized controlled trial of remnant closure after distal pancreatectomy: Does the
addition of falciform patch and fibrin glue improve outcomes? Gastroenterology
2012;142(Suppl. 1):1042–3
Abstract/full text unavailable
Cedin AC, Atallah ÁN, Andriolo RB, Cruz OL, Pignatari SN. Surgery for congenital choanal
atresia. Cochrane Database Syst Rev 2012;2:CD008993
Review
Cesana G, Olmi S, Croce E. Trans-abdominal pre-peritoneal laparoscopic inguinal hernia
repair versus classical inguinotomic repair: a randomized study. Surg Endosc 2011;25:S7
Abstract/full text unavailable
Chan MS, Melissa CS, Teoh AY, Bun TA, Chan KW, Wing CK, et al. Randomized double-
blinded prospective trial of fibrin sealant spray versus mechanical stapling in laparoscopic
total extraperitoneal hernioplasty. Ann Surg 2014;259:432–7
Letter/commentary/erratum
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Chang YR, Jang JY, Kwon W, Kang MJ, Choi DW, Choi SH, et al. Interim analysis of
prospective randomized controlled study comparing clinical early outcome including
pancreatic fistula between external and internal pancreatic drainage in
pancreaticoduodenectomy. HPB 2014;16:112
Abstract/full text unavailable
Charles JF, Barra JA, Leroy JP. [Mesenteric fold by biological glue. Experimental study and
clinical application (author’s translation).] Ann Chir 1976;30:651–5
Not a RCT
Chiu CC. Randomized clinical trial of techniques for closure of the pancreatic remnant
following distal pancreatectomy (Br J Surg 2009;96:602–7). Br J Surg 2009;96:1222
Review
Chou D, Cheng J, Chesnut R, Choudhri H, Gopinath S, Scott Graham R, et al. A
prospective, multi-center, randomized controlled study to compare a low swell formulation
of a PEG hydrogel spinal sealant as an adjunct to sutured dural repair with common dural
sealing methods. Spine J 2010;10(Suppl. 1):80
Did not meet population/
intervention criteria
Chu FCK, Yao P, Morris DL. A randomized controlled study of the efficacy of fibrin glue in
reducing fluid collections following liver surgery. ANZ J Surg 2008;78:A71
Abstract/full text unavailable
Codispoti M, Mankad PS. Significant merits of a fibrin sealant in the presence of
coagulopathy following paediatric cardiac surgery: randomised controlled trial. Eur J
Cardiothorac Surg 2002;22:200–5
Did not meet population/
intervention criteria
Conboy P, Brown DH. Use of tissue sealant for day surgery parotidectomy. J Otolaryngol
Head Neck Surg 2008;37:208–11
Not a RCT
Copurog˘lu C, Ercan S, Ozcan M, Ciftdemir M, Turan FN, Yalniz E. Comparison of
autogenous bone graft donor site haemostatic agents used in spinal surgery. Acta Orthop
Traumatol Turc 2011;45:359–64
Did not meet population/
intervention criteria
Cormio L, Perrone A, Pentimone S, Selvaggio O, Lorusso F, Di Fino G, et al. Tachosil-sealed
tubeless percutaneous nephrolithotomy in supine antero-lateral position: a prospective
study. Eur Urol Suppl 2010;9:35
Abstract/full text unavailable
Corral M, Ferko N, Hollmann S, Jamous N, Batiller J, Shen JX, et al. Clinician reported ease
of use for a novel fibrin sealant patch for hemostasis: results from three randomized
controlled trials. J Thromb Haemost 2014;12:31–2
Abstract/full text unavailable
Cruz-Korchin N, Korchin L. The use of fibrin sealant (Tisseel) in abdominoplasty. Plastic
Reconstruct Surg 2005;116(Suppl. 3):23–5
Abstract/full text unavailable
Czerny et al. 2004137 Did not meet population/
intervention criteria
D’Andrea AA, Costantino V, Sperti C, Pedrazzoli S. Human fibrin sealant in pancreatic
surgery: it is useful in preventing fistulas? A prospective randomized study. Ital J
Gastroenterol 1994;26:283–6
Did not meet population/
intervention criteria
De Boer MT, Porte RJ. Reply: Re: Fibrin sealant for prevention of resection surface-related
complications after liver resection: a randomized controlled trial. Ann Surg 2015;261:e78
Letter/commentary/erratum
Di Saverio S, Masetti M, Zanello M, De Blasiis MG, Jovine E. Re: Fibrin sealant for
prevention of resection surface-related complications after liver resection: a randomized
controlled trial. Ann Surg 2015;261:e77–8
Letter/commentary/erratum
Dobrilla G, Rutgeerts P, Rauws EAJ, Wara P, Hoos A, Dobrilla G, et al. Fibrin sealant
(Beriplast) vs polidocanol 1% in the endoscopic treatment of bleeding gastroduodenal
ulcers: final results of a phase III clinical trial on adjuvant intraportal infusion with heparin
and 5 fluorouracil (5 FU) in resectable colon cancer (EORTC GITCCG 1983 1987). European
Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer
Cooperative Group. Eur J Cancer 1997;33:1209–15
Letter/commentary/erratum
Dovellini EV, Taddeucci E, Trapani M, Valenti R, Moschi G, Cerisano G, et al. Pocket
haematoma prevention in patients who required implantation/replacement of a pacemaker
or implantable cardiac defibrillator. The PHP Study. Eur Heart J 2011;32:305
Abstract/full text unavailable
Draus JM, Huss SA, Harty NJ, Cheadle WG, Larson GM. Enterocutaneous fistula: are
treatments improving? Surgery 2006;140:570–6
Not a RCT
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Ebbehoj J, Gavrilyuk BK, Menzul VA, Paklin EL, Rochev YuA. Controlled trial of Biocol
versus Jelonet on donor sites. Burns 1996;22:557–9
Did not meet population/
intervention criteria
Eimiller A, Berg P, Born P, Barina W, Paul F, Homann J. [Fibrin glue as a sclerotherapeutic
agent.] Gastroenterol 1988;26:458
Abstract/full text unavailable
El Nakeeb A. Influence of fibrin glue on seroma formation after modified radical
mastectomy: a prospective randomized study. Breast J 2009;15:671–2
Letter/commentary/erratum
Eriksen JR. Pain and convalescence following laparoscopic ventral hernia repair. Danish
Med Bulletin 2011;58:B4369
Pre-results for Eriksen et al.183
Everts PA, Devilee RJ, Brown Mahoney C, Eeftinck-Schattenkerk M, Box HA, Knape JT,
et al. Platelet gel and fibrin sealant reduce allogeneic blood transfusions in total knee
arthroplasty. Acta Anaesthesiol Scand 2006;50:593–9
Not a RCT
Foster K, Greenhalgh D, Gamelli RL, Mozingo D, Gibran N, Neumeister M, et al. Efficacy
and safety of a fibrin sealant for adherence of autologous skin grafts to burn wounds:
results of a phase 3 clinical study. J Burn Care Res 2008;29:293–303
Did not meet population/
intervention criteria
Fullarton G, Galloway D. Randomised trial of fibrin glue versus polidocanol for bleeding
peptic ulcer. Lancet 1997;350:1397–8
Letter/commentary/erratum
Fuller CW, Gillespie MB, Nguyen SA, Jones T, Hornig JD. A double-blind, randomized,
placebo-controlled clinical trial evaluating fibrin sealant in thyroidectomy closure.
Otolaryngol Head Neck Surg 2014;151(Suppl. 1):P160–1
Abstract/full text unavailable
Garcia-Olmo D, Herreros M, Guadalajara H, DeLaQuintana P, Trebol J, Georgiev-Hristov T,
et al. Expanded adipose derived autologous stem cells for the treatment of complex
cryptoglandular fistulas. A phase III clinical trial (fatt1: Fistulaadvanced therapy trial 1) and
longterm evaluation (LTE). Dis Colon Rectum 2011;54:e68–e9
Abstract/full text unavailable
Genyk Y, Kato T, Pomposelli JJ, Lophaven KW, Chapman WC. Tachosil versus surgicel
original for the secondary treatment of local bleeding in adult patients undergoing hepatic
resection. HPB 2014;16:27
Abstract/full text unavailable
Gibran N, Luterman A, Herndon D, Lozano D, Greenhalgh DG, Grubbs L, et al. Comparison
of fibrin sealant and staples for attaching split-thickness autologous sheet grafts in patients
with deep partial- or full-thickness burn wounds: a phase 1/2 clinical study. J Burn Care Res
2007;28:401–8
Did not meet population/
intervention criteria
Gilly FN, Sayag-Beaujard AC, Francois Y. Efficacy of fibrin glue (Tisseel) in axillary lymph
node removal for breast cancer: prospective randomized trial. Eur J Surg Oncol
1996;22:397–8
Abstract/full text unavailable
Gioffrè Florio MA, Mezzasalma F, Manganaro T, Pakravanan H, Cogliandolo A. [The use of
fibrin glue in the surgery of breast carcinoma.] G Chir 1993;14:239–41
Unobtainable
Giovannacci L, Eugster T, Stierli P, Hess P, Gürke L. Does fibrin glue reduce complications
after femoral artery surgery? A randomised trial. Eur J Vasc Endovasc Surg 2002;24:196–201
Did not meet population/
intervention criteria
Gipponi M, Reboa G, Testa T, Giannini G, Strada P. Tension-free primary closure with
autologous platelet gel versus VivostatTM for the definitive treatment of chronic
sacrococcygeal pilonidal disease. In Vivo 2010;24:583–9
Did not meet population/
intervention criteria
Giusti G, Maugeri O, Piccinelli A, Graziotti P. Is sealing of percutaneous tract with
hemostatic sealant really necessary after tubeless procedure? Eur Urol Suppl 2009;8:263
Abstract/full text unavailable
Glickman M, Gheissari A, Money S, Martin J, Ballard JL. A polymeric sealant inhibits
anastomotic suture hole bleeding more rapidly than gelfoam/thrombin: results of a
randomized controlled trial. Arch Surg 2002;137:326–31
Did not meet population/
intervention criteria
González HD, Figueras Felip J. [Topical hemostatic devices in surgery: between science and
marketing.] Cir Esp 2009;85(Suppl. 1):23–8
Review
Gopal SC, Gangopadhyay AN, Mohan TV, Upadhyaya VD, Pandey A, Upadhyaya A, et al.
Use of fibrin glue in preventing urethrocutaneous fistula after hypospadias repair. J Pediatr
Surg 2008;43:1869–72
Did not meet population/
intervention criteria
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Greenhalgh DG, Gamelli RL, Lee M, Delavari M, Lynch JB, Hansbrough JF, et al. Multicenter
trial to evaluate the safety and potential efficacy of pooled human fibrin sealant for the
treatment of burn wounds. J Trauma 1999;46:433–40
Did not meet population/
intervention criteria
Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Sénéjoux A, Vitton V, et al.
Fibrin glue is effective healing perianal fistulas in patients with Crohn’s disease.
Gastroenterology 2010;138:2275–81
Did not meet population/
intervention criteria
Grimm C, Polterauer S, Helmy S, Cibula D, Zikan M, Reinthaller A, et al. A collagen-fibrin
patch (Tachosil) for the prevention of symptomatic lymphoceles after pelvic
lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial.
BMC Cancer 2014;14:1–7
Not a RCT
Grossman JA, Capraro PA, Atagi T. A prospective, randomized, double-blind trial of the use
of fibrin sealant for face lifts. Plast Reconstr Surg 2002;110:1371–2
Letter/commentary/erratum
Grund KE, Salm R, Fischer H, Becker HD. Endoscopic therapy of heavy ulcerous bleeding:
obvious advantages of fibrin glue against polidocanol in a controlled randomised study.
Endoskopie Heute 1993;6:46
Abstract/full text unavailable
Gugenheim J, Bredt LC, Iannelli A. A randomized controlled trial comparing fibrin glue and
PlasmaJet on the raw surface of the liver after hepatic resection. Hepatogastroenterology
2011;58:922–5
Did not meet population/
intervention criteria
Günay H. [Transplantation of allogeneic freeze-preserved bone spongiosa into periodontal
bone defects: clinical results.] Schweiz Monatsschr Zahnmed 1988;98:611–18
Did not meet population/
intervention criteria
Gust R, Kleine P, Fabel H. [Fibrin glue and tetracycline pleurodesis in recurrent malignant
pleural effusions. A randomized comparative study.] Med Klin 1990;85:18–23
Unobtainable
Hammond TM, Grahn MF, Lunniss PJ. Fibrin glue in the management of anal fistulae.
Colorectal Dis 2004;6:308–19
Review
Hayes Inc. InteguSeal Microbial Sealant (Kimberly-Clark Worldwide Inc.) for Prevention of
Surgical Site Infection (Structured Abstract). 2009. URL: www.hayesinc.com/hayes/crd/?
crd=10164 (accessed 19 May 2015)
Abstract/full text unavailable
Hayes Inc. Tisseel VH (Baxter Healthcare Corp.) for Cardiac Surgery (Structured Abstract).
2008. URL: www.hayesinc.com/hayes/crd/?crd=7985 (accessed 19 May 2015)
Abstract/full text unavailable
Hayes Inc. Tisseel VH (Baxter Healthcare Corp.) for Noncardiac Surgeries with Problematic
Hemostasis (Structured Abstract). 2008. URL: www.hayesinc.com/hayes/crd/?crd=7986
(accessed 19/05/15)
Abstract/full text unavailable
Heldwein W, Avenhaus W, Schönekäs H, Kaess H, Müller-Lissner S, Hasford B, et al.
Injection of fibrin tissue adhesive versus laser photocoagulation in the treatment of high-risk
bleeding peptic ulcers: a controlled randomized study. Endoscopy 1996;28:756–60
Did not meet population/
intervention criteria
Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D, FATT
Collaborative Group. Autologous expanded adipose-derived stem cells for the treatment of
complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1:
fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum
2012;55:762–72
Did not meet population/
intervention criteria
Hickey NC. Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular
surgical procedures. Br J Surg 2010;97:1790
Letter/commentary/erratum
Hidalgo M, Castillo MJ, Eymar JL, Hidalgo A. Lichtenstein inguinal hernioplasty: sutures
versus glue. Hernia 2005;9:242–4
Not a RCT
Hilten JA, Verra WC, Honohan A, Wildt-Eggen J, Nelissen R. The effectiveness of a
single-donor allogeneic fibrin sealant on functional knee recovery: a multicenter
randomized controlled trial. Transfusion 2014;54:201a
Abstract/full text unavailable
Holle J. Early postoperative efficacy of fibrin glue in face lifts: a prospective randomized
trial. Plast Reconstr Surg 2005;115:917–18
Discussion paper
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Huang QS, Hong GX, Wang FB, Kang H, Weng YX, Chen ZB. Dynamic changes in
countertraction intensity of the peripheral nerve repaired with the adhesion of fibrin glue.
Chin J Clin Rehabil 2005;9:192–4
Not a RCT
Imhof M, Ohmann C, Röher HD, Glutig H, DUESUC study group. Endoscopic versus
operative treatment in high-risk ulcer bleeding patients – results of a randomised study.
Langenbecks Arch Surg 2003;387:327–36
Did not meet population/
intervention criteria
Inghilleri G, Aloni A, Santoleri L, Mancini L, Fonti E, Rondinara G, et al. Home-made versus
commercial fibrin glue in liver surgery. Transfus Altern Transfus Med 2005;7(Suppl. 1):103
Not a RCT
Jackson MR. Tissue sealants: current status, future potential. Nat Med 1996;2:637–8 Review
Jain AK, Sukhija J. Comparison of Cut-and-Paste with Cut-and-Suture Technique of
Pterygium Surgery. Poster session presented at American Academy of Ophthalmology,
2006, Las Vegas, TX, USA
Abstract/full text unavailable
Jiang J, Yang Y, Zhang M, Fu X, Bao X, Yao K. Comparison of fibrin sealant and sutures for
conjunctival autograft fixation in pterygium surgery: one-year follow-up. Ophthalmologica
2008;222:105–11
Not a RCT
Jones BM, Grover R. Early postoperative efficacy of fibrin glue in face lifts: a prospective
randomized trial. Plast Reconstr Surg 2007;119:433–4
Discussion paper
Kamal HM, Goda HAEB. Epidural fibrin glue for treatment of post-dural puncture headache
(PDPH): comparative study with epidural blood patch. Eg J Anaesth 2009;25:41–7
Did not meet population/
intervention criteria
Kanemaru S, Umeda H, Kitani Y, Nakamura T, Hirano S, Ito J. Regenerative treatment for
tympanic membrane perforation. Otol Neurotol 2011;32:1218–23
Did not meet population/
intervention criteria
Kim A, Lopez MA, Rojas V, Broman AT, Chuck RS, Batlle JF. Comparison of preserved
amniotic membrane and dehydrated amniotic membrane allografting using fibrin glue or
sutures for attachment after excision of primary pterygium. IOVS 2007;48:5316
Abstract/full text unavailable
Kitajiri S, Tabuchi K, Hiraumi H, Kaetsu H. Relief of post-tonsillectomy pain by release of
lidocaine from fibrin glue. Laryngoscope 2001;111:642–4
Did not meet population/
intervention criteria
Klecker C, Knoll S, Moller T. [Adrenalin versus adrenalin and Beriplast as primary therapy
of acute bleeding in the upper gastrointestinal tract]. Gastroenterol 2004;42:1219
Did not meet population/
intervention criteria
Klinfelder JW, Lange DE. Application of hydroxyapatite combined with fibrin glue in
periodontal surgery. J Dent Res 1989;68:643
Abstract/full text unavailable
Kokesch-Häuser S, Beer M, Staehler G. [Effect of intraoperative fibrin gluing on lymph flow
and lymphocele formation after kidney transplantation.] Urologe A 1993;32:334–8
Did not meet population/
intervention criteria
Kraus TW, Mehrabi A, Schemmer P, Kashfi A, Berberat P, Büchler MW. Scientific evidence
for application of topical hemostats, tissue glues, and sealants in hepatobiliary surgery.
J Am Coll Surg 2005;200:418–27
Review
Kurian A, Reghunadhan I, Nair KG. Autologous blood versus fibrin glue for conjunctival
autograft adherence in sutureless pterygium surgery: a randomised controlled trial. Br J
Ophthalmol 2015;99:464–70
Did not meet population/
intervention criteria
Lantis JC 2nd, Marston WA, Farber A, Kirsner RS, Zhang Y, Lee TD, et al. The influence of
patient and wound variables on healing of venous leg ulcers in a randomized controlled
trial of growth-arrested allogeneic keratinocytes and fibroblasts. J Vasc Surg
2013;58:433–9
Outcomes not of interest
Larsen T, Devantier A, Iversen E, Fischer A, Hansen R, Dragsted J. [Treatment of testicular
hydrocele with fibrin adhesive.] Ugeskr Laeg 1986;148:896–7
Not a RCT
Lee S, Kim HR, Cho S, Huh DM, Lee EB, Ryu KM, et al. Staple line coverage after
bullectomy for primary spontaneous pneumothorax: a randomized trial. Ann Thorac Surg
2014;98:2005–11
Did not meet population/
intervention criteria
Lei QF, Cai W. Clinical observation on fibrin glue application during pterygium surgery.
Int Eye Sci 2015;15:364–6
Not a RCT
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Lesur G. Upper gastrointestinal hemorrhages not related to portal hypertension.
Hepatogastro 2002;9:445–54
Review
Levitsky S. Further information on the fibrin sealant conference. Transfusion
1996;36:845–6
Letter/commentary/erratum
Levy O, Martinowitz U, Oran A, Tauber H, Liberman N, Salai M, et al. The use of fibrin
tissue adhesive reduces blood loss and blood transfusion after total knee arthroplasty: a
prospective, randomized, multi-centre study. J Bone Joint Surg Am 2000;82(Suppl. 3):221–2
Abstract/full text unavailable
Lin HJ, Hsieh YH, Tseng GY, Perng CL, Chang FY, Lee SD. Endoscopic injection with fibrin
sealant versus epinephrine for arrest of peptic ulcer bleeding: a randomized, comparative
trial. J Clin Gastroenterol 2002;35:218–21
Did not meet population/
intervention criteria
Lindsey I, Smilgin-Humphreys MM, Cunningham C, Mortensen NJ, George BD. Randomised trial
of fibrin glue vs. conventional treatment for anal fistula. Colorectal Dis 2001;3(Suppl. 1):Oral 78
Abstract/full text unavailable
Liptrot S, Leveson S, Lund J. A prospective randomized controlled trial of fibrin glue versus
surgery in the treatment of pilonidal sinus. Br J Surg 2007;94:5
Abstract/full text unavailable
Liptrot S, Leveson S, Lund J. Fibrin glue may be better than surgery for pilonidal sinus:
results of a prospective, randomized, controlled trial and 2-year follow up. Dis Colon
Rectum 2008;51:P80
Abstract/full text unavailable
Liu H, Wei RH, Huang Y, Yang RB, Zhang C, Zhao SZ. Clinical observation on fibrin glue
technique in pterygium surgery under surface anaesthesia. Int Eye Sci 2014;14:1527–8
Did not meet population/
intervention criteria
Liu H, Wei RH, Huang Y, Yang RB, Zhang C, Zhao SZ. Clinical observation on fibrin glue
technique in pterygium surgery performed with limbal autograft transplantation. Int Eye Sci
2013;13:1498–9
Chinese
Liu W, Zhang YP, Xie MF, Liu Y. Application of fibrin glue with bandage contact lens in
pterygium surgery. Int Eye Sci 2014;14:879–81
Chinese
Llewellyn-Bennett R, English R, Turner J, Tsim N, Rayter Z, Winters Z. A randomised
controlled trial to evaluate the role of Tisseel, a fibrin sealant on seroma formation in
Latissimus dorsi breast reconstruction. Eur J Surg Oncol 2011;37:S16
Abstract/full text unavailable
Lockhart K, Teo E, Teo S, Dhillon M, van Driel Mieke L. Mesh versus non-mesh for inguinal
and femoral hernia repair. Cochrane Database Syst Rev 2015;2:CD011517
Protocol
Lowe J, Luber J, Levitsky S, Hantak E, Montgomery J, Schiestl N, et al. Evaluation of the
topical hemostatic efficacy and safety of TISSEEL VH S/D fibrin sealant compared with
currently licensed TISSEEL VH in patients undergoing cardiac surgery: a phase 3,
randomized, double-blind clinical study. J Cardiovasc Surg 2007;48:323–31
Did not meet population/
intervention criteria
Luke et al. 1986223 Not a RCT
Maca TH, Mlekusch W, Ahmadi A, Al AM, Haumer M, Sabeti S, et al. Treatment of
iatrogenic pseudoaneurysms with injection of thrombin and fibrin glue. Ann Hematol
2003;82:S59
Abstract/full text unavailable
Malhotra C, Jain AK, Sawhney A, Nawani N, Ram J. Outcomes of fibrin glue-assisted
conjunctival versus conjunctivolimbal autograft in primary pterygia with a new technique of
conjunctival resection and tenon extended removal. Cornea 2015;34:193–8
Did not meet population/
intervention criteria
Martinazzoli A, Cangemi V, Cammarata A, Ceccobelli M, Costanzo F, Corradi R, et al.
[Use of fibrin glue in breast prosthesis implantation immediately after bilateral
adenectomy.] G Chir 1995;16:457–8
Did not meet population/
intervention criteria
Martinowitz U, Levy O, Tauber H, Horoszowski H. Prospective randomized multicenter
study on efficacy and safety of fibrin tissue adhesive in knee arthroplasty. Thromb Haemost
1997;78:661–6
Abstract/full text unavailable
Martinowitz U, Levy O, Oran A, Tauber H, Heroszowski H. Fibrin tissue adhesive reduces
blood loss and blood transfusion requirements after total knee arthroplasty: a prospective,
randomized, multicenter study. Haemophilia 1998;4:186
Abstract/full text unavailable
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Mercuriali F, Inghilleri G, Aloni A, Santoleri L, Angeloro D, Capitani D, et al. Autologous
fibrin glue (AFG) reduces blood loss in patients submitted to total hip replacement (THR).
Vox Sang 2004;87(Suppl. 3):35
Abstract/full text unavailable
Milic DJ, Perisic ZD, Zivic SS, Stanojkovic ZA, Stojkovic AM, Karanovic ND, et al. Prevention
of pocket related complications with fibrin sealant in patients undergoing pacemaker
implantation who are receiving anticoagulant treatment. Europace 2005;7:374–9
Did not meet population/
intervention criteria
Milne AA. Clinical impact of fibrin sealants. Vox Sang 2004;87(Suppl. 2):29–30 Letter/commentary/erratum
Miyamoto H, Sakao Y, Sakuraba M, Oh S, Takahashi N, Miyasaka Y, et al. The effects of
sheet-type absorbable topical collagen hemostat used to prevent pulmonary fistula after
lung surgery. Ann Thorac Cardiovasc Surg 2010;16:16–20
Did not meet population/
intervention criteria
Mohindra S, Mohindra S, Gupta K. Endoscopic repair of CSF rhinorrhea: necessity of fibrin
glue. Neurol India 2013;61:396–9
Did not meet population/
intervention criteria
Moon YM, Kang JK, Park IS, Chon CY, Chung JB, Han KH. Comparison of hemostatic
effect of endoscopic injection with fibrin glue (FG) and hypertonic saline – epinephrine
(HSE) for peptic ulcer bleeding: a prospective randomized trial. Korean J Gastrointest
Endosc 1995;15:12–25
Did not meet population/
intervention criteria
Moralee SJ, Carney AS, Cash MP, Murray JA. The effect of fibrin sealant haemostasis on
post-operative pain in tonsillectomy. Clin Otolaryngol Allied Sci 1994;19:526–8
Did not meet population/
intervention criteria
Mulet Homs ME, Alio YSJL, Gobby F. Efficacy of fibrinogen as bioadhesive in cataract
surgery through scleral tunnel. Arch Soc Esp Oftalmol 1997;72:427–30
Outcomes not of interest
Murphy WG, Milne AA, Ruckley CV, Kubba AK, Palmer KR. Fibrin sealant: update on
clinical studies. Transfus Sci 1996;17:341–2
Not a RCT
Muzi MG, Nigro C, Cadeddu F, Andreoli F, Farinon AM. Randomized clinical trial of
Lichtenstein’s operation versus mesh plug for inguinal hernia repair. Br J Surg 2007;94:647
Did not meet population/
intervention criteria
Naga MI, Goubran HA, Said M, Burnouf-Radosevich M, Burnouf T, Huart JJ. A comparison
between endoscopic injection of bleeding esophageal varices using ethanolamine oleate
and fibrin glue sealant in patients with bilharzial liver fibrosis. Endoscopy 1999;31:405
Letter/commentary/erratum
NCT0212065. Effect of the Fibrin Monomer in the Integrity of the Graft during
Tympanoplasty Compared with the Effect of the Hemostatic Sponge. Clinicaltrials.gov,
2012. URL: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/034/CN-01001034/
frame.html (accessed 19 May 2015)
Insufficient data
Negro P, Basile F, Brescia A, Buonanno GM, Campanelli G, Canonico S, et al. Open
tension-free Lichtenstein repair of inguinal hernia: use of fibrin glue versus sutures for mesh
fixation. Hernia 2011;15:7–14
Not a RCT
Nervi C, Gamelli RL, Greenhalgh DG, Luterman A, Hansbrough JF, Achauer BM, et al. A
multicenter clinical trial to evaluate the topical hemostatic efficacy of fibrin sealant in burn
patients. J Burn Care Rehabil 2001;22:99–103
Did not meet population/
intervention criteria
Niekisch R. [Application possibilities of fibrin glue in dentistry and maxillofacial surgery.]
Zahn Mund Kieferheilkd Zentralbl 1980;68:555–61
Not a RCT
Novik B. Randomized trial of fixation vs nonfixation of mesh in total extraperitoneal
inguinal hernioplasty. Arch Surg 2005;140:811–12
Letter/commentary/erratum
Novik B. Fibrin glue mesh fixation in hernia repair. Ann Surg 2007;246:906–8 Letter/commentary/erratum
Öllinger R, Mihaljevic AL, Schuhmacher C, Bektas H, Vondran F, Kleine M, et al. A multicentre,
randomized clinical trial comparing the Veriset haemostatic patch with fibrin sealant for the
management of bleeding during hepatic surgery. HPB (Oxford) 2013;15:548–58
Did not meet population/
intervention criteria
Osbun JW, Ellenbogen RG, Chesnut RM, Chin LS, Connolly PJ, Cosgrove GR, et al.
A multicenter, single-blind, prospective randomized trial to evaluate the safety of a
polyethylene glycol hydrogel (Duraseal Dural Sealant System) as a dural sealant in cranial
surgery. World Neurosurg 2012;78:498–504
Did not meet population/
intervention criteria
Ota Y, Ikemiyagi Y, Takizawa K, Yamada C, Rikitake R, Suzuki M. Efficacy of covering
mucosal defects with polyglycolic acid sheets after ear or nose surgery. Laryngoscope
2015;125:567–70
Not a RCT
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Oz MC, Rondinone JF, Shargill NS. FloSeal Matrix: new generation topical hemostatic
sealant. J Card Surg 2003;18:486–93
Not a RCT
Pal Singh B, Dhakad U. Re: TachoSil Sealed tubeless percutaneous nephrolithotomy to
reduce urine leakage and bleeding: outcome of a randomized controlled study: L. Cormio,
A. Perrone, G. di Fino, N. Ruocco, M. de Siati, J. de la Rosette and G. Carrieri
2012;188:145–50. J Urol 2013;189:777–8
Letter/commentary/erratum
Pan I, Dendukuri N, McGregor M. Efficacy and Cost-Effectiveness of Collatamp-G for
Infection Prophylaxis in Cardiac Surgery. 2009. URL: www.mcgill.ca/files/tau/COLLATAMP_
CARDIAC_ REPORT.pdf (accessed 19 May 2015)
Review
Park DH, Iwashita T, Samarasena JB, Nakai Y, Chang KJ, Chao HH. Prospective randomized
comparative study using hemoclip, endoloop, and fibrin sealant for endoscopic closure of
iatrogenic duodenal perforation in a porcine model: HELLP study. Gastrointest Endosc
2011;73(Suppl. 1):AB156
Did not meet population/
intervention criteria
Park DH, Han JH, Jang JY, Lee SY. Effect of fibrin glue on post-tonsillectomy pain. Korean J
Otorhinolaryngol-Head Neck Surg 2009;52:591–3
Korean
Patel MR, Caruso PA, Yousuf N, Rachlin J. CT-guided percutaneous fibrin glue therapy of
cerebrospinal fluid leaks in the spine after surgery. Am J Roentgenol 2000;175:443–6
Not a RCT
Pescatore P, Jornod P, Borovicka J, Pantoflickova D, Suter W, Meyenberger C, et al.
Epinephrine versus epinephrine plus fibrin glue injection in peptic ulcer bleeding: a
prospective randomized trial. Gastrointest Endosc 2002;55:348–53
Did not meet population/
intervention criteria
Petersen B, Barkun A, Carpenter S, Chotiprasidhi P, Chuttani R, Silverman W, et al. Tissue
adhesives and fibrin glues. Gastrointest Endosc 2004;60:327–33
Review
Petrov DB, Manolov EP, Minchev TR, Alexov SB, Botev CN. Additional intraoperative aerostasis
with a 100% autologous fibrin glue in thoracic surgery. Eur Respir J 2001;18(Suppl. 33):524
Outcomes not of interest
Petter Puchner AH, Khakpour Z, May C, Mika K, Glaser KS, Redl H. The impact of atraumatic
fibrin sealant vs. staple mesh fixation in tapp hernia repair on chronic pain and quality of life –
results of a randomized controlled study. Surg Endosc 2010;24(Suppl. 1):S618
Abstract/full text unavailable
Pichon R, Augustovski GM, Garcia MS, Glujovsky D, Alcaraz A, Lopez A, et al. Biological
Tissue Adhesive Versus Standard Suture in Conjuctival Autograft for the Surgical Treatment
of Pterygium. 2012. URL: www.iecs.org.ar/iecs-visor-publicacion.php?cod_
publicacion=1324& amp;origen_%20publicacion=publicaciones (accessed 19 May 2015)
Abstract/full text unavailable
Pini Prato GP, Cortellini P, Agudio G, Clauser C. Human fibrin glue versus sutures in
periodontal surgery. J Periodontol 1987;58:426–31
Not a RCT
Porte RJ, Verhoef C, De Wilt JHW, Rijken AM, Klaase JM, Ayez N, et al. FibrocapsTM,
a novel fibrin sealant, for bleeding during hepatic resection: results of a phase 2,
randomized, controlled study. HPB 2012;14:133
Abstract/full text unavailable
Pulikkotil SJ, Nath S. Fibrin sealant as an alternative for sutures in periodontal surgery. J Coll
Physicians Surg Pak 2013;23:164–5
Outcomes not of interest
Pulikkotil SJ, Nath S. Effect on interleukin-1beta and interleukin-8 levels following use of
fibrin sealant for periodontal surgery. Aust Dent J 2014;59:156–64
Not a RCT
Raborn GW, Hohn FI, Grace MG, Arora BK. Tisseel, a two component fibrin tissue sealant
system: report of a trial involving anticoagulated dental patients. J Can Dent Assoc
1990;56:779–81
Review
Rauws EAJ, Rutgeerts P, Wara P, Hoos A, Solleder E, Halttunen J, et al. Fibrin sealant
(Beriplast®) v.s. polidocanol 1% in the endoscopic treatment of bleeding gastroduodenal
ulcers. Endoscopy 1996;28:S19
Abstract/full text unavailable
Rehder J, Bosnardo CA, Kraft MB, Frade MA, Guillaumon AT, Batista FR. A comparative
study of cell therapy and fibrin glue applied to chronic venous ulcers. Procedia Engineering
2013;59:85–91
Outcomes not of interest
continued
DOI: 10.3310/hta20940 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 94
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
123
. J Urol
TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Richter G, Prassler R, Rutgeerts P, Rauws E, Warn P, Hoos A, et al. Fibrin glue versus
Polidocanol 1% in ulcerous bleeding therapy – results of a multi-centre study. Endoskopie
Heute 1997;10:93
Abstract/full text unavailable
Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors
for the treatment of pulmonary embolism. Cochrane Database Syst Rev 2015;12:CD010957
Protocol
Rodig J, Dinkelaker F, Rahmanzadeh R. Reduction of ossification after cement-free hip
replacement using fibrin glue. Hefte zur Unfallheilkunde 1990;212:465–6
Abstract/full text unavailable
Rodin IuV. [Local hemostasis during the carotid endarterectomy under condition of
antithrombocytic therapy.] Klin Khir 2007;10:32–4
Not a RCT
Rousou J, Levitsky S, Gonzalez-Lavin L, Cosgrove D, Magilligan D, Weldon C, et al.
Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or
reoperation after cardiac operations. A multicenter study. J Thorac Cardiovasc Surg
1989;97:194–203
Cross-over
Rutgeerts P, Rauws E, Wara P, Swain P, Hoos A, Solleder E, et al. Randomised trial of single
and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding
peptic ulcer. Lancet 1997;350:692–6
Did not meet population/
intervention criteria
Sakoda T, Shibano A, Saitoh Y, Dake Y, Sogo H, Fujimura S, et al. [An office technique
for myringoplasty without the use of fibrin glue.] Nippon Jibiinkoka Gakkai Kaiho
2000;103:836–9
Did not meet population/
intervention criteria
Sánchez M, Anitua E, Orive G, Mujika I, Andia I. Platelet-rich therapies in the treatment of
orthopaedic sport injuries. Sports Med 2009;39:345–54
Abstract/full text unavailable
Sandrock D, Steinröder M, Emrich D. [Fibrin agglutination of thyroid gland cysts after fine
needle puncture.] Dtsch Med Wochenschr 1993;118:1–5
Did not meet population/
intervention criteria
Santini F, Luciani GB, Pessotto R, Petrilli G, Fabbri A, Mazzucco A. Current techniques to
reduce blood loss after the Ross procedure. J Heart Valve Dis 1997;6:343–6
Not a RCT
Scheer M, Steveling H, Schweigert HG, Neugebauer J, Kubler AC, Zoller JE. Efficacy of
fibrinogen and thrombin coated collagen sponge (TachoComb) in anticoagulated patients
undergoing dental surgery. Chirug Dtsch Zahnarztl Z 2004;59:220–6
Abstract/full text unavailable
Segal N, Puterman M, Rotem E, Niv A, Kaplan D, Kraus M, et al. A prospective randomized
double-blind trial of fibrin glue for reducing pain and bleeding after tonsillectomy. Int J
Pediatr Otorhinolaryngol 2008;72:469–73
Did not meet population/
intervention criteria
Segura-Castillo JL, Aguirre-Camacho H, González-Ojeda A, Michel-Perez J. Reduction of
bone resorption by the application of fibrin glue in the reconstruction of the alveolar cleft.
J Craniofac Surg 2005;16:105–12
Did not meet population/
intervention criteria
Sener BC, Saysel MY. The comparison between alloplastic bone chips with and without fibrin
glue used in maxillary sinus lifting operations. J Craniomaxillofac Surg 1998;26(Suppl. 1):3–21
Abstract/full text unavailable
Shah HN, Hegde S, Shah JN, Mohile PD, Yuvaraja TB, Bansal MB. A prospective,
randomized trial evaluating the safety and efficacy of fibrin sealant in tubeless
percutaneous nephrolithotomy. J Urol 2006;176:2488–92
Did not meet population/
intervention criteria
Shcherba SN, Polovinkin VV. [Use of Tachocomb for prevention of postoperative lymphatic
leaks in the abdomen.] Vopr Onkol 2011;57:269–70
Unobtainable
Shen L, Luo H, Tan S. Effect of fibrin glue on patients after high frequency
electrocoagulatomy for gastrointestinal protuberant lesions. Med J Wuhan Uni
2003;24:377
Chinese
Simons MP. Randomized clinical trial of fibrin sealant versus titanium tacks for mesh
fixation in laparoscopic umbilical hernia repair. Br J Surg 2011;98:1537–45
Letter/commentary/erratum
Singer M, Cintron J, Nelson R, Orsay C, Bastawrous A, Pearl R, et al. Treatment of fistulas-
in-ano with fibrin sealant in combination with intra-adhesive antibiotics and/or surgical
closure of the internal fistula opening. Dis Colon Rectum 2005;48:799–808
Did not meet population/
intervention criteria
Singh PK, Singh S, Vyas C, Singh M. Conjunctival autografting without fibrin glue or
sutures for pterygium surgery. Cornea 2013;32:104–7
Did not meet population/
intervention criteria
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Soumian S, Al-Ani S, Sterne G. Randomized clinical trial on the effect of fibrin sealant on
latissimus dorsi donor-site seroma formation after breast reconstruction (Br J Surg
2012;99:1381–1388). Br J Surg 2013;100:1671
Letter/commentary/erratum
Spinzi G, Minoli G. Injection of fibrin tissue adhesive versus laser photocoagulation in the
treatment of high-risk bleeding peptic ulcers: a controlled randomized study. Gastrointest
Endosc 1997;46:198–9
Did not meet population/
intervention criteria
Stabilini C, Fornaro R, Lazzara F, Mandolfino F, Imperatore M, Gianetta E. Suturless-
lightweight hernioplasty vs traditional Lichtenstein repair. One year results on chronic
postoperative pain. Eur Surg Res 2010;45:197
Abstract/full text unavailable
Stephens J, Robless P, Jenkins M, Cheshire N. Re: Does fibrin glue reduce complications
after femoral artery surgery? A randomised trial. Eur J Vasc Endovasc Surg 2003;25:596
Letter/commentary/erratum
Stevens MH, Stevens DC. Pain reduction by fibrin sealant in older children and adult
tonsillectomy. Laryngoscope 2005;115:1093–6
Letter/commentary/erratum
Stiller-Timor L, Goldbart AD, Segal N, Amash A, Huleihel M, Leiberman A, et al. Circulating
cytokines in patients undergoing tonsillectomy with fibrin glue. Int J Pediatr
Otorhinolaryngol 2012;76:419–22
Did not meet population/
intervention criteria
Stoeckli SJ, Moe KS, Huber A, Schmid S. A prospective randomized double-blind trial of
fibrin glue for pain and bleeding after tonsillectomy. Laryngoscope 1999;109:652–5
Did not meet population/
intervention criteria
Strohm WD, Römmele UE, Barton E, Paul-Martin C. [Injection therapy of bleeding peptic
ulcer with fibrin or polidocanol.] Dtsch Med Wochenschr 1994;119:249–56
Did not meet population/
intervention criteria
Stutz H, Hempelmann HCG. The use of autologous fibrin glue to reduce perioperative
blood loss in total knee arthroplasty – results of a controlled study. Orthopadische Praxis
2004;40:1–3
Not a RCT
Suc B, Msika S, Piccinini M, Fourtanier G, Hay JM, Flamant Y, et al. Octreotide in the
prevention of intra-abdominal complications following elective pancreatic resection:
a prospective, multicenter randomized controlled trial. Arch Surg 2004;139:288–94
Did not meet population/
intervention criteria
Szczesny T, Kubiszewska I, Rybak A, Michalkiewicz J, Szymankiewicz M, Kowalewski J. The
role of Tachosil in lymphostasis after mediastinal lymphadenectomy in lung cancer patients.
J Thorac Oncol 2011;6(Suppl. 2):876–7
Abstract/full text unavailable
Tabatabaei S, Talab SS, Kloc LS, Siddiqui MM, Akhavein A, Vazquez R, et al. Use of evicel
fibrin sealant for improving hemostasis following transurethral prostate debulking surgery
in patients with BPH. J Endourol 2014;28:A131
Abstract/full text unavailable
Takeuchi J, Suzuki H, Murata M, Kakei Y, Ri S, Umeda M. Clinical evaluation of application
of polyglycolic acid sheet and fibrin glue spray for partial glossectomy. J Oral Maxillofac
Surg 2013;71:e126–31
Not a RCT
Tamaki H, Fukushima H, Nakamura H, Kanemaru S, Fukuyama Y, Tamura Y. Control of
postoperative pain with Beriplast P in tonsillectomy. Practica Otologica 1996;89:1027–30
Did not meet population/
intervention criteria
Taylor et al. 2003199 Not a RCT
Testini M, Lissidini G, Poli E, Gurrado A, Lardo D, Piccinni G. A single-surgeon randomized
trial comparing sutures, N-butyl-2-cyanoacrylate and human fibrin glue for mesh fixation
during primary inguinal hernia repair. Can J Surg 2010;53:155–60
Did not meet population/
intervention criteria
Tian BY, Zhang H. Limbal stem cell transplantation with fibrin sealant for the treatment of
recurrent pterygium. Int J Ophthalmol 2011;11:1066–7
Chinese
Tocchhetti EV, Carter G, Goss A, Lloyd JV. Local management of haemostasis with fibrin
adhesive in patients with coagulopathies undergoing surgery. Vox Sang 2000;79(Suppl. 1):220
Abstract/full text unavailable
Tofuku K, Koga H, Yanase M, Komiya S. The use of antibiotic-impregnated fibrin sealant
for the prevention of surgical site infection associated with spinal instrumentation. Eur
Spine J 2012;21:2027–33
Not a RCT
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Topiwala P, Bansal RK. Comparative evaluation of cyanoacrylate and fibrin glue for muscle
recession in strabismus surgery. J Pediatr Ophthalmol Strabismus 2014;51:349–54
Did not meet population/
intervention criteria
Troisi RI, Bektas H, Pratschke J, Topal B, Buchler M, Schuhmacher CP, et al. A prospective,
multi-center, randomized, single-blind study to compare the VerisetTM hemostatic patch to
fibrin sealant (Tachosil) in subjects undergoing hepatic surgery. HPB 2012;14:104–5
Abstract/full text unavailable
Trombelli L, Scabbia A, Wikesjö UM, Calura G. Fibrin glue application in conjunction with
tetracycline root conditioning and coronally positioned flap procedure in the treatment of
human gingival recession defects. J Clin Periodontol 1996;23:861–7
Outcomes not of interest
Trombelli L, Scabbia A, Calura G. Effect of topical application of a fibrin-fibronectin sealing
system on healing response following periodontal surgical procedures. Clin Drug Invest
1997;14:268–75
Outcomes not of interest
Trombelli L, Scabbia A, Scapoli C, Calura G. Clinical effect of tetracycline demineralization
and fibrin-fibronectin sealing system application on healing response following flap
debridement surgery. J Periodontol 1996;67:688–93. [Erratum published in J Periodontol
1996;67:1368.]
Outcomes not of interest
Tsai CH, Hsu HC, Chen YJ, Lin MJ, Chen HT. Using the growth factors-enriched platelet
glue in spinal fusion and its efficiency. J Spinal Disord Tech 2009;22:246–50
Not a RCT
Upadhyaya VD, Gopal SC, Gangopadhyaya AN, Gupta DK, Sharma S, Upadyaya A, et al.
Role of fibrin glue as a sealant to esophageal anastomosis in cases of congenital
esophageal atresia with tracheoesophageal fistula. World J Surg 2007;31:2412–15
Did not meet population/
intervention criteria
Uy HS, Reyes JMG, Flores JP, Limbonsiong R. Human plasma derived fibrin glue (Beriplast P)
in conjunctival autografts for pterygia. IOVS 2002;43:129
Not a RCT
Vaiman et al. 2002188 Not a RCT
Vaiman M, Eviatar E, Shlamkovich N, Segal S. Effect of modern fibrin glue on bleeding
after tonsillectomy and adenoidectomy. Ann Otol Rhinol Laryngol 2003;112:410–14
Did not meet population/
intervention criteria
Valentini MF, Lissidini G, Gurrado A, Poli E, Ruggiero L, Piccinni G, et al. Comparison
among three different methods of mesh fixation in patients undergoing plug and mesh
technique for primary inguinal hernia repair: a prospective randomised controlled study.
Eur Surg Res 2010;45:198–9
Abstract/full text unavailable
Visna P, Pasa L, Cizmár I, Hart R, Hoch J. Treatment of deep cartilage defects of the knee
using autologous chondrograft transplantation and by abrasive techniques – a randomized
controlled study. Acta Chir Belg 2004;104:709–14
Did not meet population/
intervention criteria
Wagner W, Wiltfang J, Pistner H, Yildirim M, Ploder B, Chapman M, et al. Bone formation
with a biphasic calcium phosphate combined with fibrin sealant in maxillary sinus floor
elevation for delayed dental implant. Clin Oral Implants Res 2012;23:1112–17
Did not meet population/
intervention criteria
Ware P, Rutgeerts P, Rauws EAJ, Hoos A, Solleder E. Endoscopic injection therapy of
bleeding gastro-duodenal ulcers: fibrin glue (beriplast) vs. polidocanol 1%. Gut
1996;39(Suppl. 1):A5
Abstract/full text unavailable
Winters ZE, Llewellyn-Bennett R, English R, Turner J, Rayter Z, Greenwood R. A randomised
controlled trial to evaluate the role of Tisseel, a fibrin sealant on seroma formation in
latissimus dorsi breast reconstruction. Cancer Res 2011;71(Suppl. 3):P2-16-07
Abstract/full text unavailable
Wong K, Goldstraw P. Effect of fibrin glue in the reduction of postthoracotomy alveolar air
leak. Ann Thorac Surg 1997;64:979–81
Did not meet population/
intervention criteria
Wurtz A, Chambon JP, Sobecki L, Batrouni R, Huart JJ, Burnouf T. [Use of a biological glue
in partial pulmonary excision surgery. Results of a controlled trial in 50 patients.] Ann Chir
1991;45:719–23
Did not meet population/
intervention criteria
Yasumizu Y, Miyajima A, Maeda T, Hasegawa M, Takeda T, Shinoda K, et al. What
prevents lymphocele development after laparoscopic radical prostatectomy? J Endourol
2011;25:A227
Abstract/full text unavailable
Yeung SN, Lichtinger A, Kim P, Elbaz U, Ku JY, Amiran MD, et al. Superior versus inferior
conjunctival autografts combined with fibrin glue in the management of primary pterygia.
Cornea 2013;32:1582–6
Did not meet population/
intervention criteria
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TABLE 34 Excluded randomised controlled trials (continued )
Study excluded Reason for exclusion
Yoshimura M, Tsubota N, Matsuoka H, Sakamoto T. Efficacy of a pedicled pericardial fat
pad fixed with fibrin glue on postoperative alveolar air leakage. Surg Today 2002;32:26–8
Did not meet population/
intervention criteria
Yuasa K, Shimizu T, Matsubara J, Toyoda T. [Sealing effect of fibrin adhesive by various
method on protection of air leakage in lung surgery.] Kyobu Geka 1998;51:1001–5
Did not meet population/
intervention criteria
Zhang SP, Cao B, Xiu XG, Wu BB. Local application of fibrin glue carrying gatifloxacin.
J Clin Rehabil Tissue Engin Res 2011;15:431–5
Abstract/full text unavailable
Zhou LB, Guo SY, Zhang W, Du KH, Gong DQ. The efficacy of fibrin glue in radical
mastectomy. Acta Medicinae Sinica 2003;16:14–15
Unobtainable
Ziaee SA, Sarhangnejad R, Abolghasemi H, Eshghi P, Radfar MH, Ahanian A, et al.
Autologous fibrin sealant in tubeless percutaneous nephrolithotomy; a prospective study.
Urol J 2013;10:999–1003
Not a RCT
Zimmer T, Rucktäschel F, Stölzel U, Liehr RM, Schuppan D, Stallmach A, et al. Endoscopic
sclerotherapy with fibrin glue as compared with polidocanol to prevent early esophageal
variceal rebleeding. J Hepatol 1998;28:292–7
Did not meet population/
intervention criteria
Zimmer TJ, Faiss S, Liehr RM, Breitkreutz C, Klein M, Stolzel U, et al. [Fibrin glue versus
endoscopic ligature to stop acute bleeding and in the prophylaxis of early relapse of
oesophagus varices. Results of a German multi-centre study.] Gastroenterol 2005;43:828
Abstract/full text unavailable
Note
A total of 26 duplicate studies were not included in this table.
Other
Chiu PWY, Lau TS, Kwong KH, Suen DTK, Kwok PY. Impact of programmed second endoscopy with
appropriate re-treatment on peptic ulcer re-bleeding: a systematic review. Ann Coll Surg Hong Kong
2003;7:106–15.
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Appendix 4 Tables of recent and ongoing studies
TABLE 35 ClinicalTrials.gov trials
NCT Number Title Recruitment Start date URL
NCT01828892 Glue application in the treatment of
low-output fistulas
Recruiting March 2014 http://ClinicalTrials.gov/
show/NCT01828892
NCT02094885 The Bioseal vascular study Completed February 2014 http://ClinicalTrials.gov/
show/NCT02094885
NCT01613664 Efficiency of TISSEEL for sleeve
gastrectomy complications
Recruiting February 2014 http://ClinicalTrials.gov/
show/NCT01613664
NCT02040428 The Fibrin pad CV phase III study Recruiting January 2014 http://ClinicalTrials.gov/
show/NCT02040428
NCT02034799 Phase IV Bioseal study in brain
tumour surgery
Completed November 2013 http://ClinicalTrials.gov/
show/NCT02034799
NCT01993888 The EVARREST fibrin sealant patch
liver study
Completed October 2013 http://ClinicalTrials.gov/
show/NCT01993888
NCT02011698 Absorbable sutures, non absorbable
sutures or biologic fibrin glue for
protesic mesh fixing in Lichtenstein
technique for primitive groin hernia
repair: a randomised prospective
multicentric trial
Recruiting October 2013 http://ClinicalTrials.gov/
show/NCT02011698
NCT01902459 EVARREST fibrin sealant patch
post-market study
Recruiting July 2013 http://ClinicalTrials.gov/
show/NCT01902459
NCT02153593 Postoperative bleeding prevention in
massive bone tumour resection: a
multicentric, randomised, parallel,
controlled trial
Recruiting March 2013 http://ClinicalTrials.gov/
show/NCT02153593
NCT02150720 Prevention of postoperative bleeding
in subcapital femoral fractures: a
multicenter, randomised, controlled,
parallel clinical trial
Recruiting February 2013 http://ClinicalTrials.gov/
show/NCT02150720
NCT01641718 Use of human fibrin glue versus
staples for mesh fixation in
laparoscopic transabdominal
preperitoneal hernioplasty
Active, not
recruiting
January 2013 http://ClinicalTrials.gov/
show/NCT01641718
Note
All URLs accessed on 19 May 2015.
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TABLE 36 Clinicaltrialsregister.eu trials
EudraCT number Title Recruitment Start date URL
2014–003954–15 A single blinded, randomised,
controlled study to evaluate the
safety and effectiveness of
EVICEL® fibrin sealant (Human)
compared to a hydrogel sealant
as an adjunct to sutured dural
repair
Ongoing May 2015 www.clinicaltrialsregister.eu/
ctr-search/trial/2014-
003954-15/GB/
2013–004353–24 Wound management in post-
bariatric surgery investigation
for the reduction of the mean
drainage volume in patients
after abdominoplasty/lower
body lift using Artiss fibrin
sealant in comparison to the
standard procedure
Ongoing May 2014 www.clinicaltrialsregister.eu/
ctr-search/trial/2013-
004353-24/DE/
2013–002579–16 PHASE III clinical trial, single-
centre, randomised, double
blind in two groups parallel to
compare the efficacy and safety
of rich plasma growth factors
(PRGF) in front of fibrin glue
(Tissucol®) for sealing anal and
criptoglandular fistula after
48 weeks
Ongoing December 2014 www.clinicaltrialsregister.eu/
ctr-search/trial/2013-
002579-16/ES/
2013–002535–24 A phase iii randomised,
controlled, superiority study
evaluating EVARREST™ fibrin
sealant patch versus standard of
care treatment in controlling
parenchymal bleeding during
hepatic surgery
Ongoing September 2013 www.clinicaltrialsregister.eu/
ctr-search/trial/2013-
002535-24/GB/
Note
All URLs accessed on 19 May 2015.
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Appendix 6 Funnel plots for meta-analyses
Primary outcomes
Bias assessment plot
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FIGURE 42 Funnel plot for the seroma. Egger bias = –0.47 (95% CI –1.50 to 0.56; p= 0.36).
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FIGURE 43 Funnel plot for haematoma. Egger bias = –0.63 (95% CI –1.20 to –0.06; p= 0.03).
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FIGURE 44 Funnel plot for combined seroma and haematoma. Egger bias= –0.67 (95% CI –1.38 to 0.03; p= 0.06).
Secondary outcomes
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FIGURE 45 Funnel plot for haemorrhage (bleeding). Egger bias= 0.65 (95% CI –0.53 to 1.82; p= 0.26).
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FIGURE 46 Funnel plot for reoperation. Egger bias= –0.47 (95% CI –1.47 to 0.53; p = 0.33).
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FIGURE 47 Funnel plot for infections. Egger bias= 0.22 (95% CI –0.74 to 1.18; p= 0.64).
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Bias assessment plot
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FIGURE 48 Funnel plot for duration of drainage in breast surgery. Egger bias= –3.40 (95% CI –6.75 to –0.05;
p= 0.05).
No funnel plot for the duration of operation and length of hospital stay meta-analysis is reported as there
was an insufficient number of studies (< 10).
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
144
Appendix 7 Tables of excluded observational
studies
TABLE 39 Excluded observational studies
Study excluded Reason for exclusion
Abdeen K, Kato Y, Kiya N, Yoshida K, Kanno T. Neuroendoscopy in microvascular
decompression for trigeminal neuralgia and hemifacial spasm: technical note. Neurol Res
2000;22:522–6
No comparison group
Abdulla A, Neff M. Laparoscopic repair of perforated duodenal ulcer in child’s class C cirrhotic
patient. Surg Endosc 2011;25:S364
No comparison group
Abe T, Goda M, Kamida T, Fujiki M, Kobayashi H, Nakano T, et al. Overlapping free bone graft
with galea-pericranium in reconstruction of the anterior skull base to prevent CSF leak and
sequestrum formation. Acta Neurochir 2007;149:771–5
Not a comparative
observational study
Abel ME, Chiu YS, Russell TR, Volpe PA. Autologous fibrin glue in the treatment of rectovaginal
and complex fistulas. Dis Colon Rectum 1993;36:447–9
No comparison group
Abu Hilal M, Hallam MJ, Zeidan BA, Pearce NW. Management of a ruptured pseudoaneurysm
of common hepatic artery following pancreaticoduodenectomy. Sci World J 2007;7:1658–62
No comparison group
Abuzayed B, Kafadar AM, Og˘uzog˘lu SA, Canbaz B, Kaynar MY. Duraplasty using autologous
fascia lata reinforced by on-site pedicled muscle flap: technical note. J Craniofac Surg
2009;20:435–8
No comparison group
Achauer BM, Miller SR, Lee TE. The hemostatic effect of fibrin glue on graft donor sites. J Burn
Care Rehabil 1994;15:24–8
RCT
Acholonu E, Eckstein J, Patel S, Abu-Jaish W, Szomstein S. Indications, complications and long
term outcomes of remnant gastrectomy for gastrogastric fistula after divided Roux-en-Y gastric
bypass for morbid obesity. Surg Endosc 2010;24(Suppl. 1):300
No comparison group
Acholonu E, Eckstein J, Patel S, Szomstein S, Rosenthal RJ. Indications, complications and long
term outcomes of remnant gastrectomy for gastro-gastric fistula after divided Roux-en-Y gastric
bypass for morbid obesity. Obes Surg 2010;20:1005
Duplicate
Adamian LV, Mynbaev OA, Dzhakhan I. [The use of fibrin glue in obstetrics and gynecology.]
Akush Ginekol 1991;11:3–4
Not a comparative
observational study
Agarwal A, Kumar DA, Jacob S, Baid C, Agarwal A, Srinivasan S. Fibrin glue-assisted sutureless
posterior chamber intraocular lens implantation in eyes with deficient posterior capsules.
J Cataract Refract Surg 2008;34:1433–8
Not a comparative
observational study
Aghamir SM, Khazaeli MH, Meisami A. Use of Surgicel for sealing nephrostomy tract after
totally tubeless percutaneous nephrolithotomy. J Endourol 2006;20:293–5
RCT
Agha-Mir-Salim P, Beck R, Bloching M, Berghaus A. [Endoscopic treatment of iatrogenic
esophageal perforation.] Laryngorhinootologie 2000;79:39–42
No comparison group
Agresta F. Re: Spray application of fibrin glue as risk factor for subcutaneous emphysema in
laparoscopic transabdominal inguinal hernia repair. Surg Laparosc Endosc Percutan Tech
2007;17:222
Letter/commentary/reply
Agresta F, Baldazzi GA, Ciardo LF, Trentin G, Giuseppe S, Ferrante F, et al. Lightweight partially
absorbable monofilament mesh (polypropylene/poliglecaprone 25) for TAPP inguinal hernia
repair: Initial experience. Surg Laparosc Endosc Percutan Tech 2007;17:91–4
No comparison group
Agresta F, Bedin N. Transabdominal laparoscopic inguinal hernia repair: is there a place for
biological mesh? Hernia 2008;12:609–12
No comparison group
Aguilar PH, De Oliveira EP. The use of fibrin glue to stop venous bleeding in the epidural space,
vertebral venous plexus, and anterior cavernous sinus: Technical note – commentary.
Neurosurgery 2007;61(Suppl.):E51
Letter/commentary/reply
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Aguilera et al. 2013143 RCT
Agus GB, Bono AV, Mira E, Olivero S, Peilowich A, Homdrum E, et al. Hemostatic efficacy and
safety of TachoComb in surgery. Ready to use and rapid hemostatic agent. Int Surg
1996;81:316–19
No comparison group
Aida H, Kagaya S. [Successful repair of left ventricular free wall rupture with repeated mydriasis
and loss of light reflex.] Kyobu Geka 2011;64:1168–71
No comparison group
Aigner C, Wolner E, Mohl W. Management of central coronary sinus ruptures using the
pericardial patch repair technique. Ann Thorac Surg 2006;81:1275–8
No comparison group
Aitola P, Hiltunen KM, Matikainen M. Fibrin glue in perianal fistulas – a pilot study. Ann Chir
Gynaecol 1999;88:136–8
No comparison group
Ak G, Alpkılıç Bas¸kırt E, Kürklü E, Koray M, Tanyeri H, Zülfikar B. The evaluation of fibrin
sealants and tissue adhesives in oral surgery among patients with bleeding disorders. Turk J
Haematol 2012;29:40–7
RCT
Akaogi E, Mitsui K, Sohara Y, Endo S, Ishikawa S, Hori M. Treatment of postoperative
chylothorax with intrapleural fibrin glue. Ann Thorac Surg 1989;48:116–18
No comparison group
Akhras J, Tobi M, Zagnoon A. Endoscopic fibrin sealant injection with application of hemostatic
clips: a novel method of closing a refractory gastrocutaneous fistula. Dig Dis Sci 2005;50:1872–4
No comparison group
Al Harakeh AB. Complications of laparoscopic Roux-en-Y gastric bypass. Surg Clin North Am
2011;91:1225–37
Not fibrin sealant
Alashwal AH, Yaakub A, Noor RAM, Tajudin LSA. Fibrin glue for sealing early bleb leak: a case
report. Int J Ophthalmol 2009;9:831–2
No comparison group
Albala DM, Wood C, Fischer C, Hart J, Batiller J, Shen J. A randomized trial of aprotinin free
fibrin sealant versus absorbable hemostat. J Endourol 2011;25:A95
RCT
Albéniz Arbizu E, López San Román A, Garcia González M, Foruny Olcina JR, Garcia-Hoz
Rosales F, Bárcena Marugán R, et al. Fibrin-glue sealed liver biopsy in patients with a liver
transplantation or in liver transplantation waiting list: preliminary results. Transplant Proc
2003;35:1911–12
No comparison group
Albera R, Canale A, Lacilla M, Cavalot AL, Ferrero V. Delayed vertigo after stapes surgery.
Laryngoscope 2004;114:860–2
No comparison group
Albert JG. Closure of an ischemic duodenal fistula with an over-the-scope clip. Video J
Encyclopedia GI Endosc 2013;1:219–20
No comparison group
Ali A, Zayed H, Kizilates K, El Sakka K, Brown J, Halawa M, et al. The feasibility and safety of
drainless carotid endarterectomy. Interact Cardiovasc Thorac Surg 2009;8:S72
No comparison group
Ali SN, Gill P, Oikonomou D, Sterne GD. The combination of fibrin glue and quilting reduces
drainage in the extended latissimus dorsi flap donor site. Plast Reconstr Surg 2010;125:1615–19
RCT
Alibai EA, Rahmanian AK, Razmkon A, Nabavizadeh SA. Tension pneumocephalus following
pterional craniotomy for treatment of intracavernous internal carotid artery aneurysm. Emerg
Radiol 2008;15:441–4
No comparison group
Alio JL, Mulet E, Sakla HF, Gobbi F. Efficacy of synthetic and biological bioadhesives in scleral
tunnel phacoemulsification in eyes with high myopia. J Cataract Refract Surg 1998;24:983–8
RCT
Alio JL, Rodriguez AE, Martinez LM, Rio AL. Autologous fibrin membrane combined with solid
platelet-rich plasma in the management of perforated corneal ulcers: a pilot study. JAMA
Ophthalmol 2013;131:745–51
No comparison group
Alizadeh Ghavidel A, Mirmesdagh Y, Samiei N, Gholampour Dehaki M. Haemostatic role of
TachoSil surgical patch in cardiac surgery. J Cardiovasc Thorac Res 2014;6:91–5
No adverse effects
related to fibrin reported
Al-khudari S, Vitale L, Ghanem T, McLean S. Recurrent high output chyle fistula post neck
dissection resolution with conservative management. Laryngoscope 2010;120(Suppl. 4):141
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Allende CA, Allende BT, Allende BL, Bitar I, Gonzalez G. Intercondylar distal humerus fractures –
surgical treatment and results. Chir Main 2004;23:85–95
No adverse effects
related to fibrin reported
Alleyne Jr CH, Pearce JE. Nonsuture dural repair using polyglycolic acid mesh and fibrin glue:
clinical application to spinal surgery – commentary. Surg Neurol 2006;65:142–3
Letter/commentary/reply
Almer ZE, Miller NR. Delayed third cranial nerve palsy after aneurysm wrapping.
J Neuroophthalmol 2008;28:359
Letter/commentary/reply
Al-Mutairi M, AlEnezi F, Al-Einati T. Left main coronary artery ostial stenosis with biologic glue
post-Bentall procedure. Kuwait Med J 2008;40:321–3
No comparison group
Al-Qahtani K. Initial experience with hemostatic fibrin glue as adjuvant during drainless
parotidectomy. Saudi Dent J 2011;23:67–71
No comparison group
Altomare et al. 2011217 RCT
Alvarez JA, Bermejo F, Algaba A, Hernandez MP, Grau M. Surgical repair and biological therapy
for fecal incontinence in Crohn’s disease involving both sphincter defects and complex fistulas.
J Crohns Colitis 2011;5:598–607
No comparison group
Rubio Alvarez J, Sierra Quiroga J, Martinez de Alegria A, Delgado Dominguez C. Pulmonary
embolism due to biological glue after repair of type A aortic dissection. Interact Cardiovasc
Thorac Surg 2011;12:650–1
No comparison group
Al-Yamany M, Del Maestro RF. Prevention of subdural fluid collections following transcortical
intraventricular and/or paraventricular procedures by using fibrin adhesive. J Neurosurg
2000;92:406–12
Included children
Amano J, Suzuki A. Surgical treatment of cardiac involvement in Takayasu arteritis. Heart
Vessels 1992;7(Suppl. 7):168–78
No comparison group
Ambriz-Gonzalez G, Velazquez-Ramirez GA, Garcia-Gonzalez JL, De Leon-Gomez JMG,
Mucino-Hernandez MI, Gonzalez-Ojeda A, et al. Use of fibrin sealant in hypospadias surgical
repair reduces the frequency of postoperative complications. Urol Int 2007;78:37–41
Included children
Ambruoso G, Aimè G, Borsa R, Cordara G, Governa G, Polledro P, et al. [Urethro-vesical
anastomosis after radical prostatectomy and bladder replacement with the Camey II approach.]
Minerva Urol Nefrol 1994;46:159–61
No comparison group
Anagiotos A, Feyka M, Gostian AO, Lichtenstein T, Henning TD, Guntinas-Lichius O, et al.
Endoscopic laser-assisted diverticulotomy without versus with wound closure in the treatment
of Zenker’s diverticulum. Eur Arch Otorhinolaryngol 2014;271:765–70
No comparison group
Anderson NJ, Hardten DR. Fibrin glue for the prevention of epithelial ingrowth after laser in situ
keratomileusis. J Cataract Refract Surg 2003;29:1425–9
No comparison group
Andree C, Munder BIJ, Behrendt P, Hellmann S, Audretsch W, Voigt M, et al. Improved safety
of autologous breast reconstruction surgery by stabilisation of microsurgical vessel anastomoses
using fibrin sealant in 349 free DIEP or fascia-muscle-sparing (fms)-TRAM flaps: a two-centre
study. Breast 2008;17:492–8
No comparison group
Andress HJ, Mewes A, Lange V. Endoscopic hemostasis of a bleeding diverticulum of the sigma
with fibrin sealant. Endoscopy 1993;25:193
Letter/commentary/reply
Andrychowski J, Czernicki Z, Taraszewska A, Frontczak-Baniewicz M, Przytula E, Zebala M.
Granulomatous inflammation of dura mater – a rare side effect after application of hemostatic
and insulation materials in case of two-stage operation of huge meningioma. Folia Neuropathol
2012;50:417–24
No comparison group
Angioli R, Plotti F, Ricciardi R, Terranova C, Zullo MA, Damiani P, et al. The use of novel
hemostatic sealant (Tisseel) in laparoscopic myomectomy: a case-control study. Surg Endosc
2012;26:2046–53
RCT
Anonymous. [Additional aerostasis with a 100% autologous fibrin glue in lung surgery – a
prospective randomised trial.] Khirurgiia 2009;1:10–18
RCT
Anonymous. Additional aerostasis with a 100% autologous fibrin glue in lung surgery – a
prospective randomised trial. Khirurgiia 2009;1:10–18
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Anwar HM, El-Danasoury A, Hashem AN. The use of fibrin glue to seal Descemet membrane
microperforations occurring during deep anterior lamellar keratoplasty. Cornea 2012;31:1193–6
No comparison group
Apestegui C, Breitenstein S, Dutkowski P, Clavien PA. Control of severe portal bleeding by
carrier-bound fibrin sealant. Surg Today 2009;39:363–5
No comparison group
Arbes H, Bosch P, Lintner F, Salzer M. First clinical experience with heterologous cancellous
bone grafting combined with the fibrin adhesive system (F.A.S.). Arch Orthop Trauma Surg
1981;98:183–8
No comparison group
Argiriou M, Patris V, Lama N, Argiriou O, Charitos C. Off pump repair of left ventricular rupture
following mitral valve replacement: the crucial assistance of the intraaortic balloon pump. Int J
Surg Case Rep 2013;4:5–6
No comparison group
Arlt F, Trantakis C, Krupp W, Renner C, Winkler D, Strauss G, et al. Cerebrospinal fluid leak
after microsurgical surgery in vestibular schwannomas via retrosigmoidal craniotomy. Neurol
Res 2011;33:947–52
No comparison group
Arndt S, Maier W, Aschendorff A, Klenzner T, Schipper J. [Ethisorb/Ethisorb durapatch for the
transnasal duraplasty procedure?] Laryngorhinootologie 2006;85:260–4
No comparison group
Asato R, Honda K, Tsuji J, Kanda T, Ushiro K, Wtanabe Y. A new method of covering mucosal
defect after oral cancerresection – a combination of polyglycolic acid (PGA) sheet and sprayed
fibrin glue. Oral Oncol 2011;47:S150–1
Not fibrin sealant
Asensio Samper JM, Fabregat Cid G, Valia-Vera JC, De Andres JA. [Epidural fibrin glue injection
as a conservative treatment for persistent cerebrospinal fluid leakage after spinal catheterization.]
Rev Esp Anestesiol Reanim 2011;58:391–3
Letter/commentary/reply
Asrani SG, Wilensky JT. Management of bleb leaks after glaucoma filtering surgery. Use of
autologous fibrin tissue glue as an alternative. Ophthalmology 1996;103:294–8
No comparison group
Assalia A. A novel method for the management of gastric fistula complicating laparoscopic
sleeve gastrectomy: biological glue application in a combined percutaneous and endoscopic
approach. Obes Surg 2014;24:1145
No comparison group
Atallah J, Gage E, Koning J, Duggan J, Ramsey-Williams V, Scott S, et al. Treatment of
post-dural puncture headache using epidural injection of fibrin sealant as an alternative to
autologous epidural blood patch (case report). Scand J Pain 2014;5:170–2
No comparison group
Athanasiadis S, Kuhlgatz C, Girona I. [Experiences with fibrin adhesives in surgery of the rectum
and colon.] Zentralbl Chir 1984;109:1107–11
No comparison group
Athanassiadi K, Kalavrouziotis G, Bellenis I. Bronchopleural fistula after pneumonectomy:
a major challenge. Acta Chir Hung 1999;38:5–7
Not fibrin sealant
Aurangzeb A, Ahmed E, Khan SA, Ali A, Ihsan A, Mehmood S. Outcome of transcranial repair
of traumatic CSF rhinorrhea. J Ayub Med Coll Abbottabad 2012;24:47–9
No comparison group
Avalos-Gonzalez J, Portilla-deBuen E, Leal-Cortes CA, Orozco-Mosqueda A, Estrada-Aguilar MC,
Velazquez-Ramirez GA, et al. Reduction of the closure time of postoperative enterocutaneous
fistulas with fibrin sealant. World J Gastroenterol 2010;16:2793–800
No adverse effects
related to fibrin reported
Avanoglu A, Celik A, Ulman I, Ozcan C, Kavakli K, Nis¸li G, et al. Safer circumcision in patients
with haemophilia: the use of fibrin glue for local haemostasis. BJU Int 1999;83:91–4
Included children
Avisar R, Vaiman M, Sarfaty S, Shlamkovich N, Segal S, Eviatar E, et al. Using fibrin glue in
endonasal surgery (multiple letters). Isr Med Assoc J 2005;7:823–4
Letter/commentary/reply
Aydin A, Ozden BC, Mersa B. Complications of microsurgical reconstruction of obstetrical
brachial plexus palsy. Plast Reconstr Surg 2005;115:353–4
Letter/commentary/reply
Aydin K, Cokluk C, Kocabicak E, Celik B, Taslak Sengul A. Cervical screw extrusion into the
trachea leading to perforation: a case report. Chirurgia 2012;25:355–7
Not fibrin sealant
Ayloo S, Bueno R. Band erosion: laparoscopic removal of lap-band. Surg Endosc
2009;23:657–8
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Bacciu A, Falcioni M, Pasanisi E, Di Lella F, Lauda L, Flanagan S, et al. Intracranial facial nerve
grafting after removal of vestibular schwannoma. Am J Otolaryngol 2009;30:83–8
No comparison group
Bachet J, Gigou F, Laurian C, Bical O, Goudot B, Guilmet D. Four-year clinical experience with
the gelatin-resorcine-formol biological glue in acute aortic dissection. J Thorac Cardiovasc Surg
1982;83:212–17
Not fibrin sealant
Bachleda P, Utikal P, Kalinova L, Herman J. TachoSil® in the treatment of postoperative groin
lymphatic fistula. Ann Acad Med Singap 2012;41:534–5
Letter/commentary/reply
Bagot d’Arc M, Daculsi G, Emam N. Biphasic ceramics and fibrin sealant for bone
reconstruction in ear surgery. Ann Otol Rhinol Laryngol 2004;113:711–20
No comparison group
Bahar et al. 2006159 RCT
Bahar et al. 2007169 RCT
Bailey SH, Oni G, Guevara R, Wong C, Saint-Cyr M. Latissimus dorsi donor-site morbidity: the
combination of quilting and fibrin sealant reduce length of drain placement and seroma rate.
Ann Plast Surg 2012;68:555–8
No adverse effects
related to fibrin reported
Baiocchi G, Portolani N, Gheza F, Giulini SM. Collagen-based biological glue after Appleby
operation for advanced gastric cancer. World J Gastroenterol 2011;17:4044–7
No comparison group
Bajardi et al. 2009194 RCT
Bakeer M, Abd El-Gawad T, El-Metwaly Ali R, El-Morsi A, El-Badrawy M, El-Sharawy S. Low
cost biological lung volume reduction therapy for advanced emphysema. Eur Respir J
2014;44(Suppl. 58):P3705
Abstract
Balint B, Gazivoda D, Todorovic-Balint M, Lazic Z, Pavlovic M, Kanjuh V. ‘Triple-way’ approach
for the treatment of dry socket: surgery and drugs plus fibrin sealant – as a biomatrix for
‘ultra-concentrated’ platelets. Transfus Apher Sci 2014;51:221–2
Letter/commentary/reply
Bänninger H, Hardegger T, Tobler A, Barth A, Schüpbach P, Reinhart W, et al. Fibrin glue in
surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J
Haematol 1993;85:528–32
No comparison group
Barbagli G, De Stefani S, Sighinolfi MC, Annino F, Micali S, Bianchi G. Bulbar urethroplasty with
dorsal onlay buccal mucosal graft and fibrin glue. Eur Urol 2006;50:467–74
No comparison group
Barbosa MD, Gregh SL, Passanezi E. Fibrin adhesive derived from snake venom in periodontal
surgery. J Periodontol 2007;78:2026–31
No adverse effects
related to fibrin reported
Bardaxoglou E, Campion JP, Landen S, Manganas D, Siriser F, Chareton B, et al. Oesophageal
perforation: primary suture repair reinforced with absorbable mesh and fibrin glue. Br J Surg
1994;81:399
No comparison group
Barthelemy C, Fayard MO, Etaix JP, Audigier JC, Fraisse H. [Esophagobronchial fistula following
sclerosis of esophageal varices. Treatment by injection of biological glue.] Gastroenterol Clin
Biol 1984;8:772–3
Unobtainable
Basmak H, Erdogan H, Sahin A, Gürsoy H. Scleral dellen after fibrin glue use in strabismus
surgery. J Pediatr Ophthalmol Strabismus 2010;47:e1–3
No comparison group
Basmak H, Gursoy H, Cakmak AI˙, Niyaz L, Yildirim N, Sahin A. Tissue adhesives as an
alternative for conjunctival closure in strabismus surgeries. Strabismus 2011;19:59–62
Included children
Basso N. Staple-line leaks management after laparoscopic sleeve gastrectomy. Obes Surg
2009;19:1050
Not fibrin sealant
Batman C, Ozdamar Y, Aslan O, Sonmez K, Mutevelli S, Zilelioglu G. Tissue glue in sutureless
vitreoretinal surgery for the treatment of wound leakage. Ophthalmic Surg Lasers Imaging
2008;39:100–6
No comparison group
Batman C, Ozdamar Y, Mutevelli S, Sonmez K, Zilelioglu G, Karakaya J. A comparative study of
tissue glue and vicryl suture for conjunctival and scleral closure in conventional 20-gauge
vitrectomy. Eye 2009;23:1382–7
Not a comparative
observational study
continued
DOI: 10.3310/hta20940 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 94
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
149
TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Baumann P, Schumacher H, Husing J, Luntz S, Knaebel HP. A randomized, controlled,
prospective trial to evaluate the haemostatic effect of Lyostypt versus Surgicel in arterial bypass
anastomosis: ‘COBBANA’ trial. 2009;10:91
RCT
Baumann WR, Ulmer JL, Ambrose PG, Garvey MJ, Jones DT. Closure of a bronchopleural fistula
using decalcified human spongiosa and a fibrin sealant. Ann Thorac Surg 1997;64:230–3
No comparison group
Bazan A, Samper A, Lasso JM. The use of fibrin glue in vaginal reconstruction with a pudendal
thigh flap. Ann Plast Surg 1999;43:576
Letter/commentary/reply
Beer GM, Goldscheider E, Weber A, Lehmann K. Prevention of acute hematoma after face-lifts.
Aesthetic Plast Surg 2010;34:502–7
Not a valid comparison
Beese RC, Tomlinson MA, Buckenham TM. Endoluminal embolization of bilateral
atherosclerotic common iliac aneurysms with fibrin tissue glue (Beriplast). Cardiovasc Intervent
Radiol 2000;23:239–41
No comparison group
Beierlein W, Scheule AM, Antoniadis G, Braun C, Schosser R. An immediate, allergic skin
reaction to aprotinin after reexposure to fibrin sealant. Transfusion 2000;40:302–5
No comparison group
Beitzke M, Leber KA, Deutschmann H, Gattringer T, Poltrum B, Fazekas F. Cerebrovascular
complications and granuloma formation after wrapping or coating of intracranial aneurysms
with cotton gauze and human fibrin adhesives: results from a single-center patient series over a
5-year period. J Neurosurg 2013;119:1009–14
Not a valid comparison
Bekkers JA, Raap GB, Takkenberg JJ, Bogers AJ. Acute type A aortic dissection: long-term
results and reoperations. Eur J Cardiothorac Surg 2013;43:389–96
Not a valid comparison
Bektas H, Nadalin S, Schmidt J, Szabo I, Ploder B, Sharkhawy M. Hemostatic efficacy of latest
generation fibrin sealant after hepatic resection; a randomized controlled clinical study. HPB
2013;15:6–7
RCT
Bektas et al. 201465 RCT
Belboul et al. 2004133 RCT
Belcher et al. 2010136 RCT
Bellini LP, Brum GS. Cataract incision closure using fibrin adhesive. J Cataract Refract Surg
2008;34:343–4
Letter/commentary/reply
Benevento et al. 2014109 No comparison group
Benfatto G, Benfatto SM, Strazzanti A, Giovinetto RM, Jiryis A, Salina GM, et al. [Fibrin sealant
in tension free hernioplasty: our experience.] G Chir 2006;27:392–4
No adverse effects
related to fibrin reported
Benizri EI, Rahili A, Avallone S, Balestro JC, Caï J, Benchimol D. Open inguinal hernia repair by
plug and patch: the value of fibrin sealant fixation. Hernia 2006;10:389–94
No adverse effects
related to fibrin reported
Benkó I, Molnár TF, Horváth OP. A case of fibrin sealant application for closing benign trachea-
esophageal fistula (TEF). Acta Chir Hung 1997;36:25–6
No comparison group
Bense L. Intrabronchial selective coagulative treatment of hemoptysis. Report of three cases.
Chest 1990;97:990–6
RCT
Benyamini OG, Barkana Y, Hartstein M, Attas L, Avni I, Zadok D. Biological glue in pterygium
surgery with a rotational flap or sliding flaps. Cornea 2008;27:911–15
No comparison group
Beppu T, Iwatsuki M, Okabe H, Okabe K, Masuda T, Hayashi H, et al. A new approach to
percutaneous transhepatic portal embolization using ethanolamine oleate iopamidol.
J Gastroenterol 2010;45:211–17
Not a valid comparison
Bercial et al. 2012213 RCT
Berg PL, Barina W, Born P. Endoscopic injection of fibrin glue versus polidocanol in peptic ulcer
hemorrhage: a pilot study. Endoscopy 1994;26:528–30
RCT
Berger et al. 2001107 RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Bergeron E, Roux A, Demers J, Vanier LE, Moore L. A 40-year-old woman with cauda equina
syndrome caused by rectothecal fistula arising from an anterior sacral meningocele.
Neurosurgery 2010;67:E1464–7
No comparison group
Berkoff DJ, Kanaan M, Kamath G. Fibrin glue as a non-invasive outpatient treatment for
post-arthroscopic knee seromas. Knee Surg Sports Traumatol Arthrosc 2013;21:1922–4
No comparison group
Bernal JM, Naranjo S, Trugeda M, Sarralde A, Diago C, Revuelta JM. [Cardiac surgery in
Jehovah’s Witnesses. Experience in Santander, Spain.] Rev Esp Cardiol 2006;59:507–9
No comparison group
Bernard RW, Greenwald JA, Beran SJ, Morello DC. Enhancing upper lid aesthetics with the
lateral subcutaneous brow lift. Aesthet Surg J 2006;26:19–23
No comparison group
Bernardo L, Bernardo WM, Shu EB, Roz LM, Almeida CC, Monaco BA, et al. Does the use of
DuraSeal in head and spinal surgeries reduce the risk of cerebrospinal fluid leaks and
complications when compared to conventional methods of dura mater closure? Rev Assoc Med
Bras 2012;58:402–3
Not fibrin sealant
Bernasek TL, Burris RB, Fujii H, Levering MF, Polikandriotis JA, Patterson JJ. Effect on blood loss
and cost-effectiveness of pain cocktails, platelet-rich plasma, or fibrin sealant after total knee
arthroplasty. J Arthroplasty 2012;27:1448–51
No adverse effects
related to fibrin reported
Berney CR. The Endoloop technique for the primary closure of direct inguinal hernia defect
during the endoscopic totally extraperitoneal approach. Hernia 2012;16:301–5
No comparison group
Berney CR, Yeo AE. Mesh fixation with fibrin sealant during endoscopic totally extraperitoneal
inguinal hernia approach: a review of 640 repairs. Hernia 2013;17:709–17
No comparison group
Berruyer M, Amiral J, Ffrench P, Belleville J, Bastien O, Clerc J, et al. Immunization by bovine
thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and
factor V inhibitors. J Thorac Cardiovasc Surg 1993;105:892–7
No comparison group
Berzofsky CE, Holiday RA, Pitman MJ. Variability of postoperative esophagrams after
endoscopic cricopharyngeal myotomy: technique dependence. Ann Otol Rhinol Laryngol
2012;121:145–50
Not fibrin sealant
Bhavana K, Kumar R, Keshri A, Aggarwal S. Minimally invasive technique for repairing CSF
leaks due to defects of posterior table of frontal sinus. J Neurol Surg B Skull Base
2014;75:183–6
No comparison group
Binenbaum SJ, Dressner RM, Borao FJ. Laparoscopic repair of a free perforation of a marginal
ulcer after Roux-en-Y gastric bypass: a safe alternative to open exploration. JSLS
2007;11:383–8
No comparison group
Birmingham B. TEE diagnosis of mechanical AVR dysfunction associated with biological glue.
Anesth Analg 2001;93:1627–8
Letter/commentary/reply
Birth M, Figueras J, Bernardini S, Troen T, Gunther K, Mirza D, et al. Collagen fleece-bound
fibrin sealant is not associated with an increased risk of thromboembolic events or major
bleeding after its use for haemostasis in surgery: a prospective multicentre surveillance study.
Patient Saf Surg 2009;3:13
No comparison group
Bischoff G, Muehling B, Orend K, Bischoff M, Sunder-Plassmann L. A new treatment concept
for bronchial stump insufficiency. Thorac Cardiovasc Surg 2010;58:169–74
Not a valid comparison
Bittner R, Gmähle E, Gmähle B, Schwarz J, Aasvang E, Kehlet H. Lightweight mesh and
noninvasive fixation: an effective concept for prevention of chronic pain with laparoscopic
hernia repair (TAPP). Surg Endosc 2010;24:2958–64
No adverse effects
related to fibrin reported
Bittner R, Leibl BJ, Kraft B, Schwarz J. One-year results of a prospective, randomised clinical trial
comparing four meshes in laparoscopic inguinal hernia repair (TAPP). Hernia 2011;15:503–10
RCT
Black P. Cerebrospinal fluid leaks following spinal or posterior fossa surgery: use of fat grafts
for prevention and repair. Neurosurg Focus 2000;9:e4
No comparison group
Black P. Cerebrospinal fluid leaks following spinal surgery: use of fat grafts for prevention and
repair. Technical note. J Neurosurg 2002;96(Suppl. 2):250–2
No comparison group
continued
DOI: 10.3310/hta20940 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 94
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
151
TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Blinder D, Manor Y, Martinowitz U, Taicher S, Hashomer T. Dental extractions in patients
maintained on continued oral anticoagulant: comparison of local hemostatic modalities.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:137–40
No adverse effects
related to fibrin reported
Blumenkranz MS, Ohana E, Shaikh S, Chang S, Coll G, Morse LS, et al. Adjuvant methods in
macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas
exchange. Ophthalmic Surg Lasers 2001;32:198–207
No comparison group
Blute ML. Fibrin sealant for retrograde ureteroscopic closure of urine leak after partial
nephrectomy. French DB, Marcovich R, Department of Urology, University of Texas Health
Science Center, San Antonio, TX. Urol Oncol Seminars Orig Invest 2006;24:554–5
No comparison group
Boadas A, Fernandez-Palazzi F, De Bosch NB, Cedeno M, Ruiz-Saez A. Elective surgery in
patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia
Centre of Venezuela. Haemophilia 2011;17:422–7
No comparison group
Boaventura PN, Sobreira ML, Yoshida WB, Rollo HA. Treatment of postoperative inguinal
lymphocele with fibrin glue injection: case report. J Vasc Brasileiro 2007;6:190–2
No comparison group
Bochicchio G, Singla N, Gupta NY, Porter R, Renkens KL, Pattyn P, et al. An international,
multicenter, randomized, single-blind, controlled trial of a dry-powder, fibrin sealant for mild to
moderate perioperative surgical bleeding. J Am Coll Surg 2014;219(Suppl. 1):e13–14
RCT
Bochicchio et al. 2015239 RCT
Bock HC, Cohnen J, Keric N, Kantelhardt SR, Giese A. Occlusion of surgical opening of the
ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta
Neurochir 2011;153:533–9
RCT
Bodner L, Weinstein JM, Baumgarten AK. Efficacy of fibrin sealant in patients on various levels
of oral anticoagulant undergoing oral surgery. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 1998;86:421–4
No comparison group
Boenisch M, Nolst Trenité GJ. [Fibrin glue for operative correction of septal deviations.] HNO
2004;52:963–7
No comparison group
Boldo 2008173 RCT
Boldo E, Armelles A, Perez de Lucia G, Martin F, Aracil JP, Miralles JM, et al. Pain after
laparascopic bilateral hernioplasty : Early results of a prospective randomized double-blind study
comparing fibrin versus staples. Surg Endosc 2008;22:1206–9. [Erratum appears in Surg Endosc
2008;22:1210]
Duplicate
Boonstra EA, Molenaar IQ, Porte RJ, de Boer MT. Topical haemostatic agents in liver surgery:
do we need them? HPB 2009;11:306–10
Not a comparative
observational study
Borgeskov S, Balslev E. [Use of fibrin adhesive (Tisseel) in pacemaker pockets. An experimental
study.] Ugeskr Laeg 1987;149:1059–61
Not a comparative
observational study
Born P, Ott R, Rösch T. Endoscopic hemostasis using fibrin sealant for postsphincterotomy
bleeding: report of two cases. Gastrointest Endosc 2000;51:731–3
No comparison group
Borowiec AM, McCall M, Lees GM. The trans-sphincteric posterior sagittal repair of recto-urinary
and recto-vaginal fistulae using Surgisis™ mesh and fibrin sealant. Tech Coloproctol
2014;18:201–3
No comparison group
Botti G, Pascali M, Botti C, Bodog F, Gentile P, Cervelli V. Comparison of commercial fibrin
sealants in facelift surgery: a prospective study. Clin Cosmet Investig Dermatol 2013;6:273–80
Letter/commentary/reply
Bou Monsef J, Buckup J, Waldstein W, Cornell C, Boettner F. Fibrin sealants or cell saver
eliminate the need for autologous blood donation in anemic patients undergoing primary total
knee arthroplasty. Arch Orthop Trauma Surg 2014;134:53–8
No adverse effects
related to fibrin reported
Bouchot O, Bouchot-Hermouet FB, Karam G, Glemain P, Pannier M, Auvigne J. [Prevention of
complications in inguinal lymphadenectomy.] J Urol 1990;96:279–83
No comparison group
Boulos PR, Harissi-Dagher M, Kavalec C, Hardy I, Codere F. Intralesional injection of Tisseel
fibrin glue for resection of lymphangiomas and other thin-walled orbital cysts. Ophthal Plast
Reconstr Surg 2005;21:171–6
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Bouwmeester SJ, Beckers JM, Kuijer R, van der Linden AJ, Bulstra SK. Long-term results of rib
perichondrial grafts for repair of cartilage defects in the human knee. Int Orthop 1997;21:313–17
No comparison group
Boylu U, Basatac C, Tahra A, Onol FF, Gumus E. Laparoscopic ureterolithotomy with fibrin
sealant in the treatment of large impacted proximal ureteral stone. J Endourol 2013;27:A432–3
No comparison group
Bozorg Grayeli A, Mosnier I, Julien N, El Garem H, Bouccara D, Sterkers O. Long-term
functional outcome in facial nerve graft by fibrin glue in the temporal bone and
cerebellopontine angle. Eur Arch Otorhinolaryngol 2005;262:404–7
No comparison group
Bracale et al. 2014174 RCT
Bradford TJ, Wolf JS. Percutaneous injection of fibrin glue for persistent nephrocutaneous
fistula after partial nephrectomy. Urology 2005;65:799
No comparison group
Bradley JP, Gabbay JS, Taub PJ, Heller JB, O’Hara CM, Benhaim P, et al. Monobloc
advancement by distraction osteogenesis decreases morbidity and relapse. Plast Reconstr Surg
2006;118:1585–97
Not fibrin sealant
Brady AP, Malone DE, Deignan RW, O’Donovan N, McGrath FP. Fibrin sealant in interventional
radiology: a preliminary evaluation. Radiology 1995;196:573–8
Not a comparative
observational study
Brady AP, Malone DE, Tam P, McGrath FP. Closure of a duodenal fistula with fibrin sealant.
J Vasc Interv Radiol 1993;4:525–7
No comparison group
Braga Ade F, Rousselet MS, Zambelli H, Sbragia L, Barini R. [Anesthesia for intrauterine
myelomeningocele correction: case report.] Rev Bras Anestesiol 2005;55:329–35
No comparison group
Brandão RA, Costa BS, Dellaretti MA, de Carvalho GT, Faria MP, de Sousa AA. Efficacy and
safety of a porcine collagen sponge for cranial neurosurgery: a prospective case-control study.
World Neurosurg 2013;79:544–50
Not fibrin sealant
Breda A, Stepanian SV, Lam JS, Liao JC, Gill IS, Colombo JR, et al. Use of haemostatic agents
and glues during laparoscopic partial nephrectomy: a multi-institutional survey from the United
States and Europe of 1347 cases. Eur Urol 2007;52:798–803
Not a comparative
observational study
Brega Massone PP, Magnani B, Conti B, Lequaglie C, Cataldo I. Cauterization versus fibrin glue
for aerostasis in precision resections for secondary lung tumors. Ann Surg Oncol 2003;10:441–6
No adverse effects
related to fibrin reported
Breugem SJM, Rijcken THP, Albers GHR. Recurrent hemarthrosis after total knee arthroplasty
caused by pseudoaneurysm. Curr Orthop Pract 2011;22:382–4
No comparison group
Briceño J, Naranjo A, Ciria R, Díaz-Nieto R, Sánchez-Hidalgo JM, Luque A, et al. A prospective
study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver
resection. Arch Surg 2010;145:482–8
No adverse effects
related to fibrin reported
Briones-Estebanez JL, Zaragoza-Garcia JM, Martinez-Parreno C, Al-Raies Bolanos B, Plaza-Martinez A,
Blanes-Mompo JI, et al. The treatment of iatrogenic pseudoaneurysms: a comparison of the
ultrasound compression technique with the ultrasound-guided injection of human thrombin.
Angiologia 2006;58:445–50
Not surgery
Brolin RE, Lin JM. Treatment of gastric leaks after Roux-en-Y gastric bypass: a paradigm shift.
Surg Obes Relat Dis 2013;9:229–33
Not surgery
Brountzos EN, Malagari K, Papathanasiou MA, Gougoulakis A, Kelekis DA. Internal iliac artery
aneurysm embolization with fibrin sealant: a simple and effective solution. Cardiovasc Intervent
Radiol 2003;26:76–80
No comparison group
Brown JA, Hubosky SG, Gomella LG, Strup SE. Hand assisted laparoscopic partial nephrectomy
for peripheral and central lesions: a review of 30 consecutive cases. J Urol 2004;171:1443–6
No comparison group
Brown NE, Grundfast KM, Jabre A, Megerian CA, O’Malley BW, Rosenberg SI. Diagnosis and
management of spontaneous cerebrospinal fluid-middle ear effusion and otorrhea.
Laryngoscope 2004;114:800–5
Not a valid comparison
Bruck HG. Fibrin tissue adhesion and its use in rhytidectomy: a pilot study. Aesthetic Plast Surg
1982;6:197–202
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Brückner M, Grimm H, Nam VC, Soehendra N. Endoscopic treatment of a pancreatic abscess
originating from biliary pancreatitis. Surg Endosc 1990;4:227–9
No comparison group
Bruner JP, Richards WO, Tulipan NB, Arney TL. Endoscopic coverage of fetal myelomeningocele
in utero. Am J Obstet Gynecol 1999;180:153–8
No comparison group
Bruns J, Klima H. [Osteochondritis dissecans of the knee joint. Results of follow-up.] Z Orthop
Ihre Grenzgeb 1993;131:413–19
Included children
Buchanan GN, Bartram CI, Phillips RK, Gould SW, Halligan S, Rockall TA, et al. Efficacy of fibrin
sealant in the management of complex anal fistula: a prospective trial. Dis Colon Rectum
2003;46:1167–74
No comparison group
Buckley RC, Breazeale EE, Edmond JA, Brzezienski MA. A simple preparation of autologous
fibrin glue for skin-graft fixation. Plast Reconstr Surg 1999;103:202–6
No comparison group
Buda A, Fruscio R, Pirovano C, Signorelli M, Betti M, Milani R. The use of TachoSil for the
prevention of postoperative complications after groin dissection in cases of gynecologic
malignancy. Int J Gynaecol Obstet 2012;117:217–19
No adverse effects
related to fibrin reported
Buda A, Pirovano C, Fruscio R, Betti M, Cuzzocrea M, Dell’Orto F, et al. Tachosil patch for
the prevention of postoperative complications after inguinofemoral lymphadenectomy in
gynecological malignancy: a single institution case-control study. Ital J Gynaecol Obstet
2011;23:133–8
No adverse effects
related to fibrin reported
Buda A, Pirovano C, Giuliani D, Signorelli M, Lissoni AA, Chiappa V, et al. Tachosil patch
plus surgical clips for prevention of postoperative complications after inguinofemoral
lymphadenectomy for vulvar cancer: a single institution experience. Int J Gynecol Cancer
2011;21(Suppl. 3):S894
No adverse effects
related to fibrin reported
Bulajic P, Savic N, Djordjevic Z, Kecmanovic D, Bulajic M, Milicevic M, et al. Role of autologous
fibrin tissue adhesive in abdominal surgery. Acta Chir Iugosl 1999;46:43–5
Not a comparative
observational study
Bulbuller et al. 201392 RCT
Bullocks JM, Echo A, Guerra G, Stal S, Yuksel E. A novel autologous scaffold for diced-cartilage
grafts in dorsal augmentation rhinoplasty. Aesthetic Plast Surg 2011;35:569–79
No comparison group
Burnouf T, Chen TM, Tsai JC. A novel technique combining single-donor platelet gel and fibrin
glue with skin graft to heal recalcitrant lower extremity ulcers. Vox Sanguinis 2010;99:264
No comparison group
Busuttil RW. A comparison of antifibrinolytic agents used in hemostatic fibrin sealants. J Am
Coll Surg 2003;197:1021–8
Not a comparative
observational study
Butler CE. Treatment of refractory donor-site seromas with percutaneous instillation of fibrin
sealant. Plast Reconstr Surg 2006;117:976–85
No comparison group
Bylund JR, Clark CJ, Crispen PL, Lagrange CA, Strup SE. Hand-assisted laparoscopic partial
nephrectomy without formal collecting system closure: perioperative outcomes in 104
consecutive patients. J Endourol 2011;25:1853–7
No comparison group
Byrne DJ, Hardy J, Wood RA, McIntosh R, Hopwood D, Cuschieri A. Adverse influence of fibrin
sealant on the healing of high-risk sutured colonic anastomoses. J R Coll Surg Edinb
1992;37:394–8
Not fibrin sealant
Byun CS, Hwang JJ, Choi JH. Single-incision vats bullectomy with suture-lift method in primary
spontaneous pneumothorax. Innovations 2013;8:145–6
No comparison group
Caccavale A, Romanazzi F, Imparato M, Negri A, Porta A, Ferentini F. Ropivacaine for topical
anesthesia in pterygium surgery with fibrin glue for conjunctival autograft. Cornea 2010;29:375–6
No comparison group
Cachaldora-del Rio JA, Hernandez-Lahoz Ortiz I, Sanchez-Abuin J, Rielo-Arias FJ, Gallegos-Vidal M,
Fernandez-Fernandez JC, et al. Treatment of iatrogenic arterial pseudoaneurysms with human
thrombin injections. Angiologia 2002;54:390–6
No comparison group
Caers J, Reekmans A, Jochmans K, Naegels S, Mana F, Urbain D, et al. Factor V inhibitor after
injection of human thrombin (tissucol) into a bleeding peptic ulcer. Endoscopy 2003;35:542–4
No comparison group
Calabrò B, Ponsetto M, Greco R, Peradotto F, Personnettaz E, Obialero M. [Treatment of leg
ulcers with fibrin glue.] Minerva Chir 1995;50:569–74
Not surgery
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Calado E, Ayres-de-Campos D. Premature rupture of membranes at 20 weeks: report of a
successful outcome after transcervical application of fibrin glue. Fetal Diagn Ther 2007;22:14–17
No comparison group
Caldas Neto S, Oliveira RL, Caldas N. Use of in fibrin glue in the prevention of postoperative
bleeding and hematomas after septoplasty. Rev Bras Otorrinolaringol 2002;68:635–8
RCT
Callari C, Perretta S, Diana M, Dagostino J, Dallemagne B, Marescaux J. Multimedia
manuscript. Thoracoscopic management of chylothorax after esophagectomy. Surg Endosc
2012;26:1160
Not fibrin sealant
Cambal et al. 2012175 RCT
Campanelli G, Champault G, Pascual MH, Hoeferlin A, Kingsnorth A, Rosenberg J, et al.
Randomized, controlled, blinded trial of Tissucol/Tisseel for mesh fixation in patients
undergoing Lichtenstein technique for primary inguinal hernia repair: rationale and study
design of the TIMELI trial. Hernia 2008;12:159–65
RCT
Campanelli et al. 2012176 RCT
Campanelli G, Sfeclan C, Cavalli M, Biondi A. Reducing postoperative pain: the use of Tisseel
for mesh fixation in inguinal hernia repair. Surg Technol Int 2012;22:134–9
RCT
Campbell ML, Abboud EC, Dolberg ME, Sanchez JE, Marcet JE, Rasheid SH. Treatment of
refractory perianal fistulas with ligation of the intersphincteric fistula tract: preliminary results.
Am Surg 2013;79:723–7
No comparison group
Campos F, Fujio S, Sugata S, Tokimura H, Hanaya R, Bohara M, et al. Effect of thrombin
concentration on the adhesion strength and clinical application of fibrin glue-soaked sponge.
Neurol Med Chir (Tokyo) 2013;53:17–20
No comparison group
Campos JM, Pereira EF, Evangelista LF, Siqueira L, Neto MG, Dib V, et al. Gastrobronchial
fistula after sleeve gastrectomy and gastric bypass: endoscopic management and prevention.
Obes Surg 2011;21:1520–9
No comparison group
Campos JM, Siqueira LT, Meira MR, Ferraz AA, Ferraz EM, Guimaraes MJ. Gastrobronchial
fistula as a rare complication of gastroplasty for obesity: a report of two cases. J Bras Pneumol
2007;33:475–9
No comparison group
Canby-Hagino ED, Morey AF, Jatoi I, Perahia B, Bishoff JT. Fibrin sealant treatment of splenic
injury during open and laparoscopic left radical nephrectomy. J Urol 2000;164:2004–5
No comparison group
Canonico S, Benevento R, Della Corte A, Fattopace A, Canonico R. Sutureless tension-free
hernia repair with human fibrin glue (Tissucol) in soccer players with chronic inguinal pain:
initial experience. Int J Sports Med 2007;28:873–6
No comparison group
Canonico S, Benevento R, Perna G, Guerniero R, Sciaudone G, Pellino G, et al. Sutureless
fixation with fibrin glue of lightweight mesh in open inguinal hernia repair: effect on
postoperative pain: a double-blind, randomized trial versus standard heavyweight mesh.
Surgery 2013;153:126–30
RCT
Canonico S, Pacifico F, Santoriello A. The prophylaxis of haemocoagulative complications after
prosthetic surgery of inguinal hernias. Chirurgia 1995;8:88–92
No adverse effects
related to fibrin reported
Canonico S, Santoriello A, Campitiello F, Fattopace A, Corte AD, Sordelli I, et al. Mesh fixation
with human fibrin glue (Tissucol) in open tension-free inguinal hernia repair: a preliminary
report. Hernia 2005;9:330–3
No comparison group
Canonico et al. 1999177 RCT
Canziani M, Agrusti S, Bertocchi V, Cavalli M, Campanelli G, Cavaliere D, et al. The tailored
surgery in incisional hernia repair. Eur Surg Res 2010;45(3–4):168
Abstract
Canziani M, Frattini F, Cavalli M, Agrusti S, Somalvico F, Campanelli G. Sutureless mesh fibrin
glue incisional hernia repair. Hernia 2009;13:625–9
No comparison group
Cappabianca P. The awake endoscope-guided sealant technique with fibrin glue in the
treatment of postoperative cerebrospinal fluid leak after extended transsphenoidal surgery:
technical note. World Neurosurg 2014;82:e479–85
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Cappabianca P, Cavallo LM, Valente V, Romano I, D’Enza AI, Esposito F, et al. Sellar repair with
fibrin sealant and collagen fleece after endoscopic endonasal transsphenoidal surgery. Surg
Neurol 2004;62:227–33
Fibrin was used in both
groups
Cappabianca P, Esposito F, Cavallo LM, Messina A, Solari D, di Somma LG, et al. Use of equine
collagen foil as dura mater substitute in endoscopic endonasal transsphenoidal surgery. Surg
Neurol 2006;65:144–8
No comparison group
Capussotti L, Ferrero A, Viganò L, Sgotto E, Muratore A, Polastri R. Bile leakage and liver
resection: where is the risk? Arch Surg 2006;141:690–4
Included children
Carbon RT, Baar S, Waldschmidt J, Huemmer HP, Simon SI. Innovative minimally invasive
pediatric surgery is of therapeutic value for splenic injury. J Pediatr Surg 2002;37:1146–50
Included children
Cardillo G, Carbone L, Carleo F, Batzella S, Jacono RD, Lucantoni G, et al. Tracheal lacerations
after endotracheal intubation: a proposed morphological classification to guide non-surgical
treatment. Eur J Cardiothorac Surg 2010;37:581–7
No comparison group
Cardillo et al. 201241 RCT
Cardillo G, Galetta D, van Schil P, Zuin A, Filosso P, Cerfolio RJ, et al. Completion
pneumonectomy: a multicentre international study on 165 patients. Eur J Cardiothorac Surg
2012;42:405–9
RCT
Carey JN, Sheckter CC, Watt AJ, Lee GK. Intra-abdominal pedicled rectus abdominis muscle
flap for treatment of high-output enterocutaneous fistulae: case reports and review of
literature. J Plast Reconstr Aesthet Surg 2013;66:1145–8
No comparison group
Carini M, Serni S, Lapini A, Selli C, Menchi I. Endoscopic treatment of refluxing ureteric stump
following nephrectomy with Tissucol and teflon injection. Eur Urol 1989;16:312–14
No comparison group
Carlson et al. 200894 RCT
Carter et al. 2003229 RCT
Carter G, Goss AN, Lloyd J, Tocchetti R. Local haemostasis with autologous fibrin glue
following surgical enucleation of a large cystic lesion in a therapeutically anticoagulated
patient. Br J Oral Maxillofac Surg 2003;41:275–6
No comparison group
Carter et al. 201381 No comparison group
Caruso A, Manta R, Melotti G, Conigliaro R. Endoscopic treatment of a large post-surgical
fistula using combined fibrin glue spray and vicryl mesh. Dig Liver Dis 2012;44:85–6
No comparison group
Casarotto A, Militello V, Piatto G, Gruppo M, Militello C. Hernioplasty in elderly high-risk
adults: efficacy of fibrin glue. J Am Geriatr Soc 2012;60:1193–4
Letter/commentary/reply
Casas VE, Kheirkhah A, Blanco G, Tseng SC. Surgical approach for scleral ischemia and melt.
Cornea 2008;27:196–201
Not a valid comparison
Casella G, Soricelli E, Rizzello M, Trentino P, Fiocca F, Fantini A, et al. Nonsurgical treatment of
staple line leaks after laparoscopic sleeve gastrectomy. Obes Surg 2009;19:821–6
Duplicate
Cavallini M, Tallerini A, Stipa F. [Occlusion of the duct with a fibrin glue and preservation of the
pylorus after resection of the duodenum and head of the pancreas for periampullary
carcinoma.] Minerva Chir 1991;46:733–9
No comparison group
Cavallo LM, Messina A, Esposito F, de Divitiis O, Dal Fabbro M, de Divitiis E, et al. Skull base
reconstruction in the extended endoscopic transsphenoidal approach for suprasellar lesions.
J Neurosurg 2007;107:713–20
No comparison group
Cavallo LM, Solari D, Somma T, Di Somma A, Chiaramonte C, Cappabianca P. Use of equine
pericardium sheet (LYOMESH) as dura mater substitute in endoscopic endonasal
transsphenoidal surgery. Transl Med USA 2013;7:23–8
No comparison group
Cavallo LM, Solari D, Somma T, Savic D, Cappabianca P. The awake endoscope-guided sealant
technique with fibrin glue in the treatment of postoperative cerebrospinal fluid leak after
extended transsphenoidal surgery: technical note. World Neurosurg 2014;82:e479–85
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Ceccarelli G, Casciola L, Pisanelli MC, Bartoli A, Di Zitti L, Spaziani A, et al. Comparing fibrin
sealant with staples for mesh fixation in laparoscopic transabdominal hernia repair: a case
control-study. Surg Endosc 2008;22:668–73
No adverse effects
related to fibrin reported
Cecchi M, Sepich CA, Pagni G, Ippolito C, Minervini R, Fiorentini L. Painless treatment of
hydrocele: EMLA cream anaesthesia and fibrin adhesive sclerotherapy. Int Urol Nephrol
1997;29:457–9
No comparison group
Cederholm-Williams SA. Benefits of adjuvant fibrin glue in skin grafting. Med J Aust
1994;161:575
Letter/commentary/reply
Cederholm-Williams SA, Dean MG, Nicholls MD. Benefits of adjuvant fibrin glue in skin
grafting. Med J Aust 1994;161:575
Duplicate
Cedin AC, Fujita R, Cruz OL. Endoscopic transeptal surgery for choanal atresia with a stentless
folded-over-flap technique. Otolaryngol Head Neck Surg 2006;135:693–8
No comparison group
Celia A, Zeccolini G, Guazzoni G, Pansadoro V, Disanto V, Porpiglia F, et al. Laparoscopic
nephron sparing surgery: a multi-institutional European survey of 592 cases. Arch Ital Urol
Androl 2008;80:85–91
No comparison group
Celiento M, Scioti G, Pratali S, Bortolotti U. Repair of coronary artery perforation following
angioplasty using TachoSil patches. Interact Cardiovasc Thorac Surg 2010;10:328–30
No comparison group
Cellier C, Landi B, Faye A, Wind P, Frileux P, Cugnenc PH, et al. Upper gastrointestinal tract
fistulae: endoscopic obliteration with fibrin sealant. Gastrointest Endosc 1996;44:731–3
No comparison group
Cellini C, Manta R, Caruso A, Mirante VG, Bertani H, Manno M, et al. Endoscopic treatment of
post-surgical gastrointestinal fistulas: experience of a tertiary referral centre. Dig Liver Dis
2014;46:S139
Not a valid comparison
Cennamo V, Fuccio L, Giampalma E, Terzi E, Eusebi LH, Mosconi C, et al. Choledochoscope-assisted
percutaneous fibrin glue sealing of bile leak complicating transarterial chemoembolization of
hepatocellular carcinoma after liver transplantation. Endoscopy 2011;43(Suppl. 2):E238–9
No comparison group
Cerfolio RJ, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Postoperative chylothorax.
J Thorac Cardiovasc Surg 1996;112:1361–5
No comparison group
Cernea CR, Hojaij FC, De Carlucci D Jr, Tavares MR, Araujo-Filho VJ, Silva-Filho GB, et al.
Abdominal compression: a new intraoperative manoeuver to detect chyle fistulas during left
neck dissections that include level IV. Head Neck 2012;34:1570–3
No comparison group
Cerný M, Havlícek K, Sákra L, Flasar J. [Massive hemothorax following canylation of the
subcalvian vein – a case review.] Rozhl Chir 2008;87:376–9
No comparison group
Cerwenka H, Bacher H, Werkgartner G, El-Shabrawi A, Mischinger HJ. Massive liver
haemorrhage and rupture caused by HELLP-syndrome treated by collagen fleeces coated with
fibrin glue. Eur J Surg 1998;164:709–11
No comparison group
Cesana G, Olmi S, Croce E. Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair
versus classical inguinotomic repair: a randomized study. Surg Endosc 2011;25:S7
RCT
Cestaro G, De Rosa M, Gentile M. Treatment of fistula in ano with fibrin glue: preliminary
results from a prospective study. Minerva Chir 2014;69:225–8
RCT
Cha HG, Kang SG, Shin HS, Kang MS, Nam SM. Does fibrin sealant reduce seroma after
immediate breast reconstruction utilizing a latissimus dorsi myocutaneous flap? Arch Plast Surg
2012;39:504–8
No adverse effects
related to fibrin reported
Cha HS, Kim A, Nowzari H, Chang HS, Ahn KM. Simultaneous sinus lift and implant
installation: prospective study of consecutive two hundred seventeen sinus lift and four
hundred sixty-two implants. Clin Implant Dent Relat Res 2014;16:337–47
Not fibrin sealant
Chabok SY, Safaie M, Ashraf A, Emamhadi M, Behzadnia H, Alijani B, et al. Effect of fat graft
on dural tear repair in lumbar spine laminectomy surgery. Neurosurg Q 2014;24:1–4
Not a valid comparison
Chalmers et al. 2010198 RCT
continued
DOI: 10.3310/hta20940 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 94
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157
TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Chan K, Dickinson J. Surgical results following full-thickness skin grafting with tisseel in the
periocular region-cosmetic outcomes and incidence of complications. Clin Experiment
Ophthalmol 2013;41:88
No comparison group
Chan et al. 2014178 RCT
Chapman WC, Clavien P, Fung JJ, Block JE. Managing hepatic bleeding with autologous
plasma/collagen-based fibrin sealant. Arch Surg 2001;136:967
Letter/commentary/reply
Chapman et al. 200067 RCT
Chartrand C, Dumont L, Stanley P. Value of fibrin sealant in heart transplantation. Transplant
Proc 1989;21:3347–8
Not in humans
Chawla B, Tandon R. Sutureless amniotic membrane fixation with fibrin glue in symptomatic
bullous keratopathy with poor visual potential. Eur J Ophthalmol 2008;18:998–1001
No comparison group
Chen ML, Tomaszewski JJ, Matoka DJ, Ost MC. Management of urine leak after laparoscopic
cyst decortication with retrograde endoscopic fibrin glue application and ureteral stent
placement. J Endourol 2011;25:71–4
No comparison group
Chen RJ, Fang JF, Lin BC, Hsu YB, Kao JL, Kao YC, et al. Selective application of laparoscopy
and fibrin glue in the failure of nonoperative management of blunt hepatic trauma. J Trauma
1998;44:691–5
No comparison group
Chen TM, Tsai JC, Burnouf T. A novel technique combining platelet gel, skin graft, and fibrin
glue for healing recalcitrant lower extremity ulcers. Dermatol Surg 2010;36:453–60
No comparison group
Chen WL, Huang ZQ, Chai Q, Zhang DM, Wang YY, Wang HJ, et al. Percutaneous
sclerotherapy of massive macrocystic lymphatic malformations of the face and neck using fibrin
glue with OK-432 and bleomycin. Int J Oral Maxillofac Surg 2011;40:572–6
Included children
Chen WL, Huang ZQ, Li JS, Chai Q, Zhang DM. Percutaneous sclerotherapy of juvenile
nasopharyngeal angiofibroma using fibrin glue combined with OK-432 and bleomycin. Int J
Pediatr Otorhinolaryngol 2010;74:422–5
No comparison group
Chen WL, Huang ZQ, Zhang DM, Chai Q. Percutaneous sclerotherapy of massive venous
malformations of the face and neck using fibrin glue combined with OK-432 and
pingyangmycin. Head Neck 2010;32:467–72
No comparison group
Chen WL, Zhang LP, Huang ZQ, Zhou B. Percutaneous sclerotherapy of sialoceles after
parotidectomy with fibrin glue, OK-432, and bleomycin. Br J Oral Maxillofac Surg
2013;51:786–8
No comparison group
Cheng HT, Hsu YC, Wu CI. Quilting sutures, fibrin tissue adhesive or both in reducing the
incidence of seroma in the latissimus dorsi flap donor site? An evidence-based analysis. J Plast
Reconstr Aesthet Surg 2014;67:881–2
Letter/commentary/reply
Chernousov AF, Khororykh TV, Urzhumtseva GA, Urakova IaCh. [Endoscopic hemostasis of
erosive-ulcerous gastroduodenal bleeding with fibrin glue at critically ill patients.] Khirurgiia
2006;8:17–20
No comparison group
Chi JH, Sughrue M, Kunwar S, Lawton MT. The ‘yo-yo’ technique to prevent cerebrospinal fluid
rhinorrhea after anterior clinoidectomy for proximal internal carotid artery aneurysms.
Neurosurgery 2006;59:ONS–101
No comparison group
Chin Ai, Ragavendra N, Hilborne L, Gritsch HA. Fibrin sealant sclerotherapy for treatment of
lymphoceles following renal transplantation. J Urol 2003;170:380–3
No comparison group
Chin CJ, Kus L, Rotenberg BW. Use of duraseal in repair of cerebrospinal fluid leaks.
J Otolaryngol Head Neck Surg 2010;39:594–9
Letter/commentary/reply
Chirletti P, Caronna R, Fanello G, Schiratti M, Stagnitti F, Peparini N, et al.
Pancreaticojejunostomy with application of fibrinogen/thrombin-coated collagen patch
(TachoSil) in Roux-en-Y reconstruction after pancreaticoduodenectomy. J Gastrointest Surg
2009;13:1396–8
Letter/commentary/reply
Chisholm RA, Jones SN, Lees WR. Fibrin sealant as a plug for the post liver biopsy needle track.
Clin Radiol 1989;40:627–8
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Cho JM, Ahn JY, Chang JH, Kim SH. Prevention of cerebrospinal fluid rhinorrhea after
transsphenoidal surgery by collagen fleece coated with fibrin sealant without autologous tissue
graft or postoperative lumbar drainage. Neurosurgery 2011;68(Suppl.):130–6
No comparison group
Cho S, Huh DM, Kim BH, Lee S, Kwon OC, Ahn WS, et al. Staple line covering procedure after
thoracoscopic bullectomy for the management of primary spontaneous pneumothorax. Thorac
Cardiovasc Surg 2008;56:217–20
No comparison group
Cho S, Ryu KM, Jheon S, Sung SW, Kim BH, Huh DM. Additional mechanical pleurodesis after
thoracoscopic wedge resection and covering procedure for primary spontaneous pneumothorax.
Surg Endosc 2009;23:986–90
Not a valid comparison
Choi et al. 2010244 No comparison group
Chou D, Cheng J, Chesnut R, Choudhri H, Gopinath S, Scott Graham R, et al. A prospective,
multi-center, randomized controlled study to compare a low swell formulation of a PEG
hydrogel spinal sealant as an adjunct to sutured dural repair with common dural sealing
methods. Spine J 2010;10:80S
RCT
Chou D, Wang VY, Khan AS. Primary dural repair during minimally invasive microdiscectomy
using standard operating room instruments. Neurosurgery 2009;64(Suppl. 2):356–8
No comparison group
Choudhari NS, Neog A, Sharma A, Iyer GK, Srinivasan B. Our experience of fibrin sealant-assisted
implantation of Ahmed glaucoma valve. Indian J Ophthalmol 2013;61:23–7
No comparison group
Choufani et al. 2015151 RCT
Chouillard EK, Fingerhut AL. Sutureless repair of bronchial tears using fibrin sealant-reinforced
Vicryl bridge. ANZ J Surg 2006;76:419
Letter/commentary/reply
Christenson JT, Kalangos A. Autologous fibrin glue reinforced by platelets in surgery of
ascending aorta. Thorac Cardiovasc Surg 2004;52:225–9
RCT
Christine B, Carson CC. The use of adjunct hemostatic agents during peyronie’s plaque incision
and grafting: Less frequent complications secondary to hematoma formation at the site of the
graft may be possible. J Sex Med 2012;9:28
Not a valid comparison
Chryssagis K, Klugl S, Liangos A, Gutleben KJ, Brachmann J, Diegeler A. Surgical feasibility of
the injection of fibrin sealant in cardiac fat pads to reduce the incidence of postoperative atrial
fibrillation after coronary artery bypass grafting or valve surgery a pilot study. Innovations
2008;3:151–4
No comparison group
Chu W, Chien GW, Finley DS. Novel ureteroscopic technique for treatment of prolonged
caliceal leak after partial nephrectomy. J Endourol 2015;29:397–400
No comparison group
Chung HW, Mehta JS. Fibrin glue for Gundersen flap surgery. Clin Ophthalmol 2013;7:479–84 No comparison group
Chung SG, Lee SY, Kim W. Treatment of lateral epicondylitis using allogeneic adipose-derived
mesenchymal stem cells. PMR 2014;6(Suppl. 1):177
RCT
Chung W, Ko D, Sun C, Raval MJ, Brown CJ, Phang PT. Outcomes of anal fistula surgery in
patients with inflammatory bowel disease. Am J Surg 2010;199:609–13
No adverse effects
related to fibrin reported
Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa
(NovoSeven) in the treatment of two patients with type III von Willebrand’s disease and an
inhibitor against von Willebrand factor. Haemostasis 1996;26(Suppl. 1):150–4
No comparison group
Cintron JR, Park JJ, Orsay CP, Pearl RK, Nelson RL, Abcarian H. Repair of fistulas-in-ano using
autologous fibrin tissue adhesive. Dis Colon Rectum 1999;42:607–13
No comparison group
Cipolla et al. 2010110 RCT
Citardi MJ, Cox AJ 3rd, Bucholz RD. Acellular dermal allograft for sellar reconstruction after
transsphenoidal hypophysectomy. Am J Rhinol 2000;14:69–73
No comparison group
Ciurtin DH, Maghiar AM, Sfirlea M, Sookha PR, Suta A, Purza A, et al. Intraoperative
complications in laparoscopic cholecystectomy. Surg Endosc 2011;25:S119
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Clajus C, Stockhammer F, Rohde V. The intra- and postoperative management of accidental
durotomy in lumbar spine surgery: results of a German survey. Acta Neurochir
2015;157:525–30
Not a comparative
observational study
Cleaveland P, Tang V, Pollard A, Adeyoju A. Management of a patient with a chronic
nephrocutaneous fistula after partial nephrectomy using a novel technique. Int J Urol
2015;22:232–3
No comparison group
Cocero N, Pucci F, Messina M, Pollio B, Mozzati M, Bergamasco L. Autologous plasma rich in
growth factors in the prevention of severe bleeding after teeth extractions in patients with
bleeding disorders: a controlled comparison with fibrin glue. Blood Transfus 2015;13:287–94
RCT
Codispoti M, Mankad PS. Significant merits of a fibrin sealant in the presence of coagulopathy
following paediatric cardiac surgery: randomised controlled trial. Eur J Cardiothorac Surg
2002;22:200–5
RCT
Coenen VA, Gilsbach JM. Effect of arachnoid plasty using fibrin glue membrane after clipping
of ruptured aneurysm on the occurrence of complications and outcome in the elderly patients:
commentary. Acta Neurochir 2006;148:631
Letter/commentary/reply
Cohen I, Heim M, Martinowitz U, Chechick A. Orthopaedic outcome of total knee replacement
in haemophilia A. Haemophilia 2000;6:104–9
No comparison group
Cohen J, Jayram G, Mullins JK, Ball MW, Allaf ME. Do fibrin sealants impact negative outcomes
after robot-assisted partial nephrectomy? J Endourol 2013;27:1236–9
No adverse effects
related to fibrin reported
Cohen-Gadol AA, Bellew MP, Akard W, Payner TD. The application of n-butyl 2-cyanoacrylate
to repair CSF fistulas for 221 patients who underwent transsphenoidal surgery. Minim Invasive
Neurosurg 2010;53:207–9
Not fibrin sealant
Cohen-Gadol AA, Mokri B, Piepgras DG, Meyer FB, Atkinson JL. Surgical anatomy of dural defects
in spontaneous spinal cerebrospinal fluid leaks. Neurosurgery 2006;58(Suppl. 4):ON238–45
Not fibrin sealant
Colm SJ. The use of a fibrin sealant to control intraoperative bleeding during a Le Fort I
osteotomy: report of a case. J Oral Maxillofac Surg 1996;54:1014–16
No comparison group
Conboy P, Brown DH. Use of tissue sealant for day surgery parotidectomy. J Otolaryngol Head
Neck Surg 2008;37:208–11
No comparison group
Conde SM, Aguilar LT, Moreno AB, Macias MS, Garcia DM, Borrero IS, et al. A new technique
for laparoscopic ventral hernia repair: double crown with one /third of tackers and fibrin glue.
Surg Endosc 2011;25:S6
No comparison group
Copurog˘lu C, Ercan S, Ozcan M, Ciftdemir M, Turan FN, Yalniz E. Comparison of autogenous
bone graft donor site haemostatic agents used in spinal surgery. Acta Orthop Traumatol Turc
2011;45:359–64
RCT
Coral-Ghanem R, Oliveira RF, Furlanetto E, Ghanem MA, Ghanem VC. [Conjunctival autologous
transplantation using fibrin glue in primary pterygium.] Arq Bras Oftalmol 2010;73:350–3
No adverse effects
related to fibrin reported
Cormio L, Perrone A, Pentimone S, Selvaggio O, Lorusso F, Di Fino G, et al. Tachosil-sealed
tubeless percutaneous nephrolithotomy in supine antero-lateral position: a prospective study.
Eur Urol Suppl 2010;9:35
RCT
Correa ME, Annicchino-Bizzacchi JM, Jorge J, Paes de Almeida O, Ozelo MC, Aranha FJ, et al.
Clinical impact of oral health indexes in dental extraction of hemophilic patients. J Oral
Maxillofac Surg 2006;64:785–8
No comparison group
Cothren CC, McIntyre RC, Johnson S, Stiegmann GV. Management of low-output pancreatic
fistulas with fibrin glue. Am J Surg 2004;188:89–91
No comparison group
Crawford RW, Giangrande P, Murray D. Fibrin sealant reduces blood loss in total hip
arthroplasty. Hip Int 1999;9:127–32
No adverse effects
related to fibrin reported
Crul BJ, Gerritse BM, van Dongen RT, Schoonderwaldt HC. Epidural fibrin glue injection stops
persistent postdural puncture headache. Anesthesiology 1999;91:576–7
No comparison group
Curcio G, Badas R, Miraglia R, Barresi L, Tarantino I, Traina M. Duodenal stump fistula
following Roux-en-Y gastrectomy, treated with single-balloon enteroscopy using the tulip
bundle technique and fibrin glue injection. Endoscopy 2012;44(Suppl 2 UCTN):E364–5
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Czepko R, Kwinta B. [The use of TachoComb for the rhinorrhea repair in pituitary
transsphenoidal surgery.] Polim Med 2006;36:3–9
No adverse effects
related to fibrin reported
Czerny et al. 2000205 RCT
Dadeya S, Ms K. Strabismus surgery: fibrin glue versus vicryl for conjunctival closure. Acta
Ophthalmol Scand 2001;79:515–17
Included children
Dagnini G, Caldironi MW, Marin G, Patella M. Fibrin sponge plugging of hemorrhage from
laparoscopic biopsy. Gastrointest Endosc 1985;31:35–6
Technical note
Dal Pizzol MM, Roggia MF, Kwitko S, Marinho DR, Rymer S. [Use of fibrin glue in ocular
surgery.] Arq Bras Oftalmol 2009;72:308–12
No comparison group
Damiano et al. 2014184 RCT
D’Andrea AA, Costantino V, Sperti C, Pedrazzoli S. Human fibrin sealant in pancreatic surgery:
it is useful in preventing fistulas? A prospective randomized study. Ital J Gastroenterol
1994;26:283–6
RCT
Daneshrad P, Chin GY, Rice DH. Fibrin glue prevents complications of septal surgery: findings in
a series of 100 patients. Ear Nose Throat J 2003;82:196–7
No comparison group
D’Arcy FT, Jaffry SQ. A review of 100 consecutive Sutureless child and adult circumcisions. Ir J
Med Sci 2011;180:51–3
No comparison group
Darnis E, Mutungwa I, Guillaume M, Pagneux JM. Conization with fibrin sealant: retrospective
study of 150 cases. Ref Gynecol Obstet 2002;9:60–5
No comparison group
Datta D, Vlavianos P, Alisa A, Westaby D. Use of fibrin glue (beriplast) in the management of
bleeding gastric varices. Endoscopy 2003;35:675–8
No comparison group
Dattola A, Alberti A, Parisi A, Maccarone P, Dattola P, Celi S, et al. [Minimally invasive
percutaneous ultrasonography-guided treatment of postoperative splenic abscess. Personal
experience with 5 clinical cases.] Chir Ital 1999;51:451–7
Not a valid comparison
Davis BR, Sándor GK. Use of fibrin glue in maxillofacial surgery. J Otolaryngol 1998;27:107–12 No comparison group
de Boer MT, Boonstra EA, Lisman T, Porte RJ. Role of fibrin sealants in liver surgery. Dig Surg
2012;29:54–61
Not a comparative
observational study
de Boer et al. 201266 Not a comparative
observational study
de Boer MT, Porte RJ. Reply to letter: ‘Fibrin sealants do not prevent resection surface-related
complications after liver resection’. Ann Surg 2015;261:e82–3
Not a comparative
observational study
de Boer MT, Porte RJ. Reply: Re: Fibrin sealant for prevention of resection surface-related
complications after liver resection: A randomized controlled trial. Ann Surg 2015;261:e78
RCT
de Boer MT, Porte RJ. Reply: Fibrin sealant for prevention of resection surface-related
complications after liver resection in living liver donors. Ann Surg 2015;261:e82–3
Letter/commentary/reply
de Gracia J, de la Rosa D, Catalán E, Alvarez A, Bravo C, Morell F. Use of endoscopic
fibrinogen-thrombin in the treatment of severe hemoptysis. Respir Med 2003;97:790–5
No comparison group
de Hingh IH, Nienhuijs SW, Overdevest EP, Scheele K, Everts PA. Mesh fixation with autologous
platelet-rich fibrin sealant in inguinal hernia repair. Eur Surg Res 2009;43:306–9
No comparison group
de la Garza JL, Rumsey E. Fibrin glue and hemostasis in liver trauma: a case report. J Trauma
1990;30:512–13
No comparison group
de Oca J, Del Rio C, Millan M, Fraccalvieri D, Kreisler E, Golda T, et al. Long-term results of
fibrin glue for treatment of transsphincteric perianal fistula: a prospective cohort study.
Colorectal Dis 2011;13:37
No comparison group
de Oca J, Millán M, Jiménez A, Golda T, Biondo S. Long-term results of surgery plus fibrin
sealant for anal fistula. Colorectal Dis 2012;14:e12–15
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
De Stefano A, Bettarini F, Di Mare G, Neri A. [Enteric anastomosis and Tachosil®.] Minerva Chir
2011;66:183–8
No adverse effects
related to fibrin reported
de Vries J, Menovsky T, Grotenhuis JA, van Overbeeke JJ. Protective coating of cranial nerves
with fibrin glue (Tissucol) during cranial base surgery: technical note. Neurosurgery
1998;43:1242–6
No comparison group
de Wit D, Athanasiadis I, Sharma A, Moore J. Sutureless and glue-free conjunctival autograft in
pterygium surgery: a case series. Eye 2010;24:1474–7
No comparison group
Defrere J, Franckart A. Teflon/polyurethane arthroplasty of the knee: the first 2 years
preliminary clinical experience in a new concept of artificial resurfacing of full thickness
cartilage lesions of the knee. Acta Chir Belg 1992;92:217–27
No comparison group
Delanois RE, Mont MA. Does tranexamic acid reduce blood loss in total knee arthroplasty?
Commentary on an article by X. Aguilera, MD, et al.: ‘Efficacy and safety of fibrin glue and
tranexamic acid to prevent postoperative blood loss in total knee arthroplasty. A randomized
controlled clinical trial’. J Bone Joint Surg Am 2013;95:e179
RCT
Della Corte A, Baldascino F, La Marca F, Scardone M, Nappi G, Cefarelli M, et al. Hemostatic
modifications of the Bentall procedure: imbricated proximal suture and fibrin sealant reduce
postoperative morbidity and mortality rates. Tex Heart Inst J 2012;39:206–10
No comparison group
Dello Russo N. Questions concerning the safety of the tissue adhesive (Tissucol). J Periodontol
1986;57:652
Letter/commentary/reply
Depondt J, Koka VN, Nasser T, Portier F, Guedon C, Barry B, et al. Use of fibrin glue in
parotidectomy closure. Laryngoscope 1996;106:784–7
Included children
Descottes B, Bagot d’Arc M. Fibrin sealant in inguinal hernioplasty: an observational multicentre
study in 1,201 patients. Hernia 2009;13:505–10
No comparison group
Deutsch M, Meinhart J, Zilla P, Howanietz N, Gorlitzer M, Froeschl A, et al. Long-term
experience in autologous in vitro endothelialization of infrainguinal ePTFE grafts. J Vasc Surg
2009;49:352–62
Not a valid comparison
Di Carlo I, Pulvirenti E, Toro A, Ardiri A, Bertino G. Localized fluid collection after carrier-bound
fibrin sealant application on liver: complication or proof of efficacy? A long-term clinical
observational study. Hepatogastroenterology 2011;58:937–42
No comparison group
DiMonta et al. 2012117 RCT
Di Saverio S, Masetti M, Zanello M, De Blasiis MG, Jovine E. Re: Fibrin sealant for prevention
of resection surface-related complications after liver resection: a randomized controlled trial.
Ann Surg 2015;261:e77–8
RCT
Diamond et al. 2011232 RCT
Dick B, Kohnen T, Hessemer V. Fibrin glue in temporal clear corneal tunnel incision. Eur J
Implant Refract Surg 1995;7:224–8
No comparison group
Dimaio CJ, Dorfman MP, Gardner GJ, Nash GM, Schattner MA, Markowitz AJ, et al. The use of
covered esophageal self-expanding metal Stents (CSEMS) for the management of post-operative
colo-rectal anastomotic leaks. Gastrointest Endosc 2012;75(Suppl. 1):AB425–6
No comparison group
Dimitrakakis G, Podila SR, O’Keefe PA, Kulatilake NE. Biological glue: a word of careful
assessment! Interact Cardiovasc Thorac Surg 2011;13:244–5
Letter/commentary/reply
Dimitrakakis G, von Oppell UO. The use of biological glues in cardiothoracic surgery. Interact
Cardiovasc Thorac Surg 2011;13:118
Letter/commentary/reply
Dimo et al. 198980 RCT
Diner EK, Patel SV, Kwart AM. Does fibrin sealant decrease immediate urinary leakage
following radical retropubic prostatectomy? J Urol 2005;173:1147–9
RCT
Dinsmore et al. 200097 RCT
Docimo G, Limongelli P, Conzo G, Gili S, Bosco A, Rizzuto A, et al. Axillary lymphadenectomy
for breast cancer in elderly patients and fibrin glue. BMC Surg 2013;13(Suppl. 2):8
No adverse effects
related to fibrin reported
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Dolay K, Aras B, Tug˘cu V, Ozbay B, Aygün E, Tas¸çi AI. Combined treatment of iatrogenic
rectourethral fistula with endoscopic fibrin glue application and clipping. J Endourol
2007;21:433–6
No comparison group
Dong N, Li C, Chen WS, Qin WJ, Xue YH, Wu HP. Fibrin glue-assisted for the treatment of
corneal perforations using glycerin-cryopreserved corneal tissue. Int J Ophthalmol 2014;7:62–5
No comparison group
Donnez J, Nisolle M. Laparoscopic management of large ovarian endometrial cyst: use of fibrin
sealant. J Gynecol Surg 1991;7:163–6
No adverse effects
related to fibrin reported
Dovellini EV, Taddeucci E, Trapani M, Valenti R, Cerisano G, Moschi G, et al. Pocket
haematoma prevention in patients who required implantation/replacement of a pacemaker or
implantable cardiac defibrillator. The PHP study. G Ital Cardiol 2011;12(Suppl. 1):140S
RCT
Dovellini EV, Taddeucci E, Trapani M, Valenti R, Moschi G, Cerisano G, et al. Pocket
haematoma prevention in patients who required implantation/replacement of a pacemaker or
implantable cardiac defibrillator. The PHP Study. Eur Heart J 2011;32:305
Duplicate
Doyama H, Tominaga K, Yoshida N, Takemura K, Yamada S. Endoscopic tissue shielding with
polyglycolic acid sheets, fibrin glue and clips to prevent delayed perforation after duodenal
endoscopic resection. Dig Endosc 2014;26(Suppl. 2):41–5
No comparison group
Draus JM, Huss SA, Harty NJ, Cheadle WG, Larson GM. Enterocutaneous fistula: are treatments
improving? Surgery 2006;140:570–6
No adverse effects
related to fibrin reported
Droghetti et al. 2008124 RCT
Drumheller GW. Fibrin glue. Ear Nose Throat J 2003;82:483 Letter/commentary/reply
Du J, Qiu B, Tao J, Ou S, Wang Y. Sellar reconstruction using biomaterials after transsphenoidal
surgery in 449 cases of pituitary adenomas. Neurosurg Q 2014;24:22–6
No comparison group
Du X, Guo W, Liu XP, Jia X, Zhang MH, Yin T, et al. [Treatment of type II endoleak after
abdominal aortic aneurysm endovascular repair.] Zhonghua Yi Xue Za Zhi 2011;91:2955–8
No comparison group
Duchesne B, Tahi H, Galand A. Use of human fibrin glue and amniotic membrane transplant in
corneal perforation. Cornea 2001;20:230–2
No comparison group
Dumonceau JM, Cremer M, Lalmand B, Devière J. Esophageal fistula sealing: choice of stent,
practical management, and cost. Gastrointest Endosc 1999;49:70–8
No comparison group
Ebner FM, Paul A, Peters J, Hartmann M. Venous air embolism and intracardiac thrombus after
pressurized fibrin glue during liver surgery. Br J Anaesth 2011;106:180–2
No comparison group
Edelman DS. Fibrin glue fixation of bioactive extracellular matrix mesh compared with soft
prolene mesh for laparoscopic hernia repair. Surg Laparosc Endosc Percutan Tech
2008;18:569–72
No comparison group
Edelman DS. Robotic, laparoscopic inguinal hernia repair. Surg Endosc 2015;29:S467 No comparison group
Edelman DS, Selesnick H. ‘Sports’ hernia: treatment with biologic mesh (Surgisis): a preliminary
study. Surg Endosc 2006;20:971–3
No comparison group
Eden CG, Sultana SR, Murray KH, Carruthers RK. Extraperitoneal laparoscopic dismembered
fibrin-glued pyeloplasty: medium-term results. Br J Urol 1997;80:382–9
No comparison group
Eder F, Meyer F, Nestler G, Halloul Z, Lippert H. Sealing of the hepatic resection area using
fibrin glue reduces significant amount of postoperative drain fluid. World J Gastroenterol
2005;11:5984–7
No adverse effects
related to fibrin reported
Ederle A, Scattolini C, Vantgini I, Bulighin G, Scuro LA. Human fibrin sealant in upper G.I. tract
bleeding. Endoscopy 1989;21:112
Letter/commentary/reply
Eichler C, Dahdouh F, Sauerwald A, Warm M. Seroma suppression using TissuGlu® in a
high-risk patient post-mastectomy: a case report. J Med Case Rep 2013;7:138
No comparison group
Eide E, Jurgeit H. [Use of fibrin glue in pronounced Dupuytren contracture.] Handchir Mikrochir
Plast Chir 1985;17:145–6
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
El Feghaly M, Chahine E, Abi Ghanem M, Abou Zahr O, Alayli M, Abu Khalil B. Acute limb
ischaemia due to embolisation of biological glue 45 days after surgery. Eur J Vasc Endovasc
Surg 2011;41:518–20
No comparison group
El Nakeeb A. Influence of fibrin glue on seroma formation after modified radical mastectomy: a
prospective randomized study. Breast J 2009;15:671–2
RCT
El-Banhawy OA, Halaka AN, El-Hafiz Shehab El-Dien A, Ayad H. Subcranial transnasal repair of
cerebrospinal fluid rhinorrhea with free autologous grafts by the combined overlay and
underlay techniques. Minim Invasive Neurosurg 2004;47:197–202
Included children
Elderkin SJ, Epstein RJ, Seldomridge DL. Successful treatment of recurrent epithelial ingrowth
associated with interface fluid syndrome, flap necrosis, and epithelial defects following LASIK.
J Refract Surg 2011;27:70–3
No comparison group
Eleftheriadis E, Kotzampassi K. Therapeutic fistuloscopy: an alternative approach in the
management of postoperative fistulas. Dig Surg 2002;19:230–5
Not a valid comparison
Eleftheriadis E, Tzartinoglou E, Kotzampassi K, Aletras H. Early endoscopic fibrin sealing of
high-output postoperative enterocutaneous fistulas. Acta Chir Scand 1990;156:625–8
No comparison group
El-Gazzaz G, Hull T, Mignanelli E, Hammel J, Gurland B, Zutshi M. Analysis of function and
predictors of failure in women undergoing repair of Crohn’s related rectovaginal fistula.
J Gastrointest Surg 2010;14:824–9
Not a valid comparison
Ellis DA, Pelausa EO. Fibrin glue in facial plastic and reconstructive surgery. J Otolaryngol
1988;17:74–7
Not a comparative
observational study
Ellis DA, Shaikh A. The ideal tissue adhesive in facial plastic and reconstructive surgery.
J Otolaryngol 1990;19:68–72
No adverse effects
related to fibrin reported
Ellis DA, Pelausa EO. Fibrin glue in facial plastic and reconstructive surgery. J Otolaryngol
1988;17:74–7
Duplicate
Ellis DA, Shaikh A. The ideal tissue adhesive in facial plastic and reconstructive surgery.
J Otolaryngol 1990;19:68–72
Duplicate
Eloy JA, Choudhry OJ, Friedel ME, Kuperan AB, Liu JK. Endoscopic nasoseptal flap repair of
skull base defects: is addition of a dural sealant necessary? Otolaryngol Head Neck Surg
2012;147:161–6
Not fibrin sealant
Eltorai IM, Montroy RE, Kaplan SL, Ho WH. Pneumocephalus secondary to cerebrospinal fluid
leak associated with a lumbar pressure ulcer in a man with paraplegia. J Spinal Cord Med
2003;26:262–9
No comparison group
Emmert MY, Salzberg SP, Theusinger OM, Felix C, Plass A, Hoerstrup SP, et al. How good
patient blood management leads to excellent outcomes in Jehovah’s witness patients
undergoing cardiac surgery. Interact Cardiovasc Thorac Surg 2011;12:183–8
No comparison group
Engler S, Dorlars D, Riemann JF. [Endoscopic fibrin gluing of a pancreatic duct fistula following
acute pancreatitis.] Dtsch Med Wochenschr 1996;121:1396–400
No comparison group
Enoki C, Higashi S, Oohata M, Tanaka T. [A case of acute erythroblastic anemia due to
infection with human parvovirus B19 after coronary artery bypass grafting.] Kyobu Geka
2002;55:116–19
No comparison group
Epstein NE. Wound-peritoneal shunts: part of the complex management of anterior dural
lacerations in patients with ossification of the posterior longitudinal ligament. Surg Neurol
2009;72:630–4
No comparison group
Epstein NE. Tisseel utilized as hemostatic in spine surgery impacts time to drain removal and
length of stay. Surg Neurol Int 2014;5(Suppl. 7):354–61
Not a relevant
comparison
Epstein NE. Hemostasis and other benefits of fibrin sealants/glues in spine surgery beyond
cerebrospinal fluid leak repairs. Surg Neurol Int 2014;5(Suppl. 7):304–14
Not a comparative
observational study
Erba et al. 2010210 RCT
Erbagci I, Bekir N. Sutureless closure of the conjunctiva with a commercial fibrin sealant in
extraocular muscle surgery for strabismus. Strabismus 2007;15:89–94
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Erdogan A, Gurses G, Keskin H, Demircan A. The sealing effect of a fibrin tissue patch on the
esophageal perforation area in primary repair. World J Surg 2007;31:2199–203
Emergency surgery
Erdogru T, Sanli A, Celik O, Baykara M. Laparoscopic transvesical repair of recurrent
vesicovaginal fistula using with fleece-bound sealing system. Arch Gynecol Obstet
2008;277:461–4
No comparison group
Eriksen JR. Pain and convalescence following laparoscopic ventral hernia repair. Dan Med Bull
2011;58:B4369
Not a relevant
comparison
Eriksen et al. 2013183 Not a comparative
observational study
Esposito F, Cappabianca P, Fusco M, Cavallo LM, Bani GG, Biroli F, et al. Collagen-only
biomatrix as a novel dural substitute. Examination of the efficacy, safety and outcome: clinical
experience on a series of 208 patients. Clin Neurol Neurosurg 2008;110:343–51
No comparison group
Esposito F, Grimod G, Cavallo LM, Lanterna L, Biroli F, Cappabianca P. Collagen-only biomatrix
as dural substitute: what happened after a 5-year observational follow-up study. Clin Neurol
Neurosurg 2013;115:1735–7
No comparison group
Esquenazi S, Rand W, Velazquez G, Grunstein L. Novel therapeutic approach in the
management of band keratopathy using amniotic membrane transplantation with fibrin glue.
Ophthalmic Surg Lasers Imaging 2008;39:418–21
No comparison group
Esteban F, Delgado-Rodríguez M, Mochón A, Solano J, Soldado L, Solanellas J. [Study of in-patient
hospital stay following total laryngectomy: multivariable retrospective analysis of a 442 total
laryngectomies.] Acta Otorrinolaringol Esp 2006;57:176–82
Not a relevant
comparison
Etienney I, Rabahi N, Cuenod CA, Hoffmann P, Charachon A, Bauer P. Fibrin glue sealing in the
treatment of a recto-urethral fistula in Crohn’s disease: a case report. Gastroenterol Clin Biol
2009;33:1094–7
No comparison group
Evans LA, Ferguson KH, Foley JP, Rozanski TA, Morey AF. Fibrin sealant for the management of
genitourinary injuries, fistulas and surgical complications. J Urol 2003;169:1360–2
No comparison group
Evaristo-Méndez G, Sánchez-Hernández AT, Melo-Velázquez A, Ventura-Sauceda FA,
Sepúlveda-Castro RR. [Sigmoido-buttock fistula by diverticulitis: report of a rare complication.]
Cir Cir 2013;81:158–62
No comparison group
Everts PA, Devilee RJ, Brown Mahoney C, Eeftinck-Schattenkerk M, Box HA, Knape JT, et al.
Platelet gel and fibrin sealant reduce allogeneic blood transfusions in total knee arthroplasty.
Acta Anaesthesiol Scand 2006;50:593–9
Not a relevant
comparison
Fabian et al. 2003128 RCT
Falavarjani KG, Modarres M, Foroutan A, Bakhtiari P. Fibrin glue-assisted sutureless scleral
fixation. J Cataract Refract Surg 2009;35:795
Letter/commentary/reply
Falez et al. 2013154 RCT
Falsaperla M, Autorino R, Puglisi M, Damiano R, Salerno GL, Motta M, et al. Haemostatic
agents during laparoscopic nephron-sparing surgery: what about TachoSil? BJU Int
2009;104:270–1
Letter/commentary/reply
Falworth MS, Butler PM, Powell BW. The use of fibrin glue to prevent seroma formation
following sentinel node biopsy. Plast Reconstr Surg 1999;104:2331–2
Letter/commentary/reply
Fanari M, Serra S, Corona A, De Lisa A. [Use of TachoSil in laparoscopic enucleoresection
of renal masses smaller than 4 cm: our preliminary experience of 41 cases.] Urologia
2012;79(Suppl. 19):131–3
No comparison group
Farhat F, Durand M, Delahaye F, Jegaden O. Prosthetic valve sewing-ring sealing with antibiotic
and fibrin glue in infective endocarditis. A prospective clinical study. Interact Cardiovasc Thorac
Surg 2007;6:16–20
No comparison group
Farr IJ, Cole BJ, Tabet S. Prospective study of particulated juvenile allograft cartilage to treat
knee femoral cartilage lesions. Arthroscopy 2013;29(Suppl. 1):e27
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Farrag TY, Boahene KD, Agrawal N, Turner L, Byrne PJ, Earnest L, et al. Use of fibrin sealant in
closing mucocutaneous fistulas following head and neck cancer surgery. Otolaryngol Head
Neck Surg 2007;137:159–61
No adverse effects
related to fibrin reported
Faust A, Aguillard R, Finch C. Use of fibrin glue administered during bronchoscopy to seal a
persistent bronchopleural fistula: a case report. Crit Care Med 2010;38:A266
No comparison group
Fava MA, Choi CJ, El Mollayess G, Melki SA. Sandwich fibrin glue technique for attachment of
conjunctival autograft during pterygium surgery. Can J Ophthalmol 2013;48:516–20
Not a relevant
comparison
Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local
therapy during oral surgery in patients with von Willebrand disease: effective results from a
retrospective analysis of 63 cases. Haemophilia 2000;6:71–7
Included children
Fékété et al. 199291 RCT
Felipetto R, Vigano L, Cecchi M, Florentini L, Minervini R. Use of fibrin sealant in the treatment
of prostatic cutaneous fistula in a case of Pseudomonas prostatitis. Int Urol Nephrol
1995;27:563–5
No comparison group
Feng JX, Lu QS, Jing ZP, Yang Y, Nie B, Bao JM, et al. [Fibrin glue embolization treating intra-operative
type I endoleak of endovascular repair of abdominal aortic aneurysm: long-term result.] Zhonghua
Wai Ke Za Zhi 2011;49:883–7
No comparison group
Ferlitsch A, Puspok A, Wewalka F, Schoefl R, Brownstone E, Madl C, et al. A multi-centre proof
of concept study to assess efficacy and safety of a new liquid endoscopic hemostatic agent
(Seraseal/Fastact) in patients with active gastrointestinal bleeding. Gastrointest Endosc
2014;79(Suppl. 1):AB151–2
Not fibrin sealant
Fernández Lobato R, García Septiem J, Ortega Deballon P, Martín Lucas FJ, Ruíz de Adana JC,
Limones Esteban M. Tissucol application in dermolipectomy and incisional hernia repair. Int
Surg 2001;86:240–5
RCT
Fernandez-Esparrach G, Lautz DB, Thompson CC. Peroral endoscopic anastomotic reduction
improves intractable dumping syndrome in Roux-en-Y gastric bypass patients. Surg Obes Relat
Dis 2010;6:36–40
No comparison group
Fernandez-Lobato R, Angulo-Morales F, Garcia-Septiem J, Hernandez-Matias A, Marin-Lucas J,
Limones-Esteban M. Ten years of experience about laparoscopic ventral hernia repair. Surg
Endosc 2011;25:S56
No comparison group
Fernandez-Lobato R, Bagot D’Arc M, Krishnan S. An economic evaluation of fibrin sealants used
during incisional hernia with dermolipectomy procedures in Spain. Value Health 2010;13:A103
Not a comparative
observational study
Ferrarese A, Marola S, Surace A, Borello A, Bindi M, Cumbo J, et al. Fibrin glue versus stapler
fixation in laparoscopic transabdominal inguinal hernia repair: a single center 5-year experience
and analysis of the results in the elderly. Int J Surg 2014;12(Suppl. 2):94–8
No adverse effects
related to fibrin reported
Ferrer-Puchol MD, Gil-Romero J, Laso-Pablos S, Guijarro-Rosaleny J. Treatment of oesophago-
cutaneous fistula with covered stent and percutaneous fibrin tissue sealant. J Intervent Radiol
1999;14:222–5
No comparison group
Figueras et al. 200771 RCT
Filosso et al. 2013136 RCT
Finch CK, Pittman AL. Use of fibrin glue to treat a persistent pneumothorax with
bronchopleural fistula. Am J Health Syst Pharm 2008;65:322–4
No comparison group
Finck C, Lefebvre P. Implantation of esterified hyaluronic acid in microdissected Reinke’s space
after vocal fold microsurgery: first clinical experiences. Laryngoscope 2005;115:1841–7
No comparison group
Fine AP. Laparoscopic repair of inguinal hernia using Surgisis mesh and fibrin sealant. JSLS
2006;10:461–5
No comparison group
Fink D, Klein JJ, Kang H, Ergin MA. Application of biological glue in repair of intracardiac
structural defects. Ann Thorac Surg 2004;77:506–11
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Fiore A, Grandmougin D, Maureira JP, Elfarra M, Laurent N, Andronache M, et al. Efficacy of
TachoSil® as a sutureless hemostatic patch to repair a perforation of the interventricular groove
during endocardial radiofrequency ablation. J Cardiovasc Surg 2014;55:295–8
No comparison group
Fischer A, Benz S, Baier P, Hopt UT. Endoscopic management of pancreatic fistulas secondary
to intraabdominal operation. Surg Endosc 2004;18:706–8
No comparison group
Fischer et al. 2013241 RCT
Fischer CP, Wood CG, Shen J, Batiller J, Hart JC, Patel B, et al. A randomized trial of aprotinin-
free fibrin sealant versus absorbable hemostat. Clin Appl Thromb Hemost 2011;17:572–7
RCT
Fischer et al. 201172 RCT
Fleisher AG, Evans KG, Nelems B, Finley RJ. Effect of routine fibrin glue use on the duration of
air leaks after lobectomy. Ann Thorac Surg 1990;49:133–4
RCT
Flemming I. Fibrin glue in face lifts. Facial Plast Surg 1992;8:79–88 RCT
Fortelny RH, Petter-Puchner AH, Glaser KS. Fibrin sealant (Tissucol) for the fixation of hiatal
mesh in the repair of giant paraesophageal hernia: a case report. Surg Laparosc Endosc
Percutan Tech 2009;19:e91–4
No comparison group
Fortelny RH, Petter-Puchner AH, Khakpour Z, May C, Mika K, Glaser KS, et al. Spray application
of fibrin sealant with an angled spray tip device in laparoscopic inguinal hernia repair. Eur Surg
2010;42:171–6
No comparison group
Fortelny RH, Petter-Puchner AH, May C, Jaksch W, Benesch T, Khakpour Z, et al. The impact of
atraumatic fibrin sealant vs. staple mesh fixation in TAPP hernia repair on chronic pain and
quality of life: results of a randomized controlled study. Surg Endosc 2012;26:249–54
RCT
Fortunato G, Bonucci E. Two cases of reconstruction of large defects of the facial skeleton with
hydroxyapatite-fibrin glue. Rivista Italiana di Chirurgia Plastica 1996;28:17–29
No comparison group
Foster JA, Holck DE, Perry JD, Wulc AE, Burns JA, Cahill KV, et al. Fibrin sealant for Müller
muscle-conjunctiva resection ptosis repair. Ophthal Plast Reconstr Surg 2006;22:184–7
No comparison group
Foster K, Greenhalgh D, Gamelli RL, Mozingo D, Gibran N, Neumeister M, et al. Efficacy and
safety of a fibrin sealant for adherence of autologous skin grafts to burn wounds: results of a
phase 3 clinical study. J Burn Care Res 2008;29:293–303
RCT
Fountas KN, Kapsalaki EZ, Johnston KW. Cerebrospinal fluid fistula secondary to dural tear in
anterior cervical discectomy and fusion: case report. Spine 2005;30:E277–80
No comparison group
Fraioli RE, Hirsch BE, Kassam AB. Fibrin sealant for control of cerebrospinal fluid otorrhea. Am J
Otolaryngol 2008;29:135–7
No comparison group
Franco-Vidal V, Daculsi G, Bagot d’Arc M, Sterkers O, Smail M, Robier A, et al. Tolerance and
osteointegration of TricOs(TM)/MBCP in association with fibrin sealant in mastoid obliteration
after canal wall-down technique for cholesteatoma. Acta Oto-Laryngologica 2014;134:358–65
No comparison group
Frena A, Martin F. How to improve bilio-stasis in liver surgery. Chir Ital 2006;58:793–5 No comparison group
French DB, Marcovich R. Fibrin sealant for retrograde ureteroscopic closure of urine leak after
partial nephrectomy. Urology 2006;67:1085.e1–3
No comparison group
Frilling et al. 200573 RCT
Fu et al. 200978 RCT
Fuks D, Bréhant O, Dumont F, Viart L, Manaouil D, Bartoli E, et al. [Tissue adhesive treatment
of persistent recto-cutaneous fistula following Hartmann procedure.] J Chir 2007;144:35–8
No comparison group
Fuks D, Bréhant O, Dumont F, Viart L, Manaouil D, Bartoli E, et al. [Tissue adhesive treatment
of persistent recto-cutaneous fistula following Hartmann procedure.] J Chir 2007;144:35–8
Duplicate
Fuks D, Verhaeghe P, Brehant O, Sabbagh C, Dumont F, Riboulot M, et al. Results of
laparoscopic sleeve gastrectomy: a prospective study in 135 patients with morbid obesity.
Surgery 2009;145:106–13
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Fullarton G, Galloway D, Albillos A, Calleja JL, Rutgeerts P, Wara P, et al. Randomised trial of
fibrin glue versus polidocanol for bleeding peptic ulcer (multiple letters). Lancet 1997;350:1397–8
Letter/commentary/reply
Fuller CW, Gillespie MB, Nguyen SA, Jones T, Hornig JD. A double-blind, randomized,
placebo-controlled clinical trial evaluating fibrin sealant in thyroidectomy closure. Otolaryngol
Head Neck Surg 2014;151(Suppl. 1):P160–1
RCT
Fullum TM, Aluka KJ, Turner PL. Decreasing anastomotic and staple line leaks after laparoscopic
Roux-en-Y gastric bypass. Surg Endosc 2009;23:1403–8
RCT
Furey CG, Sadowski K, Ahn NU. Recurrent CSF leak following repair of incidental durotomy.
Spine J 2014;14(Suppl. 1):113
Abstract
Furrer et al. 1993116 RCT
Furuse M, Ishikawa M, Nishida N, Aoki T, Takahashi JA. Transposition of the vertebral artery
with fibrin glue adhesive in microvascular decompression: a case report. Neurosurg Q
2010;20:170–2
No comparison group
Gaertner WB, Madoff RD, Spencer MP, Mellgren A, Goldberg SM, Lowry AC. Results of
combined medical and surgical treatment of recto-vaginal fistula in Crohn’s disease. Colorectal
Dis 2011;13:678–83
No comparison group
Gagarine A, Urschel JD, Miller JD, Bennett WF, Young JE. Effect of fibrin glue on air leak and
length of hospital stay after pulmonary lobectomy. J Cardiovasc Surg 2003;44:771–3
No adverse effects
related to fibrin reported
Gage EA, Jones GE, Powelson JA, Johnson MS, Goggins WC, Fridell JA. Treatment of
enterocutaneous fistula in pancreas transplant recipients using percutaneous drainage and
fibrin sealant: three case reports. Transplantation 2006;82:1238–40
No comparison group
Galajda Z, Fulop T, Peterffy A, Alamanni F, Parolari A, Biglioli P. Subacute left ventricular
rupture complicated by free wall rupture: repair with a TachoComb sheet and Tissucol glue
(multiple letters). J Thorac Cardiovasc Surg 2002;123:1014–6
Letter/commentary/reply
Gallego JM, Barcia JA, Barcia-Mariño C. Fatal outcome related to carmustine implants in
glioblastoma multiforme. Acta Neurochir 2007;149:261–5
No comparison group
Galor A, Yoo SH, Piccoli FV, Schmitt AJ, Chang V, Perez VL. Phase I study of subconjunctival
ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J
Ophthalmol 2010;149:926–31.e2
RCT
Galosi AB, Lacetera V, Tiroli M, Conti A, Muzzonigro G. Haemostatic sponge application on
Denonvillier fascia after open nerve-sparing prostatectomy. Anticancer Res 2010;30:1430
No comparison group
Gammon RR, Prum BE Jr, Avery N, Mintz PD. Rapid preparation of small-volume autologous
fibrinogen concentrate and its same day use in bleb leaks after glaucoma filtration surgery.
Ophthalmic Surg Lasers 1998;29:1010–12
No comparison group
Ganekal S, Venkataratnam S, Dorairaj S, Jhanji V. Comparative evaluation of suture-assisted
and fibrin glue-assisted scleral fixated intraocular lens implantation. J Refract Surg
2012;28:249–52
No adverse effects
related to fibrin reported
Garcia-Caballero M, Carbajo M, Martinez-Moreno JM, Sarria M, Osorio D, Carmona JA. Drain
erosion and gastro-jejunal fistula after one-anastomosis gastric bypass: endoscopic occlusion by
fibrin sealant. Obes Surg 2005;15:719–22
No comparison group
Garcia-Olmo D, Herreros M, Guadalajara H, DeLaQuintana P, Trebol J, Georgiev-Hristov T, et al.
Expanded adipose derived autologous stem cells for the treatment of complex cryptoglandular
fistulas. A phase III clinical trial (fatt1: Fistulaadvanced therapy trial 1) and longterm evaluation
(LTE). Dis Colon Rectum 2011;54:e68–9
RCT
Garcia-Villarreal OA, Casillas-Covarrubias LE. Fibrin sealant for left ventricular rupture after
mitral valve replacement. Asian Cardiovasc Thorac Ann 2008;16:152–3
No comparison group
Garçon C, Cavaillon JP, Girard P. [The use of Tissucol in oral surgery in problems of
hemostasis.] Chir Dent Fr 1986;56:49–55
Included children
Gatti MAN, Vieira LM, Barraviera B, Barraviera S. Treatment of venous ulcers with fibrin sealant
derived from snake venom. J Venom Anim Toxins 2011;17:226–9
RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Gauthier L, Lagoutte F. [Use of a fibrin glue (Tissucol) for treating perforated or pre-perforated
corneal ulcer.] J Fr Opthalmol 1989;12:469–76
No comparison group
Gazzeri R, Fiore C, Galarza M. (EVICEL) for augmentation of dural closure: results of a
preliminary clinical study. Surg Technol Int 2014;25:265–70
No adverse effects
related to fibrin reported
Gazzeri R, Galarza M, Alfieri A, Neroni M, Roperto R. Simple intraoperative technique for minor
dural gap repair using fibrin glue and oxidized cellulose. World Neurosurg 2011;76:173–5
No comparison group
Gazzeri R, Galarza M, Fiore C, Callovini G, Alfieri A. Use of tissue-glue-coated collagen sponge
(TachoSil) to repair minor cerebral dural venous sinus lacerations: technical note. Neurosurgery
2015;11(Suppl. 2):32–6
No comparison group
Gazzeri R, Neroni M, Alfieri A, Galarza M, Faiola A, Esposito S, et al. Transparent equine
collagen biomatrix as dural repair. A prospective clinical study. Acta Neurochir
2009;151:537–43
No comparison group
Gentili ME. Epidural fibrin glue injection stops postdural puncture headache in patient with
long-term intrathecal catheterization. Reg Anesth Pain Med 2003;28:70
No comparison group
Genyk Y, Kato T, Pomposelli JJ, Lophaven KW, Chapman WC. Tachosil versus surgicel original
for the secondary treatment of local bleeding in adult patients undergoing hepatic resection.
HPB 2014;16:27
RCT
Germanidis G, Papavramidis TS, Mantzoukis K, Sapalidis K, Divanis D, Kalevrosoglou I, et al. Fibrin
glue as a protective biomembrane for a duodenal ulcer vessel. Endoscopy 2010;42(Suppl. 2):E348–9
No comparison group
Gerritse BM, van Dongen RT, Crul BJ. Epidural fibrin glue injection stops persistent
cerebrospinal fluid leak during long-term intrathecal catheterization. Anesth Analg
1997;84:1140–1
No comparison group
Ghavanini AA, Scott CA, Chan DK, Tang-Wai DF. Management of patients with spontaneous
intracranial hypotension causing altered level of consciousness: report of two cases and review
of literature. Cephalalgia 2013;33:43–51
No comparison group
Ghelardi A, di Stefano C, Galante L, Guelfi F, Migliorini P. Inguinofemoral lymphadenectomy in
patients undergoing radical vulvectomy for vulvar cancer. A new patch is able to reduce
lymphatic complications. Ital J Gynaecol Obstet 2011;23:139–46
No adverse effects
related to fibrin reported
Ghotb A, Shah JN, Binmoeller KF, Weilert F, Bhat YM. Efficacy of endoscopic treatment of
symptomatic upper gastrointestinal leaks and fistulas post-bariatric surgery: report of 25 cases.
Gastrointest Endosc 2011;73(Suppl. 1):AB395
No comparison group
Giampapa VC, Bitar GJ. Use of fibrin sealant in neck contouring. Aesthet Surg J
2002;22:519–25
No comparison group
Gibran N, Luterman A, Herndon D, Lozano D, Greenhalgh DG, Grubbs L, et al. Comparison of
fibrin sealant and staples for attaching split-thickness autologous sheet grafts in patients with
deep partial- or full-thickness burn wounds: a phase 1/2 clinical study. J Burn Care Res
2007;28:401–8
RCT
Gidaro S, Cindolo L, Lipsky K, Zigeuner R, Schips L. Efficacy and safety of the haemostasis
achieved by Vivostat system during laparoscopic partial nephrectomy. Arch Ital Urol Androl
2009;81:223–7
No comparison group
Gilat H, Rappaport Z, Yaniv E. Endoscopic transnasal cerebrospinal fluid leak repair: a 10 year
experience. Isr Med Assoc J 2011;13:597–600
Included children
Gille J, Schuseil E, Wimmer J, Gellissen J, Schulz AP, Behrens P. Mid-term results of autologous
matrix-induced chondrogenesis for treatment of focal cartilage defects in the knee. Knee Surg
Sports Traumatol Arthrosc 2010;18:1456–64
No comparison group
Gilly et al. 1998108 RCT
Gioffrè Florio MA, Mezzasalma F, Manganaro T, Pakravanan H, Cogliandolo A. [The use of
fibrin glue in the surgery of breast carcinoma.] G Chir 1993;14:239–41
RCT
Giovannacci L, Eugster T, Stierli P, Hess P, Gürke L. Does fibrin glue reduce complications after
femoral artery surgery? A randomised trial. Eur J Vasc Endovasc Surg 2002;24:196–201
RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Giovannacci L, Renggli JC, Eugster T, Stierli P, Hess P, Gürke L. Reduction of groin lymphatic
complications by application of fibrin glue: preliminary results of a randomized study. Ann Vasc
Surg 2001;15:182–5
RCT
Girard S, Sideman M, Spain DA. A novel approach to the problem of intestinal fistulization
arising in patients managed with open peritoneal cavities. Am J Surg 2002;184:166–7
No comparison group
Gisbertz SS, Sosef MN, Festen S, Gerhards MF. Treatment of fistulas in ano with fibrin glue.
Dig Surg 2005;22:91–4
No comparison group
Giugno A, Maugeri R, D’Arpa S, Visocchi M, Iacopino DG. Complex reconstructive surgery
following removal of extra-intracranial meningiomas, including the use of autologous fibrin
glue and a pedicled muscle flap. Interdisc Neurosurg 2014;1:84–7
No comparison group
Giuliani G, Coletta D, Farina A, Guerra F, Velluti F, Iaquinandi F, et al. Perineal surgical
approach to treat rectourethral fistula with Tachosil© patch apposition: a case report.
Tech Coloproctol 2013;17:138
No comparison group
Glimåker H, Björck CG, Hallstensson S, Ohlsén L, Westman B. Avoiding blow-out of the aortic
stump by reinforcement with fibrin glue. A report of two cases. Eur J Vasc Surg 1993;7:346–8
No comparison group
Glitsch A, von Bernstorff W, Seltrecht U, Partecke I, Paul H, Heidecke CD. Endoscopic transanal
vacuum-assisted rectal drainage (ETVARD): an optimized therapy for major leaks from
extraperitoneal rectal anastomoses. Endoscopy 2008;40:192–9
No comparison group
Glover W, Chavis TV, Daniel TM. Fibrin glue application through the flexible fiberoptic
bronchoscope: closure of bronchopleural fistulas. J Thorac Cardiovasc Surg 1987;93:470–2
No comparison group
Godeberge P, Blain A, Christidis C, Denet C, Levard H, Mal F, et al. Biological glue in the
treatment of postoperative fistula in colorectal surgery. Acta Endoscopica 2009;39:424–8
No comparison group
Goerler H, Oppelt P, Abel U, Haverich A. Safety of the use of Tissucol Duo S in cardiovascular
surgery: retrospective analysis of 2149 patients after coronary artery bypass grafting. Eur J
Cardiothorac Surg 2007;32:560–6
Includes emergency
surgery; overall 9.3% of
patients
Gonfiotti et al. 2011130 RCT
González-Ojeda A, Avalos-González J, Muciño-Hernández MI, López-Ortega A, Fuentes-Orozco C,
Sánchez-Hochoa M, et al. Fibrin glue as adjuvant treatment for gastrocutaneous fistula after
gastrostomy tube removal. Endoscopy 2004;36:337–41
No adverse effects
related to fibrin reported
Gopal SC, Gangopadhyay AN, Mohan TV, Upadhyaya VD, Pandey A, Upadhyaya A, et al. Use
of fibrin glue in preventing urethrocutaneous fistula after hypospadias repair. J Pediatr Surg
2008;43:1869–72
RCT
Grau AE, Durán JA. Treatment of a large corneal perforation with a multilayer of amniotic
membrane and TachoSil. Cornea 2012;31:98–100
No comparison group
Graziano F, Certo F, Basile L, Maugeri R, Grasso G, Meccio F, et al. Autologous fibrin sealant
(Vivostat) in the neurosurgical practice: part I: intracranial surgical procedure. Surg Neurol Int
2015;6:77
No comparison group
Greco DP, Fei L, Guerriero L, Pradella P, Mazzola M, Magistro C, et al. Feasibility and
effectiveness of primary umbilical hernia repair with biologic graft: preliminary study. Acta Chir
Belg 2014;114:125–30
No comparison group
Greco S, Tringali A, Familiari P, Boskoski I, Perri V, Costamagna G. A rescue therapy for
refractory post-sphincterotomy and post-papillectomy bleeding: fibrin glue injection. Dig Liver
Dis 2015;47:e153
Not a relevant
comparison
Greenberg R, Kashtan H, Skornik Y, Werbin N. Treatment of pilonidal sinus disease using fibrin
glue as a sealant. Tech Coloproctol 2004;8:95–8
No comparison group
Greenberg R, Werbin N, Skornik Y, Kaplan O. [Repair of anorectal fistulas using fibrin glue
tissue adhesive – preliminary experience in 15 patients.] Harefuah 2002;141:1021–4, 1091
No comparison group
Greenhalgh DG, Gamelli RL, Lee M, Delavari M, Lynch JB, Hansbrough JF, et al. Multicenter
trial to evaluate the safety and potential efficacy of pooled human fibrin sealant for the
treatment of burn wounds. J Trauma 1999;46:433–40
RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Grewing R, Mester U. Fibrin sealant in the management of complicated hypotony after
trabeculectomy. Ophthalmic Surg Lasers 1997;28:124–7
No comparison group
Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Sénéjoux A, Vitton V, et al.
Fibrin glue is effective healing perianal fistulas in patients with Crohn’s disease.
Gastroenterology 2010;138:2275–81
RCT
Groitl H, Scheele J. Initial experience with the endoscopic application of fibrin tissue adhesive in
the upper gastrointestinal tract. Surg Endosc 1987;1:93–7
No comparison group
Grossman JA, Capraro PA, Atagi T. A prospective, randomized, double-blind trial of the use of
fibrin sealant for face lifts. Plast Reconstr Surg 2002;110:1371–2
RCT
Gubitosi A, Docimo G, Parmeggiani D, Pirozzi R, Vitiello C, Schettino P, et al. Acellular bovine
pericardium dermal matrix in immediate breast reconstruction after skin sparing mastectomy.
Int J Surg 2014;12(Suppl. 1):205–8
No comparison group
Gubitosi A, Ruggiero R, Docimo G, Avenia N, Villaccio G, Esposito A, et al. Hepatic cirrhosis
and groin hernia: binomial or dichotomy? Our experience with a safe surgical treatment
protocol. Ann Ital Chir 2011;82:197–204
No comparison group
Gugenheim J, Bredt LC, Iannelli A. A randomized controlled trial comparing fibrin glue and
PlasmaJet on the raw surface of the liver after hepatic resection. Hepatogastroenterology
2011;58:922–5
RCT
Guilmet D, Bachet J, Goudot B, Laurian C, Gigou F, Bical O, et al. Use of biological glue in
acute aortic dissection. Preliminary clinical results with a new surgical technique. J Thorac
Cardiovasc Surg 1979;77:516–21
Emergency surgery
Gündog˘du AG, Yaziciog˘lu A, Kara M, Kanbak M, Dog˘an R. [The use of tissue glue and its
effect on hospital cost in patients undergoing pulmonary surgery.] Tuberk Toraks
2006;54:157–60
No adverse effects
related to fibrin reported
Guo S, Wagner RS, Forbes BJ, DeRespinis PA, Caputo AR. Cut and paste: sutureless
conjunctival closure in strabismus surgery. J Pediatr Ophthalmol Strabismus 2010;47:228–30
No comparison group
Gürer B, Kertmen H, Akturk UD, Kalan M, Sekerci Z. Use of the bovine pericardial patch and
fibrin sealant in meningomyelocele closure. Acta Neurochir 2014;156:1345–50
No comparison group
Gursoy S, Yapucu MU, Ucvet A, Yazgan S, Basok O, Ermete S. Fibrin glue administration to
support bronchial stump line. Asian Cardiovasc Thorac Ann 2008;16:450–3
No comparison group
Gutierrez C, Barrios JE, Lluna J, Vila JJ, Garcia-Sala C, Roca A, et al. Recurrent
tracheoesophageal fistula treated with fibrin glue. J Pediatr Surg 1994;29:1567–9
Not fibrin sealant
Gutiérrez Calzada JL, Burgos Rodríguez R. [Partial transplantectomy combined with substitution
of the urinary tract, in the treatment of segmental renal infarction after transplantation.] Arch
Esp Urol 1996;49:1093–9
No comparison group
Gutiérrez San Román C, Barrios JE, Lluna J, Ibañez V, Hernández E, Ayuso L, et al. Long-term
assessment of the treatment of recurrent tracheoesophageal fistula with fibrin glue associated
with diathermy. J Pediatr Surg 2006;41:1870–3
No comparison group
Gutiérrez-Calzada JL, Ramos-Titos J, González-Bonilla JA, Garcia-Vaquero AS, Martin-Morales A,
Burgos-Rodríguez R. Caliceal fistula formation following renal transplantation: management
with partial nephrectomy and ureteral replacement. J Urol 1995;153:612–14
No comparison group
Haas S. The use of a surgical patch coated with human coagulation factors in surgical routine:
a multicenter postauthorization surveillance. Clin Appl Thromb Hemost 2006;12:445–50
No comparison group
Habesoglu TE, Kulekci S, Habesoglu M, Deveci I, Deveci S, Toros S, et al. Comparative
outcomes of using fibrin glue in septoplasty and its effect on mucociliary activity. Otolaryngol
Head Neck Surg 2010;142:394–9
No adverse effects
related to fibrin reported
Hadzhiev B. [Treatment of chronic anorectal fistulas by fibrin sealant.] Khirurgiia 2008;3:41–5 No comparison group
Haga T, Kurihara M, Kataoka H. Spontaneous pneumothorax with persistent air leakage and
invasive procedures. Intern Med 2013;52:2189–92
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Haim N, Neufeld D, Ziv Y, Tulchinsky H, Koller M, Khaikin M, et al. Long term success of fibrin
glue in the treatment of perianal fistulae – a multicenter study. Colorectal Dis 2010;12:52
No comparison group
Haim N, Neufeld D, Ziv Y, Tulchinsky H, Koller M, Khaikin M, et al. Long-term success of fibrin
glue in the treatment of perianal fistulas – a multicenter study. Dis Colon Rectum 2010;53:576
No comparison group
Haim N, Neufeld D, Ziv Y, Tulchinsky H, Koller M, Khaikin M, et al. Long-term results of fibrin
glue treatment for cryptogenic perianal fistulas: a multicenter study. Dis Colon Rectum
2011;54:1279–83
No comparison group
Haim N, Neufeld D, Ziv Y, Tulchinsky H, Koller M, Khaikin M, et al. Long-term results of fibrin
glue in the treatment of perianal fistulas: a multicenter study. Tech Coloproctol 2011;15:240
No comparison group
Haim N, Neufeld D, Ziv Y, Tulchinsky H, Koller M, Khaikin M, et al. Long-term success of fibrin
glue in the treatment of perianal fistulas-a multicenter study. Tech Coloproctol 2011;15:121
Duplicate
Halfpenny W, Fraser JS, Adlam DM. Comparison of 2 hemostatic agents for the prevention of
postextraction hemorrhage in patients on anticoagulants. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 2001;92:257–9
RCT
Hall et al. 2009160 RCT
Halverson AL, Hull TL, Fazio VW, Church J, Hammel J, Floruta C. Repair of recurrent
rectovaginal fistulas. Surgery 2001;130:753–7
No comparison group
Hammond et al. 2011219 RCT
Hanai M, Kobayashi Y, Miyata K, Yoneyama F, Hattori T, Yuas N. Gastric tube-pulmonary
fistula after esophageal reconstruction treated by endoscopic fibrin glue injection: a case report.
Nihon Shokaki Geka Gakkai Zasshi 2001;34:329–33
No comparison group
Harries K, Masoud A, Brown TH, Richards DG. Endoscopic placement of fibrin sealant as a
treatment for a long-standing Boerhaave’s fistula. Dis Esophagus 2004;17:348–50
No comparison group
Hashimoto K, Shirakashi M, Watanabe J, Fukuchi T, Sawaguchi S, Kushiro M, et al. A case of
the use of fibrin glue in leaking filtering bleb. Nihon Ganka Kiyo 1997;48:357–61
No comparison group
Hata N, Hisada K, Torisu R, Suzuki SO, Kameda K, Sasaki T. Foreign body granuloma associated
with dura-cranioplasty after resection of convexity meningioma with extracranial extension:
case report. Neurol Med Chir 2011;51:236–8
No comparison group
Hatzichristodoulou G, Fiechtner S, Gschwend JE, Lahme S. Long-term results after partial plaque
excision and grafting with collagen fleece in Peyronie’s disease. Eur Urol Suppl 2015;14:e133
No comparison group
Hatzichristodoulou G, Gschwend JE, Lahme S. Surgical correction of Peyronie’s curvature by
partial plaque excision or incision and grafting with collagen fleece – first results of a
prospective, multicenter study. Eur Urol Suppl 2011;10:317
No comparison group
Hausmann M, Keller R. [Thoracoscopic pleurodesis in spontaneous pneumothorax.] Schweiz
Med Wochenschr 1994;124:97–104
No comparison group
Hayashi K, Nagano J, Hattori S. Adhesive arachnoiditis after percutaneous fibrin glue treatment
of a sacral meningeal cyst. J Neurosurg Spine 2014;20:763–6
No comparison group
Hayward PJ, Mackay IS. Fibrin glue in nasal septal surgery. J Laryngol Otol 1987;101:133–8 No comparison group
Heldwein W, Avenhaus W, Schönekäs H, Kaess H, Müller-Lissner S, Hasford B, et al. Injection
of fibrin tissue adhesive versus laser photocoagulation in the treatment of high-risk bleeding
peptic ulcers: a controlled randomized study. Endoscopy 1996;28:756–60
RCT
Helvind NM, Andresen K, Rosenberg J. Lower reoperation rates with the use of fibrin sealant
versus tacks for mesh fixation. Surg Endosc 2013;27:4184–91
Emergency surgery
Hennis HL, Stewart WC, Jeter EK. Infectious disease risks of fibrin glue. Ophthalmic Surg
1992;23:640
Letter/commentary/reply
Herbrig K, Pistrosch F, Gross P, Palm C. Resumption of peritoneal dialysis after transcutaneous
treatment of a peritoneal leakage using fibrin glue. Nephrol Dial Transplant 2006;21:2037–8
Letter/commentary/reply
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Hernandez C, Romero RJ, Lamoureux J, Seetharamaiah R, Garcia PE, Gallas M, et al. Gastric
bypass postoperative clinical parameters using fibrin sealant. Bariatr Surg Pract Patient Care
2014;9:102–5
No comparison group
Herold G, Danz B. Endoscopic (-ERC) fibrin sealing and histoacryl sealing of an abscess
induced bilio-hepatico-cutaneous and a bilio-hepatico-phrenico-bronchial fistulous system.
Z Gastroenterol 1995;33:605–9
No comparison group
Herold G, Preclik G, Stange F. Gastroduodenal ulcer hemorrhage: endoscopic injection therapy
using a fibrin sealant. Hepatogastroenterology 1994;41:116–19
No comparison group
Hester TR Jr, Gerut ZE, Shire JR, Nguyen DB, Chen AH, Diamond J, et al. Exploratory,
randomized, controlled, phase 2 study to evaluate the safety and efficacy of adjuvant fibrin
sealant VH S/D 4 S-Apr (ARTISS) in patients undergoing rhytidectomy. Aesthet Surg J
2013;33:323–33
RCT
Hester et al. 2013231 RCT
Heusse JL, Hivelin M, Lepage C, Santini C, Lantieri L. [Fibrin sealant significantly decrease
postoperative drainage in breast reconstruction by deep inferior epigastric perforator (DIEP)
flap.] Ann Chir Plast Esthet 2012;57:50–8
No adverse effects
related to fibrin reported
Hevia M, Abascal-Junquera JM, Sacristan R, Suarez J, Lobo B, Mendez S, et al. [Haemostasis
control during laparoscopic partial nephrectomy without parenchymal renorrhaphy: the
VIVOSTAT experience.] Actas Urol Esp 2013;37:47–53
No comparison group
Hick EJ, Morey AF. Initial experience with fibrin sealant in pendulous urethral reconstruction.
Is early catheter removal possible? J Urol 2004;171:1547–9
No adverse effects
related to fibrin reported
Hick S, Demers PE, Brunette I, La C, Mabon M, Duchesne B. Amniotic membrane
transplantation and fibrin glue in the management of corneal ulcers and perforations: a review
of 33 cases. Cornea 2005;24:369–77
Not a relevant
comparison
Hickey NC. Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular
surgical procedures. Br J Surg 2010;97:1790
RCT
Hida K, Yamaguchi S, Seki T, Yano S, Akino M, Terasaka S, et al. Nonsuture dural repair using
polyglycolic acid mesh and fibrin glue: clinical application to spinal surgery. Surg Neurol
2006;65:136–42
No comparison group
Hidalgo M, Castillo MJ, Eymar JL, Hidalgo A. Lichtenstein inguinal hernioplasty: sutures versus
glue. Hernia 2005;9:242–4
RCT
Hidalgo MP, Ferrero EH, Ortiz MA, Castillo JM, Hidalgo AG. Incisional hernia in patients at risk:
can it be prevented? Hernia 2011;15:371–5
No comparison group
Higashiyama M, Takami K, Higaki N, Kodama K. Pulmonary middle lobe fixation using
TachoComb in patients undergoing right upper lobectomy with complete oblique fissure.
Interact Cardiovasc Thorac Surg 2004;3:107–9
No comparison group
Hillerdal G, Gustafsson G, Wegenius G, Englesson S, Hedenström H, Hedenstierna G. Large
emphysematous bullae. Successful treatment with thoracoscopic technique using fibrin glue in
poor-risk patients. Chest 1995;107:1450–3
No comparison group
Hino M, Ishiko O, Honda KI, Yamane T, Ohta K, Takubo T, et al. Transmission of symptomatic
parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol 2000;108:194–5
No comparison group
Hino M, Yamamura R, Nishiki S, Ohta K, Yamane T, Takubo T, et al. [Human parvovirus B19-
induced aplastic crisis in a patient treated with fibrin sealant.] Rinsho Ketsueki 1999;40:145–9
No comparison group
Hivelin M, Heusse JL, Matar N, Lepage C, Lantieri L. Fibrin sealant decreases postoperative
drainage in immediate breast reconstruction by deep inferior epigastric perforator flap after
mastectomy with axillary dissection. Microsurgery 2011;31:18–25
No comparison group
Hjortrup A, Moesgaard F, Kjaergård J. Fibrin adhesive in the treatment of perineal fistulas.
Dis Colon Rectum 1991;34:752–4
No comparison group
Höckel M, Klose KJ. Treatment of non-neoplastic nipple discharge with fibrin adhesive. Lancet
1987;2:331–2
Letter/commentary/reply
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Hodges SD, Humphreys SC, Eck JC, Covington LA. Management of incidental durotomy
without mandatory bed rest. A retrospective review of 20 cases. Spine 1999;24:2062–4
No comparison group
Hofmann HS, Rettig G, Radke J, Neef H, Silber RE. Iatrogenic ruptures of the tracheobronchial
tree. Eur J Cardiothorac Surg 2002;21:649–52
No comparison group
Hofstetter C, Segovia E, Vara-Thorbeck R. Treatment of uncomplicated hydatid cyst of the liver
by closed marsupialization and fibrin glue obliteration. World J Surg 2004;28:173–8
No comparison group
Hohendorff B, Siepen W, Spiering L, Staub L, Schmuck T, Boss A. Long-term results after
operatively treated Achilles tendon rupture: fibrin glue versus suture. J Foot Ankle Surg
2008;47:392–9
Included children
Hölscher AH, Schröder W, Bollschweiler E, Beckurts KT, Schneider PM. [How safe is high
intrathoracic esophagogastrostomy?] Chirurg 2003;74:726–33
No comparison group
Holub Z, Kliment Jr L. The effectiveness of collagen fleece combined with a fibrin glue in
hemostasis during laparoscopic surgery. J Gynecol Surg 1999;15:185–91
No adverse effects
related to fibrin reported
Honda K, Asato R, Tsuji J, Kanda T, Ushiro K, Watanabe Y. Extended application of polyglycolic
acid sheet combined with sprayed fibrin glue to advanced oral cancers. Oral Oncol 2011;47:S151
No comparison group
Honda K, Ishiko O, Tsujimura A, Hino M, Hirai K, Itoh F, et al. Neutropenia accompanying
parvovirus B19 infection after gynecologic surgery. Acta Haematol 2000;103:186–90
No comparison group
Hong CK, Kim YB, Hong JB, Lee KS. Sealing of cerebrospinal fluid leakage during conventional
transsphenoidal surgery using a fibrin-coated collagen fleece. J Clin Neurosci 2015;22:696–9
No adverse effects
related to fibrin reported
Huang and Qian 201493 RCT
Huang et al. 201564 RCT
Huguier M, Barrier A, Gouillat C, Suc B, Jaeck D, Launois B. [Pancreaticoduodenectomy for
cancer of the head of the pancreas.] J Chir 2008;145:9–15
Not a comparative
observational study
Huh JW, Kim HR, Kim YJ. Anastomotic leakage after laparoscopic resection of rectal cancer:
the impact of fibrin glue. Am J Surg 2010;199:435–41
No adverse effects
related to fibrin reported
Hurtgen M, Linder A, Friedel G, Toomes H. Video-assisted thoracoscopic pleurodesis. A survey
conducted by the German Society for Thoracic Surgery. Thorac Cardiovasc Surg 1996;44:199–203
Emergency surgery
Hutter et al. 2014237 RCT
Hvass U, Chatel D, Assayag P, Juliard JM, Caliani J, Oroudji M, et al. [Repair of post-infarction
left ventricular wall ruptures by biological glue and a flap from the pericardium. Results from 2
to 10 years.] Arch Mal Coeur Vaiss 1996;89:1255–8
No comparison group
Hvass U, Chatel D, Assayag P, Juliard JM, Caliani J, Oroudji M, et al. [Repair of post-infarction
left ventricular wall ruptures by biological glue and a flap from the pericardium. Results from 2
to 10 years.] Arch Mal Coeur Vaiss 1996;89:1255–8
Duplicate
Iankin AV. [Tachocomb plates efficacy in prevention of lymphorrhea in radical operations for
gastric cancer.] Khirurgiia 2006;11:44–6
Unobtainable
Ikeda T, Sasaki M, Yamada N, Takamori A, Tanabe S, Okada A, et al. Controlling air leaks
using free pericardial fat pads as surgical sealant in pulmonary resection. Ann Thorac Surg
2015;99:1170–5
Not a relevant
comparison
Imai K, Taniguchi M, Watanabe K, Einama T, Karasaki H, Kono T, et al. Efficacy of fibrin glue
spray and polyglycolic acid sheet for the protection of transection surface after liver resection.
HPB (Oxford) 2012;14:517–18
Abstract
Imhof M, Ohmann C, Roher HD, Glutig H, Duesuc study g. Endoscopic versus operative
treatment in high-risk ulcer bleeding patients – results of a randomised study. Langenbecks
Arch Surg 2003;387:327–36
RCT
Inderbitzi RG, Krebs T, Stirneman T, Ulrich A. Treatment of postoperative chylothorax by fibrin
glue application under thoracoscopic view with use of local anesthesia. J Thorac Cardiovasc
Surg 1992;104:209–10
Letter/commentary/reply
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Inghilleri G, Santoleri L, Cristallo A, Aloni A, Mancini L, Rondinara G, et al. Homemade vs
commercial fibrin glue in liver surgery. Blood Transfus 2006;4:81–91
Fibrin was used in both
groups
Ishikura Y, Odagiri S, Shimazu A, Yoshimatsu H. Left ventricular rupture following mitral valve
replacement – a report of two cases. Jpn J Surg 1990;20:699–703
No comparison group
Ishio K. Delayed postoperative labyrinthine fistula. Otolaryngol Head Neck Surg (Tokyo)
1995;67:1024–9
No comparison group
Ito H, Kimura T, Sameshima T, Aiyama H, Nishimura K, Ochiai C, et al. Reinforcement of
pericranium as a dural substitute by fibrin sealant. Acta Neurochir 2011;153:2251–4
No comparison group
Ito H, Nakayama H, Arai H, Karita S, Shotsu A, Fujita A. [Prevention of parenchymal air leakage
after lung resection; comparison of effectiveness in drug formation of fibrin adhesive.] Kyobu
Geka 2003;56:1014–16
Fibrin was used in both
groups
Izzo F, Palaia R, Albino V, Amore A, di Giacomo R, Piccirillo M, et al. Hepatocellular carcinoma
and liver metastases: clinical data on a new dual-lumen catheter kit for surgical sealant infusion
to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and
loco-regional treatments. Infectious Agents Cancer 2015;10:11
No comparison group
Jabłon´ski S, Brocki M, Klejszmit P, Kutwin L, Wawrzycki M, S´migielski J. Repair of
postpneumonectomy bronchopleural fistula using pedicled pericardial flap supported by fibrin
glue. Int Wound J 2015;12:154–9
Not a relevant
comparison
Jackson et al. 1999193 RCT
Jain et al. 200499 RCT
Johnsen S, Ermuth T, Tanczos E, Bannasch H, Horch RE, Zschocke I, et al. Treatment of
therapy-refractive ulcera cruris of various origins with autologous keratinocytes in fibrin sealant.
VASA 2005;34:25–9
No comparison group
Johnson et al. 2005100 RCT
Johnston WK, Montgomery JS, Seifman BD, Hollenbeck BK, Wolf JS. Fibrin glue v sutured
bolster: lessons learned during 100 laparoscopic partial nephrectomies. J Urol 2005;174:47–52
No adverse effects
related to fibrin reported
Jones BM, Grover R. Avoiding hematoma in cervicofacial rhytidectomy: a personal 8-year quest.
Reviewing 910 patients. Plast Reconstr Surg 2004;113:381–7
Not a relevant
comparison
Jones BM, Grover R. Early postoperative efficacy of fibrin glue in face lifts: a prospective
randomized trial. Plast Reconstr Surg 2007;119:433–4
RCT
Jonk A, van Dongen JA, Kroon BB. Prevention of seroma following axillary lymph node
dissection or radical mastectomy; ineffectiveness of fibrin glue sealing technique. Neth J Surg
1987;39:135
Unobtainable
Joseph et al. 2004200 RCT
Jurczak F, Laridon JY, Raffaitin P, Redon Y, Pousset JP. [Long-term follow-up of the treatment
of high anal fistulas using fibrin glue.] J Chir 2009;146:382–6
No comparison group
Kahook MY, Noecker RJ. Fibrin glue-assisted glaucoma drainage device surgery. Br J
Ophthalmol 2006;90:1486–9
No adverse effects
related to fibrin reported
Kamal HM, Goda HAEB. Epidural fibrin glue for treatment of post-dural puncture headache
(PDPH): comparative study with epidural blood patch. Egypt J Anaesth 2009;25:41–7
RCT
Kamer FM, Nguyen DB. Experience with fibrin glue in rhytidectomy. Plast Reconstr Surg
2007;120:1045–51
RCT
Kanazawa R, Sato S, Iwamoto N, Teramoto A. Allergic reaction following arachnoid plasty with
a fibrin sealant. Neurol Med Chir 2010;50:608–10
No comparison group
Kanemaru S, Umeda H, Kitani Y, Nakamura T, Hirano S, Ito J. Regenerative treatment for
tympanic membrane perforation. Otol Neurotol 2011;32:1218–23
RCT
Kang GC, Sng KW, Tay AG. Modified technique for frontal sinus obliteration using calvarial
bone and Tisseel glue. J Craniofac Surg 2009;20:528–31
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Kaplonyi G, Zimmerman I, Frenyo AD, Farkas T, Nemes G. The use of fibrin adhesive in the
repair of chondral and osteochondral injuries. Injury 1988;19:267–72
No comparison group
Karim MA, Ali A. Simple technique to manage redundant skin after laparoscopic ventral hernia
repair. Asian J Endosc Surg 2013;6:137–9
No comparison group
Karlikaya C, Ucan E, Oto O, Akkoclu A, Cimrin A, Akpinar O. Successful fibrin glue repair of
iatrogenic bronchial rupture. Respir Med 1993;87:397–8
Letter/commentary/reply
Karvonen JA, Gronroos JM, Nikulainen V, Gullichsen R, Salminen P. Endoscopic treatment of
internal gastrointestinal fistulas with fibrin glue. Surg Laparosc Endosc Percutan Tech
2013;23:37–40
No comparison group
Kaseda S, Aoki T, Hangai N, Omoto T, Yamamoto S, Sugiura H. Treating bullous lung disease
with Holmium YAG laser in conjunction with fibrin glue and DEXON mesh. Lasers Surg Med
1998;22:219–22
No comparison group
Kaseda S, Aoki T, Hangai N, Shimizu K, Kiguchi H. One hundred consecutive treatments with
holmium: YAG laser for pulmonary bullae: especially in conjunction with gelatin-resorcinol
formaldehyde-glutaraldehyde glue adhesion. Lasers Surg Med 2001;28:255–8
Not fibrin sealant
Kassam A, Horowitz M, Carrau R, Snyderman C, Welch W, Hirsch B, et al. Use of tisseel fibrin
sealant in neurosurgical procedures: incidence of cerebrospinal fluid leaks and cost-benefit
analysis in a retrospective study. Neurosurgery 2003;52:1102–5
Included children
Katkhouda N. Application of fibrin glue after hepatectomy might still be justified. Ann Surg
2008;247:399-400
RCT
Katoch CD, Chandran VM, Bhattacharyya D, Barthwal MS. Closure of bronchopleural fistula by
interventional bronchoscopy using sealants and endobronchial devices. Med J Armed Forces
India 2013;69:326–9
No comparison group
Kauer WKH, Stein HJ, Dittler HJ, Siewert JR. Stent implantation as a treatment option in
patients with thoracic anastomotic leaks after esophagectomy. Surg Endosc 2008;22:50–3
No comparison group
Kavanagh MC, Ohr MP, Czyz CN, Cahill KV, Perry JD, Holck DE, et al. Comparison of fibrin
sealant versus suture for wound closure in Muller muscle-conjunctiva resection ptosis repair.
Ophthal Plast Reconstr Surg 2009;25:99–102
No adverse effects
related to fibrin reported
Kawamura M, Kase K, Sawafuji M, Watanabe M, Horinouchi H, Kobayashi K. Staple-line
reinforcement with a new type of polyglycolic acid felt. Surg Laparosc Endosc Percutan Tech
2001;11:43–6
No comparison group
Kawamura M, Sawafuji M, Watanabe M, Horinouchi H, Kobayashi K. Frequency of
transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery.
Ann Thorac Surg 2002;73:1098–100
No comparison group
Keller R. [Thoracoscopic pleurodesis in persistent and recurrent pneumothorax.] Zentralbl Chir
1992;117:267–9
No comparison group
Khafagy W, Zedan S, Setiet A, El-Awady S, El-Shobaky MT. Autologous fibrin glue in treatment
of fistula in ano. Coloproctology 2001;23:17–21
No adverse effects
related to fibrin reported
Khaleal F, Berney C. The role of fibrin glue in decreasing chronic pain in laparoscopic totally
extraperitoneal (TEP) inguinal hernia repair: a single surgeon’s experience. ANZ J Surg
2011;81:154–8
No comparison group
Kheirkhah A, Casas V, Blanco G, Li W, Hayashida Y, Chen YT, et al. Amniotic membrane
transplantation with fibrin glue for conjunctivochalasis. Am J Ophthalmol 2007;144:311–13
No comparison group
Kheirkhah A, Casas V, Sheha H, Raju VK, Tseng SC. Role of conjunctival inflammation in
surgical outcome after amniotic membrane transplantation with or without fibrin glue for
pterygium. Cornea 2008;27:56–63
No adverse effects
related to fibrin reported
Kheirkhah A, Ghaffari R, Kaghazkanani R, Hashemi H, Behrouz MJ, Raju VK. A combined
approach of amniotic membrane and oral mucosa transplantation for fornix reconstruction in
severe symblepharon. Cornea 2013;32:155–60
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Kiejna N, Lubocki M, Wegrzyn K, Rzepecki P. Laparoscopic nephron sparing surgery (LNSS)
using a clamp on the renal parenchyma and haemostatic material on the loge of the tumor.
Eur Urol Suppl 2011;10:653
No comparison group
Kilic B, Turna A, Demirkaya A, Kaynak K. A prospective randomized trial comparing
heterologous and autologous fibrin sealants for the control of alveolar air leak. Interact
Cardiovasc Thorac Surg 2013;17(Suppl. 1):1–62
RCT
Kim HH, Mun HJ, Park YJ, Lee KW, Shin JP. Conjunctivolimbal autograft using a fibrin adhesive
in pterygium surgery. Korean J Ophthalmol 2008;22:147–54
No comparison group
Kim HJ, Huh JW, Kim HR, Kim YJ. Oncologic impact of anastomotic leakage in rectal cancer
surgery according to the use of fibrin glue: case-control study using propensity score matching
method. Am J Surg 2014;207:840–6
No comparison group
Kim HK, Park HS. Fibrin glue-assisted augmented amniotic membrane transplantation for the
treatment of large noninfectious corneal perforations. Cornea 2009;28:170–6
No comparison group
Kim TS, Oh JH, Rhew HY. ‘Off-clamp, non-renorrhaphy’ laparoscopic partial nephrectomy with
perirenal fat and gerota’s fascia reapproximation: initial experience and perioperative outcomes.
J Laparoendosc Adv Surg Tech A 2014;24:339–44
No comparison group
Kim YA, Steinbacher DM. Demineralized bone-fibrin sandwich for genioplasty. Aesthetic Plast
Surg 2014;38:755–8
RCT
Kim YA, Steinbacher DM. Demineralized bone-fibrin sandwich for genioplasty. Aesthet Plast
Surg 2014;38:755–8
No comparison group
Kimura N, Kawahito K, Murata S, Yamaguchi A, Adachi H, Ino T. Pitfalls of sutureless repair of
a blow-out type left ventricular free wall rupture. Jpn J Thorac Cardiovasc Surg 2005;53:382–5
No comparison group
Kinahan TJ, Johnson HW. Tisseel in hypospadias repair. Can J Surg 1992;35:75–7 No adverse effects
related to fibrin reported
Kingsnorth AN, Shahid MK, Valliattu AJ, Hadden RA, Porter CS. Open onlay mesh repair for
major abdominal wall hernias with selective use of components separation and fibrin sealant.
World J Surg 2008;32:26–30
Fibrin data not shown
separately from control
Kinoshita T. Usefulness of intrapleural administration of a large amount of diluted fibrin glue
for intractable pneumothoraces. J Wakayama Med Soc 1998;49:289–96
No comparison group
Kinoshita T, Miyoshi S, Suzuma T, Sakurai T, Enomoto K, Yoshimasu T, et al. Intrapleural
administration of a large amount of diluted fibrin glue for intractable pneumothorax. A clinical
study based on 57 cases: including 2 unsuccessful cases. Jpn J Thorac Cardiovasc Surg
2003;51:41–7
No comparison group
Kirkegaard P, Madsen PV. [Closure of fistula with fibrin-glue.] Ugeskr Laeg 1982;144:3832–4 Unobtainable
Kirkegaard P, Madsen PV. Perineal sinus after removal of the rectum. Occlusion with fibrin
adhesive. Am J Surg 1983;145:791–4
No comparison group
Kitago M, Matsui J, Tanabe M, Kawachi S, Itano O, Shinoda M, et al. Pylorus-preserving
pancreatoduodenectomy with gastrointestinal reconstruction by the imanaga method enable
the endoscopic examination of pancreatojejunostomy or choledochojejunostomy anastomosis.
HPB (Oxford) 2012;14:672
No comparison group
Kjaergard and Trumbull 1998138 RCT
Kjølhede P, Rydén G, Hewardt P. Abdominal urethrocystopexy using fibrin sealant. A
prospective study of long-term efficacy. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:93–6
No comparison group
Kluba et al. 2012145 RCT
Knox Cartwright NE, Tole DM. Potential complication of fibrin sealant. J Cataract Refract Surg
2008;34:881–2
Letter/commentary/reply
Kobayashi M, Suzuki K, Ichinose Y, Hashimoto K, Matsumoto K, Yamanaka H. Intractable fecal
fistula cured by a combination of conservative therapy using fibrin adhesive agent and
complicating. Jpn J Clin Urol 1989;43:815–17
No comparison group
continued
DOI: 10.3310/hta20940 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 94
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177
TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Kobayashi S, Nagano H, Marubashi S, Wada H, Eguchi H, Takeda Y, et al. Fibrin sealant with
PGA felt for prevention of bile leakage after liver resection. Hepatogastroenterology
2012;59:2564–8
Fibrin was used in both
groups
Kohno et al. 199275 RCT
Kon NF, Masumo H, Nakajima S, Tozawa R, Kimura M, Maeda S. [Anaphylactic reaction to
aprotinin following topical use of biological tissue sealant.] Masui 1994;43:1606–10
No comparison group
Konety BR. Fibrin glue v sutured bolster: lessons learned during 100 laparoscopic partial
nephrectomies. Urol Oncol 2006;24:88
Letter/commentary/reply
Koranyi et al. 2005162 No adverse effects
related to fibrin reported
Korotin DP, Pavlunin AV, Artifexova AA. Surgical prevention technique of the primary bronchus
stump insufficiency using a fibrin-collagenic plate. Sovrem Tekhnologii Med 2011;2011:61–6
No adverse effects
related to fibrin reported
Kosmidis C, Efthimiadis C, Anthimidis G, Levva S, Prousalidis J, Papapolychroniadis K, et al.
Combined left hepatectomy with fenestration and using a harmonic scalpel, fibrin glue and
closed suction drainage to prevent bile leakage and ascites in the management of symptomatic
polycystic liver disease: a case report. J Med Case Rep 2009;3:7442
No comparison group
Kowalski C, Kastuar S, Mehta V, Brolin RE. Endoscopic injection of fibrin sealant in repair of
gastrojejunostomy leak after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis
2007;3:438–42
No adverse effects
related to fibrin reported
Kram HB, Nathan RC, Stafford FJ, Fleming AW, Shoemaker WC. Fibrin glue achieves
hemostasis in patients with coagulation disorders. Arch Surg 1989;124:385–7
No comparison group
Kram HB, Ocampo HP, Yamaguchi MP, Nathan RC, Shoemaker WC. Fibrin glue in renal and
ureteral trauma. Urology 1989;33:215–18
No comparison group
Krämer SC, Görich J, Rilinger N, Siech M, Aschoff AJ, Vogel J, et al. Embolization for
gastrointestinal hemorrhages. Eur Radiol 2000;10:802–5
No comparison group
Kruger T, Lisy M, Kalhil M, Nagy C, Stock UA, Wildhirt SM. Matrix-based repair of acute type-a
aortic dissections as an alternative to conventional glue repair. Innovations 2012;7:105
No comparison group
Kudo H, Sakagami Y, Kawamura A, Tamaki N. Delayed cerebrospinal fluid rhinorrhea seven
months after transsphenoidal surgery for pituitary adenoma – case report. Neurol Med Chir
2000;40:160–3
No comparison group
Kumar A, Maartens NF, Kaye AH. Evaluation of the use of BioGlue in neurosurgical procedures.
J Clin Neurosci 2003;10:661–4
No comparison group
Kurian A, Reghunadhan I, Nair KG. Autologous blood versus fibrin glue for conjunctival
autograft adherence in sutureless pterygium surgery: a randomised controlled trial. Br J
Ophthalmol 2015;99:464–70
RCT
Lalos O, Berglund AL, Bjerle P. The long-term outcome of retropubic urethrocystopexy (sutures
and fibrin sealant) and pubococcygeal repair. Acta Obstet Gynecol Scand 2000;79:135–9
No comparison group
Lam FC, Kasper E. Augmented autologous pericranium duraplasty in 100 posterior fossa
surgeries – a retrospective case series. Neurosurgery 2012;71(Suppl. 2):ons302–7
No comparison group
Lam FC, Penumaka A, Chen CC, Fischer EG, Kasper EM. Fibrin sealant augmentation with
autologous pericranium for duraplasty after suboccipital decompression in Chiari 1 patients:
a case series. Surg Neurol Int 2013;4:6
No comparison group
Lamm P, Adelhard K, Juchem G, Weitkunat R, Milz S, Kilger E, et al. Fibrin glue in coronary
artery bypass grafting operations: casting out the Devil with Beelzebub? Eur J Cardiothorac
Surg 2007;32:567–72
No valid comparison
Lamont JP, Hooker G, Espenschied JR, Lichliter WE, Franko E. Closure of proximal colorectal
fistulas using fibrin sealant. Am Surg 2002;68:615–18
No comparison group
Lang et al. 2004134 RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Lange V, Meyer G, Wenk H, Schildberg FW. Fistuloscopy – an adjuvant technique for sealing
gastrointestinal fistulae. Surg Endosc 1990;4:212–16
RCT
Lassen et al. 2006141 RCT
Lau 2005172 RCT
Laws ER. Sellar repair with fibrin sealant and collagen fleece after endoscopic endonasal
transsphenoidal surgery. Commentary. Surg Neurol 2004;62:233
Letter/commentary/reply
Lebowitz RA, Hoffman RA, Roland JT, Cohen NL. Autologous fibrin glue in the prevention of
cerebrospinal fluid leak following acoustic neuroma surgery. Am J Otol 1995;16:172–4
Fibrin was used in both
groups
Lee FY, Leung KL, Lai PB, Lau JW. Selection of patients for laparoscopic repair of perforated
peptic ulcer. Br J Surg 2001;88:133–6
Emergency surgery
Lee S, Kim HR, Cho S, Huh DM, Lee EB, Ryu KM, et al. Staple line coverage after bullectomy for
primary spontaneous pneumothorax: a randomized trial. Ann Thorac Surg 2014;98:2005–11
RCT
Lee JH, Kang NY. Comparison of fibrin glue and sutures for conjunctival wound closure in
strabismus surgery. Korean J Ophthalmol 2011;25:178–84
RCT
Lee et al. 2009227 RCT
Lehnhardt M, Hauser J, Daigeler A, Fredersdorf S, Dragieva G, Ploder B, et al. A variant PDGF
incorporated into fibrin sealant for treatment of burn patients undergoing autologous mesh
skin grafting. Burns 2009;35:S43
RCT
Lei QF, Cai W. Clinical observation on fibrin glue application during pterygium surgery. Int Eye
Sci 2015;15:364–6
RCT
Leonardo C, De Mayo E, Franco G, Zampelli A, Tiesi A, Tartaglia N, et al. Modified ‘pluck’
technique with tissucol for the management of distal ureter during nephroureterectomy. Eur
Urol Suppl 2009;8:347
No comparison group
Levy O, Martinowitz U, Oran A, Tauber C, Horoszowski H. The use of fibrin tissue adhesive to
reduce blood loss and the need for blood transfusion after total knee arthroplasty. A
prospective, randomized, multicenter study. J Bone Joint Surg 1999;81:1580–8
RCT
Lewandowski B. [Topical treatment of bleeding post removed teeth in patients with prosthetic
heart valves whose receiving long-term of oral anticoagulant therapy.] Pol Merkur Lekarski
2002;12:20–4
No comparison group
Liang HS, Hu M, Zhu XS, Zhao HB. Fibrin glue plus danshen injection in the prevention of
postoperative lower back pain due to epidural adhesion: a synchronous controlled study. Chin J
Clin Rehabil 2005;9:16–17
RCT
Lillemoe et al. 200483 RCT
Lin JM, Brolin RE. Treatment of gastric leaks after roux-en-y gastric bypass: a paradigm shift.
Surg Obes Relat Dis 2011;7:373–4
No comparison group
Lin R, Zhang FJ, Yu BW. Fibrin sealant and anaphylactic shock. Chin J New Drugs
2010;19:203–6
Review
Lippert E, Klebl FH, Schweller F, Ott C, Gelbmann CM, Scholmerich J, et al. Fibrin glue in the
endoscopic treatment of fistulae and anastomotic leakages of the gastrointestinal tract. Int J
Colorectal Dis 2011;26:303–11
No comparison group
Liu H, Wei RH, Huang Y, Yang RB, Zhang C, Zhao SZ. Clinical observation on fibrin glue
technique in pterygium surgery performed with limbal autograft transplantation. Int Eye Sci
2013;13:1498–9
RCT
Liu et al. 201413 Not a comparative
observational study
Liu W, Zhang YP, Xie MF, Liu Y. Application of fibrin glue with bandage contact lens in
pterygium surgery. Int Eye Sci 2014;14:879–81
RCT
Llewellyn-Bennett et al. 2012101 RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Lobel B, Ordonez O, Olivo JF, Cipolla B, Milon D, Leveque JM, et al. [Radical prostatectomy and
biologic glue.] Prog Urol 1991;1:440–4
No adverse effects
related to fibrin reported
Locatelli D, Vitali M, Custodi VM, Scagnelli P, Castelnuovo P, Canevari FR. Endonasal
approaches to the sellar and parasellar regions: closure techniques using biomaterials. Acta
Neurochir 2009;151:1431–7
No adverse effects
related to fibrin reported
Lopez et al. 2013129 RCT
Lovisetto et al. 2007180 RCT
Low JC, von Niederhäusern B, Rutherford SA, King AT. Pilot study of perioperative accidental
durotomy: does the period of postoperative bed rest reduce the incidence of complication? Br J
Neurosurg 2013;27:800–2
No comparison group
Lowe J, Luber J, Levitsky S, Hantak E, Montgomery J, Schiestl N, et al. Evaluation of the topical
hemostatic efficacy and safety of TiSSEEL VH S/D fibrin sealant compared with currently licensed
TISSEEL VH in patients undergoing cardiac surgery: a phase 3, randomized, double-blind clinical
study. J Cardiovasc Surg 2007;48:323–31
RCT
Lu Q, Feng J, Yang Y, Nie B, Bao J, Zhao Z, et al. Treatment of type I endoleak after
endovascular repair of infrarenal abdominal aortic aneurysm: success of fibrin glue sac
embolization. J Endovasc Ther 2010;17:687–93
No comparison group
Lund JN, Leveson SH. Fibrin glue in the treatment of pilonidal sinus: results of a pilot study.
Dis Colon Rectum 2005;48:1094–6
No comparison group
Mabrouk et al. 2013214 RCT
Macias CA, Sandler B, Barajas-Gamboa JS, Valero M, Cheverie J, Talamini MA, et al.
Standardized protocol utilization decreases rate of complications: A study of laparoscopic sleeve
gastrectomy in 189 consecutive patients. Surg Endosc 2013;27:S489
No comparison group
Maharaj et al. 2006230 RCT
Mahdy RA, Wagieh MM. Safety and efficacy of fibrin glue versus vicryl sutures in recurrent
pterygium with amniotic membrane grafting. Ophthalmic Res 2012;47:23–6
RCT
Maisano et al. 2009140 RCT
Makiyama K, Sakata R, Sano F, Yamanaka H, Nakaigawa N, Yao M, et al. Clinical comparison
between microporrus polysaccharide hemispheres (MPH) and fibrin glue during laparoscopic
partial nephrectomy. J Endourol 2012;26:A258–9
Abstract
Malik and Kumar 2010171 RCT
Mammis A, Agarwal N, Mogilner AY. Alternative treatment of intracranial hypotension
presenting as postdural puncture headaches using epidural fibrin glue patches: two case
reports. Int J Neurosci 2014;124:863–6
No comparison group
Maralcan G, Bas¸konus¸ I, Aybasti N, Gökalp A. The use of fibrin glue in the treatment of
fistula-in-ano: a prospective study. Surg Today 2006;36:166–70
No comparison group
Maralcan G, Bas¸konus¸ I, Gökalp A, Borazan E, Balk A. Long-term results in the treatment of
fistula-in-ano with fibrin glue: a prospective study. J Korean Surg Soc 2011;81:169–75
No comparison group
Marangos IP, Rosok BI, Kazaryan AM, Rosseland AR, Edwin B. Effect of TachoSil patch in
prevention of postoperative pancreatic fistula. J Gastrointest Surg 2011;15:1625–9
No comparison group
Marchac and Greensmith 2005226 RCT
Marta et al. 2010135 RCT
Martin and Au 201386 RCT
Martin II, Yuen L, Au K. Does fibrin glue sealant decrease the rate of anastomotic leak
following pancreaticoduodenectomy? Results of a prospective randomized trial. HPB
2012;14:84
RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Martin-Mateos RM, Lopez-San Roman A, García-Sánchez C, Garcia-Hoz F, Gil-Grande LA,
Gómez EG, et al. Fibrin-glue-sealed liver biopsy: indications, complications and results.
J Gastrointestin Liver Dis 2014;23:100–1
Letter/commentary/reply
Matsuse S, Maruyama A, Hara Y. Nitrogenous subcutaneous emphysema caused by spray
application of fibrin glue during retroperitoneal laparoscopic surgery. J Anesth 2011;25:426–30
No comparison group
Matthews TW, Briant TD. The use of fibrin tissue glue in thyroid surgery: resource utilization
implications. J Otolaryngol 1991;20:276–8
No adverse effects
related to fibrin reported
McConnell et al. 2012146 RCT
McGoldrick JP, White RW. Fibrin sealant in coronary artery surgery – the devil is always in the
detail! Eur J Cardiothorac Surg 2008;33:949–50
Letter/commentary/reply
Meister T, Kuhlgatz J, Floer M. Over-the-Scope Clip (OTSC) application as rescue therapy for
postoperative enterocutaneous fistula closure. Acta Chir Belg 2014;114:87–9
No comparison group
Melissa CS, Bun TAY, Wing CK, Chung TY, Wai NEK, Tat LH. Randomized double-blinded
prospective trial of fibrin sealant spray versus mechanical stapling in laparoscopic total
extraperitoneal hernioplasty. Ann Surg 2014;259:432–7
RCT
Menegolo M, Frigatti P, Antonello M, Lepidi S, Morelli I, Scrivere P, et al. Prevention of type ii
endoleaks by coils and fibrin glue embolization of the aneurysmatic sac. Interact Cardiovasc
Thorac Surg 2011;12:S52–3
Abstract
Menovsky T. Editorial note on: the clinical study of repairing cauda equina fibres with fibrin
glue after lumbar fracture and dislocation. Spinal Cord 2010;48:638
Letter/commentary/reply
Mentens R, Stalmans P. Comparison of fibrin glue and sutures for conjunctival closure in pars
plana vitrectomy. Am J Ophthalmol 2007;144:128–31
No adverse effects
related to fibrin reported
Mentens R, Stalmans P. Comparison of postoperative comfort in 20 gauge versus 23 gauge
pars plana vitrectomy. Bull Soc Belge Ophtalmol 2009;311:5–10
Not a relevant
comparison
Messmann H, Schaller P, Andus T, Lock G, Vogt W, Gross V, et al. Effect of programmed
endoscopic follow-up examinations on the rebleeding rate of gastric or duodenal peptic ulcers
treated by injection therapy: a prospective, randomized controlled trial. Endoscopy
1998;30:583–9
RCT
Mikhail AA, Kaptein JS, Bellman GC. Use of fibrin glue in percutaneous nephrolithotomy.
Urology 2003;61:910–14
Included children
Mikulas J, Laurinc P, Kazik P, Mraz R. Haemostatic use of Tachosil in partial nephrectomy –
initial experience. Eur Urol Suppl 2010;9:636
No comparison group
Milde LN. An anaphylactic reaction to fibrin glue. Anesth Analg 1989;69:684–6 No comparison group
Milic DJ, Perisic ZD, Zivic SS, Stanojkovic ZA, Stojkovic AM, Karanovic ND, et al. Prevention of
pocket related complications with fibrin sealant in patients undergoing pacemaker implantation
who are receiving anticoagulant treatment. Europace 2005;7:374–9
RCT
Milne et al. 1995201 RCT
Milne et al. 1996203 RCT
Minami K, Saito Y, Shomura Y, Imamura H. [A device to prevent an air-leakage after a
thoracoscopic surgery for spontaneous pneumothorax.] Kyobu Geka 2003;56:904–7
Emergency surgery
MiriBonjar et al. 2012103 RCT
Miscusi M, Polli FM, Forcato S, Coman MA, Ricciardi L, Ramieri A, et al. The use of surgical
sealants in the repair of dural tears during non-instrumented spinal surgery. Eur Spine J
2014;23:1761–6
No adverse effects
related to fibrin reported
Mishra A, Shah S, Nar AS, Bawa A. The role of fibrin glue in the treatment of high and low
fistulas in ano. J Clin Diagn Res 2013;7:876–9
Not a relevant
comparison
continued
DOI: 10.3310/hta20940 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 94
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
181
TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Mita K, Ito H, Fukumoto M, Murabayashi R, Koizumi K, Hayashi T, et al.
Pancreaticojejunostomy using a fibrin adhesive sealant (TachoComb) for the prevention of
pancreatic fistula after pancreaticoduodenectomy. Hepatogastroenterology 2011;58:187–91
No comparison group
Mita K, Ito H, Fukumoto M, Murabayashi R, Koizumi K, Hayashi T, et al. A fibrin adhesive
sealing method for the prevention of pancreatic fistula following distal pancreatectomy.
Hepatogastroenterology 2011;58:604–8
No comparison group
Mithal C, Agarwal P, Mithal N. Pterygium surgery with conjunctival limbal autograft with fibrin
glue under topical anaesthesia with lignocaine 2% jelly. Nepal J Ophthalmol 2011;3:151–4
No comparison group
Mitsuhata H, Horiguchi Y, Saitoh J, Saitoh K, Fukuda H, Hirabayasi Y, et al. An anaphylactic
reaction to topical fibrin glue. Anesthesiology 1994;81:1074–7
No comparison group
Miyamoto H, Futagawa T, Wang Z, Yamazaki A, Morio A, Sonobe S, et al. Fibrin glue and
bioabsorbable felt patch for intraoperative intractable air leaks. Jpn J Thorac Cardiovasc Surg
2003;51:232–6
No comparison group
Mizuno H, Hitomi S, Nakamura T, Shimizu Y. [Clinical experience of the combined use of
polyglycolide non-woven felt with fibrin glue to prevent postoperative pulmonary fistula.] Nihon
Kyobu Geka Gakkai Zasshi 1995;43:1559–64
Not a relevant
comparison
Moench et al. 2010250 RCT
Molloy et al. 2007147 RCT
Montorsi et al. 201284 RCT
Moore et al. 2001111 RCT
Moralee SJ, Carney AS, Cash MP, Murray JA. The effect of fibrin sealant haemostasis on
post-operative pain in tonsillectomy. Clin Otolaryngol Allied Sci 1994;19:526–8
RCT
Morita Y, Nishii O, Kido M, Tsutsumi O. Parvovirus infection after laparoscopic hysterectomy
using fibrin glue hemostasis. Obstet Gynecol 2000;95:1026
No comparison group
Morris MS, Morey AF, Stackhouse DA, Santucci RA. Fibrin sealant as tissue glue: preliminary
experience in complex genital reconstructive surgery. Urology 2006;67:688–91
No comparison group
Mortenson et al. 2008120 RCT
Moser et al. 2008126 RCT
Mueller TJ, DaJusta DG, Cha DY, Kim IY, Ankem MK. Ureteral fibrin sealant injection of the
distal ureter during laparoscopic nephroureterectomy – a novel and simple modification of the
pluck technique. Urology 2010;75:187–92
No comparison group
Muntean W, Zenz W, Edlinger G, Beitzke A. Severe bleeding due to factor V inhibitor after
repeated operations using fibrin sealant containing bovine thrombin. Thromb Haemost
1997;77:1223
Letter/commentary/reply
Muramatsu T, Ohmori K, Shimamura M, Furuichi M, Takeshita S, Negishi N. Staple line
reinforcement with fleece-coated fibrin glue (TachoComb) after thoracoscopic bullectomy for
the treatment of spontaneous pneumothorax. Surg Today 2007;37:745–9
Emergency surgery
Murphy WG, Milne AA, Ruckley CV, Kubba AK, Palmer KR. Fibrin sealant: update on clinical
studies. Transfus Sci 1996;17:341–2
Review
Mustonen et al. 2004104 RCT
Nakahira J, Ishii H, Sawai T, Minami T. Fibrin glue on an aortic cusp detected by transesophageal
echocardiography after valve-sparing aortic valve replacement: a case report. J Med Case Rep
2015;9:53
No comparison group
Nakamura et al. 2005236 RCT
Narotam PK, José S, Nathoo N, Taylon C, Vora Y. Collagen matrix (DuraGen) in dural repair:
analysis of a new modified technique. Spine 2004;29:2861–7
No comparison group
Nativ et al. 201259 RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Navarro-Rodriguez E, Gomez-Luque I, Diaz-Jimenez N, Rioja-Torres P, Bascunana-Estudillo G,
Ruiz-Rabelo JF, et al. Effectiveness of an absorbable fibrin sealant patch to reduce lymphoceles
formation after axillary lymphadenectomy for breast cancer: a matched-pair analysis. Am J Surg
2014;208:824–30
No adverse effects
related to fibrin reported
Nelson RL, Cintron J, Abcarian H. Dermal island-flap anoplasty for transsphincteric fistula-in-ano:
assessment of treatment failures. Dis Colon Rectum 2000;43:681–4
No comparison group
Nervi C, Gamelli RL, Greenhalgh DG, Luterman A, Hansbrough JF, Achauer BM, et al. A
multicenter clinical trial to evaluate the topical hemostatic efficacy of fibrin sealant in burn
patients. J Burn Care Rehabil 2001;22:99–103
RCT
Neuss H, Raue W, Koplin G, Schwenk W, Reetz C, Mall JW. Intraoperative application of fibrin
sealant does not reduce the duration of closed suction drainage following radical axillary lymph
node dissection in melanoma patients: a prospective randomized trial in 58 patients. World J
Surg 2008;32:1450–5
RCT
Neuss et al. 2009118 RCT
Nieuwendaal CP, van der Meulen IJ, Mourits M, Lapid-Gortzak R. Long-term follow-up of
pterygium surgery using a conjunctival autograft and Tissucol. Cornea 2011;30:34–6
No comparison group
Nishizawa S, Yokota N, Yokoyama T, Mukodaka H, Watanabe T, Hoshino T, et al. Prevention
of postoperative complications in skull base surgery for nasal or paranasal sinus carcinoma
invading the skull base. J Clin Neurosci 2001;8(Suppl. 1):67–70
No comparison group
Nistor RF. Fibrin sealant in coronary artery bypass grafting surgery; reflection on risk and
benefit. Eur J Cardiothorac Surg 2008;33:317
Letter/commentary/reply
Notarnicola A, Moretti L, Martucci A, Spinarelli A, Tafuri S, Pesce V, et al. Comparative efficacy
of different doses of fibrin sealant to reduce bleeding after total knee arthroplasty. Blood
Coagul Fibrinolysis 2012;23:278–84
RCT
Novik B, Hagedorn S, Mörk UB, Dahlin K, Skullman S, Dalenbäck J. Fibrin glue for securing the
mesh in laparoscopic totally extraperitoneal inguinal hernia repair: a study with a 40-month
prospective follow-up period. Surg Endosc 2006;20:462–7
No comparison group
Ochiai T, Sonoyama T, Soga K, Inoue K, Ikoma H, Shiozaki A, et al. Application of polyethylene
glycolic acid felt with fibrin sealant to prevent postoperative pancreatic fistula in pancreatic
surgery. J Gastrointest Surg 2010;14:884–90
No comparison group
Ochsner MG, Maniscalco-Theberge ME, Champion HR. Fibrin glue as a hemostatic agent in
hepatic and splenic trauma. J Trauma 1990;30:884–7
No comparison group
Ofikwu GI, Sarhan M, Ahmed L. EVICEL glue-induced small bowel obstruction after
laparoscopic gastric bypass. Surg Laparosc Endosc Percutan Tech 2013;23:e38–40
No comparison group
Ohta M, Komatsu F, Abe H, Sakamoto S, Tsugu H, Oshiro S, et al. Complication caused by use
of fibrin glue in vessel transposition for trigeminal neuralgia. Neurol Med Chir 2008;48:30–2
No comparison group
Ohwada et al. 19988 Not a relevant
comparison
Oliver et al. 2001228 RCT
Oliver et al. 2002215 RCT
Öllinger R, Mihaljevic AL, Schuhmacher C, Bektas H, Vondran F, Kleine M, et al. A multicentre,
randomized clinical trial comparing the Veriset™ haemostatic patch with fibrin sealant for the
management of bleeding during hepatic surgery. HPB 2013;15:548–58
RCT
Olmi S, Erba L, Bertolini A, Scaini A, Croce E. Fibrin glue for mesh fixation in laparoscopic
transabdominal preperitoneal (TAPP) hernia repair: indications, technique, and outcomes. Surg
Endosc 2006;20:1846–50
No comparison group
Olmi S, Erba L, Bertolini A, Scaini A, Mastropasqua E, Conti M, et al. [Use of fibrin glue (Tissucol)
for mesh fixation in laparoscopic transabdominal hernia repair.] Chir Ital 2005;57:753–9
No comparison group
Olmi et al. 2007259 No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Olmi S, Scaini A, Erba L, Croce E. Use of fibrin glue (Tissucol) in laparoscopic repair of
abdominal wall defects: preliminary experience. Surg Endosc 2007;21:409–13
No comparison group
Olsen TW, Sternberg P Jr, Capone A Jr, Martin DF, Lim JI, Grossniklaus HE, et al. Macular hole
surgery using thrombin-activated fibrinogen and selective removal of the internal limiting
membrane. Retina 1998;18:322–9
No comparison group
Olsha O, Hadar T, Dalo RA, Verocherinsky N, Ashkenazi I. Fibrin sealant to reduce drainage
after axillary dissection. Ann Surg Oncol 2014;21:92–3
Not a relevant
comparison
Olsha O, Hadar T, Noy V, Verocherinsky N, Abu Dalo R, Ashkenazi I. Fibrin sealant to reduce
lymphatic drainage after axillary dissection. Eur J Cancer 2014;50:S130–1
No comparison group
Omote Y, Kubo Y. [Effectiveness of fibrin glue in preventing postoperative pulmonary air
leakage.] Kyobu Geka 1994;47:355–9
No adverse effects
related to fibrin reported
Orsel I, Guillaume A, Feiss P. [Anaphylactic shock caused by fibrin glue.] Ann Fr Anesth Reanim
1997;16:292–3
No comparison group
Oswald AM, Joly LM, Gury C, Disdet M, Leduc V, Kanny G. Fatal intraoperative anaphylaxis
related to aprotinin after local application of fibrin glue. Anesthesiology 2003;99:762–3
Letter/commentary/reply
Ozdamar Y, Mutevelli S, Han U, Ileri D, Onal B, Ilhan O, et al. A comparative study of tissue
glue and vicryl suture for closing limbal-conjunctival autografts and histologic evaluation after
pterygium excision. Cornea 2008;27:552–8
RCT
Ozeki M, Watanabe N, Miyamoto N, Takahashi M, Murakami S, Sekiya Y, et al. Prevention of
postoperative meningitis in cochlear implantation: the advantage of the use of temporal muscles
and fibrin glue for the shield of cochleostomy. Cochlear Implants Int 2004;5(Suppl. 1):73–5
Abstract
Palacios Jaraquemada JM, Pesaresi M, Nassif JC, Hermosid S. Anterior placenta percreta:
surgical approach, hemostasis and uterine repair. Acta Obstet Gynecol Scand 2004;83:738–44
Not a relevant
comparison
Parker MC, Pohlen U, Borel Rinkes IH, Delvin T. The application of TachoSil® for sealing
colorectal anastomosis: a feasibility study. Colorectal Dis 2013;15:252–7
No comparison group
Pavlik Marangos I, Røsok BI, Kazaryan AM, Rosseland AR, Edwin B. Effect of TachoSil patch in
prevention of postoperative pancreatic fistula. J Gastrointest Surg 2011;15:1625–9
No adverse effects
related to fibrin reported
Pescatore P, Jornod P, Borovicka J, Pantoflickova D, Suter W, Meyenberger C, et al. Epinephrine
versus epinephrine plus fibrin glue injection in peptic ulcer bleeding: a prospective randomized
trial. Gastrointest Endosc 2002;55:348–53
RCT
Petersen B, Barkun A, Carpenter S, Chotiprasidhi P, Chuttani R, Silverman W, et al. Tissue
adhesives and fibrin glues. Gastrointest Endosc 2004;60:327–33
Not a comparative
observational study
Petsas T, Siamblis D, Giannakenas C, Tepetes K, Dougenis D, Spiropoulos K, et al. Fibrin glue
for sealing the needle track in fine-needle percutaneous lung biopsy using a coaxial system:
Part II – Clinical study. Cardiovasc Intervent Radiol 1995;18:378–82
RCT
Petter Puchner AH, Khakpour Z, May C, Mika K, Glaser KS, Redl H. The impact of atraumatic
fibrin sealant vs. staple mesh fixation in tapp hernia repair on chronic pain and quality of life –
results of a randomized controlled study. Surg Endosc 2010;24(Suppl. 1):618
RCT
Pfuhl JP, Rucker KJ, Schafer D, Baumann R. Extrauterine pregnancy after tubal anastomosis
with fibrin glue-light microscopy. Arch Gynecol Obstet 1989;245:436–7
Abstract
Phillips AW, Viswanath YK, Burns JK, Hall CE, Horgan AF. Use of fibrin glue for fixation of
mesh and approximation of Peritoneum in Transabdominal Preperitoneal (TAPP) inguinal hernia
repair: technical feasibility and early surgical outcomes. Surg Laparosc Endosc Percutan Tech
2014;24:e43–5
No comparison group
Pilon F, Tosato F, Danieli D, Campanile F, Zaramella M, Milite D. Intrasac fibrin glue injection
after platinum coils placement: the efficacy of a simple intraoperative procedure in preventing
type II endoleak after endovascular aneurysm repair. Interact Cardiovasc Thorac Surg
2010;11:78–82
No adverse effects
related to fibrin reported
Pilone et al. 201289 RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Por YM, Tan YL, Mehta JS, Tan DT. Intracameral fibrin tissue sealant as an adjunct in tectonic
lamellar keratoplasty for large corneal perforations. Cornea 2009;28:451–5
No comparison group
Porpiglia F, Fiori C, Bertolo R, Mele F, Valentino F, Di Stasio A, et al. Complications after
laparoscopic partial nephrectomy in a recent series. J Urol 2011;185:e314–15
No comparison group
Porpiglia F, Renard J, Billia M, Morra I, Terrone C, Scarpa RM. Biological glues and collagen
fleece for hemostasis during laparoscopic partial nephrectomy: technique and results of
prospective study. J Endourol 2007;21:423–8
No adverse effects
related to fibrin reported
Porte RJ, Verhoef C, De Wilt JHW, Rijken AM, Klaase JM, Ayez N, et al. FibrocapsTM, a novel
fibrin sealant, for bleeding during hepatic resection: results of a phase 2, randomized,
controlled study. HPB (OXFORD) 2012;14:133
RCT
Powell BS, Wandrey D, Voeller GR. A technique for placement of a bioabsorbable prosthesis
with fibrin glue fixation for reinforcement of the crural closure during hiatal hernia repair.
Hernia 2013;17:81–4
No comparison group
Prado et al. 2006187 RCT
Probst EN, Grzyska U, Westphal M, Zeumer H. Preoperative embolization of intracranial
meningiomas with a fibrin glue preparation. Am J Neuroradiol 1999;20:1695–702
No comparison group
Pruthi RS, Chun J, Richman M. The use of a fibrin tissue sealant during laparoscopic partial
nephrectomy. BJU Int 2004;93:813–17
No comparison group
Pugao R, Perenack J. Delayed reaction to fibrin sealant after facelift surgery: a case report and
literature review. J Oral Maxillofac Surg 2012;70:e44–5
No comparison group
Rábago LR, Ventosa N, Castro JL, Marco J, Herrera N, Gea F. Endoscopic treatment of
postoperative fistulas resistant to conservative management using biological fibrin glue.
Endoscopy 2002;34:632–8
No comparison group
Ramon Rabago L, Moral I, Delgado M, Guerra I, Quintanilla E, Castro JL, et al. [Endoscopic
treatment of gastrointestinal fistulas with biological fibrin glue.] Gastroenterologia y
Hepatologia 2006;29:390–6
No comparison group
Randelli F, Banci L, Ragone V, Pavesi M, Randelli G. Effectiveness of fibrin sealant after
cementless total hip replacement: a double-blind randomized controlled trial. Int J
Immunopathol Pharmacol 2013;26:189–97
RCT
Randelli et al. 2014149 RCT
Raquel SS, Gonzalez S, Nicolas R, Crego R, Tome C, Estevez S, et al. Staple line reinforcement
with tissue glue sealant (Tissucol) during the learning curve of laparoscopic bariatric surgery.
Obes Surg 2009;19:1045
No comparison group
Reddy M, Schöggl A, Reddy B, Saringer W, Weigel G, Matula C. A clinical study of a
fibrinogen-based collagen fleece for dural repair in neurosurgery. Acta Neurochir
2002;144:265–9
No comparison group
Reppenhagen S, Reichert JC, Rackwitz L, Rudert M, Raab P, Daculsi G, et al. Biphasic bone
substitute and fibrin sealant for treatment of benign bone tumours and tumour-like lesions.
Int Orthop 2012;36:139–48
No comparison group
Richmon JD, Tian Y, Husseman J, Davidson TM. Use of a sprayed fibrin hemostatic sealant after
laser therapy for hereditary hemorrhagic telangiectasia epistaxis. Am J Rhinol 2007;21:187–91
Included children
Romeo F, Pagano N, Carlino A, Rando G, Strangio G, Vitetta E, et al.Multimodal endoscopic
approach to postsurgical gastro-esophageal anastomotic leaks. Gastrointest Endosc 2010;71:AB132
No comparison group
Rousou J, Levitsky S, Gonzalez-Lavin L, Cosgrove D, Magilligan D, Weldon C, et al. Randomized
clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac
operations. A multicenter study. J Thorac Cardiovasc Surg 1989;97:194–203
RCT
Rudelstorfer B, Loidl K, Heider R. [Wound closure of the fallopian tube with fibrin glue:
endoscopic organ preserving therapy of extrauterine pregnancy.] Gynakol Geburtshilfliche
Rundsch 1997;37:62–7
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Ruggiero R, Procaccini E, Gili S, Cremone C, Parmeggiani D, Conzo G, et al. New trends on
fibrin glue in seroma after axillary lymphadenectomy for breast cancer. G Chir 2009;30:306–10
RCT
Ruggiero R, Procaccini E, Piazza P, Docimo G, Iovino F, Antoniol G, et al. Effectiveness of fibrin
glue in conjunction with collagen patches to reduce seroma formation after axillary
lymphadenectomy for breast cancer. Am J Surg 2008;196:170–4
No adverse effects
related to fibrin reported
Sabatini et al. 2012148 RCT
Sadik KW, Bonatti H, Schmitt T. Injection of fibrin glue for temporary treatment of an ascites
leak from a ruptured umbilical hernia in a patient with liver cirrhosis. Surgery 2008;143:574
Letter/commentary/reply
Sadik KW, Laibstain S, Northup PG, Kashmer D, Schmitt TM, Bonatti HJR. Closure of ascites
leaks with fibrin glue injection in patients with end-stage liver disease. J Laparoendosc Adv Surg
Tech A 2011;21:609–14
No comparison group
Sáenz Medina J, Redondo González E, Hernández-Atance JM, Crespo Martínez L, Llanes
González L, Rendón Sánchez D, et al. Renocolic fistula as a complication of radiofrequency in
the treatment of renal cell carcinoma. Arch Esp Urol 2010;63:74–7
No comparison group
Safan et al. 2009235 RCT
Saha et al. 2011204 RCT
Saha et al. 2012197 RCT
Salgado W, Rosa GV, Nonino-Borges CB, Ceneviva R. Prospective and randomized comparison
of two techniques of staple line reinforcement during open Roux-en-Y gastric bypass:
oversewing and bioabsorbable Seamguard®. J Laparoendosc Adv Surg Tech A 2011;21:579–82
RCT
Samimi DB, Hamilton DR. Recalcitrant epithelial ingrowth in patients with compromised eyelid
function. J Refract Surg 2008;24:544–6
No comparison group
Sanal M. Does fibrin glue cause foreign body reactions? Eur J Pediatr Surg 1993;3:190 Letter/commentary/reply
Sanchez-Mendez JI, Lopez-Rodriguez MJ, Sanchez-Martinez C, Martinez-Garcia MT,
Iniesta Donate MD, Ordas Santotomas J. Fibrin sealant for the prevention of axillary seroma
formation after axillary lymph node dissection. A prospective randomized study. Cancer Res
2009;69:4139
RCT
Santoro E, Agresta F, Buscaglia F, Mulieri G, Mazzarolo G, Bedin N, et al. Preliminary
experience using fibrin glue for mesh fixation in 250 patients undergoing minilaparoscopic
transabdominal preperitoneal hernia repair. J Laparoendosc Adv Surg Tech A 2007;17:12–15
No adverse effects
related to fibrin reported
Santulli P, Marcellin L, Touboul C, Ballester M, Darai E, Rouzier R. Experience with TachoSil in
obstetric and gynecologic surgery. Int J Gynaecol Obstet 2011;113:112–15
No comparison group
Sapala JA, Wood MH, Schuhknecht MP. Anastomotic leak prophylaxis using a vapor-heated
fibrin sealant: report on 738 gastric bypass patients. Obes Surg 2004;14:35–42
No comparison group
Sarnicola V, Vannozzi L, Motolese PA. Recurrence rate using fibrin glue-assisted ipsilateral
conjunctival autograft in pterygium surgery: 2-year follow-up. Cornea 2010;29:1211–14
No comparison group
Satoi S, Toyokawa H, Yanagimoto H, Yamamoto T, Hirooka S, Yui R, et al. Reinforcement of
pancreticojejunostomy using polyglycolic acid mesh and fibrin glue sealant. Pancreas
2011;40:16–20
No adverse effects
related to fibrin reported
Sautter NB, Batra PS, Citardi MJ. Endoscopic management of sphenoid sinus cerebrospinal fluid
leaks. Ann Otol Rhinol Laryngol 2008;117:32–9
No comparison group
Savva A, Taylor MJ, Beatty CW. Management of cerebrospinal fluid leaks involving the
temporal bone: report on 92 patients. Laryngoscope 2003;113:50–6
No adverse effects
related to fibrin reported
Schaller B, Baumann A. Headache after removal of vestibular schwannoma via the retrosigmoid
approach: a long-term follow-up-study. Otolaryngol Head Neck Surg 2003;128:387–95
No comparison group
Scheele J, Schricker KT, Goy RD, Lampe I, Panis R. [Risk of hepatitis in fibrin gluing in general
surgery.] Med Welt 1981;32:783–8
Unobtainable
Schenk et al. 2003195 RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Schenk et al. 2002196 RCT
Schettino AM, Franco D, Franco T, Filho JM, Vendramin FS. Use of autologous fibrin glue
(platelet-poor plasma) in abdominal dermolipectomies. Aesthetic Plast Surg 2012;36:1296–301
Not fibrin sealant
Scheule AM, Beierlein W, Lorenz H, Ziemer G. Repeated anaphylactic reactions to aprotinin in
fibrin sealant. Gastrointest Endosc 1998;48:83–5
No comparison group
Schlenker M, Ringelstein EB. Epidural fibrin clot for the prevention of post-lumbar puncture
headache: a new method with risks. J Neurol Neurosurg Psychiatr 1987;50:1715
Letter/commentary/reply
Schmidt SC, Langrehr JM. Re: Spray application of fibrin glue as risk factor for subcutaneous
emphysema in laparoscopic transabdominal inguinal hernia repair. Surg Laparosc Endosc
Percutan Tech 2007;17:221–2
Letter/commentary/reply
Scholz et al. 2002121 RCT
Schopf SK, von Ahnen M, von Ahnen T, Schardey HM. [Observations on the use of TachoSil® in
cholecystectomy – a multicentre, prospective, single-arm cohort study.] Zentralbl Chir
2012;137:55–60
No comparison group
Schwartz et al. 200477 RCT
Segal N, Puterman M, Rotem E, Niv A, Kaplan D, Kraus M, et al. A prospective randomized
double-blind trial of fibrin glue for reducing pain and bleeding after tonsillectomy. Int J Pediatr
Otorhinolaryngol 2008;72:469–73
RCT
Séguin JR, Frapier JM, Colson P, Chaptal PA. Fibrin sealant improves surgical results of type A
acute aortic dissections. Ann Thorac Surg 1991;52:745–8
Emergency surgery
Séguin JR, Picard E, Frapier JM, Chaptal PA. Repair of the aortic arch with fibrin glue in type A
aortic dissection. J Card Surg 1994;9:734–8
No comparison group
Seiler RW, Mariani L. Sellar reconstruction with resorbable vicryl patches, gelatin foam, and
fibrin glue in transsphenoidal surgery: a 10-year experience with 376 patients. J Neurosurg
2000;93:762–5
No comparison group
Sentovich SM. Fibrin glue for anal fistulas: long-term results. Dis Colon Rectum
2003;46:498–502
No comparison group
Seo JK, Kim HJ, Koh JK, Hong SK, Jung SY, Hwang SH, et al. The use of fibrin glue in osmidrosis
surgery with a cartilage shaver: 18 patients. J Am Acad Dermatol 2013;68(Suppl. 1):AB223
No comparison group
Seok Y, Cho S, Lee E. Bronchial stump coverage with fibrin glue-coated collagen fleece in lung
cancer patients who underwent pneumonectomy. Ann Thorac Cardiovasc Surg 2014;20:117–22
No adverse effects
related to fibrin reported
Shah HN, Hegde S, Shah JN, Mohile PD, Yuvaraja TB, Bansal MB. A prospective, randomized
trial evaluating the safety and efficacy of fibrin sealant in tubeless percutaneous
nephrolithotomy. J Urol 2006;176:2488–92
RCT
Shah HN, Kausik V, Hedge S, Shah JN, Bansal MB. Initial experience with hemostatic fibrin glue
as adjuvant during tubeless percutaneous nephrolithotomy. J Endourol 2006;20:194–8
No adverse effects
related to fibrin reported
Sharma et al. 2003164 RCT
Sharma SK, Perry KT, Turk TM. Endoscopic injection of fibrin glue for the treatment of
urinary-tract pathology. J Endourol 2005;19:419–23
No comparison group
Shehadeh-Mashor R, Srinivasan S, Boimer C, Lee K, Tomkins O, Slomovic AR. Management of
recurrent pterygium with intraoperative mitomycin C and conjunctival autograft with fibrin
glue. Am J Ophthalmol 2011;152:730–2
No comparison group
Shen L, Luo H, Tan S. Effect of fibrin glue on patients after high frequency electrocoagulatomy
for gastrointestinal protuberant lesions. Med J Wuhan Uni 2003;24:377
RCT
Shimada Y, Hongo M, Miyakoshi N, Sugawara T, Kasukawa Y, Ando S, et al. Dural substitute
with polyglycolic acid mesh and fibrin glue for dural repair: technical note and preliminary
results. J Orthop Sci 2006;11:454–8
Fibrin was used in both
groups
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Shin IS, Lee DW, Lew DH. Efficacy of quilting sutures and fibrin sealant together for prevention
of seroma in extended latissimus dorsi flap donor sites. Arch Plast Surg 2012;39:509–13
Fibrin was used in both
groups
Shinohara H, Koizumi T, Aoki T, Yoshiya K, Koike T, Tsuchida M. Intrapleural administration of
a combination of cisplatin and fibrin glue for pleural lavage cytology-positive patients with
non-small cell lung cancer. J Thorac Oncol 2013;8:S508
Not a relevant
comparison
Siemer et al. 2007221 RCT
Silas AM, Forauer AR, Perrich KD, Gemery JM. Sclerosis of postoperative lymphoceles:
avoidance of prolonged catheter drainage with use of a fibrin sealant. J Vasc Interv Radiol
2006;17:1791–5
No comparison group
Silecchia et al. 200862 RCT
Silecchia G, Boru CE, Mouiel J, Rossi M, Anselmino M, Tacchino RM, et al. Clinical evaluation
of fibrin glue in the prevention of anastomotic leak and internal hernia after laparoscopic
gastric bypass: preliminary results of a prospective, randomized multicenter trial. Obes Surg
2006;16:125–31
RCT
Silecchia G, Iossa A, Cavallaro G, Rizzello M, Longo F. Reinforcement of hiatal defect repair
with absorbable mesh fixed with non-permanent devices. Minim Invasive Ther Allied Technol
2014;23:302–8
Not a comparative
observational study
Singer M, Cintron J, Nelson R, Orsay C, Bastawrous A, Pearl R, et al. Treatment of fistulas-in-ano
with fibrin sealant in combination with intra-adhesive antibiotics and/or surgical closure of the
internal fistula opening. Dis Colon Rectum 2005;48:799–808
RCT
Sintler et al. 2005202 RCT
Skovgaard et al. 2013150 RCT
Slupski P, Jarzemski P, Listopadzki S, Wisniewski P. Suture-free laparoscopic partial
nephrectomy - improvement of hemostasis with human fibrinogen and thrombin-coated
collagen patch (TachoSil). Eur Urol Suppl 2010;9:636
Abstract
Sokullu O, Sanioglu S, Orhan G, Kut MS, Hastaoglu O, Karaca P, et al. New use of teflon to
reduce bleeding in modified bentall operation. Tex Heart Inst J 2008;35:147–51
No comparison group
Soumian S, Al-Ani S, Sterne G. Randomized clinical trial on the effect of fibrin sealant on
latissimus dorsi donor-site seroma formation after breast reconstruction (Br J Surg
2012;99:1381–8). Br J Surg 2013;100:1671
RCT
Sozen et al. 2011212 RCT
Sozen S, Topuz O, Keceli M, Tukenmez M, Onceken O, Tuna O. The use of fibrin glue in
surgical treatment of pilonidal sinus disease: a prospective study in the limberg flap procedure.
Pak J Med Sci 2011;27:537–40
RCT
Spotnitz WD, Dalton MS, Baker JW, Nolan SP. Successful use of fibrin glue during 2 years of
surgery at a university medical center. Am Surg 1989;55:166–8
No comparison group
Srinivasan et al. 2009167 RCT
Stanojkovic Z, Milic D, Zivic S, Perisic Z. Application effect of fibrin sealant in patients
undergoing pacemaker implantation. Vox Sang 2009;96:238
Abstract
Sterkers O, Becherel P, Sterkers JM. [Repair of the facial nerve exclusively by fibrin glue.
56 cases.] Ann Otolaryngol Chir Cervicofac 1989;106:176–81
No comparison group
Stoeckli SJ, Moe KS, Huber A, Schmid S. A prospective randomized double-blind trial of fibrin
glue for pain and bleeding after tonsillectomy. Laryngoscope 1999;109:652–5
RCT
Sugg U. [Risk of transmission of hepatitis through human fibrin adhesives.] Dtsch Med
Wochenschr 1985;110:1161–2
No adverse effects
related to fibrin reported
Suzuki A, Amano J, Tanaka H, Sakamoto T, Sunamori M. Surgical consideration of aortitis
involving the aortic root. Circulation 1989;80:I222–32
Not a relevant
comparison
Swain BT, Ellis CN. Fibrin glue treatment of low rectal and pouch-anal anastomotic sinuses.
Dis Colon Rectum 2004;47:253–5
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Swan et al. 2011113 RCT
Szczesny T, Kubiszewska I, Rybak A, Michalkiewicz J, Szymankiewicz M, Kowalewski J. The role
of Tachosil in lymphostasis after mediastinal lymphadenectomy in lung cancer patients. J Thorac
Oncol 2011;6(Suppl. 2):876–7
RCT
Tachibana et al. 2003122 RCT
Taguchi Y, Suzuki R, Okada M, Sekino H. Spinal arachnoid cyst developing after surgical
treatment of a ruptured vertebral artery aneurysm: a possible complication of topical use of
fibrin glue. Case report. J Neurosurg 1996;84:526–9
No comparison group
Takeuchi et al. 2005234 RCT
Tan LA, Takagi I, Straus D, O’Toole JE. Management of intended durotomy in minimally
invasive intradural spine surgery: clinical article. J Neurosurg Spine 2014;21:279–85
No comparison group
Tan QT, Lee CM, Tan VKM, Ong KW. The use of Tisseel fibrin sealant in seroma reduction after
mastectomy – a pilot study. Breast 2015;24:S133
Abstract
Târcoveanu E, Lupas¸cu C, Moldovanu R, Vlad N, Bradea C, Vasilescu A. [Fibrin-collagen patch
(TachoComb) in general surgery. Indications and results.] Rev Med Chir Soc Med Nat Iasi
2007;111:396–401
No comparison group
Terasaka S, Iwasaki Y, Kuroda S, Uchida T. [A novel method of dural repair using polyglycolic
acid non-woven fabric and fibrin glue: clinical results of 140 cases.] No Shinkei Geka
2006;34:1109–17
No comparison group
Terashima M, Fujiwara S, Yaginuma GY, Takizawa K, Kaneko U, Meguro T. Outcome of
percutaneous intrapericardial fibrin-glue injection therapy for left ventricular free wall rupture
secondary to acute myocardial infarction. Am J Cardiol 2008;101:419–21
No comparison group
Than KD, Baird CJ, Olivi A. Polyethylene glycol hydrogel dural sealant may reduce incisional
cerebrospinal fluid leak after posterior fossa surgery. Neurosurgery 2008;63(Suppl. 1):ON182–6
Not fibrin sealant
Tirindelli MC, Flammia G, Cudillo L, Dentamaro T, Picardi A, Annibali O, et al. Fibrin glue
directly applied on damaged bladder mucosa during cystoscopy is highly effective to treat
severe, refractory, haemorrhagic cystitis after allogeneic transplant. Bone Marrow Transplant
2010;45:S12
No comparison group
Tirindelli MC, Flammia G, Sergi F, Cerretti R, Cudillo L, Picardi A, et al. Fibrin glue for refractory
hemorrhagic cystitis after unrelated marrow, cord blood, and haploidentical hematopoietic
stem cell transplantation. Transfusion 2009;49:170–5
No comparison group
Tirindelli MC, Flammia GP, Bove P, Cerretti R, Cudillo L, de Angelis G, et al. Fibrin glue therapy
for severe hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Biol
Blood Marrow Transplant 2014;20:1612–17
No comparison group
Tiscione D, Cicuto S, Luciani L, Vattovani V, Coccarelli F, Malossini G. Use of fibrin gel (Tissucol)
as hemostatic agent during laparoscopic partial nephrectomy: our experience. Anticancer Res
2010;30:1520–1
No comparison group
Toman N, Buschmann A, Muehlberger T. [Fibrin glue and seroma formation following
abdominoplasty.] Chirurg 2007;78:531–5
Fibrin was used in both
groups
Tomizawa Y, Endo M, Kitamura M, Shiikawa A, Yagi Y, Koyanagi H. [Coronary artery bypass
graft stenosis suspected to be due to hemostatic agents: a case report.] Kyobu Geka
1991;44:764–6
No comparison group
Topart P, Vandenbroucke F, Lozac’h P. Tisseel versus tack staples as mesh fixation in totally
extraperitoneal laparoscopic repair of groin hernias: a retrospective analysis. Surg Endosc
2005;19:724–7
No adverse effects
related to fibrin reported
Topgül K, Anadol AZ, Güngör B, Malazgirt Z. Laparoscopic bilateral hernia repair using fibrin
sealant: technical report of two cases. J Laparoendosc Adv Surg Tech A 2005;15:638–41
No comparison group
Topiwala P, Bansal RK. Comparative evaluation of cyanoacrylate and fibrin glue for muscle
recession in strabismus surgery. J Pediatr Ophthalmol Strabismus 2014;51:349–54
RCT
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Tournoux F, Karila-Cohen D, Hvass U, Peytavin G, Phelippeau G, Vahanian A. [Neutropenia and
fever after aorto-coronary bypasses.] Ann Chir 2004;129:174–6
No comparison group
Tredwell SJ, Sawatzky B. The use of fibrin sealant to reduce blood loss during Cotrel-Dubousset
instrumentation for idiopathic scoliosis. Spine 1990;15:913–15
RCT
Tripoloni DE, Schierano MC. Comments about the article ‘Open tension-free Lichtenstein repair
of inguinal hernia: use of fibrin glue versus sutures for mesh fixation’ by Negro et al. Hernia
2012;16:235–6
Letter/commentary/reply
Troisi RI, Bektas H, Pratschke J, Topal B, Buchler M, Schuhmacher CP, et al. A prospective,
multi-center, randomized, single-blind study to compare the VerisetTM hemostatic patch to fibrin
sealant (Tachosil) in subjects undergoing hepatic surgery. HPB 2012;14:104–5
RCT
Truong S, Bohm G, Klinge U, Stumpf M, Schumpelick V. Results after endoscopic treatment of
postoperative upper gastrointestinal fistulas and leaks using combined Vicryl plug and fibrin
glue. Surg Endosc 2004;18:1105–8
No comparison group
Tsuji Y, Fujishiro M, Kodashima S, Ono S, Niimi K, Mochizuki S, et al. Polyglycolic acid sheets
and fibrin glue decrease the risk of bleeding after endoscopic submucosal dissection of gastric
neoplasms (with video). Gastrointest Endosc 2015;81:906–12
Not a comparative
observational study
Tsuji Y, Ohata K, Gunji T, Shozushima M, Hamanaka J, Ohno A, et al. Endoscopic tissue
shielding method with polyglycolic acid sheets and fibrin glue to cover wounds after colorectal
endoscopic submucosal dissection (with video). Gastrointest Endosc 2014;79:151–5
No comparison group
Udén et al. 199398 RCT
Ulusoy et al. 200396 RCT
Ussat S, Lodes U, Wex C, Rapp L, Schulz HU, Meyer F. [Successful closure of a postoperative
esophagobronchial fistula following esophageal resection using fibrin glue.] Dtsch Med
Wochenschr 2013;138:1406–9
RCT
Uy HS, Reyes JMG, Flores JDG, Lim-Bon-Siong R. Comparison of fibrin glue and sutures for
attaching conjunctival autografts after pterygium excision. Ophthalmology 2005;112:667–71
No comparison group
Vaiman M, Eviatar E. Lymphatic fistulae after neck dissection: the fibrin sealant treatment.
J Surg Oncol 2008;98:467–71
RCT
Vaiman et al. 2002188 No comparison group
Vaiman M, Eviatar E, Shlamkovich N, Segal S. Effect of modern fibrin glue on bleeding after
tonsillectomy and adenoidectomy. Ann Otol Rhinol Laryngol 2003;112:410–14
RCT
Vaiman et al. 2005191 RCT
Vaiman et al. 2005189 RCT
Vaiman M, Segal S, Eviatar E. Fibrin glue treatment for epistaxis. Rhinology 2002;40:88–91 RCT
Valenti A, Rivkin E, Carandina S, Steiger A, Polliand C, Rizk N, et al. Laparoscopy sleeve
gastrectomy: 220 cases in a comparative study with three buttressing methods applied on
stapler line. Obes Surg 2013;23:1053
Not a comparative
observational study
Van Velthoven V, Clarici G, Auer LM. Fibrin tissue adhesive sealant for the prevention of CSF
leakage following transsphenoidal microsurgery. Acta Neurochir 1991;109:26–9
No comparison group
Vaxman et al. 1995112 RCT
Vaxman et al. 1995251 RCT
Verhoef et al. 2015240 RCT
Vichare N, Choudhary T, Arora P. A comparison between fibrin sealant and sutures for
attaching conjunctival autograft after pterygium excision. Med J Armed Forces India
2013;69:151–5
No adverse effects
related to fibrin reported
Vitton V, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn’s
anal fistulas with fibrin glue injection. Aliment Pharmacol Ther 2005;21:1453–7
No comparison group
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TABLE 39 Excluded observational studies (continued )
Study excluded Reason for exclusion
Waclawiczek HW, Boeckl O. [Clinical experience with fibrin gluing in general and thoracic
surgery.] Zentralbl Chir 1986;111:16–24
No comparison group
Wang et al. 2003153 RCT
Wang et al. 2001144 RCT
Wang X, Ren J, Zhu W, Li N, Li J. Fibrin sealant prevents gastrointestinal anastomosis
dehiscence in intra-abdominal sepsis. Int Surg 2007;92:27–31
No comparison group
Watanabe G, Haverich A, Speier R, Dresler C, Borst HG. Surgical treatment of active infective
endocarditis with paravalvular involvement. J Thorac Cardiovasc Surg 1994;107:171–7
No comparison group
White N, Carver ED, Rodrigues D, Dover S, Magdum S, Nishikawa H, et al. Calvarial
remodelling for sagittal synostosis: does fibrin glue (Tisseel) reduce post-operative blood
transfusion requirements? Childs Nerv Syst 2009;25:867–9
Included children
Willecocq C, Pizzoferrato AC, Fauconnier A, Bader G. [Use of glue in laparoscopic
sacrocolpopexy. A comparative study about 32 cases.] Gynecol Obstet Fertil 2014;42:822–6
No adverse effects
related to fibrin reported
Wong K, Goldstraw P. Effect of fibrin glue in the reduction of postthoracotomy alveolar air
leak. Ann Thorac Surg 1997;64:979–81
RCT
Yeom JS, Buchowski JM, Shen HX, Liu G, Bunmaprasert T, Riew KD. Effect of fibrin sealant on
drain output and duration of hospitalization after multilevel anterior cervical fusion: a
retrospective matched pair analysis. Spine 2008;33:E543–7
No adverse effects
related to fibrin reported
Yildirim AE, Dursun E, Ozdol C, Divanlioglu D, Nacar OA, Koyun OK, et al. Using an autologous
fibrin sealant in the preventing of cerebrospinal fluid leak with large skull base defect following
endoscopic endonasal transsphenoidal surgery. Turk Neurosurg 2013;23:736–41
No comparison group
Yin W, Pauza K, Olan W, Doerzbacher J. Long-term outcomes from a prospective, multicenter
investigational device exemption (IDE) pilot study of intradiscal fibrin sealant for the treatment
of discogenic pain. Pain Med 2011;12:1446–7
No comparison group
Yu L, Gu T, Song L, Shi E, Fang Q, Wang C, et al. Fibrin sealant provides superior hemostasis
for sternotomy compared with bone wax. Ann Thorac Surg 2012;93:641–4
No comparison group
Yuan Q, Bai XM, Cheng L, Gu XS, Jin Y. Efficacy of fibrin glue in percutaneous transhepatic
obliteration for the management of upper gastrointestinal bleeding in patients with portal
hypertension. Shijie Huaren Xiaohua Zazhi 2012;20:3397–402
RCT
Yüksel et al. 2010158 No comparison group
Zacharias T, Ferreira N. Carrier-bound fibrin sealant compared to oxidized cellulose application
after liver resection. HPB 2012;14:839–47
No adverse effects
related to fibrin reported
Zhang YH, Gu TX, Zhang GW, Wang C, Liu Y, Yu Y. Injection of fibrin glue directly into the
sternum for sternal bleeding in old patients with osteoporosis during coronary artery bypass.
J Clin Rehabil Tiss Engin Res 2011;15:4735–8
RCT
Zhou D, Shen L, Jin Y, Bennet S, Wang W, McLennan G. Efficacy and safety of selective arterial
embolization with fibrin glue in the treatment of primary postpartum hemorrhage: a
prospective study of 61 cases. J Vasc Interv Radiol 2012;23(Suppl. 1):105–6
Abstract
Zmora O, Neufeld D, Ziv Y, Tulchinsky H, Scott D, Khaikin M, et al. Prospective, multicenter
evaluation of highly concentrated fibrin glue in the treatment of complex cryptogenic perianal
fistulas. Dis Colon Rectum 2005;48:2167–72
No comparison group
Zoumalan R, Rizk SS. Hematoma rates in drainless deep-plane face-lift surgery with and
without the use of fibrin glue. Arch Facial Plast Surg 2008;10:103–7
No adverse effects
related to fibrin reported
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Appendix 8 Sensitivity analysis random-effects
model (DerSimonian and Laird55)
Primary outcomes
Seroma development
OR meta-analysis plot (random effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Wong 2011182 0.862 (0.011 to 70.345)
Mabrouk 2013214 0.060 (0.001 to 0.489)
Ulusoy 200396 1.818 (0.308 to 12.953)
Udén 199398 1.561 (0.530 to 4.614)
Tolver 2013181 0.574 (0.085 to 3.169)
Swan 2011113 0.895 (0.326 to 2.453)
Sözen 2011212 3.632 (0.550 to 39.842)
Segura-Castillo 2005105 0.188 (0.018 to 1.172)
Olmi 2007259 0.371 (0.048 to 2.119)
Olmi 2007185 0.317 (0.041 to 1.758)
Olmi 2007259 0.405 (0.052 to 2.354)
Neuss 2009118 1.341 (0.407 to 4.452)
Mustonen 2004104 0.642 (0.150 to 2.697)
Mortenson 2008120 0.846 (0.094 to 7.709)
Moore 2001111 1.000 (0.116 to 13.262)
Moore 2001111 0.667 (0.068 to 9.653)
Moore 2001111 0.469 (0.041 to 7.341)
Moench 2010250 1.268 (0.204 to 9.012)
Miri Bonjar 2012103 0.604 (0.132 to 2.598)
Maharaj 2006230 0.126 (0.003 to 1.314)
Llewellyn-Bennett 2012101 3.379 (0.028 to infinity)
Lau 2005172 4.480 (1.354 to 17.119)
Ko 2009102 0.811 (0.276 to 2.346)
Johnson 2005100 0.700 (0.262 to 1.856)
Jain 200499 0.746 (0.225 to 2.455)
Hester 2013231 1.000 (0.179 to 5.591)
Gilly 1998108 1.163 (0.015 to 92.893)
Gilly 1994115 2.353 (0.111 to 145.635)
Dinsmore 200097 2.500 (0.368 to 19.869)
Damiano 2014184 0.573 (0.151 to 1.879)
Chan 2014178 1.356 (0.415 to 4.594)
Carlson 200894 0.751 (0.255 to 2.168)
Bracale 2014174 7.442 (0.418 to infinity)
Boldo 2008173 1.212 (0.305 to 4.852)
Berger 2011107 0.846 (0.265 to 2.689)
Benevento 2014109 0.138 (0.003 to 1.294)
Altinli 2007206 0.313 (0.000 to 39.000)
Combined (random) 0.863 (0.680 to 1.096)
OR (95% CI)
FIGURE 49 Seroma development in all surgical specialties: fibrin sealant vs. standard care. Pooled OR 0.86 (95% CI
0.68 to 1.10; p= 0.23).
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OR meta-analysis plot (random effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Ulusoy 200396 1.818 (0.308 to 12.953)
Udén 199398 1.561 (0.530 to 4.614)
Swan 2011113 0.895 (0.326 to 2.453)
Segura-Castillo 2005105 0.188 (0.018 to 1.172)
Neuss 2009118 1.341 (0.407 to 4.452)
Mustonen 2004104 0.642 (0.150 to 2.697)
Mortenson 2008120 0.846 (0.094 to 7.709)
Moore 2001111 1.000 (0.116 to 13.262)
Moore 2001111 0.667 (0.068 to 9.653)
Moore 2001111 0.469 (0.041 to 7.341)
Miri Bonjar 2012103 0.604 (0.132 to 2.598)
Llewellyn-Bennett 2012101 3.379 (0.028 to infinity)
Ko 2009102 0.811 (0.276 to 2.346)
Johnson 2005100 0.700 (0.262 to 1.856)
Jain 200499 0.746 (0.225 to 2.455)
Gilly 1998108 1.163 (0.015 to 92.893)
Gilly 1994115 2.353 (0.111 to 145.635)
Dinsmore 200097 2.500 (0.368 to 19.869)
Carlson 200894 0.751 (0.255 to 2.168)
Berger 2001107 0.846 (0.265 to 2.689)
Benevento 2014109 0.138 (0.003 to 1.294)
Combined (random) 0.860 (0.648 to 1.141)
OR (95% CI)
FIGURE 50 Seroma development in breast surgery: fibrin sealant vs. standard care. Pooled OR 0.86 (95% CI 0.65 to
1.14; p= 0.30).
OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Wong 2011182 0.86 (0.01 to 70.35)
Tolver 2013181 0.57 (0.08 to 3.17)
Olmi 2007259 0.40 (0.05 to 2.36)
Olmi 2007259 0.36 (0.05 to 2.13)
Olmi 2007185 0.31 (0.04 to 1.76)
Lau 2005172 4.48 (1.35 to 17.12)
Damiano 2014184 0.57 (0.15 to 1.88)
Chan 2014178 1.36 (0.42 to 4.59)
Bracale 2014174 7.74 (0.44 to infinity)
Boldo 2008173 1.21 (0.30 to 4.85)
Combined (random) 0.93 (0.51 to 1.72)
OR (95% CI)
FIGURE 51 Seroma development in hernia surgery: fibrin sealant vs. standard care. Pooled OR 0.93 (95% CI 0.51 to
1.72; p= 0.825).
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Haematoma development
OR meta-analysis plot (random effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Wang 2001144 0.250 (0.005 to 2.837)
Vaiman 2002188 0.248 (0.000 to 7.474)
Vaiman 2002188 0.248 (0.000 to 7.474)
Tolver 2013181 0.082 (0.000 to 1.048)
Swan 2011113 1.057 (0.013 to 85.197)
Sroka 201590 0.469 (0.008 to 9.365)
Siemer 2007221 0.896 (0.424 to 1.891)
Sabatini 2012131 0.293 (0.027 to 1.834)
Olmi 2007259 0.322 (0.000 to 4.563)
Olmi 2007185 0.417 (0.000 to 7.301)
Olmi 2007259 0.417 (0.000 to 7.301)
Oliver 2001228 3.154 (0.026 to infinity)
Noun 199670 0.759 (0.197 to 2.738)
Neuss 2009118 0.482 (0.008 to 9.887)
Moore 2001111 2.838 (0.132 to infinity)
Moore 2001111 1.216 (0.009 to infinity)
Miri Bonjar 2012103 0.931 (0.063 to 13.699)
Llewellyn-Bennett 2012151 0.654 (0.156 to 2.488)
Lee 2009227 0.158 (0.000 to 5.221)
Lassen 2006141 0.800 (0.067 to 6.213)
Johnson 2005100 1.167 (0.081 to 16.819)
Hester 2013231 0.240 (0.005 to 2.521)
Cormio 2012222 0.128 (0.000 to 2.290)
Cipolla 2010110 0.987 (0.012 to 78.484)
Canonico 1999177 0.184 (0.000 to 5.290)
Boldo 2008173 0.182 (0.000 to 5.285)
Bektas 201465 1.292 (0.250 to 7.144)
Aguilera 2013143 3.158 (0.238 to 169.846)
Aguilera 2013143 0.191 (0.000 to 5.304)
Combined (random) 0.661 (0.463 to 0.945)
OR (95% CI)
FIGURE 52 Haematoma development in all surgical specialties: fibrin sealant vs. standard care. Pooled OR 0.66
(95% CI 0.46 to 0.94; p= 0.023).
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OR meta-analysis plot (random effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100
Swan 2011113 1.057 (0.013 to 85.197)
Neuss 2009118 0.482 (0.008 to 9.887)
Moore 2001111 2.838 (0.132 to infinity)
Moore 2001111 1.216 (0.009 to infinity)
Miri Bonjar 2012103 0.931 (0.063 to 13.699)
Llewellyn-Bennett 2012101 0.654 (0.156 to 2.488)
Johnson 2005100 1.167 (0.081 to 16.819)
Cipolla 2010110 0.987 (0.012 to 78.484)
Combined (random) 0.864 (0.411 to 1.816)
OR (95% CI)
FIGURE 53 Haematoma development in breast surgery: fibrin sealant vs. standard care. Pooled OR 0.86
(95% CI 0.41 to 1.82; p= 0.70).
OR meta-analysis plot (random effects)
1 2 5 10
Tolver 2013181 0.08 (0.00 to 1.05)
Olmi 2007259 0.32 (0.00 to 4.56)
Olmi 2007185 0.42 (0.00 to 7.30)
Olmi 2007259 0.42 (0.00 to 7.30)
Canonico 1999177 0.18 (0.00 to 5.29)
Boldo 2008173 0.18 (0.00 to 5.28)
Combined (random) 0.23 (0.07 to 0.79)
OR (95% CI)
FIGURE 54 Haematoma development in hernia surgery: fibrin sealant vs. standard care. Pooled OR 0.23
(95% CI 0.07 to 0.79; p= 0.02).
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OR meta-analysis plot (random effects)
0.001 0.01 0.10.20.5 1 2 5 10 100 1000
Wang 2001144 0.250 (0.005 to 2.837)
Sabatini 2012148 0.293 (0.027 to 1.834)
Lassen 2006141 0.800 (0.067 to 6.213)
Aguilera 2013143 3.158 (0.238 to 169.846)
Aguilera 2013143 0.191 (0.000 to 5.304)
Combined (random) 0.529 (0.209 to 1.340)
OR (95% CI)
FIGURE 55 Haematoma development in orthopaedic surgery: fibrin sealant vs. standard care. Pooled OR 0.53
(95% CI 0.21 to 1.34; p= 0.18).
OR meta-analysis plot (random effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10
Sroka 201590 0.469 (0.008 to 9.365)
Noun 199670 0.759 (0.197 to 2.738)
Bektas 201465 1.292 (0.250 to 7.144)
Combined (random) 0.865 (0.375 to 1.993)
OR (95% CI)
FIGURE 56 Haematoma development in upper GI tract surgery: fibrin sealant vs. standard care. Pooled OR 0.86
(95% CI 0.38 to 1.99; p= 0.73).
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Seroma and haematoma combined
OR meta-analysis plot (random effects)
0.001 0.01 0.10.2 0.5 1 2 5 10 100 1000
Wong 2011182 0.862 (0.011 to 70.345)
Wang 2001144 0.250 (0.005 to 2.837)
Mabrouk 2013214 0.060 (0.001 to 0.489)
Vaiman 2002188 0.248 (0.000 to 0.000)
Vaiman 2002188 0.248 (0.000 to 0.000)
Ulusoy 200396 1.818 (0.308 to 12.953)
Udén 199398 1.561 (0.530 to 4.614)
Tolver 2013181 0.255 (0.043 to 1.096)
Swan 2011113 0.900 (0.328 to 2.468)
Sroka 201590 0.469 (0.008 to 9.365)
Sözen 2011212 3.632 (0.550 to 39.842)
Siemer 2007221 0.896 (0.424 to 1.891)
Segura-Castillo 2005105 0.188 (0.018 to 1.172)
Sabatini 2012148 0.293 (0.027 to 1.834)
Olmi 2007259 0.311 (0.041 to 1.763)
Olmi 2007259 0.270 (0.036 to 1.499)
Olmi 2007185 0.253 (0.034 to 1.393)
Oliver 2001228 3.154 (0.026 to infinity)
Noun 199670 0.759 (0.197 to 2.738)
Neuss 2009118 1.151 (0.360 to 3.693)
Mustonen 2004104 0.642 (0.150 to 2.697)
Mortenson 2008120 0.846 (0.094 to 7.709)
Moore 2001111 1.875 (0.229 to 23.502)
Moore 2001111 0.667 (0.068 to 9.653)
Moore 2001111 0.667 (0.068 to 9.653)
Moench 2010250 1.268 (0.204 to 9.012)
Miri Bonjar 2012103 0.648 (0.172 to 2.380)
Maharaj 2006230 0.126 (0.003 to 1.314)
Lovisetto 2007180 1.684 (0.317 to 11.124)
Llewellyn-Bennett 2012101 0.804 (0.211 to 2.902)
Lee 2009227 0.158 (0.000 to 5.221)
Lau 2005172 4.480 (1.354 to 17.119)
Lassen 2006141 0.800 (0.067 to 6.213)
Ko 2009102 0.811 (0.276 to 2.346)
Johnson 2005100 0.727 (0.277 to 1.902)
Jain 200499 0.746 (0.225 to 2.455)
Hester 2013231 0.598 (0.147 to 2.203)
Gilly 1998108 1.163 (0.015 to 92.893)
Gilly 1994115 2.353 (0.111 to 145.635)
Dinsmore 200097 2.500 (0.368 to 19.869)
Damiano 2014184 0.573 (0.151 to 1.879)
Cormio 2012222 0.128 (0.000 to 2.290)
Cipolla 2010110 0.987 (0.012 to 78.484)
Chan 2014178 1.356 (0.415 to 4.594)
Carlson 200894 0.751 (0.255 to 2.168)
Canonico 1999177 0.184 (0.000 to 5.290)
Bracale 2014174 7.737 (0.435 to infinity)
Boldo 2008173 0.831 (0.214 to 3.215)
Berger 2011107 0.846 (0.265 to 2.689)
Benevento 2014109 0.138 (0.003 to 1.294)
Bektas 201465 1.292 (0.250 to 7.144)
Altinli 2007206 0.313 (0.000 to 39.000)
Aguilera 2013143 3.158 (0.238 to 169.846)
Aguilera 2013143 0.191 (0.000 to 5.304)
Combined (random) 0.797 (0.649 to 0.979)
OR (95% CI)
FIGURE 57 Seroma and haematoma development combined in all surgical specialties: fibrin sealant vs. standard
care. Pooled OR 0.80 (95% CI 0.65 to 0.98; p = 0.03).
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Secondary dichotomous outcomes
Haemorrhage (bleeding)
OR meta-analysis plot (random effects)
0.001 0.01 0.10.2 0.5 1 2 5 10 100 1000
Yüksel 2010158 3.105 (0.026 to infinity)
Uy 2005168 3.286 (0.026 to infinity)
Taylor 2003199 0.990 (0.179 to 5.476)
Suc 200385 0.462 (0.145 to 1.389)
Silecchia 200862 0.198 (0.000 to 5.319)
Saha 2012197 1.000 (0.013 to 79.620)
Nativ 201259 3.000 (0.019 to infinity)
Montorsi 201284 0.294 (0.006 to 3.729)
Moench 2010250 0.938 (0.012 to 74.802)
Marta 2010135 0.503 (0.045 to 3.582)
Lang 2004134 2.905 (0.025 to infinity)
Kohno 199275 1.000 (0.068 to 14.664)
Ko 2009102 1.568 (0.170 to 19.520)
Kakaei 201374 0.062 (0.000 to 0.933)
Jain 200499 3.105 (0.026 to infinity)
Czerny 2000205 1.714 (0.069 to 117.746)
Canonico 1999177 0.132 (0.003 to 1.276)
Combined (random) 0.690 (0.415 to 1.147)
OR (95% CI)
FIGURE 58 Haemorrhage (bleeding) in all surgical specialties: fibrin sealant vs. standard care. Pooled OR 0.69
(95% CI 0.41 to 1.15; p= 0.15).
OR meta-analysis plot (random effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100
Silecchia 200862 0.198 (0.000 to 5.319)
Suc 200385 0.462 (0.145 to 1.389)
Montorsi 201284 0.294 (0.006 to 3.729)
Moench 2010250 0.938 (0.012 to 74.802)
Kohno 199275 1.000 (0.068 to 14.664)
Kakaei 201374 0.062 (0.000 to 0.933)
Combined (random) 0.431 (0.204 to 0.910)
OR (95% CI)
FIGURE 59 Haemorrhage (bleeding) in upper GI tract surgery: fibrin sealant vs. standard care. Pooled OR 0.43
(95% CI 0.20 to 0.91; p= 0.03).
DOI: 10.3310/hta20940 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 94
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
199
OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Marta 2010135 0.50 (0.04 to 3.58)
Czerny 2000205 1.71 (0.07 to 117.75)
Lang 2004134 2.90 (0.02 to infinity)
Combined (random) 0.91 (0.25 to 3.39)
OR (95% CI)
FIGURE 60 Haemorrhage (bleeding) in cardiothoracic surgery: fibrin sealant vs. standard care. Pooled OR 0.91
(95% CI 0.25 to 3.39; p= 0.89).
OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Ko 2009102 1.57 (0.17 to 19.52)
Jain 200499 3.11 (0.03 to infinity)
Combined (random) 1.85 (0.37 to 9.15)
OR (95% CI)
FIGURE 61 Haemorrhage (bleeding) in vascular surgery: fibrin sealant vs. standard care. Pooled OR 1.85
(95% CI 0.37 to 9.15; p= 0.45).
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OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Taylor 2003199 0.99 (0.18 to 5.48)
Saha 2012197 1.00 (0.01 to 79.62)
Combined (random) 0.99 (0.28 to 3.50)
OR (95% CI)
FIGURE 62 Haemorrhage (bleeding) in vascular surgery: fibrin sealant vs. standard care. Pooled OR 0.99
(95% CI 0.28 to 3.50; p= 0.99).
OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Uy 2005168 3.29 (0.03 to infinity)
Yüksel 2010158 3.11 (0.03 to infinity)
Combined (random) 3.19 (0.32 to 32.33)
OR (95% CI)
FIGURE 63 Haemorrhage (bleeding) in eye surgery: fibrin sealant vs. standard care. Pooled OR 3.19 (95% CI 0.32 to
32.33; p = 0.33).
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Reoperation
OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Tavilla 201560 0.84 (0.45 to 1.53)
Suc 200385 0.75 (0.32 to 1.77)
Schwartz 200477 0.36 (0.14 to 0.91)
Martin 201386 0.75 (0.17 to 3.12)
Marta 2010135 1.23 (0.31 to 5.23)
Maisano 2009140 0.35 (0.06 to 1.56)
Llewellyn-Bennett 2012101 1.48 (0.47 to 4.77)
Kjaergard 1998138 0.33 (0.00 to 42.55)
Hutter 2014237 0.59 (0.17 to 1.88)
Huang 201493 0.03 (0.00 to 0.29)
Furrer 1993116 1.00 (0.06 to 15.77)
Bochicchio 2015239 0.17 (0.00 to 19.42)
Berger 2011107 0.34 (0.00 to 41.69)
Anegg 2007125 2.08 (0.11 to 124.43)
Aguilera 2013143 1.00 (0.01 to 80.43)
Aguilera 2013143 1.00 (0.01 to 80.39)
Combined (random) 0.71 (0.52 to 0.95)
OR (95% CI)
FIGURE 64 Reoperation in all surgical specialties: fibrin sealant vs. standard care. Pooled OR 0.71 (95% CI 0.52 to
0.95; p= 0.02).
OR meta-analysis plot (random effects)
0.1 0.2 0.5 1 2 5 10 100 1000
Marta 2010135 1.23 (0.31 to 5.23)
Anegg 2007125 2.08 (0.11 to 124.43)
Combined (random) 1.37 (0.46 to 4.04)
OR (95% CI)
FIGURE 65 Reoperation in cardiothoracic lung surgery: fibrin sealant vs. standard care. Pooled OR 1.37 (95% CI 0.46
to 4.04; p= 0.57).
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OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Tavilla 201560 0.84 (0.45 to 1.53)
Maisano 2009140 0.35 (0.06 to 1.56)
Kjaergard 1998138 0.33 (0.00 to 42.55)
Combined (random) 0.72 (0.43 to 1.21)
OR (95% CI)
FIGURE 66 Reoperation in cardiothoracic heart surgery: fibrin sealant vs. standard care. Pooled OR 0.72 (95% CI
0.43 to 1.21; p= 0.22).
OR meta-analysis plot (random effects)
0.1 0.2 0.5 1 2 5
Suc 200385 0.75 (0.32 to 1.77)
Schwartz 200477 0.36 (0.14 to 0.91)
Martin 201386 0.75 (0.17 to 3.12)
Huang 201493 0.03 (0.00 to 0.29)
Combined (random) 0.46 (0.20 to 1.06)
OR (95% CI)
FIGURE 67 Reoperation in upper GI tract surgery: fibrin sealant vs. standard care. Pooled OR 0.46 (95% CI 0.20 to
1.06; p= 0.07).
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OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Llewellyn-Bennett 2012101 1.48 (0.47 to 4.77)
Furrer 1993116 1.00 (0.06 to 15.77)
Berger 2001107 0.34 (0.00 to 41.69)
Combined (random) 1.24 (0.51 to 3.00)
OR (95% CI)
FIGURE 68 Reoperation in breast surgery: fibrin sealant vs. standard care. Pooled OR 1.24 (95% CI 0.51 to 3.00; p= 0.64).
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Infections
OR meta-analysis plot (random effects)
0.001 0.01 0.10.2 0.5 1 2 5 10 100 1000
Ulusoy 200396 1.000 (0.012 to 81.479)
Tavilla 201560 0.546 (0.143 to 1.826)
Tachibana 2003122 0.500 (0.008 to 10.493)
Neuss 2009118 0.861 (0.257 to 2.869)
Nativ 201259 0.185 (0.000 to 29.250)
Mortenson 2008120 0.778 (0.147 to 4.103)
Moore 2001111 1.098 (0.009 to infinity)
Moore 2001111 2.143 (0.067 to infinity)
Moore 2001111 1.216 (0.009 to infinity)
Montorsi 201284 0.177 (0.000 to 4.766)
Moench 2010250 2.903 (0.224 to 154.905)
Mellin 1989170 0.122 (0.027 to 0.447)
Chan 2014178 2.669 (0.414 to 28.843)
Martin 201386 2.417 (0.409 to 17.082)
Marta 2010135 1.020 (0.013 to 80.626)
Maharaj 2006230 2.455 (0.020 to infinity)
Levy 199914 2.074 (0.101 to 126.661)
Lillemoe 200483 1.145 (0.147 to 8.898)
Kohno 199275 0.483 (0.008 to 9.868)
Ko 2009102 1.568 (0.170 to 19.520)
Jain 200499 1.000 (0.012 to 81.266)
Huang 201564 0.318 (0.000 to 39.000)
Gonfiotti 2011130 0.143 (0.000 to 2.485)
Frilling 200573 2.327 (0.315 to 26.561)
Fischer 201172 0.483 (0.008 to 9.574)
Chalmers 2010198 0.755 (0.144 to 3.679)
Aguilera 2013143 1.000 (0.012 to 80.435)
Aguilera 2013143 0.325 (0.000 to 39.000)
Combined (random) 0.788 (0.546 to 1.137)
OR (95% CI)
FIGURE 69 Infections in all surgeries: fibrin sealant vs. standard care. Pooled OR 0.79 (95% CI 0.55 to 1.14; p= 0.20).
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OR meta-analysis plot (random effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Huang 201564 0.318 (0.000 to 39.000)
Martin 201386 2.417 (0.409 to 17.082)
Montorsi 201284 0.177 (0.000 to 4.766)
Lillemoe 200483 1.145 (0.147 to 8.898)
Moench 2010250 2.903 (0.224 to 154.905)
Kohno 199275 0.483 (0.008 to 9.868)
Frilling 200573 2.327 (0.315 to 26.561)
Fischer 201172 0.483 (0.008 to 9.574)
Combined (random) 1.218 (0.584 to 2.540)
OR (95% CI)
FIGURE 70 Infections in upper GI tract surgery: fibrin sealant vs. standard care. Pooled OR 1.22 (95% CI 0.58 to
2.54; p= 0.60).
OR meta-analysis plot (random effects)
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100
Ulusoy 200396 1.000 (0.012 to 81.479)
Tachibana 2003122 0.500 (0.008 to 10.493)
Mortenson 2008120 0.778 (0.147 to 4.103)
Moore 2001111 1.098 (0.009 to infinity)
Moore 2001111 2.143 (0.067 to infinity)
Moore 2001111 1.216 (0.009 to infinity)
Ko 2009102 1.568 (0.170 to 19.520)
Neuss 2009118 0.861 (0.257 to 2.869)
Jain 200499 1.000 (0.012 to 81.266)
Combined (random) 0.947 (0.493 to 1.819)
OR (95% CI)
FIGURE 71 Infections in breast surgery: fibrin sealant vs. standard care. Pooled OR 0.95 (95% CI 0.49 to 1.82; p= 0.87).
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OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Levy 199914 2.07 (0.10 to 126.66)
Aguilera 2013143 1.00 (0.01 to 80.43)
Aguilera 2013143 0.33 (0.00 to 39.00)
Combined (random) 1.03 (0.21 to 5.15)
OR (95% CI)
FIGURE 72 Infections in orthopaedic surgery: fibrin sealant vs. standard care. Pooled OR 1.034 (95% CI 0.21 to
5.15; p= 0.97).
OR meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Marta 2010135 1.02 (0.01 to 80.63)
Gonfiotti 2011130 0.14 (0.00 to 2.48)
Combined (random) 0.41 (0.05 to 3.12)
OR (95% CI)
FIGURE 73 Infections in cardiothoracic lung surgery: fibrin sealant vs. standard care. Pooled OR 0.41 (95% CI 0.05
to 3.12; p= 0.39).
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Secondary continuous outcomes
Duration of operation
Effect size meta-analysis plot (random effects)
–20 –10 100
Sroka 201590
Musella 201488
DL pooled weighted MD –4.66257 (95% CI –12.715135 to 3.389996)
FIGURE 74 Mean duration of gastric surgery in minutes: fibrin sealant vs. no sealant. Pooled MD –4.66 (95% CI
–12.71 to 3.39; p= 0.26). DL, DerSimonian and Laird.55
Effect size meta-analysis plot (random effects)
–150 –100 –50 0 50
Noun 199670
Liu 199369
DL pooled weighted MD –14.959524 (95% CI –54.247356 to 24.328308)
FIGURE 75 Mean duration of hepatic resection without liver mobilisation in minutes: fibrin sealant vs. standard
care. Pooled MD –14.96 (95% CI –54.2 to 24.3; p= 0.46). DL, DerSimonian and Laird.55
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Effect size meta-analysis plot (random effects)
–40 –15 100 35 60 85
Uetsuji 199468
Figueras 200771
DL pooled weighted MD 19.069127 (95% CI 2.75428 to 35.383973)
FIGURE 76 Mean duration of hepatic resection with liver mobilisation in minutes: fibrin sealant vs. standard care.
Pooled MD 19.07 (95% CI 2.75 to 35.38; p= 0.02). DL, DerSimonian and Laird.55
Effect size meta-analysis plot (random effects)
–50 –40 –30 –20 –10 0
Yüksel 2010158
Uy 2005168
Sati 2014163
Rubin 2011166
Ratnalingam 2010165
Malik 2010171
Kucukerdonmez 2010157
Karalezli 2008161
DL pooled weighted MD –17.927043 (95% CI –23.35147 to –12.502616)
FIGURE 77 Mean duration of eye surgery in minutes: fibrin sealant vs. sutures. Pooled MD –17.93 (95% CI –23.35 to
–12.50; p < 0.01). DL, DerSimonian and Laird.55
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Effect size meta-analysis plot (random effects)
–5 –4 –3 –2 –1 10
Damiano 2014184
Campanelli 2012176
DL pooled weighted MD –2.564442 (95% CI –3.56903 to –1.559854)
FIGURE 78 Mean duration of hernia surgery in minutes: fibrin sealant vs. sutures. Pooled MD –2.56 (95% CI –3.57
to –1.56; p< 0.01). DL, DerSimonian and Laird.55
Effect size meta-analysis plot (random effects)
–10 –4 20 8 14 20 26
Lovisetto 2007180
Chan 2014178
DL pooled weighted MD 8.975308 (95% CI –2.202557 to 20.153173)
FIGURE 79 Mean duration of hernia surgery in minutes: fibrin sealant vs. staples. Pooled MD 8.98 (95% CI –2.20 to
20.15; p= 0.12). DL, DerSimonian and Laird.55
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Length of hospital stay
Effect size meta-analysis plot (random effects)
–15 –10 –5 50
Martin 201386
Lillemoe 200483
DL pooled weighted MD –1.4031 (95% CI –1.720005 to –1.086196)
FIGURE 80 Length of hospital stay in days in pancreatic surgery: fibrin sealant vs. standard care. Pooled MD –1.40
(95% CI –1.72 to –1.09; p< 0.01). DL, DerSimonian and Laird.55
Effect size meta-analysis plot (random effects)
–0.7 –0.2 0.30 0.8 1.3
Silecchia 200862
Musella 201488
DL pooled weighted MD 0.0725 (95% CI –0.393352 to 0.538352)
FIGURE 81 Length of hospital stay in days in gastric surgery: fibrin sealant vs. standard care. Pooled MD 0.07
(95% CI –0.39 to 0.54; p= 0.76). DL, DerSimonian and Laird.55
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Effect size meta-analysis plot (random effects)
–4 –2 20 4
Rena 2009127
Gonfiotti 2011130
Filosso 2013136
DL pooled weighted MD –1.204045 (95% CI –3.218937 to 0.810847)
FIGURE 82 Length of hospital stay in days in cardiothoracic lung surgery: fibrin sealant vs. standard care. Pooled
MD –1.20 (95% CI –3.22 to 0.81; p= 0.24). DL, DerSimonian and Laird.55
Effect size meta-analysis plot (random effects)
–15 –10 –5 50 10
Vaxman 1995112
Mustonen 2004104
Moore 1997106
Gilly 1998108
Gilly 1994115
Furrer 1993116
Berger 2001107
Benevento 2014109
DL pooled weighted MD –0.86742 (95% CI –1.748391 to 0.01355)
FIGURE 83 Length of hospital stay in days in breast surgery: fibrin sealant vs. standard care. Pooled MD –0.87
(95% CI –1.75 to 0.01; p= 0.05). DL, DerSimonian and Laird.55
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Effect size meta-analysis plot (random effects)
–5.0 –2.5 2.5
Randelli 2014149
Kluba 2012145
Aguilera 2013143
Aguilera 2013143
  0  
DL pooled weighted MD 0.067034 (95% CI –0.744829 to 0.878897)
FIGURE 84 Length of hospital stay in days for knee surgery: fibrin sealant vs. standard care. Pooled MD 0.07
(95% CI –0.74 to 0.88; p= 0.87). DL, DerSimonian and Laird.55
Duration of drainage
Effect size meta-analysis plot (random effects)
–10.0 –7.5 –5.0 –2.5 2.50
Vaxman 1995112
Vaxman 1995112
Ulusoy 200396
Segura-Castillo 2005105
Mustonen 2004104
Mustonen 2004104
Moore 1997106
Di Monta 2012117
Ko 2009102
Gilly 1994115
Furrer 1993116
Cipolla 2010110
Berger 2001107
Benevento 2014109
DL pooled weighted MD –1.057099 (95% CI –1.692967 to –0.421231)
FIGURE 85 Duration of drainage in days in breast and axillary lymph nodes surgery: fibrin sealant vs. standard care.
Pooled MD –1.06 (95% CI –1.69 to –0.42; p= 0.00). DL, DerSimonian and Laird.55
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Effect size meta-analysis plot (random effects)
–3.0 –0.5 2.00 4.5
Liu 199369
Kohno 199275
Kakaei 201374
Bektas 201465
DL pooled weighted MD –0.273959 (95% CI –0.822145 to 0.274227)
FIGURE 86 Duration of drainage in days for liver surgery: fibrin sealant vs. standard care. Pooled MD –0.27
(95% CI –0.82 to 0.27; p= 0.33). DL, DerSimonian and Laird.55
Effect size meta-analysis plot (random effects)
–8.0 –5.5 –3.0 –0.5 2.00
Rena 2009127
Moser 2008126
Gonfiotti 2011130
Filosso 2013136
Czerny 2004137
DL pooled weighted MD –2.10341 (95% CI –3.649164 to –0.557656)
FIGURE 87 Duration of drainage in days for lung surgery: fibrin sealant vs. standard care. Pooled MD –2.10
(95% CI –3.65 to –0.56; p= 0.01). DL, DerSimonian and Laird.55
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Appendix 9 Data tables for randomised
controlled trials
TABLE 40 Seroma development data: all RCTs
Study (author, year)
Group (n/N)
Total population size across all studiesFibrin sealant Standard care
Altinli et al., 2007206 0/16 1/16 –
Benevento et al., 2014109 1/30 6/30 –
Berger et al., 2001107 11/29 13/31 –
Boldo, 2008173 9/22 8/22 –
Bracale et al., 2014174 3/50 0/50 –
Carlson et al., 200894 9/70 11/67 –
Chan et al., 2014178 9/64 7/65 –
Damiano et al., 2014184 5/216 10/252 –
Dinsmore et al., 200097 6/14 3/13 –
Gilly et al., 1994115 2/19 1/21 –
Gilly et al., 1998108 1/50 1/58 –
Hester et al., 2013231 4/75 4/75 –
Jain et al., 200499 10/29 12/29 –
Johnson et al., 2005100 14/38 20/44 –
Ko et al., 2009102 10/47 12/48 –
Lau, 2005172 16/46 5/47 –
Llewellyn-Bennett et al., 2012101 1/48 0/53 –
Mabrouk et al., 2013214 1/30 11/30 –
Maharaj et al., 2006230 1/28 5/22 –
Miri Bonjar et al., 2012103 5/31 7/29 –
Moench et al., 201476 4/65 3/61 –
Moore et al., 2001111 3/19 2/7 –
Moore et al., 2001111 4/19 2/7 –
Moore et al., 2001111 6/21 2/7 –
Mortenson et al., 2008120 3/16 3/14 –
Mustonen et al., 2004104 7/19 10/21 –
Neuss et al., 2009118 12/29 10/29 –
Olmi et al., 2007259 1.7/50 12/150 –
Olmi et al., 2007259 1.7/50 15/150 –
Olmi et al., 2007259 1.7/50 13/150 –
Segura-Castillo et al., 2005105 2/22 8/23 –
Sözen et al., 2011212 6/25 2/25 –
continued
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TABLE 40 Seroma development data: all RCTs (continued )
Study (author, year)
Group (n/N)
Total population size across all studiesFibrin sealant Standard care
Swan et al., 2011113 17/36 19/38 –
Tolver et al., 2013181 3/50 5/50 –
Udén et al., 199398 23/36 17/32 –
Ulusoy et al., 200396 5/27 3/27 –
Wong et al., 2011182 1/30 1/26 –
Total 228/1586 275/1886 3472
TABLE 41 Haematoma development data: all RCTs
Study (author, year)
Group (n/N)
Total population size across all studiesFibrin sealant Standard care
Aguilera et al., 2013143 0/42 2/42 –
Aguilera et al., 2013143 3/41 1/41 –
Bektas et al., 201465 5/35 4/35 –
Boldo, 2008173 0/22 2/22 –
Canonico et al., 1999177 0/25 2/25 –
Cipolla et al., 2010110 1/80 1/79 –
Cormio et al., 2012222 0/49 3/47 –
Hester et al., 2013231 1/75 4/75 –
Johnson et al., 2005100 2/38 2/44 –
Lassen et al., 2006141 2/22 4/36 –
Lee et al., 2009227 0/9 2/9 –
Llewellyn-Bennett et al., 2012101 5/48 8/53 –
Miri Bonjar et al., 2012103 2/31 2/29 –
Moore et al., 2001111 1/19 0/7 –
Moore et al., 2001111 3/21 0/7 –
Neuss et al., 2009118 1/29 2/29 –
Noun et al., 199670 6/35 9/42 –
Oliver et al., 2001228 1/20 0/20 –
Olmi et al., 2007259 0/50 3/150 –
Olmi et al., 2007259 0/50 3/150 –
Olmi et al., 2007259 0/50 4/150 –
Sabatini et al., 2012148 2/35 6/35 –
Siemer et al., 2007221 40/92 22/93 –
Sroka et al., 201590 1/49 2/47 –
Swan et al., 2011113 1/36 1/38 –
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TABLE 41 Haematoma development data: all RCTs (continued )
Study (author, year)
Group (n/N)
Total population size across all studiesFibrin sealant Standard care
Tolver et al., 2013181 0/50 5/50 –
Vaiman et al., 2002188 0/68 0.5/34 –
Vaiman et al., 2002188 0/68 0.5/34 –
Wang et al., 2001144 1/25 4/28 –
Total 58/1214 99/1451 2665
TABLE 42 Seroma and haematoma development combined data: all RCTs
Study (author, year)
Group (n/N)
Total population size across all studiesFibrin sealant Standard care
Aguilera et al., 2013143 0/42 2/42 –
Aguilera et al., 2013143 3/41 1/41 –
Altinli et al., 2007206 0/16 1/16 –
Bektas et al., 201465 5/35 4/35 –
Benevento et al., 2014109 1/30 6/30 –
Berger et al., 2001107 11/29 13/31 –
Boldo, 2008173 9/22 10/22 –
Bracale et al., 2014174 3/50 0/52 –
Canonico et al., 1999177 0/25 2/25 –
Carlson et al., 200894 9/70 11/67 –
Chan et al., 2014178 9/64 7/65 –
Cipolla et al., 2010110 1/80 1/79 –
Cormio et al., 2012222 0/49 3/47 –
Damiano et al., 2014184 5/216 10/252 –
Dinsmore et al., 200097 6/14 3/13 –
Gilly et al., 1994115 2/19 1/21 –
Gilly et al., 1998108 1/50 1/58 –
Hester et al., 2013231 5/75 8/75 –
Jain et al., 200499 10/29 12/29 –
Johnson et al., 2005100 16/38 22/44 –
Ko et al., 2009102 10/47 12/48 –
Lassen et al., 2006141 2/22 4/36 –
Lau, 2005172 16/46 5/47 –
Lee et al., 2009227 0/9 2/9 –
Llewellyn-Bennett et al., 2012101 6/48 8/53 –
Lovisetto et al., 2007180 5/99 3/98 –
continued
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TABLE 42 Seroma and haematoma development combined data: all RCTs (continued )
Study (author, year)
Group (n/N)
Total population size across all studiesFibrin sealant Standard care
Mabrouk et al., 2013214 1/30 11/30 –
Maharaj et al., 2006230 1/28 5/22 –
Miri Bonjar et al., 2012103 7/31 9/29 –
Moench et al., 2010250 4/65 3/61 –
Moore et al., 2001111 4/19 2/7 –
Moore et al., 2001111 4/19 2/7 –
Moore et al., 2001111 9/21 2/7 –
Mortenson et al., 2008120 3/16 3/14 –
Mustonen et al., 2004104 7/19 10/21 –
Neuss et al., 2009118 13/29 12/29 –
Noun et al., 199670 6/35 9/42 –
Oliver et al., 2001228 1/20 0/20 –
Olmi et al., 2007259 1.67/50 15/150 –
Olmi et al., 2007259 1.67/50 18/150 –
Olmi et al., 2007259 1.67/50 17/150 –
Sabatini et al., 2012148 2/35 6/35 –
Segura-Castillo et al., 2005105 2/22 8/23 –
Siemer et al., 2007221 20/92 22/93 –
Sözen et al., 2011212 6/25 2/25 –
Sroka et al., 201590 1/49 2/47 –
Swan et al., 2011113 18/36 20/38 –
Tolver et al., 2013181 3/50 10/50 –
Udén et al., 199398 23/36 17/32 –
Ulusoy et al., 200396 5/27 3/27 –
Vaiman et al., 2002188 0/68 0.5/34 –
Vaiman et al., 2002188 0/68 0.5/34 –
Wang et al., 2001144 1/25 4/28 –
Wong et al., 2011182 1/30 1/26 –
Total 282/2310 366/2566 4876
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TABLE 44 Reoperation data: all RCTs
Study (author, year)
Group (n/N)
Total population size across all studiesFibrin sealant Standard care
Aguilera, 2013143 1/42 1/42 –
Aguilera, 2013143 1/41 1/41 –
Anegg et al., 2007125 2/75 1/77 –
Berger et al., 2001107 0/29 1/31 –
Bochicchio et al., 2015239 0/480 1/239 –
Furrer et al., 1993116 2/15 2/15 –
Hutter et al., 2014237 6/113 10/116 –
Huang and Qian, 201493 0/48 12/47 –
Kjaergard and Trumbull, 1998138 0/11 1/12 –
Llewellyn-Bennett et al., 2012101 10/48 8/53 –
Maisano et al., 2009140 3/59 8/60 –
Marta et al., 2010135 6/148 5/151 –
Martin and Au, 201386 5/25 8/32 –
Schwartz et al., 200477 10/58 23/63 –
Suc et al., 200385 15/102 15/80 –
Tavilla et al., 201560 23/722 27/714 –
Total 84/2016 124/1773 3789
TABLE 43 Haemorrhage (bleeding) data: all RCTs
Study (author, year)
Group (n/N)
Total population size across all studiesFibrin sealant Standard care
Canonico et al., 1999177 1/25 6/25 –
Czerny et al., 2000205 2/9 1/7 –
Jain et al., 200499 1/29 0/29 –
Kakaei et al., 201374 0/15 5/15 –
Ko et al., 2009102 3/47 2/48 –
Kohno et al., 199275 2/31 2/31 –
Lang et al., 2004134 1/95 0/91 –
Marta et al., 2010135 2/148 4/151 –
Moench et al., 2010250 1/65 1/61 –
Montorsi et al., 201284 1/145 3/130 –
Nativ et al., 201259 1/4 0/3 –
Saha et al., 2012197 1/70 1/70 –
Silecchia et al., 200862 0/160 2/160 –
Suc et al., 200385 7/102 11/80 –
Taylor et al., 2003199 4/100 4/99 –
Uy et al., 2005168 1/11 0/11 –
Yüksel et al., 2010158 1/29 0/29 –
Total 29/1085 42/1040 2125
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TABLE 45 Infections data: all RCTs
Study (author, year)
Group (n/N)
Total population size
across all studiesFibrin sealant Standard care
Aguilera et al., 2013143 0/42 1/42 –
Aguilera et al., 2013143 1/41 1/41 –
Chalmers et al., 2010198 4/75 5/72 –
Chan et al., 2014178 5/64 2/65 –
Fischer et al., 201172 1/60 2/59 –
Frilling et al., 200573 4/53 2/59 –
Gonfiotti et al., 2011130 0/91 3/94 –
Huang et al., 201564 0/21 1/21 –
Jain et al., 200499 1/29 1/29 –
Ko et al., 2009102 3/47 2/48 –
Kohno et al., 199275 1/31 2/31 –
Levy et al., 199914 2/29 1/29 –
Lillemoe et al., 200483 3/58 3/66 –
Maharaj et al., 2006230 1/28 0/22 –
Marta et al., 2010135 1/148 1/151 –
Martin and Au 201386 5/25 3/32 –
Mellin and Kondler 1989170 4/51 16/39 –
Moench et al., 2010250 3/65 1/61 –
Montorsi et al., 201284 0/145 2/130 –
Moore et al., 2001111 1/19 0/7 –
Moore et al., 2001111 2/19 0/7 –
Moore et al., 2001111 1/21 0/7 –
Mortenson et al., 2008120 7/16 7/14 –
Nativ et al., 201259 0/4 1/3 –
Neuss et al., 2009118 10/29 11/29 –
Tachibana et al., 2003122 1/21 2/22 –
Tavilla et al., 201560 5/722 9/714 –
Ulusoy et al., 200396 1/27 1/27 –
Total 67/1981 80/1921 3902
TABLE 46 Duration of operation data: all RCTs
Study (author, year)
Group
Note Surgery area
Fibrin sealant Standard care
n Mean SD n Mean SD
Bulbuller et al., 201392 6 138.2 21.57 15 138.1 19.77 C Upper GI tract: bowel
Bulbuller et al., 201392 6 138.2 21.57 16 196 19.77 C Upper GI tract: bowel
Bulbuller et al., 201392 6 138.2 21.57 16 166.4 19.77 C Upper GI tract: bowel
Musella et al., 201488 50 82.8 5.2 50 84.3 6.2 Upper GI tract: bowel
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TABLE 46 Duration of operation data: all RCTs (continued )
Study (author, year)
Group
Note Surgery area
Fibrin sealant Standard care
n Mean SD n Mean SD
Pilone et al., 201289 15 108 21.57 15 102 19.77 C Upper GI tract: bowel
Silecchia et al., 200862 160 149.4 36.5 160 142.7 34.1 Upper GI tract: bowel
Sroka et al., 201590 49 64 23 47 54 19 Upper GI tract: bowel
Sroka et al., 201590 49 64 23 49 74 21 Upper GI tract: bowel
Uetsuji, 199468 25 362 131 39 280 85 Upper GI tract: liver
Liu and Lui, 199369 20 294.5 65.3 20 343 184 Upper GI tract: liver
without mobilisation
Noun et al., 199670 35 252 90 42 258 108 Upper GI tract: liver
without mobilisation
Uetsuji et al., 199468 25 362 131 39 342 111 Upper GI tract: liver
with mobilisation
Figueras et al., 200771 150 282 76.3 150 263 73.1 Upper GI tract: liver
with mobilisation
Mortenson et al., 2008120 16 227 16.2 14 261 16.8 Breast/lymph
Moore et al., 1997106 32 135 16.2 31 132 16.8 Breast/lymph
Cambal et al., 2012175 50 48.5 11.11 50 44 11.77 Hernia
Campanelli et al., 2012176 158 39.8 12.1 158 41.5 11.9 Hernia
Damiano et al., 2014184 216 48.89 5.71 252 51.6 6.27 Hernia
Lovisetto et al., 2007180 99 53.8 7.61 98 39.6 7.61 Hernia
Chan et al., 2014178 64 75.84 19.01 65 73.09 21.31 Hernia
Bahar et al., 2007169 42 16 3.94 39 28 4 C Eye
Bahar et al., 2006159 39 16 3.94 26 20 4 C Eye
Hall et al., 2009160 25 12.04 3.94 25 26.04 4 C Eye
Karalezli et al., 2008161 25 15.7 2.4 25 32.5 6.7 Eye
Kucukerdonmez et al., 2010157 32 11.22 2.4 38 18.7 2.2 Eye
Malik and Kumar, 2010171 50 18.24 2.2 25 26.6 1.93 Eye
Ratnalingam et al., 2010165 68 16.93 2.85 69 29.84 5.65 Eye
Rubin et al., 2011166 21 19.05 6.12 26 48.5 7.13 Eye
Sati et al., 2014163 30 15.5 1.2 30 27.63 1.63 Eye
Uy et al., 2005168 11 27.8 1 11 67 3.6 Eye
Yüksel et al., 2010158 29 23.42 13.34 29 41.45 3.2 Eye
Filosso et al., 2013136 13 216 24 11 240 30 Cardiothoracic: lung
Lopez et al., 2013129 179 165.6 82.6 167 155.5 81.6 Cardiothoracic: lung
Maisano et al., 2009140 59 249 77 60 235 59 Cardiothoracic: heart
Fischer et al., 2013241 60 247.8 140.4 30 253.4 141.8 Mixed
Maggiore et al., 2011233 35 98.4 7.8 35 98 9.5 Gynaecological
Takeuchi et al., 2005234 29 112 45.8 16 103 30.6 Gynaecological
Takeuchi et al., 2005234 30 108 41.7 16 103 30.6 Gynaecological
C, computed.
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TABLE 47 Length of hospital stay data: all RCTs
Study
(author, year)
Group
Note Surgery area
Fibrin sealant Standard care
n Mean SD n Mean SD
Noun et al., 199670 35 10.8 4 42 11.3 5 Upper GI tract: liver
Carter et al., 201381 50 6.4 51 7.3 6.75 Check values Upper GI tract: pancreas
Lillemoe et al.,
200483
58 12.2 0.8 66 13.6 1 Upper GI tract: pancreas
Martin and Au,
201386
25 14.1 12.7 32 17.4 17.5 Upper GI tract: pancreas
Musella et al.,
201488
50 5.1 1.1 50 5.2 1.2 Upper GI tract: bowel
Pilone et al., 201289 15 6.5 2.65 15 7 1.5 C Upper GI tract: bowel
Schwartz et al.,
200477
58 9 4 63 10.5 5 Values taken from
Noun et al.70
(reporting on SD
for liver surgery)
Upper GI tract: bowel
Silecchia et al.,
200862
160 7.1 4.2 160 6.7 1.8 Upper GI tract: bowel
Aguilera et al.,
2013143
42 7.6 5.3 42 7.5 2.6 Joints: knee
Aguilera et al.,
2013143
41 7.2 4.5 41 6.8 2.4 Joints: knee
Kluba et al., 2012145 12 12.67 5.1 12 13.67 2.7 Joints: knee
Molloy et al.,
2006147
50 4.82 4.3 50 5.86 2.55 C Joints: knee
Randelli et al.,
2014149
31 9 2.3 31 9 2.5 Joints: knee
Lassen et al.,
2006141
22 7 36 7 Joints: hip
Wang et al., 2003153 38 4.9 43 5.3 Joints: hip
Benevento et al.,
2014109
30 2.08 1.06 30 4.08 1.05 Breast/lymph
Berger et al.,
2001107
29 9.1 2.7 31 9.3 3.6 Breast/lymph
Furrer et al., 1993116 15 18 11 15 22 16 Breast/lymph
Mustonen et al.,
2004104
19 3.9 1 21 3.7 1 Breast/lymph
Vaxman et al.,
1995251
20 10.8 3.5 19 9.4 3.5 Breast/lymph
Gilly et al., 1994115 19 6.46 1.85 21 8.47 2.62 Breast/lymph: inguinal
or axillary lymph nodes
Udén et al., 199398 36 5.7 32 4.3 Breast/lymph: inguinal
or axillary lymph nodes
Gilly et al., 1998108 50 8 1.6 58 10.1 2.1 Breast/lymph: axillary
lymph nodes
Moore et al.,
1997106
32 1.18 0.6 31 1.41 0.69 Breast/lymph: breast
and axillary lymph
nodes
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TABLE 47 Length of hospital stay data: all RCTs (continued )
Study
(author, year)
Group
Note Surgery area
Fibrin sealant Standard care
n Mean SD n Mean SD
Lovisetto et al.,
2007180
99 1 98 1 Hernia
Olmi et al., 2007259 50 1 150 1.1 Hernia
Olmi et al., 2007259 50 1 150 1.1 Hernia
Olmi et al., 2007259 50 1 150 1.2 Hernia
Cormio et al.,
2012222
49 2.75 1.68 47 5.15 1.74 Urology
Czerny et al.,
2000205
9 10 7 10.5 Vascular
Anegg et al.,
2007125
75 6.2 2 77 7.7 2.2 C Cardiothoracic: lung
Droghetti et al.,
2008124
20 11 2 20 14.3 2.2 C Cardiothoracic: lung
Fabian et al.,
2003128
50 4.6 2 50 4.9 2.2 C Cardiothoracic: lung
Filosso et al.,
2013136
13 6.9 1.4 11 9.5 0.5 Cardiothoracic: lung
Gonfiotti et al.,
2011130
91 7.64 3.56 94 7 3.33 Cardiothoracic: lung
Rena et al., 2009127 30 5.87 1.07 30 7.5 3.2 Cardiothoracic: lung
Tavilla et al., 201560 722 5.99 3.95 714 6.07 4.21 Cardiothoracic: heart
C, computed.
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TABLE 48 Duration of drainage data: all RCTs
Study (author, year)
Group
Note Surgery area
Fibrin sealant Standard care
n Mean SD n Mean SD
Maisano et al., 2009140 59 3.9 7.4 60 2.8 4.4 Cardiothoracic: heart
Berger et al., 2001107 29 3.8 1.9 31 3.9 1.8 Breast/lymph
Benevento et al., 2014109 30 2 1.4 30 4 1.6 Breast/lymph
Cipolla et al., 2010110 80 4.5 1.7 79 5.1 1.9 Breast/lymph
Di Monta et al., 2012117 37 20 5 33 23 5 Breast/lymph
Dinsmore et al., 200097 14 16.5 1.9 13 12.3 2.3 C Breast/lymph
Furrer et al., 1993116 15 8.6 4.2 15 11.7 9.1 Breast/lymph
Gilly et al., 1994115 19 4.85 2.06 21 7.19 2.59 Breast/lymph
Ko et al., 2009102 47 3.3 0.9 48 3.8 1.4 Breast/lymph
Moore et al., 1997106 32 3.9 1.7 31 6.9 1.19 Breast/lymph
Mustonen et al., 2004104 19 3.3 1.2 21 3.1 0.9 Breast/lymph
Mustonen et al., 2004104 19 2.2 0.8 21 2.3 0.7 Breast/lymph
Nielsen et al., 1985123 10 4.4 1.9 20 4.4 2.3 C Breast/lymph
Nielsen et al., 1985123 8 6.5 1.9 20 4.4 2.3 C Breast/lymph
Segura-Castillo et al., 2005105 22 5.09 1.48 23 8.96 2.33 Breast/lymph
Ulusoy et al., 200396 27 9.88 0.59 27 9.66 0.58 Breast/lymph
Vaxman et al., 1995112 20 5.85 2.7 19 4.89 1.9 Breast/lymph
Vaxman et al., 1995112 20 2.3 1 19 2.95 1.2 Breast/lymph
Erba et al., 2010210 5 4 1 5 6 1 Plastic
Oliver et al., 2002215 5 8.2 5 6.3 Plastic
Oliver et al., 2002215 4 9.5 4 9.3 Plastic
Oliver et al., 2002215 5 4.6 5 9.6 Plastic
Oliver et al., 2002215 8 4.1 8 4.9 Plastic
Czerny et al., 2000205 9 2 7 2 Vascular
Randelli et al., 2014149 31 0.81 0.16 31 0.8 0.11 Joints
Bektas et al., 201465 35 8.7 7.4 35 8.1 4.1 Upper GI tract: liver
Fischer et al., 201172 60 6.6 4.33 59 7.6 2.58 C Upper GI tract: liver
Frilling et al., 200573 53 8.2 4.33 59 5.7 2.58 C Upper GI tract: liver
Kakaei et al., 201374 15 3.66 0.97 15 4.06 0.7 Upper GI tract: liver
Kohno et al., 199275 31 7.2 5.1 31 6.3 2.7 Upper GI tract: liver
Liu and Lui, 199369 20 7.85 3.85 20 8.35 2.81 Upper GI tract: liver
Czerny et al., 2004137 40 2.53 0.17 40 2.97 0.14 Cardiothoracic: lung
Filosso et al., 2013136 13 6.1 1.7 11 10.8 2.4 Cardiothoracic: lung
Gonfiotti et al., 2011130 91 6 3.1 94 6.5 5.4 Cardiothoracic: lung
Moser et al., 2008126 25 2.83 1.96 25 5.88 2.96 Cardiothoracic: lung
Rena et al., 2009127 30 3.53 1.59 30 5.9 3.72 Cardiothoracic: lung
C, computed.
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